May 18, 2002

Dear Colleagues and Guests:

Welcome to the 155th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care into the future.

This year's Annual Meeting theme is "The 21st Century Psychiatrist." Many sessions throughout the week will highlight an important aspect of the theme. Please make a special effort to attend the Monday afternoon Presidential Symposium, from 2:00 p.m.-5:00 p.m., entitled, "What Will the 21st Century Bring to the Training of Psychiatrists?"

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in Philadelphia. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation on Monday night at 6:00 p.m., where we will honor all those being inducted as fellows and many receiving awards from the APA.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Philip R. Muskin and the members of the Scientific Program Committee, Marvin Kanefield, D.O., and the members of the Local Arrangements Committee, and to the APA staff who work on the Annual Meeting.

Welcome to Philadelphia 2002.

Sincerely,

Richard K. Harding, M.D.
President
Dear APA Members and Guests:

Welcome to Philadelphia, PA, and the 155th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “The 21st Century Psychiatrist,” chosen by our President, Dr. Richard K. Harding. Let me draw your attention to just a few of the many exciting sessions presented this week. On Monday we will present the Presidential Symposium entitled, “What Will the 21st Century Bring to the Training of Psychiatrists?” Throughout the week we will feature sessions presented in collaboration with the Substance Abuse and Mental Health Service Administration. David Satcher, M.D., will present the APAs Patient Advocacy Award Lecture on Wednesday, at 9:00 a.m.

The Local Arrangements Committee, under the excellent guidance of its Chairperson, Marvin Kanefield, D.O., has developed a wide array of activities that will help you take advantage of Philadelphia. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation will begin at 6:00 p.m., a new time, on Monday, May 20. Rodger McFarlane, recipient of APA’s Patient Advocacy Award, will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the Program Book that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field. Several forums, as well as numerous other sessions, will focus on aspects of the terrorist attacks, terrorists, and the response efforts to deal with the psychological sequelae of the events.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to Philadelphia. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Philip R. Muskin, M.D.
Chairperson
Scientific Program Committee
**APA 155th ANNUAL MEETING**

Philadelphia, PA ■ May 18-23, 2002

---

### KEY LOCATIONS - CONVENTION CENTER

<table>
<thead>
<tr>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APA Resource Center</td>
<td>Room 304, Level 300 (formerly the Scientific Program Office &amp; Meetings Management)</td>
</tr>
<tr>
<td>APA Resource Center</td>
<td>Room 105 A/B, Street Level</td>
</tr>
<tr>
<td>A/V Preview Room</td>
<td>Room 303 B, Level 300</td>
</tr>
<tr>
<td>CME Course Enrollment</td>
<td>Exhibits Halls A-C, Level 200</td>
</tr>
<tr>
<td>Computerized Evaluation</td>
<td>APA Resource Center</td>
</tr>
<tr>
<td>Daily Bulletin</td>
<td>Room 310, Level 300</td>
</tr>
<tr>
<td>Education Office</td>
<td>Room 305, Level 300</td>
</tr>
<tr>
<td>Exhibit Office</td>
<td>Level 200</td>
</tr>
<tr>
<td>Exhibits/Publishers' Bookfair</td>
<td>Exhibits Halls A-C, Level 200</td>
</tr>
<tr>
<td>Information/Locator Center</td>
<td>Street Level</td>
</tr>
<tr>
<td>Lost &amp; Found</td>
<td>Room 304, Level 300</td>
</tr>
<tr>
<td>Message Center</td>
<td>Bridge, Level 200</td>
</tr>
<tr>
<td>On-Site Job Bank and Placement Center</td>
<td>APA Resource Center</td>
</tr>
<tr>
<td>Psychiatric Services</td>
<td>APPI Bookstore, Exhibit Halls A-C</td>
</tr>
<tr>
<td>Registration</td>
<td>Exhibits Halls A-C, Level 200</td>
</tr>
</tbody>
</table>

### FIRST AID

Located in Room BF2, Exhibit Hall B, Level 200, Convention Center. Hours of operation: Tuesday, May 14, through Thursday, May 23, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be operated by Registered Nurses. Information on emergency services may be found on page 1 of the *Leisure Time Activities Brochure*.

### COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 18, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 23, at 6:00 p.m. The Convention Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Services Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Convention Center.

### EXHIBITS

Commercial and educational exhibits are located in Exhibit Halls A-C, Level 200, Convention Center, along with the Publishers' Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center will open on Saturday, May 18, 10:00 a.m.-5:00 p.m., and the Publishers' Bookfair will open on Saturday, May 18, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 19, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 20-21, 10:00 a.m.-6:00 p.m., and Wednesday, May 22, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 22 at 3:00 p.m. Please refer to the *APA Exhibits Guide* for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

### INFORMATION/LOCATOR CENTER

Located in the Lobby, Street Level, Convention Center and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

---

### MESSAGE CENTER

Located on the Bridge, Level 200, Convention Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

### APA RESOURCE CENTER

Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation will be: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 20-21, 10:00 a.m.-6:00 p.m.; and Wednesday, May 22, 10:00 a.m.-5:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, and APA Job Bank.

### APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The on-line APA Job Bank will power the popular on-site Job Bank providing tools for both employers and candidates at the APA's Annual Meeting. With new features such as résumé posting, enhanced job searching, and response tracking, the Job Bank provides the best opportunity available for career research and on-site interviews. Candidates and employers are encouraged to activate their resume and jobs postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, www.psych.org, and click on the Job Bank icon. You may also contact us by phone (888-884-8242) or e-mail (employers@healthcareers.com) prior to the meeting, or stop by the Job Bank booth on-site.

### APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms 105 A/B, Street Level, Convention Center. Hours of operation: Saturday, May 18, 12 noon-5:00 p.m.; Sunday- Monday, May 19-22, 8:00 a.m.-6:00 p.m.; and Thursday, May 23, 8:00 a.m.-12 noon.

The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, conferences, and Master Educator Clinical Consultations.

### DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 310, Level 300, by 12 noon prior to the date of publication.

### CENTER FOR INTERNATIONAL GUESTS

**Bienvenidos, Willkommen, Bienvenue, Welcome!**

Located in the Commonwealth Hall, Second Floor, Loews. Hours of operation: Saturday, May 18, through Wednesday, May 22, 8:00 a.m.-6:00 p.m.; and Thursday, May 23, from 8:00 a.m.-3:00 p.m. All international visitors are invited. These activities are supported by Pfizer Pharmaceuticals Group.

---

[Page II]
WOMEN'S RESOURCE CENTER
Located in Room 303A, Level 300, Convention Center. Hours of operation: Sunday, May 19, through Monday, May 20, 7:00 a.m.-5:00 p.m. Meet and network with other women psychiatrists and peruse materials on women's programs offered by APA and other organizations. Special events will include an informal session for women on passing the boards, a meeting of the women's mentoring network, and a networking meeting for District Branch committees on women. The Center is funded by an unrestricted educational grant from Wyeth Pharmaceuticals.

IMG HOSPITALITY CENTER
Located in Room 303A, Level 300, Convention Center. Hours of operation: Tuesday, May 21, through Wednesday, May 22, 8:00 a.m.-6:00 p.m. Stop by the Center to meet and network with your colleagues. From 12 noon-1:30 p.m. both days, there will be informal sessions on "Acculturation, Language: Problems and Solutions for IMGs and ECFMGs: Friend or Foe?"

BUSINESS CENTERS
Convention Center
Location: Between Exhibit Halls B & C
Times of operation: Monday-Sunday, 8:00 a.m.-6:00 p.m.

Loews
Location: 3rd Floor
Times of operation: Monday-Friday, 6:30 a.m.-9:00 p.m.
Saturday-Sunday, 8:00 a.m.-5:00 p.m.

Marriott - Kinkos
Location: Main Level, Market Street Exit
Times of operation: open 24 hours

REGISTRATION
ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE
Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 7:30 a.m.-5:00 p.m.; Monday through Tuesday, May 20-21, 7:30 a.m.-6:00 p.m.; Wednesday, May 22, 7:30 a.m.-5:00 p.m.; and Thursday, May 23, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS
Full-Time Registration (North American Members)..............$235.00
Full-Time Registration (International Members)..................$500.00
Members-in-Training (Member Class MT)..........................$70.00
Daily Registration (North American Members)....................$120.00
Daily Registration (International Members)......................$255.00
Medical Students no charge

NONMEMBERS
Full-Time Registration ............................................$710.00
Nonmember Residents, Students, Advocacy
Group Members or Mental Health Chaplains.....................90.00
Daily Registration (all "Nonmember" categories)................360.00
Medical Students no charge

GUEST REGISTRATION
One only per full-time registrant....................................95.00
Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.

One-Day Exhibit Hall Only Pass (18 and older)...............10.00
On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day[s] they present).

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER
FULL-TIME STUDENTS must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

NAME BADGES
Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Convention Personnel.

CME COURSE ENROLLMENT
TICKET PURCHASE REQUIRED
FOR CME COURSES
Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 7:30 a.m.-5:00 p.m.; Monday through Tuesday, May 20-21, 7:30 a.m.-6:00 p.m.; Wednesday, May 22, 7:30 a.m.-5:00 p.m.; and Thursday, May 23, 7:30 a.m.-2:00 p.m. Tickets for CME Courses not sold by April 13 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 18. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION
Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH
Located on the Bridge, Level 200, Convention Center. Hours of operation: Saturday, May 18, through Wednesday, May 22, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

APA PERIODICALS
Complimentary copies of the latest issues of American Journal of Psychiatry, Psychiatric Services, Psychiatric News, Academic Psychiatry, the American Journal of Geriatric Psychiatry, the Journal of Neuropsychiatry, and Psychosomatics may be obtained at the APA/APPI Periodicals Exhibit in the APA Resource Center. Staff will sell discounted subscriptions to all APA/APPI journals and demonstrate online access for subscribers. They will also show authors and reviewers how to use Manuscript Central, the new Web-based (Continued on next page)
manuscript submission and review system. Staff of the American Journal of Psychiatry and Psychiatric Services will be available to answer authors’ questions. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office, Room 304, Level 300, Convention Center.

Written announcements, suggestions for articles, letters to the editor, or manuscript submission and review system. Staff of the American Journal of Psychiatry and Psychiatric Services will be available to answer authors’ questions. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office, Room 304, Level 300, Convention Center.

CONTINUING MEDICAL EDUCATION

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Psychopharmacology, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposium, Telecommunication sessions, and Workshops. Other program activities may be considered Category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, Research Consultations With, Round Table Discussion, and some Media Sessions, and Lectures. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance log sheet found in the front of the 2002 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available. The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities. CME report forms may be obtained from the Department of CME at the APA. Staff will be available in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Resource Center, all located in the Convention Center) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

We expect "sell out” attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

• Please find seating as far forward as possible.
• Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
• Store materials under chairs to maximize seating capacity.
• Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.

• If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. Non-media registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

CHILD CARE SERVICE

ACCENT in Children's Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children’s activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT's professional, specially-trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff is comprised of teachers, professional childcare providers, and mothers who simply love working with children and have completed ACCENT's specialized training program. Camp APA is headquartered at the Loews Philadelphia Hotel for the exclusive use of APA registrants and their families. Children aged six months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children younger than six years old. The older children will enjoy arts and crafts projects, active games, and much more. Field Trips will depart and return to the on-site Camp APA Activity Center each day. ACCENT provides an exceptional caregiver to child ratio: 1:2 for children 6-12 months; 1:3 for children 13-36 months; 1:5 for children 3-12 years; and 1:8 for children 12 years and older. Please complete the Registration Form to participate in this great opportunity. If you have any questions, please e-mail us at registration@accentoca.com.
GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day’s sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate “Days-at-a-Glance,” which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in the Convention Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

<table>
<thead>
<tr>
<th>Year</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>May 17-22</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>2004</td>
<td>May 1-6</td>
<td>New York, NY</td>
</tr>
<tr>
<td>2005</td>
<td>May 21-26</td>
<td>Atlanta, GA</td>
</tr>
</tbody>
</table>

APA CLINICAL MEETINGS

THE INSTITUTE ON PSYCHIATRIC SERVICES

<table>
<thead>
<tr>
<th>Year</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>October 9-13</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>2003</td>
<td>October 29-Nov 2</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>2004</td>
<td>October 6-10</td>
<td>Atlanta, GA</td>
</tr>
<tr>
<td>2005</td>
<td>October 5-9</td>
<td>San Diego, CA</td>
</tr>
</tbody>
</table>

Tentative program schedules and hotel information for the 2002 Institute on Psychiatric Services are available at the Information/Locator Center, located on the Street Level, Convention Center.

TABLE OF CONTENTS

Floor Plans for Convention Center, Loews, Marriott, and Wyndham .......................................................... VI-XII
City Map...................................................................................................................................................... XIII
Special Acknowledgments ......................................................... XVI-XV
Format Descriptions ........................................................................................................ XVI-XVII
Disclosure Information .................................................................................................................. XVIII-XXX
Saturday Sessions........................................................................................................................... 1-3
Audiotape Sales Information ................................................................. 4
Sunday Sessions ........................................................................................................................... 5-12
Monday Sessions ........................................................................................................................... 13-36
Tuesday Sessions ........................................................................................................................... 37-64
Wednesday Sessions .................................................................................................................... 65-86
Thursday Sessions ........................................................................................................................ 87-98
Topic Index .......................................................................................................................................... 99-112
Participant Index........................................................................................................................... 113-123
American Psychiatric Publishing Inc. ................................................................. 124-125
Call for 2003 Annual Meeting Papers ......................................................................................... 126
Industry-Supported Symposia................................................................................................. 127-151
2002 Institute on Psychiatric Services .................................................................................. 152
APA Resource Center.................................................................................................................. Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers’ Bookfair, Hospitality Lounge, and Dining Facilities in the Convention Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

© American Psychiatric Association.
Loews

Fourth Floor
Marriott
Level 4

33,000-square-foot Franklin Hall accommodates 165 8' x 10' or 10' x 10' booths; 9.5'-14.5' ceiling height.

Level 5
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Symposia, "Diagnosis and Treatment Issues in Child and Adolescent Bipolar Disorders," Sunday, May 19, 8:00 a.m.; "New Developments in the Treatment of Bipolar Disorder," Sunday, May 19, 7:00 p.m.; and support of the Industry-Supported Breakfast Symposium, "The Pathophysiology and Treatment of Impulsivity and Aggression in Psychiatric Disorders," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 19, 2:30 p.m.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture, Thursday, May 23, 9:00 a.m.

American Psychiatric Foundation: co-support of the APA Award for Research in Psychiatry; support of the Disaster Psychiatry Fellowship; and support of the APIRE Practice Research Network (PRN).

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Wednesday, May 22, 9:00 a.m.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Career reception and meeting.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Customizing Care for Patients with Bipolar Disorder," Sunday, May 19, 1:30 p.m.; "Molecules of the Mind: The Science of Schizophrenia," Sunday, May 19, 7:00 p.m.; "The Burden of Schizophrenia: Why Patients Don't Get Better," Wednesday, May 22, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Antipsychotic Pharmacotherapy and the Hippocampal Oath: Above All Do No Harm," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the George Tarjan Award Lecture, Monday, May 20, 9:00 a.m.; the APA/AstraZeneca Fellowship and reception, Tuesday, May 21, 7:00 p.m.; and support of the American Psychiatric Foundation "Conversations" event, Tuesday, May 21, 5:30 p.m.

Aventis: support of the Travel Fellowship for Women Residents in Psychiatry and Leadership Luncheon, Sunday, May 19, 12:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposia, "Advances in the Treatment of Psychosis: Minimizing the Burden of Disease," Sunday, May 19, 8:00 a.m.; "Challenges and Opportunities in the Management of Psychotic Disorders," Sunday, May 19, 1:30 p.m.; the Industry-Supported Breakfast Symposium, "Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the Solomon Carter Fuller Award Reception; and the shuttle bus system.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program; support of the APIRE Practice Research Network (PRN); support of the special Annual Meeting series "Access to Quality Care: What Really Works?" and training activities of the AIDS Education Project.

Center for Abuse Prevention: support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

Cephalon Inc.: support of the Industry-Supported Symposium, "Identification and Management of Daytime Fatigue and Sleepiness in Psychiatry," Wednesday, May 22, 7:00 p.m.

Cyberonics, Inc.: support of the Industry-Supported Symposium, "Long-Term Management of Mood Disorders," Sunday, May 19, 1:30 p.m.

Eisai Inc., Pfizer Inc.: support of the Industry-Supported Symposium, "Psychiatry Practice Paradigm: The Emerging Role of the Psychiatrist in Treating Alzheimer’s Disease," Saturday, May 18, 7:00 p.m.; and "Explorations in Dementia: New and Current Perspectives," Wednesday, May 22, 7:00 p.m.

Elk Lilly and Company: support of the Industry-Supported Symposium, "New Approaches for Treating ADHD: The Whole Life Perspective," Saturday, May 18, 7:00 p.m.; "Treating Psychotic Illness Across the Life Span: Are Drugs Enough?" Sunday, May 19, 8:00 a.m.; "Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder," Sunday, May 19, 7:00 p.m.; "Clinical Differences in Serotonin and Norepinephrine Antidepressant Effects," Tuesday, May 21, 7:00 p.m.; support of the Industry-Supported Breakfast Symposium, "One Size Doesn’t Fit All: Depression Therapies for the 21st Century," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "Therapeutic Challenges, Novel Approaches: Antipsychotics in the Management of Mood and Anxiety Disorders," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; and "Noncholinergic Treatments for Alzheimer’s Disease: Present Knowledge, Future Hope," Wednesday, May 22, 7:00 p.m.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Wednesday, May 22, 11:00 a.m.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards in child and adolescent psychiatry.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "Molecules and Mood Disorders: Drug Discovery and the Treatment of Depression," Saturday, May 18, 7:00 p.m.; "Late-Life Depression: Old Myths and New Data," Sunday, May 19, 8:00 a.m.; and "Noncholinergic Treatments for Alzheimer’s Disease: Present Knowledge, Future Hope," Wednesday, May 22, 7:00 p.m.

GlaxoSmithKline: support of the Industry-Supported Symposia, "Bipolar Disorder: New Nationwide Data on Misdiagnosis and Community Costs," Saturday, May 18, 7:00 p.m.; "Recent Developments in the Science and Treatment of PTSD," Sunday, May 19, 1:30 p.m.; "Bipolar Depression and Rapid Cycling: Current Management Strategies," Tuesday, May 21, 7:00 p.m.; "The New Neurobiology of Mood and Anxiety Disorders," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Clinical Challenges in Depression," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "Chronic Episodic Disorders: Comorbidity and Comprehensive Integrated Treatment," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program; the annual contribution to the APA Presidential Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; and the registration portfolio.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Wednesday, May 22, 9:00 a.m.
SPECIAL ACKNOWLEDGMENTS

Ittleson Foundation, Inc.: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Antipsychotic Therapy and Cardiovascular Disease: The Unfolding Story," Saturday, May 18, 7:00 p.m.; "The Adherence Challenge: Chronic Issues and Emerging Solutions with Antipsychotic Therapy," Sunday, May 19, 1:30 p.m.; "Managing Aggression Across the Life Span: From the Pediatric to the Geriatric Patient," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the reception for Kun-Po Soo Award recipients, Wednesday, May 22; and the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Illness Program.

Johnson & Johnson: support of the International Leadership Dinner, Wednesday, May 22, 7:00 p.m.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.

Merck & Co., Inc.: support of the William C. Menninger Memorial Convocation Lecture, Monday, May 20, 6:00 p.m.; and an unrestricted educational grant in support of various scientific sessions.

National Institute of Mental Health: co-support of the APA/NIMH Benjamin Rush Award Lecture, Tuesday, May 21, 11:00 a.m.; American Psychiatric Institute for Research and Education Annual Meeting activities for research trainees; and the Program for Minority Research Training in Psychiatry (PMRTP).

National Institute on Drug Abuse: support of the American Psychiatric Institute for Research and Education/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposia, "Behavioral Disturbances in Dementia: Diagnostic and Treatment Guidelines," Tuesday, May 21, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposia, "Depressive Subtypes: The Multiple Faces of Depression," Sunday, May 19, 8:00 a.m.; and "The Aging Brain and Vulnerability to Depression," Sunday, May 19, 1:30 p.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposium, "Advances in the Understanding and Treatment of Binge-Eating Disorder," Wednesday, May 22, 7:00 p.m.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 19, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposia, "Improving Patient Outcomes Across the Spectrum of Bipolar Disorder," Saturday, May 18, 7:00 p.m.; "Treatment of Anxiety Disorders: Where Are We, and Where Are We Going?" Sunday, May 19, 7:00 p.m.; "Raising Expectations in Schizophrenia: Enhancing Long-Term Outcomes," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Age, Gender, and Diagnosis: Influences on Drug Response," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 20, 7:00 a.m.; the "Abstracts-On-Disk" Program; and the APA Daily Bulletin newspaper.

The Pfizer Pharmaceuticals Group: support of the International Hospitality Suite, a daily visitor center for international delegates.

The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program: support of the ECP luncheon, Tuesday, May 21, 12:00 p.m.

Roche Laboratories, a member of the Roche Group: support of the Benjamin Rush Award Lecture, Tuesday, May 21, 9:00 a.m.

Sanofi-Synthelabo, Inc.: support of the Residents, Medical Student, and Training Directors Luncheon, Tuesday, May 21, 12:00 p.m.


Shire US, Inc.: support of the Industry-Supported Symposium, "Adult ADHD: From Research to Clinical Practice," Wednesday, May 22, 7:00 p.m.

Solvay Pharmaceuticals, Inc.: "Treating Fear: Perspectives on the Biology and Therapy of Anxiety Disorders," Tuesday, May 21, 7:00 p.m.; and the beverage service in the exhibit hall.

Somerset Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, "Atypical Depression: Overview and New Developments," Sunday, May 19, 7:00 p.m.

Substance Abuse and Mental Health Services Administration: support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, "Recovery from Depression: New Perspectives to Improve Outcomes," Sunday, May 19, 8:00 a.m.; "Treatment of Mood and Anxiety Disorders in Women: What Is Evidence and What Is Art?" Sunday, May 19, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Understanding Sleep Medicine: What the Psychiatrist Needs to Know," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D./Ph.D. Psychiatric Research Fellowship; the Women's Resource Center and Display; the IMG Hospitality Suite; the Alexandra Symonds Award Lecture, Tuesday, May 21, 2:00 p.m.; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA News Network."
## FORMAT DESCRIPTIONS

### ADVANCES IN PSYCHOPHARMACOLOGY
This three-and-one-half hour session will summarize important new clinical and research findings in the field of psychopharmacology, based in part, on material contained in the *American Psychiatric Publishing Textbook of Psychopharmacology, Second Edition*. Authors of selected chapters from the textbook will present material from the chapters. The topics were selected by the editors to represent areas of clinical psychopharmacology of greatest importance to APA members.

### ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

### CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

### DEBATE
Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

### DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

### FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

### LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

### MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

### MEDIA SESSIONS
In these sessions, a videotape of educational value is shown. Videotapes may illustrate innovation in: patient assessment, diagnosis, treatment, and education; practice management, medical records, information systems, and research; professional education; public awareness and education; psychiatric interpretations of meaning in media; assessment of the biopsychosocial effects of media on individuals; social/cultural issues and mental health/illness; and the human spirit as seen in the arts and humanities.

### MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

### NEW RESEARCH
This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

### RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.
RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

ROUNDTABLE
This 90-minute format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

TELECOMMUNICATION SESSIONS
These three-hour sessions are presented in a computer software demonstration format (i.e., on computer and LCD projector provided for projection on a large screen). Topic areas include telepsychiatry, virtual reality, internet, electronic medical records, and information technology.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and oral or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires oral disclosure of discussion of unapproved uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening, Inc; Eli Lilly and Company; Alza Pharmaceuticals; GlaxoSmithKline</td>
<td>67</td>
</tr>
<tr>
<td>Lenard A. Adler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories</td>
<td>3, 33, 56</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories</td>
<td>33, 56</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation</td>
<td>5, 30</td>
</tr>
<tr>
<td>Albert J. Allen, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>3</td>
</tr>
<tr>
<td>Anne Alonso, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Cyberonics; Eli Lilly and Company; GlaxoSmithKline; Lichwer Pharma; Novartis Pharmaceuticals Corporation; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Roche Laboratories; a member of the Roche Group; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth Pharmaceuticals</td>
<td>61</td>
</tr>
<tr>
<td>Jay D. Amsterdam, M.D.</td>
<td>Eli Lilly and Company; Somerset Pharmaceuticals, Inc.; Pfizer Inc.; Organon Inc.; Forest Laboratories, Inc.; Merck &amp; Co., Inc.; Wyeth Pharmaceuticals; GlaxoSmithKline; Biopharm; Organon Inc.</td>
<td>96</td>
</tr>
<tr>
<td>Jose C. Appolinario, M.D.</td>
<td>Knoll Pharmaceutical Company</td>
<td>32</td>
</tr>
<tr>
<td>Ralph Aquila, M.D.</td>
<td>Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Kimberly A. Arlinghaus, M.D.</td>
<td>Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Abbott Laboratories; Cephalon, Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Jorge L. Armenteros, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>63</td>
</tr>
<tr>
<td>Peter M. Appuperle, M.D.</td>
<td>Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>7</td>
</tr>
<tr>
<td>Robert W. Baker, M.D.</td>
<td>Eli Lilly and Company</td>
<td>24, 75</td>
</tr>
<tr>
<td>Benjamin H. K. Balderson, Ph.D.</td>
<td>Group Health Cooperative (employee)</td>
<td>59</td>
</tr>
<tr>
<td>Richard Balon, M.D.</td>
<td>Bristol-Myers Squibb; GlaxoSmithKline; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Organon Inc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Merck &amp; Co., Inc.</td>
<td>97</td>
</tr>
<tr>
<td>Paul J. Barreira, M.D.</td>
<td>Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Gail M. Barton, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>19</td>
</tr>
<tr>
<td>Mark S. Bauer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Philip M. Becker, M.D.</td>
<td>Cephalon, Inc.</td>
<td>49</td>
</tr>
<tr>
<td>Bernard D. Beitzman, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline</td>
<td>8, 29</td>
</tr>
<tr>
<td>Ruth M. Benca, M.D.</td>
<td>Wyeth Pharmaceuticals; Cephalon, Inc.; Sanofi Pharmaceuticals, Inc.; National Institute of Mental Health; Merck &amp; Co., Inc.; Seprocar, Inc.</td>
<td>85</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Shire U.S., Inc.; Glaxo, Inc.; Cephalon, Inc.; GlaxoSmithKline; Eli Lilly and Company, Alza Pharmaceuticals; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>86</td>
</tr>
<tr>
<td>Bradley F. Boeve, M.D.</td>
<td>Pfizer Inc.; Eisai Inc.</td>
<td>86</td>
</tr>
<tr>
<td>Howard E. Bock, M.D.</td>
<td>American Psychiatric Press Inc.</td>
<td>27, 50</td>
</tr>
<tr>
<td>Soo Borson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Forest Laboratories, Inc.; Wyeth Pharmaceuticals</td>
<td>63</td>
</tr>
</tbody>
</table>

XVIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; R.W. Johnson Pharmaceutical Institute; Sanofi Pharmaceuticals, Inc.; Stanley Foundation; UCB Pharma, Inc.</td>
<td>8, 11</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Pfizer Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb</td>
<td>37, 55, 87</td>
</tr>
<tr>
<td>George Brainard, Ph.D.</td>
<td>Bio-Brice, Inc; Philips</td>
<td>8</td>
</tr>
<tr>
<td>Olga Brawman-Mintzer, M.D.</td>
<td>AstraZeneca Pharmaceuticals, Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation</td>
<td>87</td>
</tr>
<tr>
<td>Alan F. Breier, M.D.</td>
<td>Eli Lilly and Company</td>
<td>95</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Johnson and Johnson; Ortho-Biotech; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>29</td>
</tr>
<tr>
<td>Lawrence Brown, M.D.</td>
<td>GlaxoSmithKline; AGVRON</td>
<td>44</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>Alza Pharmaceuticals; American Psychiatric Press Inc.; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire U.S., Inc.; The Psychological Corporation; Yale University Press</td>
<td>1, 3, 78</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Eli Lilly and Company, Janssen Pharmaceuticals and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>86, 96</td>
</tr>
<tr>
<td>Kathryn A. Burns, M.D.</td>
<td>Eli Lilly and Company</td>
<td>69</td>
</tr>
<tr>
<td>George Bush, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company, Shire U.S., Inc.</td>
<td>86</td>
</tr>
<tr>
<td>Ira R. Byock, M.D.</td>
<td>Purdue; Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; Knoll</td>
<td>70</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>National Institute of Mental Health; Abbott Laboratories; Ciba Geigy Corporation, Pharmaceutical Division; Merck &amp; Co., Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; MacArthur Foundation; National Alliance for Research in Schizophrenia and Affective Disorders; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; Sandoz Pharmaceuticals Corporation; Stanley Foundation; TAP Pharmaceuticals; UCB Pharma; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Organon Inc.; GlaxoSmithKline; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals; Shire U.S., Inc.; Teva Pharmaceuticals</td>
<td>3, 5, 63</td>
</tr>
<tr>
<td>Lori Calabrese, M.D.</td>
<td>GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb</td>
<td>37</td>
</tr>
<tr>
<td>Joshua W. Calhoun, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Bristol-Myers Squibb; Organon Inc.; GlaxoSmithKline; Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>80</td>
</tr>
<tr>
<td>Linda L. Carpenter, M.D.</td>
<td>Corcept; Pfizer Inc.; Forest Laboratories, Inc.; Merck &amp; Co., Inc.; Cyberonics; Organon Inc.; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline</td>
<td>6, 11, 52</td>
</tr>
<tr>
<td>Diana Carter, M.B.</td>
<td>GlaxoSmithKline</td>
<td>8</td>
</tr>
<tr>
<td>William F. Carter, M.D.</td>
<td>Eli Lilly and Company; Wyeth Pharmaceuticals; Ortho-McNeil Pharmaceuticals</td>
<td>86</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company, Janssen Pharmaceuticals and Research Foundation; Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation</td>
<td>64, 65</td>
</tr>
<tr>
<td>David Castle, M.D.</td>
<td>Eli Lilly and Company</td>
<td>55</td>
</tr>
<tr>
<td>Patrizia A. Cavazzoni, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>47</td>
</tr>
<tr>
<td>Carlyle H. Chan, M.D.</td>
<td>Medscape</td>
<td>38, 52</td>
</tr>
<tr>
<td>Kiki D. Chang, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Kyong-Mi Chang, M.D.</td>
<td>Wyeth Pharmaceuticals; Visopharma</td>
<td>44</td>
</tr>
<tr>
<td>Dennis S. Charney, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Cyberonics; Dov Pharmaceuticals; Eli Lilly and Company; Forest Laboratories, Inc.; Infosetiberg; Janssen Pharmaceuticals and Research Foundation; Merck &amp; Co., Inc.; Mindsense; Mitsubishi Chemical; Novartis Pharmaceuticals Corporation; Organon Inc.; Pfizer Inc.; Pharmacy Corporation; R.W. Johnson Pharmaceutical Research Institute; Sepracor, Inc.; Skil; GlaxoSmithKline; Somerset Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Velva Pharmaceuticals</td>
<td>34, 97</td>
</tr>
<tr>
<td>Joseph A. Cheong, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>25, 51</td>
</tr>
<tr>
<td>James C.Y. Chou</td>
<td>Pass the Boards, Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company, Janssen Pharmaceuticals and Research Foundation; AstraZeneca Pharmaceuticals; Abbott Laboratories; Pfizer Inc.</td>
<td>30</td>
</tr>
<tr>
<td>Anita H. Clayton, M.D.</td>
<td>Corcept; Forest Laboratories, Inc.; GlaxoSmithKline; Organon Inc.; Pfizer Inc.; Pharmacy Corporation; Eli Lilly and Company; Bristol-Myers Squibb; Organon, Inc.</td>
<td>65</td>
</tr>
<tr>
<td>Judith A. Cohen, M.D.</td>
<td>Pfizer Inc.</td>
<td>71, 94, 95</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Forest Laboratories, Inc.; Janssen Pharmaceutical and Research Foundation; Eli Lilly and Company, Organon Inc.; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>11, 23, 57</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XIX</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Steven A. Cole, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; IVAX Pharmaceuticals; Novartis Pharmaceuticals Corporation; Eli Lilly and Company</td>
<td>63, 96</td>
</tr>
<tr>
<td>Kathryn M. Connor, M.D.</td>
<td>Pfzer Inc.; Eli Lilly and Company; PureWorld Botanicals; Ancile Pharmaceuticals; GlaxoSmithKline</td>
<td>8</td>
</tr>
<tr>
<td>Barbara Comblatt, Ph.D.</td>
<td>Otsuka Pharmaceuticals; Janssen Pharmaceutica and Research Foundation</td>
<td>65, 87</td>
</tr>
<tr>
<td>Paul T. Costa, Jr., Ph.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.; Shire U.S., Inc.; Otsuka Pharmaceuticals; Sumitomo; Wyeth Pharmaceuticals; GlaxoSmithKline</td>
<td>6</td>
</tr>
<tr>
<td>Andrew J. Cudler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>55</td>
</tr>
<tr>
<td>Daniella David, M.D.</td>
<td>Pfizer Inc.; American Home Products; GlaxoSmithKline; Proctor and Gamble; Triangle Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; Ancile; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Wyeth Pharmaceuticals; Organon Inc.; PureWorld; Schwabe; MultiHealth Systems, Inc.; Guilford Publications; American Psychiatric Association</td>
<td>8, 64</td>
</tr>
<tr>
<td>Jonathan R.T. Davidson, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; Pfizer Inc.; Lundbeck; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Wyeth Pharmaceuticals</td>
<td>71</td>
</tr>
<tr>
<td>Kenneth L. Davis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; Mitsubishi; Scirex</td>
<td>12</td>
</tr>
<tr>
<td>Denise De Guzman, M.D.</td>
<td>Pharmacia Corporation</td>
<td>77</td>
</tr>
<tr>
<td>Deborah Deas, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.</td>
<td>58</td>
</tr>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>National Institute of Mental Health; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Otsuka Pharmaceuticals, Pharmaceuticals Corporation; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Boehringer Ingelheim; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals</td>
<td>38</td>
</tr>
<tr>
<td>David G. Dinges, Ph.D.</td>
<td>Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>64</td>
</tr>
<tr>
<td>Karl Doghramji, M.D.</td>
<td>Sanofi Pharmaceuticals, Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; Cephalon, Inc.</td>
<td>13, 23, 27, 86</td>
</tr>
<tr>
<td>Rachelle S. Doody, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Merz; Forest Laboratories, Inc.; Fujisawa; Elan Pharmaceuticals</td>
<td>85</td>
</tr>
<tr>
<td>P. Murali Doraiswamy, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Elan Pharmaceuticals; Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; National Institutes of Health; Forest Laboratories, Inc.; Lundbeck</td>
<td>64</td>
</tr>
<tr>
<td>Robert T. Dunn, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Mitsubishi; Cyberonics; Pharmacia Corporation; Organon Inc.</td>
<td>90</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>13, 33, 37, 47</td>
</tr>
<tr>
<td>Steven A. Epstein, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals</td>
<td>49</td>
</tr>
<tr>
<td>Milton K. Erman, M.D.</td>
<td>Searle; Pharmacia Corporation; Wyeth Pharmaceuticals; Pfizer Inc.; Takeda Pharmaceuticals; Neurocrine Biosciences; Orphan Medical; Sepracor, Inc.; Resmed Sanofi Pharmaceuticals, Inc.; Cephalon, Inc.; Forest Laboratories, Inc.</td>
<td>13, 37</td>
</tr>
<tr>
<td>Javier I. Escobar, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Johnson and Johnson</td>
<td>1</td>
</tr>
<tr>
<td>Raymond A. Faber, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>1, 5</td>
</tr>
<tr>
<td>Stephen V. Farone, Ph.D.</td>
<td>Alza Pharmaceuticals; Shire U.S., Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; GlaxoSmithKline; SG Cowan</td>
<td>86</td>
</tr>
<tr>
<td>Martin K. Farrow, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>64</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals; Organon Inc.; Bristol-Myers Squibb; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Sanofi Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals, Inc.; Pharmavite; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lorette Pharmaceuticals; Lichtwer Pharma</td>
<td>6, 13</td>
</tr>
<tr>
<td>Jan A. Fawcett, M.D.</td>
<td>National Institute of Mental Health; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc.; Theodore and Vada Stanley Foundation; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Merck &amp; Co., Inc.; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.</td>
<td>29, 96</td>
</tr>
<tr>
<td>Joel S. Feiner, M.D.</td>
<td>Eli Lilly and Company; Telecare</td>
<td>32</td>
</tr>
</tbody>
</table>

XX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen J. Ferrando, M.D.</td>
<td>Merck &amp; Co., Inc.; Pfizer Inc.</td>
<td>29, 61</td>
</tr>
<tr>
<td>Howard Fillit, M.D.</td>
<td>Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>92</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Abbott Laboratories; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Merck Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Pfizer Inc.; Somerset Pharmaceuticals, Inc.; Shire U.S., Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Organon Inc.; Forest Laboratories, Inc.</td>
<td>5, 14, 38</td>
</tr>
<tr>
<td>Mara J. Fiorentino, M.D.</td>
<td>Eli Lilly and Company</td>
<td>71</td>
</tr>
<tr>
<td>Kathleen M. Fisher, Ph.D.</td>
<td>Pfizer Inc.; Organon Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Manor Health Care; Abbott Laboratories; Bristol-Myers Squibb; Organon Inc.</td>
<td></td>
</tr>
<tr>
<td>Marc Fishman, M.D.</td>
<td>Potomac Healthcare Foundation; Mortain Manor Treatment Center</td>
<td>80</td>
</tr>
<tr>
<td>Lois T. Fliherty, M.D.</td>
<td>Merck &amp; Co., Inc.; Pfizer Inc.</td>
<td>39, 89</td>
</tr>
<tr>
<td>Lyle B. Forehand, Jr., M.D.</td>
<td>GlaxoSmithKline</td>
<td>25</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Abbott Laboratories; Forest Laboratories, Inc.; Schering Plough; Merck &amp; Co., Inc.; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Suburban Hill Hospital</td>
<td>44</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Pfizer Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; National Institute of Mental Health</td>
<td></td>
</tr>
<tr>
<td>W. Gordon Franklin, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>3, 13, 96</td>
</tr>
<tr>
<td>Jean A. Frazier, M.D.</td>
<td>Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Robert Freedman, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Matthew J. Friedman, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline</td>
<td>71</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Cephalon, Inc.</td>
<td>2, 3, 5, 34, 63</td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
<td>33, 56</td>
</tr>
<tr>
<td>Joseph Gal, Ph.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2</td>
</tr>
<tr>
<td>David R. Gastfriend, M.D.</td>
<td>Dupont Pharma; Purdue Pharma; Bristol-Myers Squibb; CSAT; State of Oklahoma; Earley Corporation</td>
<td>33</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Cyberonics; Bristol-Myers Squibb; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; Hoechst Marion Roussel; Vela Pharmaceuticals, Best Practice; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; GlaxoSmithKline</td>
<td>60, 81</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Cyberonics; Magstim; Netonics; Donitec; Medtronic</td>
<td>9, 15, 81</td>
</tr>
<tr>
<td>S. Nassir Ghaemi, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Abbott Laboratories; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company</td>
<td>33, 62, 65, 88</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Merck Medco Managed Care</td>
<td>23, 70</td>
</tr>
<tr>
<td>Michael J. Gitlin, M.D.</td>
<td>Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline</td>
<td>90</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Organon Inc.</td>
<td>65, 87</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Cortex Pharmaceuticals; AstraZeneca Pharmaceuticals; Devereux Foundation</td>
<td></td>
</tr>
<tr>
<td>R. Rao Gogineni, M.D.</td>
<td>Devereux Foundation</td>
<td>31, 84</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; R.W. Johnson; Shire U.S., Inc.; Pharmacia Corporation</td>
<td>11, 33, 62, 63</td>
</tr>
<tr>
<td>Stephen M. Goldfinger, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Mallinckrodt; AstraZeneca Pharmaceuticals</td>
<td>35, 71, 89</td>
</tr>
<tr>
<td>Karl Goodfinger, M.D.</td>
<td>Advanced Immunity, Inc.; GlaxoSmithKline; PharmaCorporation; Merck &amp; Co., Inc.; Cambridge University Press</td>
<td>29, 61, 89</td>
</tr>
<tr>
<td>Marianne Goodman, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>84, 87</td>
</tr>
<tr>
<td>Paul J. Goodnick, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline</td>
<td>47</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>Abbott Laboratories; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Pfizer Inc.; Eli Lilly and Company; Scios Nova Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>33, 62, 90</td>
</tr>
<tr>
<td>Guy M. Goodwin, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>8, 11</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>Eli Lilly and Company; National Institute of Mental Health; NARSAD; Pfizer Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Wyeth Pharmaceuticals; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Forest Laboratories, Inc.; Lundbeck; Solvay Pharmaceuticals, Inc.; Merck &amp; Co., Inc.; Sanofi Pharmaceuticals, Inc.; UCB Pharma; Purdue; Aventis; Xenova</td>
<td>3, 63</td>
</tr>
<tr>
<td>Elizabeth Gould, Ph.D.</td>
<td>GlaxoSmithKline</td>
<td>63</td>
</tr>
<tr>
<td>Tana A. Grady-Weliky, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline</td>
<td>65</td>
</tr>
<tr>
<td>Kevin F. Gray, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>5</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation</td>
<td>83, 98</td>
</tr>
<tr>
<td>John H. Greist, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>Nichole D. Grier, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>70</td>
</tr>
<tr>
<td>Mark S. Groves, M.D.</td>
<td>GlaxoSmithKline</td>
<td>22</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline</td>
<td>13, 37</td>
</tr>
<tr>
<td>Ellen Haller, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb</td>
<td>52, 76</td>
</tr>
<tr>
<td>Mark B. Hannner, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>55</td>
</tr>
<tr>
<td>Roger F. Haskett, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>23</td>
</tr>
<tr>
<td>Keith A. Hawkins, Psy.D.</td>
<td>Eli Lilly and Company</td>
<td>95</td>
</tr>
<tr>
<td>Stephen H. Heidel, M.D.</td>
<td>Integrated Insights (employer)</td>
<td>7</td>
</tr>
<tr>
<td>Howard A. Heit, M.D.</td>
<td>Purdue Pharma; McNeil Pharmaceutical; Abbott Laboratories</td>
<td>62</td>
</tr>
<tr>
<td>David J. Hellestein, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Distra Products; Wyeth Pharmaceuticals; Merck &amp; Co., Inc.; National Institute of Mental Health; National Institute on Drug Abuse</td>
<td>92</td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>37, 64</td>
</tr>
<tr>
<td>John F. Hendrick, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Organon Inc.; Wyeth Pharmaceuticals</td>
<td>48</td>
</tr>
<tr>
<td>Scott W. Henggeler, Ph.D.</td>
<td>MST Services, Inc.</td>
<td>95</td>
</tr>
<tr>
<td>Charles H. Hennekens, M.D.</td>
<td>Pfizer Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Paula L. Hensleys, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company</td>
<td>77</td>
</tr>
<tr>
<td>Jerrold W. Hill, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>92</td>
</tr>
<tr>
<td>Robert A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Eli Lilly and Company; Pfizer Inc.; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; Sepracor, Inc.; Novartis Pharmaceuticals Corporation</td>
<td>3, 11</td>
</tr>
<tr>
<td>Max Hirshkowitz, Ph.D.</td>
<td>Wyeth Pharmaceuticals; Seacle; Lorex Bertek; Pharmacia Corporation; Cephalon, Inc.; Merck &amp; Co., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Sepracor, Inc.; Takeda Pharmaceuticals</td>
<td>78</td>
</tr>
<tr>
<td>Eric Holland, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Wyeth Pharmaceuticals</td>
<td>34, 64, 84, 87</td>
</tr>
<tr>
<td>Michael A. Hollifield, M.D.</td>
<td>Eli Lilly and Company</td>
<td>77</td>
</tr>
<tr>
<td>Roy P. Houghtalen, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>89</td>
</tr>
<tr>
<td>Robert H. Howland, M.D.</td>
<td>Cyberonics, Inc.</td>
<td>52</td>
</tr>
<tr>
<td>Rona Hu, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb</td>
<td>13</td>
</tr>
<tr>
<td>James I. Hudson, M.D.</td>
<td>Eli Lilly and Company, Pfizer Inc.; Ortho-McNeil Pharmaceuticals; Elan Pharmaceuticals; Merck &amp; Co., Inc.; Knoll</td>
<td>86</td>
</tr>
<tr>
<td>James J. Hudziak, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company</td>
<td>64</td>
</tr>
<tr>
<td>Douglas H. Hughes, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>63</td>
</tr>
<tr>
<td>Thomas D. Hurwitz, M.D.</td>
<td>Seacle; Wyeth Pharmaceuticals</td>
<td>27, 78</td>
</tr>
<tr>
<td>Mostafa M. Hussain</td>
<td>National Institute of Mental Health; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Pfizer Inc.</td>
<td>52, 64</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>19, 30</td>
</tr>
<tr>
<td>Steven E. Hyler, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>14, 56</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Naveed Iqbal, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Pfizer Inc.; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb</td>
<td>19</td>
</tr>
<tr>
<td>Richard S. Jackson, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation</td>
<td>7</td>
</tr>
<tr>
<td>Richard L. Jaffe, M.D.</td>
<td>Pfizer Inc.</td>
<td>38</td>
</tr>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Penentech; National Institutes of Health; Pfizer Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Sepracor, Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>24, 38</td>
</tr>
<tr>
<td>Kathleen Jarboe, R.N.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company</td>
<td>9</td>
</tr>
<tr>
<td>Robin B. Jarrett, Ph.D.</td>
<td>Cyberonics, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Michael D. Jibson, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.</td>
<td>85</td>
</tr>
<tr>
<td>David C. Jimerson, M.D.</td>
<td>Abbott Laboratories</td>
<td>7</td>
</tr>
<tr>
<td>David E. Jaranson, M.S.W.</td>
<td>Ortho-McNeil Products; Janssen Pharmaceutica and Research Foundation; Purdue Pharma</td>
<td>62</td>
</tr>
<tr>
<td>Ned H. Kahn, M.D.</td>
<td>GlaxoSmithKline; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Neurocrine</td>
<td>11</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Bristol-Myers Squibb; Lundbeck; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals</td>
<td>9, 13</td>
</tr>
<tr>
<td>Shitij Kapur, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Neuronmolecular, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.</td>
<td>82, 96</td>
</tr>
<tr>
<td>David J. Katzenlick, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; MacArthur Foundation; Organon Inc.; Robert Wood Johnson Foundation; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Pharmacia Corporation; Johnson and Johnson; Healthcare Technology Systems, Inc.</td>
<td>60</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals; Merck &amp; Co., Inc.</td>
<td>11, 81, 93</td>
</tr>
<tr>
<td>Samuel J. Keith, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>9</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Merck &amp; Co., Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Mitsubishi Pharmaceuticals; Scirex; Vela Pharmaceuticals; Sepracor, Inc.; Somnet Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.; Cypress Bioscience</td>
<td>11, 60</td>
</tr>
<tr>
<td>Charles H. Kellner, M.D.</td>
<td>Somatics, Inc.</td>
<td>1, 38</td>
</tr>
<tr>
<td>Justine M. Kent, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>63</td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Bristol-Myers Squibb; Elan Pharmaceuticals; AstraZeneca Pharmaceuticals; Shire U.S., Inc.; Cephalon, Inc.</td>
<td>5, 63</td>
</tr>
<tr>
<td>Paul A. Kettl, M.D.</td>
<td>Pfizer Inc.; Organon Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Manor HealthCare; Abbott Laboratories; Bristol-Myers Squibb</td>
<td>42, 80</td>
</tr>
<tr>
<td>Clinton D. Kiltz, Ph.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline</td>
<td>63</td>
</tr>
<tr>
<td>Steven A. King, M.D.</td>
<td>Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Purdue; Endo</td>
<td>2</td>
</tr>
<tr>
<td>Ellen Kingsley, M.A.</td>
<td>Additude Magazine; Atia Pharmaceuticals; Shire U.S., Inc.; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Eli Lilly and Company; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>38</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Schering Plough</td>
<td>34, 43, 66</td>
</tr>
<tr>
<td>Mitchel A. Kling, M.D.</td>
<td>Cyberonics, Inc.</td>
<td>52</td>
</tr>
<tr>
<td>Harold W. Koenigsberg, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>74, 84</td>
</tr>
<tr>
<td>Anthony L. Komaroff, M.D.</td>
<td>Cephalon, Inc.</td>
<td>86</td>
</tr>
</tbody>
</table>

XXIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lilli Kopala, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Lundbeck; Novartis Pharmaceuticals Corporation; Pfizer Inc.</td>
<td>13</td>
</tr>
<tr>
<td>Susan G. Koenstein, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Pharmacia Corporation; Mitsubishi; Biowal; Berlex Laboratories; Novartis Pharmaceuticals Corporation; Merck &amp; Co., Inc. Cyberonics, Inc.</td>
<td>6, 9</td>
</tr>
<tr>
<td>Thomas R. Kosten, M.D.</td>
<td>Abbott Laboratories; Schering Pharmaceuticals</td>
<td>66, 95</td>
</tr>
<tr>
<td>Robert A. Kovatch, M.D.</td>
<td>Abbott Laboratories; Solvay Pharmaceuticals, Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Diana M. Kozupa, M.D.</td>
<td>GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Eli Lilly and Company</td>
<td>97</td>
</tr>
<tr>
<td>Lois Kranz, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>8, 13, 78</td>
</tr>
<tr>
<td>Henry R. Kranzler, M.D.</td>
<td>Best Practice/Drug Abuse Sciences; Centra Pharma</td>
<td>55</td>
</tr>
<tr>
<td>Christopher J. Kratochvil, M.D.</td>
<td>Eli Lilly and Company; Alza Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>3, 83</td>
</tr>
<tr>
<td>Ranga K. Krishnan, M.D.</td>
<td>Eisai Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Forest Laboratories, Inc.; Abbott Laboratories; Bristol-Myers Squibb; Du Pont Pharma; GlaxoSmithKline; Janssen Pharmaceuticals and Research Foundation; Merck &amp; Co., Inc.; Organon Inc.; Pharmacia Corporation; Somerset Pharmaceuticals, Inc.</td>
<td>6, 11</td>
</tr>
<tr>
<td>Elisabeth J.S. Kunkel, M.D.</td>
<td>Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Wyeth Pharmaceuticals; Pfizer Inc.</td>
<td>75</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>3, 34, 63</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Lundbeck; Servier; Lievebook; Organon Inc.; Wyeth Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceuticals and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>17, 58, 70, 94</td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D.</td>
<td>Pfizer Inc.</td>
<td>25, 93</td>
</tr>
<tr>
<td>Ellen Lebenluft, M.D.</td>
<td>Pfizer Inc.; Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; Johnson and Johnston</td>
<td>3</td>
</tr>
<tr>
<td>Alan I. Levenson, M.D.</td>
<td>Psychiatrists' Purchasing Group, Inc.</td>
<td>18</td>
</tr>
<tr>
<td>Frances R. Levin, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline</td>
<td>34, 44, 55</td>
</tr>
<tr>
<td>Saul M. Levin, M.D.</td>
<td>SAMHSA/CSAT</td>
<td>90, 93</td>
</tr>
<tr>
<td>Jeffrey M. Levine, M.D.</td>
<td>Wyeth Pharmaceuticals; GlaxoSmithKline; Pfizer Inc.</td>
<td>44</td>
</tr>
<tr>
<td>David A. Lewis, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; Pfizer Inc.; AstraZeneca Pharmaceuticals; Hoechst Marion Roussel; Pharmacia Corporation</td>
<td>9, 10, 12</td>
</tr>
<tr>
<td>Barry D. Liebowitz, Ph.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>85</td>
</tr>
<tr>
<td>Walter Ling, M.D.</td>
<td>Roxane Laboratories; Schering Plough</td>
<td>50</td>
</tr>
<tr>
<td>Paul S. Links, M.D.</td>
<td>Eli Lilly and Company, Canada, Inc.</td>
<td>81</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>MagStim Company</td>
<td>14</td>
</tr>
<tr>
<td>Maria D. Llorente, M.D.</td>
<td>Abbott Laboratories</td>
<td>32</td>
</tr>
<tr>
<td>Miklos F. Losonczy, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals</td>
<td>19</td>
</tr>
<tr>
<td>Joe Lovelace, J.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>9</td>
</tr>
<tr>
<td>R. Bruce Lydiard, M.D.</td>
<td>Bristol-Myers Squibb; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Forest Laboratories, Inc.; Roche Laboratories, a member of the Roche Group; AstraZeneca Pharmaceuticals</td>
<td>10, 61, 87</td>
</tr>
<tr>
<td>Constandine G. Lyketsos, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a Division of Eli Lilly and Company, Du Pont Pharma; Abbott Laboratories; Eisai Inc.; Bristol-Myers Squibb</td>
<td>7</td>
</tr>
<tr>
<td>Gerald A. Maguire, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Husseini K. Manji, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company, Janssen Pharmaceutica and Research Foundation; Oxford Glycosciences; Chiron; AstraZeneca Pharmaceuticals; Abbott Laboratories; Pharmacia Corporation</td>
<td>12</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>National Institutes of Health; Stanley Foundation; Eli Lilly and Company; Martek Biosciences; Cyberonics; Abbott Laboratories; Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>9, 11, 81</td>
</tr>
<tr>
<td>John S. March, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Shire U.S., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company, Alza Pharmaceuticals; Somerset Pharmaceuticals, Inc.; Medeva; Celgene; Bristol-Myers Squibb</td>
<td>87</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td>9, 38</td>
</tr>
</tbody>
</table>

XXIV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>John C. Markowitz, M.D.</td>
<td>National Institute of Mental Health; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; American Psychiatric Press Inc.; Basic Books; Wyeth Pharmaceuticals</td>
<td>6, 48, 66, 96</td>
</tr>
<tr>
<td>Robert C. Marks, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>24</td>
</tr>
<tr>
<td>Prakash S. Massand, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Health Care Technology; Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Searle; Solvay Pharmaceuticals, Inc.</td>
<td>3, 37, 63, 96</td>
</tr>
<tr>
<td>Donna Masterman, M.D.</td>
<td>Pfizer Inc.; Eisai Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; Fujiwara; Neotherapeutics; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation</td>
<td>86</td>
</tr>
<tr>
<td>Marig R. Mavissakalian, M.D.</td>
<td>Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>22</td>
</tr>
<tr>
<td>Una D. McCann, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb</td>
<td>81</td>
</tr>
<tr>
<td>Richard H. McCarthy, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company</td>
<td>71</td>
</tr>
<tr>
<td>Christopher J. McDougle, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company</td>
<td>14</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Forest Laboratories, Inc.; Elan Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil Pharmaceuticals</td>
<td>86</td>
</tr>
<tr>
<td>Joseph P. McEvoy, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>9, 10</td>
</tr>
<tr>
<td>Patrick D. McGorry, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb</td>
<td>9</td>
</tr>
<tr>
<td>Alan J. Mendelowitz, M.D.</td>
<td>Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>64, 85</td>
</tr>
<tr>
<td>Ricardo P. Mendoza, M.D.</td>
<td>Pfizer Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>70</td>
</tr>
<tr>
<td>Matthew A. Menza, M.D.</td>
<td>Cephalon, Inc.</td>
<td>92</td>
</tr>
<tr>
<td>David Michelson, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>47</td>
</tr>
<tr>
<td>Frederick E. Miller, M.D.</td>
<td>Pfizer Inc.</td>
<td>74</td>
</tr>
<tr>
<td>Matthew S. Miller, Ph.D.</td>
<td>Cephalon, Inc. (employer)</td>
<td>49</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>7, 25, 85</td>
</tr>
<tr>
<td>Shaila Misri, M.D.</td>
<td>GlaxoSmithKline, Wyeth Pharmaceuticals</td>
<td>8</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories</td>
<td>7, 30</td>
</tr>
<tr>
<td>Gary S. Moak, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>Francisco A. Moreno, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>18, 64</td>
</tr>
<tr>
<td>Philip Morris, Ph.D.</td>
<td>Dupont Pharma</td>
<td>83</td>
</tr>
<tr>
<td>Grover M. Murphy, M.D.</td>
<td>Organon Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Dominique L. Musselman, M.D.</td>
<td>DANA Foundation; GlaxoSmithKline; National Institutes of Health; Schering Plough; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>13</td>
</tr>
<tr>
<td>Ziad H. Nahas, M.D.</td>
<td>Cyberonics, Inc.; Neotonus, Inc.</td>
<td>14, 52</td>
</tr>
<tr>
<td>Henry A. Narrallah, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; National Institutes of Health; Bristol-Myers Squibb</td>
<td>13, 37</td>
</tr>
<tr>
<td>Rebecca R. Neal, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>19</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals</td>
<td>6, 64</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Acadia Pharmaceuticals; Cypress Biosciences; Cytori; McNeil Pharmaceuticals; Merck &amp; Co., Inc.; Neurocrine Biosciences; Sanofi Pharmaceuticals, Inc.; Vela</td>
<td>11, 63</td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Thomas Newton, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>52</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Innopaharma, Bristol-Myers Squibb; Cybergene; Lichtner; Pfizer Inc.; Forest Laboratories, Inc.</td>
<td>2, 6</td>
</tr>
<tr>
<td>Carol S. North, M.D.</td>
<td>GlaxoSmithKline, Bristol-Myers Squibb</td>
<td>8, 97</td>
</tr>
<tr>
<td>Andrei Novac, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.</td>
<td>71</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline</td>
<td>75</td>
</tr>
<tr>
<td>Charles P. O'Brien, M.D.</td>
<td>Dupont Pharma</td>
<td>18, 83, 94</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Mary B. O'Malley, M.D.</td>
<td>Cephalon, Inc.</td>
<td>49, 86</td>
</tr>
<tr>
<td>N. Kalaya Okereke, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>47</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems</td>
<td>5, 19, 25, 30</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>Pharcia Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Ancile Pharma; GlaxoSmithKline; Eli Lilly and Company; Psychological Corporation; Abbott Laboratories</td>
<td>11, 57</td>
</tr>
<tr>
<td>Michael J. Owens, Ph.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Abbott Laboratories; Eli Lilly and Company</td>
<td>2, 63, 65</td>
</tr>
<tr>
<td>Michelle T. Pato, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Pfizer Inc.</td>
<td>38</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>9, 13, 95</td>
</tr>
<tr>
<td>Frederick Petty, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Edmond H.T. Pi, M.D.</td>
<td>Eli Lilly and Company</td>
<td>70</td>
</tr>
<tr>
<td>Debra A. Pinals, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>90</td>
</tr>
<tr>
<td>Daniel Pine, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals</td>
<td>35, 63</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>10</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmacia Corporation; UCB Pharma</td>
<td>62, 63</td>
</tr>
<tr>
<td>Marc N. Potenza, M.D.</td>
<td>GlaxoSmithKline; Forest Laboratories, Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>64</td>
</tr>
<tr>
<td>David W. Peeve, M.D.</td>
<td>Forest Laboratories, Inc.; Pfizer Inc.</td>
<td>26</td>
</tr>
<tr>
<td>Annelle B. Primm, M.D.</td>
<td>Pfizer Inc.</td>
<td>43</td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td>GlaxoSmithKline; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Abza Pharmaceuticals</td>
<td>1, 78</td>
</tr>
<tr>
<td>Andres J. Pumariega, M.D.</td>
<td>Center for Mental Health Services</td>
<td>90</td>
</tr>
<tr>
<td>Arturo G. Quiaion, M.D.</td>
<td>Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>25</td>
</tr>
<tr>
<td>Ljiliana Radulovic, M.D.</td>
<td>Abbott Laboratories</td>
<td>92</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems</td>
<td>5</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Abbott Laboratories; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation; Robert Wood Johnson; UBC Pharma; Wyeth Pharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>2, 34</td>
</tr>
<tr>
<td>Scott L. Rauch, M.D.</td>
<td>GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>8</td>
</tr>
<tr>
<td>William T. Regeosnoed, M.D.</td>
<td>Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>43</td>
</tr>
<tr>
<td>William E. Reichman, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Organon Inc.; Forest Laboratories, Inc.</td>
<td>2, 7</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>66, 93</td>
</tr>
<tr>
<td>Perry J. Ressler, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline</td>
<td>63</td>
</tr>
<tr>
<td>Charles F. Reynolds III, M.D.</td>
<td>GlaxoSmithKline; Forest Laboratories, Inc.; Organon Inc.</td>
<td>5, 9</td>
</tr>
<tr>
<td>Mary Ann Richardson, Ph.D.</td>
<td>Scientific Hospital Supplies, Ltd.</td>
<td>75</td>
</tr>
<tr>
<td>Mark A. Riddle, M.D.</td>
<td>Best Practice; Excerpta Medical; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb, Shire U.S., Inc.; Solvay Pharmaceuticals, Inc.; National Institute of Mental Health</td>
<td>98</td>
</tr>
<tr>
<td>Gustavo C. Roman, M.D.</td>
<td>Eisai Inc.</td>
<td>86</td>
</tr>
<tr>
<td>Steven P. Roote, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Pharmacia Corporation</td>
<td>5, 9</td>
</tr>
<tr>
<td>Mark R. Rosekind, Ph.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>13</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Cyberonics; Eli Lilly and Company; Forest Laboratories, Inc.; Lichtwer Pharma; Organon Inc.; Wyeth Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Thomas Roth, Ph.D.</td>
<td>Wyeth Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; Avenirs; Sepacor, Inc.; Neurocrine; Merek &amp; Co., Inc.; Proctor and Gamble; Takeda Pharmaceuticals; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.</td>
<td>37, 85</td>
</tr>
<tr>
<td>Barbara O. Rothbaum, Ph.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Virtually Better; Somerset Pharmaceuticals, Inc.</td>
<td>8, 11</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Cyberronics; Robert Wood Johnson Foundation; National Institute of Mental Health; Stanley Foundation; Wyeth Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck &amp; Co., Inc.; Pfizer Inc.; Pharmacia Corporation</td>
<td>9, 60</td>
</tr>
<tr>
<td>Donna H. Ryan, M.D.</td>
<td>Wyeth Pharmaceuticals; Abbott Laboratories; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Amgen; Bristol-Myers Squibb; Ergo; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Warner Lambert; Regeneron Pharmaceuticals; Schering Plough; Proctor and Gamble; TAP Pharmaceuticals; Wyeth Pharmaceuticals</td>
<td>65</td>
</tr>
<tr>
<td>J. Michael Ryan, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Abbott Laboratories; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals</td>
<td>2, 86</td>
</tr>
<tr>
<td>Neal D. Ryan, M.D.</td>
<td>Pfizer Inc.; Abbott Laboratories; Hoffman-LaRoche; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Wyeth Pharmaceuticals</td>
<td>13</td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Elan; Sanofi Pharmaceuticals Inc.; Scios Nova Pharmaceuticals; Solvay Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals</td>
<td>8, 11, 92</td>
</tr>
<tr>
<td>Harold A. Sackeim, Ph.D.</td>
<td>Pfizer Inc.; Forest Laboratories, Inc.; Cyberronics</td>
<td>5, 9, 81</td>
</tr>
<tr>
<td>Mary Sano, Ph.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Merck &amp; Co., Inc.; Fujisawa; Pfizer Inc.</td>
<td>85</td>
</tr>
<tr>
<td>Norman Sartorius, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>6, 60</td>
</tr>
<tr>
<td>Seddon R. Savage, M.D.</td>
<td>Muro Astra Medica; Ortho-McNeil Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Purdue Pharma</td>
<td>62</td>
</tr>
<tr>
<td>Franklin R. Schnieker, M.D.</td>
<td>Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; GlaxoSmithKline</td>
<td>61</td>
</tr>
<tr>
<td>Nina R. Schooler, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>30, 64</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Pfizer Inc.</td>
<td>13, 87</td>
</tr>
<tr>
<td>Dean Schuyler, M.D.</td>
<td>Wyeth Pharmaceuticals; Pfizer Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Marcia Scott, M.D.</td>
<td>Prudential</td>
<td>7</td>
</tr>
<tr>
<td>Yvette Sealy, Ph.D.</td>
<td>Bedford Community Health Center</td>
<td>44</td>
</tr>
<tr>
<td>Larry J. Seidman, Ph.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Shire U.S., Inc.</td>
<td>86</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>GlaxoSmithKline</td>
<td>2, 34, 47</td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>GlaxoSmithKline</td>
<td>15</td>
</tr>
<tr>
<td>M. Katherine Shear, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
<td>11</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories; Alza Pharmaceuticals; Forest Laboratories, Inc.; GlaxoSmithKline; Layton Bioscience; Lilly Research Laboratories, a division of Eli Lilly and Company; Lundbeck; Organon Inc.; Pharmacia Corporation; Pfizer Inc.; Pierre Fabre; Wyeth Pharmaceuticals; American Medical Association; Andrope Foundation; Bristol-Myers Squibb; Eisai Inc.; International Clinical Research; Janssen Pharmaceutica and Research Foundation; Kali Duphar Laboratories; Mead Johnson Laboratories; Meck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Quintiles; Sanofi Pharmaceuticals Corporation; Synthélabo; Tampa General Hospital-University Psychiatry Center; TAP Pharmaceuticals; Warner Chilcott Pharmaceutical Company; Worldwide Clinical Trials; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Boots Pharmaceuticals; Charter Hospitals; Ciba Geigy Corporation; Pharmaceutical Division; Dista Products; Excerpta Medica Asia; Humana; ICI; Marion Merrill Dow; McNeil Pharmaceuticals; Organon Inc.; Novo Nordisk Pharmaceuticals Inc.; Rhone-Poulenc Rorer Pharmaceuticals; Roerig; Schering Plough; Corporation; Solvay Pharmaceuticals, Inc.; Layton Bioscience; Medical Outcome Systems</td>
<td>8, 13</td>
</tr>
<tr>
<td>Richard C. Shelton, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Rhone-Poulenc Rorer Pharmaceuticals; Sanofi Pharmaceuticals Inc.; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.</td>
<td>65, 87, 96</td>
</tr>
<tr>
<td>Larry J. Siever, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>65, 84, 87</td>
</tr>
<tr>
<td>Linmarie Slikich, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>48</td>
</tr>
<tr>
<td>Deborah R. Simkin, M.D.</td>
<td>Pfizer Inc.; Alza Pharmaceuticals; GlaxoSmithKline</td>
<td>83, 84</td>
</tr>
<tr>
<td>Gregory E. Simon, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.</td>
<td>59</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>10</td>
</tr>
<tr>
<td>Samuel G. Siris, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Merck &amp; Co., Inc.</td>
<td>30</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Organon Inc.; Forest Laboratories, Inc.; Eisai Inc.</td>
<td>86</td>
</tr>
</tbody>
</table>

XXVII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Kaiser, Bristol-Myers Squibb; Pfizer Inc.; Upsher-Smith; National Institute of Mental Health</td>
<td>5</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Boston Life Sciences; Bristol-Myers Squibb; Eisai Inc.; GlaxoSmithKline; Glaxtech, Lilly Research Laboratories, a division of Eli Lilly and Company; Medeva; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire U.S., Inc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
<td>3, 86</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Research Foundation; Lundbeck; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmacia Corporation; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Watson; Wyeth Pharmaceuticals; Yamanauchi; AstraZeneca Pharmaceuticals; Abbott Laboratories; Aventis, Fabeck; Faire; Fluorox; Lundbeck; Neurocrine; Novartis Pharmaceuticals Corporation; Pierre Fabre; Sanofi; Roche; Sumimoto</td>
<td>61</td>
</tr>
<tr>
<td>Judy L. Stange, Ph.D.</td>
<td>SAMHSA (employer)</td>
<td>90</td>
</tr>
<tr>
<td>Dan J. Stein, M.D.</td>
<td>MRC Unit on Anxiety Disorders (employer)</td>
<td>57</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Allergan; Alza Pharmaceuticals; Janssen Pharmaceutical Research Foundation; Hoffman-LaRoche; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmaceutical Research Institute</td>
<td>61</td>
</tr>
<tr>
<td>Hans Steiner, M.D.</td>
<td>Abbott Laboratories; Pfizer Inc.; Janssen Pharmaceutical Research Foundation</td>
<td>14, 65</td>
</tr>
<tr>
<td>Jonathan W. Stewart, M.D.</td>
<td>Organon Inc.</td>
<td>6</td>
</tr>
<tr>
<td>Nada L. Stotland, M.D.</td>
<td>Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>49</td>
</tr>
<tr>
<td>Eric C. Strain, M.D.</td>
<td>Schering-Plough Corp.</td>
<td>55, 66</td>
</tr>
<tr>
<td>David L. Sultzer, M.D.</td>
<td>Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutical Research Foundation</td>
<td>7</td>
</tr>
<tr>
<td>Patricia Suppes, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmaceutical Research Institute</td>
<td>8, 11</td>
</tr>
<tr>
<td>Alan C. Swann, M.D.</td>
<td>Abbott Laboratories; GlaxoSmithKline; UCB, Bristol-Myers Squibb; Shire U.S., Inc.; Novartis Pharmaceuticals Corporation; Shire U.S., Inc.; Robert Wood Johnson</td>
<td>65, 87</td>
</tr>
<tr>
<td>Holly A. Swartz, M.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company</td>
<td>3, 37</td>
</tr>
<tr>
<td>Carol A. Tamringer, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>12</td>
</tr>
<tr>
<td>Rajiv Tandon, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company, Janssen Pharmaceutical Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.</td>
<td>38, 85, 93</td>
</tr>
<tr>
<td>Steven D. Targum, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>14</td>
</tr>
<tr>
<td>Pierre N. Tariot, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division; Bissai Inc.; Eli Lilly and Company; Janssen Pharmaceutical Research Foundation; Lundbeck; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Berlex; Pharmacia Corporation; Schwabe</td>
<td>2, 7, 86</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Merck &amp; Co., Inc.; Organon Inc.; Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.</td>
<td>6, 11, 59, 66</td>
</tr>
<tr>
<td>Diane S. Thompson, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Pfizer Inc.</td>
<td>87</td>
</tr>
<tr>
<td>Joyce A. Tinsley, M.D.</td>
<td>Pfizer Inc.</td>
<td>76</td>
</tr>
<tr>
<td>Mauricio F. Tohen, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>24, 48</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td>18, 42, 72</td>
</tr>
<tr>
<td>Madhukar H. Trivedi, M.D.</td>
<td>Abbott Laboratories; Akzo, Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Organon Inc.; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutical Research Foundation; Johnson and Johnson; National Institute of Mental Health; Mead Johnson; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals</td>
<td>9, 60</td>
</tr>
<tr>
<td>John W. Tsuang, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutical Research Foundation</td>
<td>52</td>
</tr>
<tr>
<td>Phebe M. Tucker, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Ortho-McNeil</td>
<td>8</td>
</tr>
<tr>
<td>Anilla Turgay, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Purdue Pharmaceuticals, Inc.; Eli Lilly and Company; Neate</td>
<td>74, 91</td>
</tr>
<tr>
<td>Michael A. Van Ameringen, M.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutical Research Foundation; Bristol-Myers Squibb</td>
<td>22</td>
</tr>
<tr>
<td>Meera Vaswani, Ph.D.</td>
<td>All India Institute of Medical Sciences (employer)</td>
<td>74</td>
</tr>
<tr>
<td>Sanjeev Venkatakrnan, M.D.</td>
<td>Organon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutical Research Foundation</td>
<td>7</td>
</tr>
<tr>
<td>Sumer Verma, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Abbott Laboratories; GlaxoSmithKline; Searle; Janssen Pharmaceutical Research Foundation; Neurotherapeutics</td>
<td>6</td>
</tr>
</tbody>
</table>

XXVIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garry M. Vickar, M.D.</td>
<td>Eli Lilly and Company, Johnson and Johnson, Merck &amp; Co., Inc.; GlaxoSmithKline; Pfizer Inc.; Elan; Wyeth Pharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>Bruce S. Victor, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories</td>
<td>15</td>
</tr>
<tr>
<td>Walter V. Vieweg, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>3</td>
</tr>
<tr>
<td>Adele C. Viguera, M.D.</td>
<td>Wyeth Pharmaceuticals; Eli Lilly and Company</td>
<td>11, 32</td>
</tr>
<tr>
<td>Joseph R. Volpicelli, M.D.</td>
<td>Malinchkrodt, Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Organon Inc.; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Celastra; Lamictal</td>
<td>3, 5</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Knoll Pharmaceuticals; Eli Lilly and Company; Ortho-McNeil Pharmaceuticals</td>
<td>59, 86</td>
</tr>
<tr>
<td>James K. Walsh, Ph.D.</td>
<td>Pharmacia Corporation; Lorex Pharmaceuticals; Searle; Pfizer Inc.; Abbott Laboratories; Amerin Cyanamid; Hoffman-LaRoche; Merck &amp; Co., Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Takeda Pharmaceuticals; Ancile Pharmaceuticals; Neurocine Biosciences; Cephalon, Inc.; Sepracor, Inc.; Whitehall-Robins; Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; CoCensys Pharmaceuticals; Proctor and Gamble</td>
<td>85</td>
</tr>
<tr>
<td>Khakasa H. Wapenyi, M.D.</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>29, 75</td>
</tr>
<tr>
<td>Julia K. Warnock, M.D.</td>
<td>Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Pfizer; Solvay Pharmaceuticals, Inc.</td>
<td>65, 87</td>
</tr>
<tr>
<td>Deborah Wasilchak</td>
<td>Community Care Behavior Health (employer)</td>
<td>43</td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.</td>
<td>9, 86, 92</td>
</tr>
<tr>
<td>Daniel R. Weinberger, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>6, 12, 86</td>
</tr>
<tr>
<td>Robert M. Weinzieb, M.D.</td>
<td>Dupont Pharma</td>
<td>44</td>
</tr>
<tr>
<td>Ria B. Weisberg, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>22</td>
</tr>
<tr>
<td>Myrna M. Weissman, Ph.D.</td>
<td>GlaxoSmithKline</td>
<td>3, 97</td>
</tr>
<tr>
<td>Elizabeth B. Weller, M.D.</td>
<td>GlaxoSmithKline; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Organon Inc.; Johnson and Johnson</td>
<td>97</td>
</tr>
<tr>
<td>Gary L. Wenk, Ph.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>85</td>
</tr>
<tr>
<td>Joyce C. West, Ph.D.</td>
<td>AIRE</td>
<td>60</td>
</tr>
<tr>
<td>Mark D. Wiederhold, M.D.</td>
<td>The Virtual Reality Medical Center; VR Health; Interactive Media Institute</td>
<td>98</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Alza Pharmaceuticals; Abbott Laboratories; Merck; Shire U.S., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; National Institute of Mental Health; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; NICMH</td>
<td>5, 47</td>
</tr>
<tr>
<td>Denise E. Wilfley, Ph.D.</td>
<td>Abbott Laboratories; Ortho-McNeil Pharmaceuticals</td>
<td>86</td>
</tr>
<tr>
<td>Martin S. Willick, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>6</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Cephalon, Inc.; Wyeth Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Searle</td>
<td>10, 27, 86</td>
</tr>
<tr>
<td>Donna A. Wirshing, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Organon Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; PPD Pharmaco</td>
<td>3</td>
</tr>
<tr>
<td>Scott W. Woods, M.D.</td>
<td>Eli Lilly and Company</td>
<td>95</td>
</tr>
<tr>
<td>Mary R. Worthen</td>
<td>Eli Lilly and Company</td>
<td>11</td>
</tr>
<tr>
<td>Janet Woznuk, M.D.</td>
<td>Alza Pharmaceuticals; Pharmacia Corporation; Eli Lilly and Company</td>
<td>3, 38</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindstreet</td>
<td>18, 26, 30, 66, 78</td>
</tr>
<tr>
<td>Kevin R. Wylie, M.D.</td>
<td>Pfizer, Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>49</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company</td>
<td>7, 26, 30, 77</td>
</tr>
<tr>
<td>Rachel Yehuda, Ph.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>8, 71</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Berlex; Pfizer Inc.; American Home Products; Wyeth Pharmaceuticals</td>
<td>11, 87</td>
</tr>
<tr>
<td>Stuart Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>13, 37</td>
</tr>
<tr>
<td>John M. Zajacck, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Cephalon, Inc.; Cyberonics; GlaxoSmithKline; Lichtwer Pharma; MITICO, Inc.; Otsuka Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals; Abbott Laboratories; Pharmacon Corporation</td>
<td>37</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.</td>
<td>33</td>
</tr>
</tbody>
</table>
The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nancy C. Andreasen, M.D.</td>
<td>82</td>
</tr>
<tr>
<td>William Arroyo, M.D.</td>
<td>89</td>
</tr>
<tr>
<td>Gregory L. Barker</td>
<td>41</td>
</tr>
<tr>
<td>Guido Belsasso, M.D.</td>
<td>89</td>
</tr>
<tr>
<td>Eric G. Bing, M.D.</td>
<td>94</td>
</tr>
<tr>
<td>Herve Bokobza, M.D.</td>
<td>59</td>
</tr>
<tr>
<td>Gary Cobb</td>
<td>80</td>
</tr>
<tr>
<td>Marvis Frazier</td>
<td>80</td>
</tr>
<tr>
<td>Amansingh M. Ghorpade, M.D.</td>
<td>48</td>
</tr>
<tr>
<td>Jodi Goldstein, J.D.</td>
<td>76</td>
</tr>
<tr>
<td>Norma Hatot</td>
<td>77</td>
</tr>
<tr>
<td>Ruben J. Hernandez-Serrano, M.D.</td>
<td>84</td>
</tr>
<tr>
<td>Michael J. Kittay, M.D.</td>
<td>90</td>
</tr>
<tr>
<td>Louis J. Kraus, M.D.</td>
<td>89</td>
</tr>
<tr>
<td>Earl C. Lawrence, M.A.</td>
<td>41</td>
</tr>
<tr>
<td>Alexandra MacLean, M.D.</td>
<td>59</td>
</tr>
<tr>
<td>Cesare Maffei, M.D.</td>
<td>31</td>
</tr>
<tr>
<td>Farris Tuma, Sc.D.</td>
<td>71</td>
</tr>
<tr>
<td>Mike Ward</td>
<td>41</td>
</tr>
<tr>
<td>Wendy Williams</td>
<td>80</td>
</tr>
<tr>
<td>Lishan Workeneh, M.D.</td>
<td>42</td>
</tr>
</tbody>
</table>
8:00 a.m. Sessions

COURSES 1-5
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room 102 B, Street Level, Convention Center
COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW
Co-Directors: Paul R. Miller, M.D., Charles Chiu, M.D.

COURSE 2 8:00 a.m.-12 noon
Room 104 A, Street Level, Convention Center
ANTIPSYCHOTIC-INDUCED MOVEMENT DISORDERS: ASSESSMENT AND TREATMENT
Director: Leonardo Cortese, M.D.
Faculty: Richard Williams, M.D., Michael Caligiuri, Ph.D.

COURSE 3 8:00 a.m.-12 noon
Room 104 B, Street Level, Convention Center
ADD IN CHILDREN AND ADOLESCENTS
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 4 8:00 a.m.-12 noon
Room 109 A, Street Level, Convention Center
WRITING ABOUT CLINICAL EXPERIENCES
Director: John S. Strauss, M.D.

COURSE 5 8:00 a.m.-12 noon
Room 203 B, Level 200, Convention Center
ECT IN NEUROLOGICAL DISORDERS
Co-Directors: Georgios Petrides, M.D., Charles H. Kellner, M.D.
Faculty: C. Edward Coffey, M.D., Raymond A. Faber, M.D., Max Fink, M.D., Chitra Malur, M.D.

9:00 a.m. Sessions

COURSES 6-11
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 102 A, Street Level, Convention Center
BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT
Co-Directors: Christopher G. Fichtner, M.D., Thomas A. Simpatico, M.D.
Faculty: L. Mark Russakoff, M.D., Stuart B. Silver, M.D., S. Atezaz Saeed, M.D., Shivkumar Hatti, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 106 A, Street Level, Convention Center
INTERPERSONAL PSYCHOTHERAPY
Director: Scott P. Stuart, M.D.
Faculty: Michael Robertson, M.D.

COURSE 8 9:00 a.m.-4:00 p.m.
Room 111 A, Street Level, Convention Center
PERSONALITY AND POLITICAL BEHAVIOR
Director: Jerold M. Post, M.D.

COURSE 9 9:00 a.m.-4:00 p.m.
Room 112 A, Street Level, Convention Center
PSYCHIATRY UPDATE FOR THE INTERNATIONAL SPANISH-SPEAKING COLLEAGUE (IN SPANISH)
Director: Gabriel Kaplan, M.D.
Faculty: Javier I. Escobar, M.D., Jorge R. Petit, M.D., Eduardo Dunayevich, M.D., Rodrigo A. Pizarro, M.D., Dario F. Mirski, M.D., Ana Kaplan, M.D.
SUNDAY

COURSE 10  9:00 a.m.-4:00 p.m.
Room 112 B, Street Level, Convention Center
MULTIMODAL TREATMENT OF EATING DISORDERS
Co-Directors: Kathryn J. Zerbe, M.D., Mae S. Sokol, M.D.

COURSE 11  9:00 a.m.-4:00 p.m.
Room 103 A, Level 200, Convention Center
OUTCOMES: USE OF RATING SCALES
Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.

1:00 p.m. Sessions

COURSES 12-16
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 12  1:00 p.m.-5:00 p.m.
Room 104 A, Street Level, Convention Center
EVIDENCE-BASED MANAGEMENT OF SAD: FOCUS ON LIGHT THERAPY
Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

COURSE 13  1:00 p.m.-5:00 p.m.
Room 104 B, Street Level, Convention Center
NEUROENDOCRINOLOGY IN MOOD DISORDER: DYSREGULATION AND TREATMENT
Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.
Faculty: D. Jeffrey Newport, M.D., Stuart N. Seidman, M.D.

COURSE 14 - WITHDRAWN

COURSE 15  1:00 p.m.-5:00 p.m.
Room 108 B, Street Level, Convention Center
THE EVALUATION AND MANAGEMENT OF PAIN
Director: Steven A. King, M.D.

COURSE 16  1:00 p.m.-5:00 p.m.
Room 109 A, Street Level, Convention Center
DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH
Director: Milton Kramer, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-6
INDUSTRY-SUPPORTED SYMPOSIUM 1
7:00 p.m.-10:00 p.m.
Millennium Hall, Second Floor, Loews
PSYCHIATRY PRACTICE PARADIGM: THE EMERGING ROLE OF THE PSYCHIATRIST IN TREATING ALZHEIMER'S DISEASE
Supported by Eisai Inc., Pfizer Inc.
Chp: Pierre N. Tariot, M.D.
A Mild Cognitive Impairment Versus Early Alzheimer's Disease
J. Michael Ryan, M.D.
B Mild to Moderate Alzheimer's Disease
Pierre N. Tariot, M.D.
C Depression in Alzheimer's Disease
William E. Reichman, M.D.
D Dementia with Abnormal Neurological Features
J. Michael Ryan, M.D.
E Severe Dementia with Agitation and Nursing Home Issues
William E. Reichman, M.D.
F Psychosis in Alzheimer's Disease
William E. Reichman, M.D.
G Practice Management
Gary S. Moak, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
7:00 p.m.-10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews
MOLECULES AND MOOD DISORDERS: DRUG DISCOVERY AND THE TREATMENT OF DEPRESSION
Supported by Forest Laboratories, Inc.
Chp: Jerrold F. Rosenbaum, M.D.
A Antidepressant Drug Discovery: The Ways, Means, and Needs
Michael J. Owens, Ph.D.
B The Phenomenon of Single Isomer Drugs
Joseph Gal, Ph.D.
C Refining Current Therapies: Clinical Implications to the Treatment of Depression
C. Lindsay DeVane, Pharm.D.
Andrew A. Nierenberg, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 3
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

BIPOLAR DISORDER: NEW NATIONWIDE DATA ON MISDIAGNOSIS AND COMMUNITY COSTS
Supported by GlaxoSmithKline

Chp: Mark A. Frye, M.D.

A Prevalence and Burden of Depression in the Community and Primary Care
Myrna M. Weissman, Ph.D.

B The True Prevalence of Bipolar Spectrum Disorder
Robert M.A. Hirschfeld, M.D.

C Human Suffering and Economic Burden in a Large Community Sample
Joseph R. Calabrese, M.D.

D New Developments in the Treatment of Bipolar Depression
Mark A. Frye, M.D.

E The Challenge of Bipolar Disorder in Children and Adolescents
Karen D. Wagner, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

IMPROVING PATIENT OUTCOMES ACROSS THE SPECTRUM OF BIPOLAR DISORDER
Supported by Pfizer Inc.

Chp: David J. Kupfer, M.D.

A Managing the Pendulum of Mood in Bipolar Disorder
Jack M. Gorman, M.D.

B Acute Mania: Pharmacologic Treatment Strategies
David J. Kupfer, M.D.

C Phase-Specific Psychotherapy for Bipolar Disorder
Holly A. Swartz, M.D.

D Gender Variation in Bipolar Disorder
Ellen Leibenluft, M.D.

E The Longitudinal Course of Bipolar Disorder Across the Life Cycle
Ellen Frank, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

NEW APPROACHES FOR TREATING ADHD: THE WHOLE-LIFE PERSPECTIVE
Supported by Eli Lilly and Company

Chp: Christopher J. Kratochvil, M.D.
Co-Chp: Janet Wozniak, M.D.

A ADHD: DSM-IV and Beyond
Thomas F. Brown, Ph.D.

B ADHD: Phenotypes and Pathophysiologies
Albert J. Allen, M.D., David Michelson, M.D.

C New ADHD Treatment Options on the Horizon
Christopher J. Kratochvil, M.D.

D From Childhood to Adolescence: Diagnosis and Comorbidity Issues
Thomas J. Spencer, M.D.

E Issues in Diagnosing and Treating the Adult ADHD Patient
Lenard A. Adler, M.D.

Discussant: Janet Wozniak, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

ANTIPSYCHOTIC THERAPY AND CARDIOVASCULAR DISEASE: THE UNFOLDING STORY
Supported by Janssen Pharmaceuticals

Chp: Donald C. Goff, M.D.

A Antipsychotic Therapy in Patients with Comorbidities: Issues and Polypharmacy
Donald C. Goff, M.D.

B Torsade de Pointes, QT, and Antipsychotic Drugs
Walter V. Vieweg, M.D.

C A Focus on Health: Metabolic Consequences of Antipsychotic Therapy
Donna A. Wirshing, M.D.

D Antipsychotics and Diabetes: A Current Perspective on Epidemiology
Michael J. Sernyak, M.D.

E Mechanisms of Antipsychotic-Induced Glucose Dysregulation and Insulin Resistance
John W. Newcomer, M.D.
Audiotapes
Recorded Live!

High Quality Continues for the 2002 Annual Meeting...

Live recordings will be available for most of the following:

• Lectures • Advances in Research
• Presidential Symposium • Medical Updates
• Scientific and Clinical Reports • Symposia
• Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth in the Convention Center, Level II Lobby.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ◆ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
INDUSTRY-SUPPORTED SYMPOSIA 7

INDUSTRY-SUPPORTED SYMPOSIUM 7
8:00 a.m.-11:00 a.m.
Millennium Hall, Second Floor, Loews

DIAGNOSIS AND TREATMENT ISSUES IN CHILD AND ADOLESCENT BIPOLAR DISORDERS
Supported by Abbott Laboratories

Chp.: Karen D. Wagner, M.D.

A Diagnosis and Course of Bipolar Disorder in Children and Adolescents
   Karen D. Wagner, M.D.

B Genetic and Environmental Effects of Bipolar Disorder on Families and Offspring
   Kiki D. Chang, M.D.

C Pharmacologic Treatment of Children and Adolescents with Bipolar Disorders
   Robert A. Kowatch, M.D.

D Novel and Maintenance Treatment Approaches in Pediatric Bipolarity
   Robert L. Findling, M.D.

E Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile Bipolar Disorder
   Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 8

INDUSTRY-SUPPORTED SYMPOSIUM 8
8:00 a.m.-11:00 a.m.
Regency Ballrooms A-C, Second Floor, Loews

LATE-LIFE DEPRESSION: OLD MYTHS AND NEW DATA
Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A Late-Life Depression: Neuroanatomy and Medical Comorbidity
   Anand Kumar, M.D.

B Depression: Pseudodementia and Executive Dysfunction
   George S. Alexopoulos, M.D.

C How Long Should Antidepressant Trials Be in Geriatric Depression?
   Harold A. Sackeim, Ph.D., Steven P. Roose, M.D., Tal Burt, M.D.

D Treatment of Depression in the Old and the Old-Old
   Steven P. Roose, M.D.

E Interpersonal Psychotherapy Therapy in Late-Life Depression: Who Benefits?
   Charles F. Reynolds III, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

DEPRESSIVE SUBTYPES: THE MULTIPLE FACES OF DEPRESSION
Supported by Organon Inc.

Chp.: Maurizio Fava, M.D.

A Atypical Depression: An Often Under-Recognized Condition
Jonathan W. Stewart, M.D.

B Treatment Challenges in Anxious Depression
Maurizio Fava, M.D.

C Melancholic Depression: Are Dual-Action Antidepressants Superior to Selective Agents?
J. Craig Nelson, M.D.

D Vascular Depression
Ranga K. Krishnan, M.D.

E Practical Approach to Psychotic Depression
Linda L. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
8:00 a.m.-11:00 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

RECOVERY FROM DEPRESSION: NEW PERSPECTIVES TO IMPROVE OUTCOMES
Supported by Wyeth Pharmaceuticals

Chp.: Michael E. Thase, M.D.

A Recovery from Depression: Conceptual Underpinnings
Michael E. Thase, M.D.

B Augmentation and Combination Strategies for the Newer Antidepressants
Andrew A. Nierenberg, M.D.

C Combining Psychotherapy and Medication for Depression
John C. Markowitz, M.D.

D Maximizing Efficacy in the Treatment of Chronic Depression
Susan G. Kornstein, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

TREATING PSYCHOTIC ILLNESS ACROSS THE LIFE SPAN: ARE DRUGS ENOUGH?
Supported by Eli Lilly and Company

Chp.: Paul J. Barreira, M.D.
Co-Chp.: Sumer Verma, M.D.

A Psychotic Illness in Children
Jean A. Frazier, M.D.

B From Getting by to Getting Better
Gerald A. Maguire, M.D.

C Raising the Bar of Expectations
Ralph Aquila, M.D.

D Madness and the Rest of a Life
Anne Alonso, Ph.D.

E Best Practices in Psychosocial Rehabilitation for Psychotic Illnesses
Paul J. Barreira, M.D.

F Is the Cheapest Alternative the Most Economical?
Sumer Verma, M.D.

9:00 a.m. Sessions

COURSES 23-29
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 23 9:00 a.m.-4:00 p.m.
Room 102 A, Street Level, Convention Center

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY:
CARE MANAGEMENT, LAW, AND ETHICS

Co-Directors: Christopher G. Fichtner, M.D., Wesley Sowers, M.D.
Faculty: Stephen H. Dinwiddie, M.D., William G. Wood, M.D., Steven Moffic, M.D., John A. Talbott, M.D.
SUNDAY

COURSE 24  9:00 a.m.-4:00 p.m.
Room 102 B, Street Level, Convention Center
THE SUBJECTIVE EXPERIENCE: CRUCIAL KEYS TO THERAPY AND TO THE HUMAN MIND
Director: Vincenzo R. Sanguineti, M.D.
Faculty: Donatella Marazziti, M.D.

COURSE 25  9:00 a.m.-4:00 p.m.
Room 104 A, Street Level, Convention Center
THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES
Director: David C. Jimerson, M.D.
Faculty: Michael J. Devlin, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 26  9:00 a.m.-4:00 p.m.
Room 106 A, Street Level, Convention Center
MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE
Director: Cecilia M. Mikalac, M.D.

COURSE 27  9:00 a.m.-4:00 p.m.
Room 108 A, Street Level, Convention Center
ALZHEIMER’S DISEASE: ADVANCED APPROACHES TO TREATMENT
Director: William E. Reichman, M.D.
Faculty: Constantine G. Lyketsos, M.D., David L. Sultzer, M.D., Peter M. Aupperle, M.D., Jacobo E. Mintzer, M.D., Pierre N. Tariot, M.D.

COURSE 28  9:00 a.m.-4:00 p.m.
Room 111 A, Street Level, Convention Center
MEDICAL ETHICS 101
Director: Edmund G. Howe, M.D.

COURSE 29  9:00 a.m.-4:00 p.m.
Room 113 C, Street Level, Convention Center
BUILD YOUR OWN RELATIONAL DATABASE ELECTRONIC MEDICAL RECORD
Director: Daniel A. Deutschman, M.D.

1:00 p.m. Sessions

COURSES 30-38
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 30  1:00 p.m.-5:00 p.m.
Room 104 B, Street Level, Convention Center
INTRODUCTION TO CORRECTIONAL PSYCHIATRY
Co-Directors: James E. Dillon, M.D., Lee H. Rome, M.D.
Faculty: Richard S. Jackson, M.D., Sanjeev Venkataraman, M.D.

COURSE 31  1:00 p.m.-5:00 p.m.
Room 107 A, Street Level, Convention Center
INTEGRATIVE PSYCHOTHERAPY SUPERVISION: BASIC TOOLS
Director: Paul Rodenhauser, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)
12:30 p.m.-1:30 p.m.
Rooms 201 A-C, Level 200, Convention Center
CALL TO ORDER
Richard K. Harding, M.D., President

MEMORIAL TO DECEASED MEMBERS
ANNOUNCEMENT OF ELECTION RESULTS
Catherine S. May, M.D., Chairperson,
Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Pedro Ruiz, M.D.
Treasurer: Carol A. Bernstein, M.D.
Speaker, Assembly: Nada L. Stotland, M.D.
Speaker-Elect, Assembly: Albert C. Gaw, M.D.
Chairperson, By-Laws Committee:
Jo-Ellyn M. Ryall, M.D.
Chairperson, Elections Committee:
Yvonne B. Ferguson, M.D.
Chairperson, Membership Committee:
Bernard A. Katz, M.D.
Medical Director: Steven M. Mirin, M.D.

ANNUAL FORUM
ADJOURNMENT
*Members-in-Training, General Members, Fellows, Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.
SUNDAY

COURSE 33  1:00 p.m.-5:00 p.m.
Room 108 B, Street Level, Convention Center

PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM

Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.B., Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

COURSE 34  1:00 p.m.-5:00 p.m.
Room 109 A, Street Level, Convention Center

EVIDENCE-GUIDED DUAL DIAGNOSIS TREATMENT

Director: Andrew P. Ho, M.D.
Faculty: Robert Chang, M.D., Davin A. Agustines, M.D., Carol Giannini, M.P.H., James Smith, M.D., David Haponski, M.S.W.

COURSE 35  1:00 p.m.-5:00 p.m.
Room 112 A, Street Level, Convention Center

IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE

Director: Lois Krahn, M.D.
Faculty: Mark R. Hansen, M.D., Steven I. Altchuler, M.D., Jarrett W. Richardson, M.D.

COURSE 36  1:00 p.m.-5:00 p.m.
Room 112 B, Street Level, Convention Center

INTEGRATING PHARMACOTHERAPY AND PSYCHOTHERAPY

Co-Directors: Barton J. Blinder, M.D., Bernard D. Beitman, M.D.
Faculty: Mark G. Barad, M.D.

COURSE 37  1:00 p.m.-5:00 p.m.
Room 113 B, Street Level, Convention Center

PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE

Director: Carol S. North, M.D.
Faculty: Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

COURSE 38  1:00 p.m.-5:00 p.m.
Room 203 B, Level 200, Convention Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
Faculty: George Brainard, Ph.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 13-18

INDUSTRY-SUPPORTED SYMPOSIUM 13
1:30 p.m.-4:30 p.m.
Millennium Hall, Second Floor, Loews

RECENT DEVELOPMENTS IN THE SCIENCE AND TREATMENT OF PTSD
Supported by GlaxoSmithKline

Chp.: Jonathan R.T. Davidson, M.D.
Co-Chp.: Rachel Yehuda, Ph.D.

A Risk and Resilience Factors in PTSD
Rachel Yehuda, Ph.D.

B What Can Neuroimaging Teach Us About PTSD?
Scott L. Rauch, M.D.

C Medication Strategies in PTSD
David V. Sheelaan, M.D.

D Treatment of PTSD with Exposure Therapy
Barbara O. Rothbaum, Ph.D.

E Using Assessment Tools in Clinical Practice: When, Why, and How?
Kathryn M. Connor, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
1:30 p.m.-4:30 p.m.
Regency Ballrooms A-C, Second Floor, Loews

CUSTOMIZING CARE FOR PATIENTS WITH BIPOLAR DISORDER
Supported by AstraZeneca Pharmaceuticals

Chp.: Gary S. Sachs, M.D.

A Intervention for Refractory Patients
Patricia Suppes, M.D.

B Significance of Psychosis
Charles L. Bowden, M.D.

C Choosing Initial Mood Stabilizer After Acute Mania
Guy M. Goodwin, M.D.

D Selection of an Acute Treatment Strategy: Sequential Versus Stratified Approach
Gary S. Sachs, M.D.

E Dealing with Common Problems During Ongoing Treatment in Bipolar Disorder
W. Gordon Frakle, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

THE AGING BRAIN AND VULNERABILITY TO DEPRESSION
Supported by Organon Inc.

Chp.: Charles F. Reynolds III, M.D.

A Age, Neurobiology, and Treatment Response
Madhukar H. Trivedi, M.D.

B The Impact on Cognition of Pharmacological Treatment for Late-Life Depression
Ruth O'Hara, Ph.D., Alan F. Schatzberg, M.D., Greer M. Murphy, M.D.

C Pharmacogenetics in Geriatric Depression
Greer M. Murphy, M.D.

D Treatment of the Depressed: Old-Old in Outpatient and Long-Term Care Settings
Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

LONG-TERM MANAGEMENT OF MOOD DISORDERS
Supported by Cybervncs, Inc.

Chp.: A. John Rush, M.D.
Co-Chp.: Harold A. Sackeim, Ph.D.

A Does Medication Change the Long-Term Course of Mood Disorders?
Susan G. Kornstein, M.D.

B Does Psychotherapy Change the Long-Term Course of Mood Disorders?
Robin B. Jarrett, Ph.D.

C Does ECT Alter the Long-Term Course of Mood Disorders?
Harold A. Sackeim, Ph.D.

D Vagus Nerve Stimulation for Depression: Methods and Mechanisms
Mark S. George, M.D.

E Does Vagus Stimulation Change the Long-Term Course of Mood Disorders?
Lauren B. Marangell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
1:30 p.m.-4:30 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

THE ADHERENCE CHALLENGE: CHRONIC ISSUES AND EMERGING SOLUTIONS WITH ANTIPSYCHOTIC THERAPY
Supported by Janssen Pharmaceuticals

Chp.: John M. Kane, M.D.
Co-Chp.: Stephen R. Marder, M.D.

A Approaching the Adherence Challenge
Stephen R. Marder, M.D., Donna A. Wirshing, M.D., William C. Wirshing, M.D.

B Pharmacologic Options for Schizophrenia: Implications for Compliance
John M. Kane, M.D.

C Research Experience with Long-Acting Atypical Antipsychotic Medication
Samuel J. Keith, M.D.

D Views from the Nursing Perspective: Problems and Solutions
Kathleen Jarboe, R.N.

Discussant: Joe Lovelace, J.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF PSYCHOTIC DISORDERS
Supported by Bristol-Myers Squibb Company

Chp.: Diana O. Perkins, M.D.
Co-Chps.: Jeffrey A. Lieberman, M.D., Joseph P. McEvoy, M.D.

A Intervening Early in the Evolution of Schizophrenia: Need for Novel Approaches During the Prodromal Phase

B New Advances in Schizophrenia Pharmacotherapy: Management of Acute Episodes
Diana O. Perkins, M.D.

C Improving Long-Term Outcomes in Patients with Schizophrenia
Peter J. Weiden, M.D.

(Continued on next page)
D The Impact of Safety and Tolerability on Patients' Satisfaction with Therapy
Joseph P. McEvoy, M.D.

E Mechanism of Action as Predictor for Clinical Utility: Lessons from Schizophrenia Research
Jeffrey A. Lieberman, M.D.

2:30 p.m. Sessions

LECTURE 1
2:30 p.m.-4:00 p.m.
Lecture Hall 114, Street Level, Convention Center
AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE
John Monahan, Ph.D.
Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence
Chp.: Brian Crowley, M.D.
Co-Chp.: Michael A. Norko, M.D.
Legislatures, courts, and the public have come to expect that mental health professionals can provide accurate assessment of the risk for violence in mentally ill persons. John Monahan, Ph.D., one of the authors of Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence, reviews the study's decision-tree approach for identifying patients at risk for violence and discusses the implications of the approach for the everyday clinical practice of risk assessment and risk management. Dr. Monahan, a clinical psychologist, is the Henry L. and Grace Doherty Charitable Foundation Professor of Law at the University of Virginia in Charlottesville, where he is also Professor of Psychology and Legal Medicine. He directed the MacArthur Foundation's Research Network on Mental Health and the Law from 1988 to 1998 and now directs the Foundation's initiative on mandated community treatment. Dr. Monahan formerly received APA's Manfred Guttmacher award for his book The Clinical Prediction of Violent Behavior and APA's Isaac Ray Award for his contributions to forensic psychiatry. He has been elected to the Institute of Medicine of the National Academy of Sciences. He received his doctoral degree from Indiana University.

THIS SESSION WILL BE AUDIOTAPED.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 19-24

INDUSTRY-SUPPORTED SYMPOSIUM 19
7:00 p.m.-10:00 p.m.
Millennium Hall, Second Floor, Loews
TREATMENT OF ANXIETY DISORDERS: WHERE ARE WE, AND WHERE ARE WE GOING?
Supported by Pfizer Inc.
Chp.: R. Bruce Lydiard, M.D.

A Comorbidities and Issues to Consider in the Management of Anxiety Disorders
Ronald C. Kessler, Ph.D.

B Management of Depression and Demoralization in Anxiety Disorders
Naomi M. Simon, M.D.

C Managing the Disordered Sleep Associated with Anxiety and Mood Disorders
John W. Winkelman, M.D.

D GAD: Long-Term Treatment to Improve Outcome
Mark H. Pollack, M.D.

E Current and Future Treatments for Anxiety: Efficacy and Tolerability
R. Bruce Lydiard, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 20
7:00 p.m.-10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews

ATYPICAL DEPRESSION: OVERVIEW AND NEW DEVELOPMENTS
Supported by Somerset Pharmaceuticals, Inc.

Chp.: Ranga K. Krishnan, M.D.
Co-Chp.: Charles B. Nemeroff, M.D.

A The Biology of Atypical Depression
Ranga K. Krishnan, M.D.

B The Biology of PTSD and Atypical Depression: The Role of Early-Life Trauma
Linda L. Carpenter, M.D.

C Diagnostic Issues in Atypical Depression
Ned H. Kalin, M.D.

D Psychotherapy in the Treatment of Major Depression
Barbara O. Rothbaum, Ph.D.

E New Treatments for Atypical Depression
Charles B. Nemeroff, M.D.

Discussant: Martin B. Keller, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

NEW DEVELOPMENTS IN THE TREATMENT OF BIPOLAR DISORDER
Supported by Abbott Laboratories

Chp.: Robert M.A. Hirschfeld, M.D.

A Advances in the Treatment of Mania
Gary S. Sachs, M.D.

B Update on the Treatment of Bipolar Depression
Robert M.A. Hirschfeld, M.D.

C Stabilizing the Course of Refractory Bipolar Illness:
Meeting the Challenges of Dysphoric States and Mixed Mania
Patricia Suppes, M.D.

D Update on Psychosocial Treatments of Bipolar Disorder
Michael W. Otto, Ph.D.

E The Multiple Goals of Maintenance Treatment
Charles L. Bowden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN: WHAT IS EVIDENCE AND WHAT IS ART?
Supported by Wyeth Pharmaceuticals

Chp.: Kimberly A. Yonkers, M.D.

A Treatment of Mood Disorders in Pregnancy and the Postpartum Period
Lee S. Cohen, M.D.

B Course and Treatment of Bipolar Illness During Pregnancy and the Postpartum Period
Adele C. Viguera, M.D.

C New Strategies in Managing PMDD
Kimberly A. Yonkers, M.D.

D Gender as a Factor
M. Katherine Shear, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

PRIMARY MOOD STABILIZERS AS THE CORNERSTONE OF TREATMENT FOR BIPOLAR DISORDER
Supported by Eli Lilly and Company

Chp.: Paul E. Keck, Jr., M.D.

A Mania and Mood Stabilization: What's New?
Lauren B. Marangell, M.D.

B Practical Approaches to Recognizing and Managing Side Effects
Paul E. Keck, Jr., M.D.

C Treating Depression and Suicidality
Michael E. Thase, M.D.

D Update on the Treatment of Rapid-Cycling Bipolar Disorder
Joseph F. Goldberg, M.D.

E Compliance and Optimizing Function
Guy M. Goodwin, M.D.

F The Doctor/Patient Relationship: How to Get Help for the One You Love
Mary R. Worthen

11
MEDIA SESSION 1 7:00 p.m.-10:00 p.m.
Washington Rooms A-C, Third Floor, Loews

HOLOCAUST MEMORIES
Chp.: Maurice Preter, M.D.

1 Our Children
(68 minutes)

Distributor: Mimi Krant
NCJF-Brandeis University
Lowen 102 MS053
Waltham, MA 02454

Our Children illustrates the impact of massive psychological trauma on childhood and adult development. In this Yiddish-language feature made in Poland, part docudrama, part melancholic comedy, famous Yiddish comedians Dzigan and Shumacher visit an orphanage near the city of Lodz to perform for an audience of Jewish orphans who survived the Holocaust. Their performance, although well intentioned, stirs up painful memories of recent events, but also offends the children by the sentimentalized and naïve depiction of wartime conditions. Having all lived through the reality of separation and loss, the children take over the stage, oust the performers, and tell their stories.

Discussants: Maurice Preter, M.D., Yehuda Nir, M.D., Dori Laub, M.D., Harold J. Bursztajn, M.D.

MEDIA SESSION 2 7:00 p.m.-10:00 p.m.
Congress Rooms A-C, Fourth Floor, Loews

PSYCHIATRY GOES TO THE MOVIES
Co-Chps.: Steven E. Hyler, M.D., Harvey R. Greenberg, M.D.

2 Memento
(120 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

Memento is a film about the quest of Leonard Shelby. Although he wears expensive, tailored suits, and drives a late-model Jaguar sedan, he lives in cheap anonymous motels, paying his way with thick wads of cash. Shelby looks like a successful businessman; however, his only work is the pursuit of vengeance. He spends all his time tracking and punishing the man who raped and murdered his wife. The difficulty of locating his wife's killer is compounded by the fact that he suffers from a rare untreatable form of memory loss. Although he can recall details from his life before the "accident," Leonard cannot remember what happened within 15 minutes of the event. The police dismiss his suspicions; therefore, Leonard's complex life has become an all consuming quest for justice.

Discussant: Steven E. Hyler, M.D.
MONDAY, MAY 20, 2002

155TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 25-30

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 25, PART 1
7:00 a.m.-8:30 a.m.
Millennium Hall, Second Floor, Loews

CLINICAL CHALLENGES IN DEPRESSION
Supported by GlaxoSmithKline

Chp.: Prakash S. Masand, M.D.

A Special Challenges in Treating Bipolar Depression and Psychotic Depression
David V. Sheehan, M.D.

B Growing Up Depressed: The Underserved Child and Adolescent
Neal D. Ryan, M.D.

C Cardiovascular Disease and Depression: A Deadly Comorbidity
Dominique L. Musselman, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 1
7:00 a.m.-8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews

NOVEL ANTIPSYCHOTIC DRUGS: ADVANCES IN THE TREATMENT OF PSYCHOTIC SPECTRUM DISORDERS
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Bench to Bedside: Rational Selection of Medications in Treating Schizophrenia
Rona Hu, M.D.

B What We Have Learned About the Long-Term Management of Schizophrenia: What Constitutes Treatment Refractoriness?
John M. Kane, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH: ABOVE ALL DO NO HARM
Supported by AstraZeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.

A Medical Morbidity and Mortality in Patients with Schizophrenia
S. Charles Schulz, M.D.

B Minimizing Acute and Long-Term Movement Disorders with Atypical Antipsychotics
Lilli Kopala, M.D., David Whitehorn, Ph.D., Hazel Woodley, R.N., Connie Hault, M.D., Heather Milliken, M.D., S. Devarajan, M.D., Uttam J. Wadhwa, M.D.

C Weight Gain and Obesity Secondary to Atypicals: Immediate and Long-Term Health Threats
Diana O. Perkins, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

UNDERSTANDING SLEEP MEDICINE: WHAT THE PSYCHIATRIST NEEDS TO KNOW
Supported by Wyeth Pharmaceuticals

Chp.: Milton K. Erman, M.D.

A Sleep, Safety, and Public Policy
Mark R. Rosekind, Ph.D.

B Sleep Disorders: What the Psychiatrist Needs to Know
Lois Krahn, M.D.

C Innovative Strategies in the Management of Insomnia
Karl Doghramji, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1
7:00 a.m.-8:30 a.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

ONE SIZE DOESN'T FIT ALL: DEPRESSION THERAPIES FOR THE 21ST CENTURY
Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A The Physical Manifestations of Depression
John H. Greist, M.D.

B Improving Outcomes in the Long-Term Treatment of Depression: Giving Patients a Choice
Maurizio Fava, M.D.

C Adapting Psychotherapies to a Patient's Individual Needs
Ellen Frank, Ph.D.
MONDAY

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1
7:00 a.m.-8:30 a.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

BREAKING THE SILENCE OF CHILDREN'S MENTAL ILLNESS: NATIONAL INITIATIVES, EARLY DETECTION, AND NEW PHARMACOTHERAPIES
Supported by Janssen Pharmaceuticals

Chp.: Robert L. Findling, M.D.

A Mental Illness in Children: Diagnosing Outside the Box
Hans Steiner, M.D.

B Atypical Antipsychotics in Pediatric Psychiatry: Efficacy in Well-Designed Trials
Christopher J. McDougle, M.D.

RESIDENT'S SESSION
7:00 a.m.-8:30 a.m.
Salon II, First Floor, Courtyard by Marriott

MEET THE EXPERTS: SUNNY-SIDE UP
Chp.: Richard K. Harding, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include addiction/substance abuse, administrative psychiatry, child/adolescent psychiatry, consultation-liaison, cultural competency, emergency/disaster psychiatry, "how to be an expert witness: forensic psychiatry," geriatric psychiatry, leadership development, public/community psychiatry, psychiatry, law and ethics, psycho-dynamic psychotherapy, research, and women's mental health, among others.

8:00 a.m. Sessions

COURSES 39-44
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 39 8:00 a.m.-12 noon
Ormandy East, Street Level, DoubleTree

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.
Faculty: Sarah H. Lisanby, M.D., Martin P. Szuba, M.D.

COURSE 40 8:00 a.m.-12 noon
Concerto B, Third Floor, DoubleTree

PSYCHIATRIC CONSULTATIONS IN MEDICAL SETTINGS: THE BASICS

Director: Richard L. Elliott, M.D.

COURSE 41 8:00 a.m.-12 noon
Overture, Third Floor, DoubleTree

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 42 8:00 a.m.-12 noon
Minuet, Fourth Floor, DoubleTree

TEACHING PSYCHIATRY: LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

COURSE 43 8:00 a.m.-12 noon
Rhapsody, Fourth Floor, DoubleTree

FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH

Director: John S. Rolland, M.D.

COURSE 44 8:00 a.m.-12 noon
Sonata 5, Fifth Floor, DoubleTree

USING HUMANITIES TO UNDERSTAND MOOD DISORDERS

Director: Emilie S. Passow, Ph.D.
Faculty: Jerome S. Gans, M.D., Steven D. Targum, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 103 B, Street Level, Convention Center

CONTRASTING PSYCHOPATHOLOGY IN ADOLESCENTS AND ADULTS

Moderator: Lynda A. Tenhundfeld, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR
CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART 1
9:00 a.m.-12 noon
Rooms 106 A/B, Street Level, Convention Center

LIVES AND TREATMENTS: TWO PATIENTS, TWO THERAPISTS
Moderator: James W. Lomax II, M.D.
Presenters: Glen O. Gabbard, M.D., Irma J. Bland, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR

COURSES 45-50
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 45 9:00 a.m.-4:00 p.m.
Ormandy West, Street Level, DoubleTree

PASS THE BOARDS! THE PART II ORAL EXAM
Director: James C.Y. Chou, M.D.
Faculty: Gregory C. Bunt, M.D.

COURSE 46 9:00 a.m.-4:00 p.m.
Orchestra Room, Second Floor, DoubleTree

ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.

COURSE 47 9:00 a.m.-4:00 p.m.
Aria A, Third Floor, DoubleTree

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT
Director: Robert P. Granscher, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.
Concerto A, Third Floor, DoubleTree

DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT
Director: James F. Masterson, M.D.

COURSE 49 9:00 a.m.-4:00 p.m.
Symphony Ballroom, Third Floor, DoubleTree

ADVANCES IN NEUROPSYCHIATRY
Director: C. Edward Coffey, M.D.
Faculty: Michael R. Trimble, M.D., Mark S. George, M.D.

COURSE 50 9:00 a.m.-4:00 p.m.
Sonata 4, Fifth Floor, DoubleTree

ISSUES IN TRANSPERSONAL PSYCHIATRY
Director: Bruce W. Scotton, M.D.
Faculty: Allan B. Chinen, M.D., John R. Battista, M.D., William W. Foote, M.D., John F. Hiatt, M.D., Francis G. Lu, M.D., Bruce S. Victor, M.D.

DISCUSSION GROUPS 1-4
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

1 Leslie H. Gise, M.D., on Save Time, Make Money, Have Fun! Outpatient Group Therapy for the Seriously Mentally Ill
Room 410, Level 4, Marriott

2 Lenore C. Terr, M.D., on What Makes People Change?
Room 413, Level 4, Marriott

3 Kelly L. Cozza, M.D., and Scott C. Armstrong, M.D., on Quickie Guide to the Cytochrome P450 System (Meet the Authors)
Room 501, Level 5, Marriott

4 Nehama Dresner, M.D., on Postpartum Depression: Prevention and Intervention
Room 502, Level 5, Marriott

LECTURES 2-3

LECTURE 2
9:00 a.m.-10:30 a.m.
Rooms 108 A/B, Street Level, Convention Center
John M. Oldham, M.D.

Personality Disorders: New Findings and Current Controversies
Chp.: John G. Gunderson, M.D.
Co-Chp.: Andrew F. Skodol II, M.D.

Patterns of adaptive and maladaptive behavior have been described for centuries, and broad personality types have been identified, yet whether maladaptive behavior fits within familiar medical models of pathology remains controversial. John M. Oldham, M.D., draws on recent neurobiological research and clinical, longitudinal studies of DSM-IV personality disorders to examine current debate about the relationship between personality and personality disorder. Dr. Oldham is Director of the New York State Psychiatric Institute.
and Chief Medical Officer of the New York State Office of Mental Health. He is also the Elizabeth K. Dollard Professor of Clinical Psychiatry, Medicine, and Law and Acting Chairman of the Department of Psychiatry at Columbia University College of Physicians and Surgeons. In addition, he is a Training and Supervising Psychoanalyst at Columbia University Center for Psychoanalytic Training and Research and maintains a private practice of adult and forensic psychiatry. An APA Fellow, Dr. Oldham chaired the APA work group that developed the Practice Guidelines for the Treatment of Borderline Personality Disorder and currently chairs the APA Committee on Quality Indicators. Dr. Oldham graduated from Baylor College of Medicine in Houston and received his psychiatric training at New York State Psychiatric Institute and his psychoanalytic training at Columbia University.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3
9:00 a.m.-10:30 a.m.
Rooms 109 A/B, Street Level, Convention Center

APA’S GEORGE TARJAN AWARD LECTURE
Pedro Ruiz, M.D.

Accessing Care: A Challenge to the Poor and Disadvantaged
Chp.: Gopalakrishna D. Upadhya, M.D.
Co-Chp.: Godhard Oepen, M.D.

Despite overall improvement in the socioeconomic conditions of the United States during the last decade, major gaps remain in the health and mental health delivery system. Pedro Ruiz, M.D., discusses the disproportionate representation of the poor and disadvantaged among Americans who lack health insurance and suggests ways of improving access to health and mental health care for this group. Dr. Ruiz is Professor and Vice-Chair for Clinical Affairs and Medical Director of the Mental Sciences Institute at the University of Texas Health Science Center in Houston. Dr. Ruiz has held senior leadership positions in several professional organizations, including the APA, where he currently serves as Secretary as well as Chairperson of the Ethics Appeal Board, Vice-Chairperson of the Council on Addiction Psychiatry, and a member of the Commission on Global Psychiatry. He has received the Simon Bolivar Award, the Administrative Psychiatry Award, and a Special Presidential Commendation from APA, and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. The author of more than 350 publications, he is the co-editor of Substance Abuse: A Comprehensive Textbook. Born in Cuba, Dr. Ruiz graduated from the University of Paris, France, and trained in psychiatry at the University of Miami Medical School.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Elissa P. Benedek, M.D., on Child Forensic Psychiatry

Contemporary Issues
Room 111 A, Street Level, Convention Center

2 Francine Cournos, M.D., on the Aftermath of Childhood Parental Loss
Room 301, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ATTENDANCE.

MEDIA SESSIONS 3-4

MEDIA SESSION 3 9:00 a.m.-10:30 a.m.
Washington Rooms A-C, Third Floor, Loews

AMERICAN FRENZY
Chp.: Jonathan M. Metzl, M.D.

3 Time Frenzy
(58 minutes)

Distributor: University of California Extension
Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

Time Frenzy, produced by Bob Gliner, a multi-award-winning documentarian and Professor of Sociology at San Jose State University, is a thought-provoking documentary that explores the psychological, sociological, philosophical, and cultural ramifications of our increasingly fast-paced lives. Time Frenzy examines this new "24-7" reality, compares the American "work and consume" lifestyle with that of other countries, and probes the impact of technology on personal relationships, education, health, and the environment.

MEDIA SESSION 4 9:00 a.m.-10:30 a.m.
Congress Rooms A-C, Fourth Floor, Loews

PUPPETRY OF PERSONALITY
Chp.: Ian E. Alger, M.D.
Co-Chp.: Ferruccio A. DiCori, M.D.

4 The Puppets of Di Cori: New Psychodrama Approach
(70 minutes)
Ferruccio A. di Cori, M.D., is an innovator of many therapeutic techniques that combine the arts and various theoretical approaches to handling problems in relationships throughout the life cycle. In this demonstration, two adolescent students from the “therapeutic theater course,” which Dr. di Cori gives to an audience of over 100 students at the University of Rome, volunteer to participate. They are invited to throw to the floor two loosely articulated, amorphous rag doll figures that land in unanticipated positions vis-à-vis each other on the floor. He then directs the students in pairs and small groups in an imaginative discourse as they project themselves into the lives of the rag doll figures on the floor. This involvement leads to an emerging recognition by them of their personalities, ambitions, and conflicts.

NEW RESEARCH YOUNG INVESTIGATORS’ POSTER SESSION 1
9:00 a.m.-10:30 a.m.
Exhibit Hall D, Street Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

ROUND TABLE DISCUSSION
9:00 a.m.-10:30 a.m.
Rooms 107 A/B, Street Level, Convention Center

GOVERNMENT RESPONSE TO TERRORISM
Moderator: Randall D. Marshall, M.D.
Participants: John J. Worthington III, M.D., Mary Jane England, M.D., Sharon E. Carpinello, Ph.D., Regina Dolan-Sewell, Ph.D., Chip J. Felton, M.S.W., Peter S. Jensen, M.D., Matthew J. Friedman, M.D., Robert S. Pynoos, M.D., Jane D. Plapinger, M.P.H., Arieh Y. Shalev, M.D.

SYMPOSIUM 1
9:00 a.m.-12 noon
Room 113 B, Street Level, Convention Center

EVIDENCE-BASED PSYCHODYNAMIC THERAPY
PART I: STUDYING CLINICAL WORK
American Academy of Psychoanalysis and American Psychoanalytic Association

Chp.: Sheila Haftel-Gray, M.D.
Co-Chp.: Ann-Louise S. Silver, M.D.

A The Analytic Process Scales II: Intervention Quality and Patient Productivity
Sherwood Waldron, Jr., M.D.

B The Analytic Process Scales
Anna M. Burton, M.D.

C An Outcome Study for Psychodynamic Psychotherapy of Panic Disorder
Barbara L. Milrod, M.D., Fredric N. Busch, M.D.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 1-11

COMPONENT WORKSHOP 1
9:00 a.m.-10:30 a.m.
Rooms 102 A/B, Street Level, Convention Center

HOW TO CONVINCE CORPORATE CEOs THAT MENTAL HEALTH IS A GOOD INVESTMENT
APA Committee on APA/Business Relationships
Co-Chps.: Norman A. Clemens, M.D., Lloyd I. Sederer, M.D.
Participants: Leonard T. Sperry, M.D., Paul W. Heck

COMPONENT WORKSHOP 2
9:00 a.m.-10:30 a.m.
Room 103 A, Street Level, Convention Center

JUSTICE AND HEALTH EQUITY IN GLOBAL PSYCHIATRY
APA Commission on Global Psychiatry
Chp.: Arthur M. Kleinman, M.D.
Participants: Benedetto Saraceno, M.D, Ahmed M.F. Okasha, M.D., Carl C. Bell, M.D., Vikram Patel, Ph.D.

COMPONENT WORKSHOP 3
9:00 a.m.-10:30 a.m.
Room 104 A, Street Level, Convention Center

THE AMERICAN PSYCHIATRIC ASSOCIATION AND ITS ALLIANCE GO TO AMERICA’S SCHOOLS
APA Alliance
Chp.: Alicia A. Munoz, B.S.C.
Participants: Carol Skiljan, Jorge A. Zapatel, M.D.

COMPONENT WORKSHOP 4
9:00 a.m.-10:30 a.m.
Room 104 B, Street Level, Convention Center

WHEN YOUR PHYSICIAN PATIENT IS FROM AN ETHNIC MINORITY: A CROSS-CULTURAL APPROACH TO TREATMENT
APA Committee on Physician Health, Illness, and Impairment
Co-Chps.: Carmen T. Webb, M.D., Patti Tighe, M.D.
Participants: William B. Lawson, M.D., Raymond M. Reyes, M.D., Hagit Bat-Avi, M.D., Jimmie C. Holland, M.D.
COMPONENT WORKSHOP 5  9:00 a.m.-10:30 a.m.  
Room 111 B, Street Level, Convention Center

THE PSYCHIATRIST AND MIGRATION IN THE 21ST CENTURY  
APA Rhode Island Psychiatric Society
Co-Chps.: Shahbaz A. Khan, M.D., Thomas O. Osinowo, M.D.  
Participants: Alison M. Heri, M.D., Kaz M. Salahuddin, M.D.,  
Madelyn H. Hicks, M.D., Deji Ayonrinde, M.D.

COMPONENT WORKSHOP 6  9:00 a.m.-10:30 a.m.  
Rooms 112 A/B, Street Level, Convention Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE  
APA Psychiatrists' Purchasing Group, Inc.
Chp.: Alan I. Levenson, M.D.  
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D.,  
Jacqueline M. Melonas, J.D.

COMPONENT WORKSHOP 7  9:00 a.m.-10:30 a.m.  
Rooms 302/303, Level 3, Marriott

THE PHILADELPHIA STORY: A VA UNIVERSITY OF ADDICTION RESEARCH COLLABORATION  
APA Consortium on Organized Service Systems
Chp.: Laurent S. Lehmann, M.D.  
Participants: George E. Woody, M.D., Charles P. O'Brien, M.D.,  
Laura F. McNicholas, M.D., A. Thomas McLellan, Ph.D.

COMPONENT WORKSHOP 8  9:00 a.m.-10:30 a.m.  
Room 307, Level 3, Marriott

SUBSTANCE ABUSE IN SPECIAL POPULATIONS  
APA Council on Addiction Psychiatry
Chp.: Ramon Solhkhah, M.D.  
Participants: Richard T. Suchinsky, M.D., Seeth Vivek, M.D.

COMPONENT WORKSHOP 9  9:00 a.m.-10:30 a.m.  
Independence Ballrooms II/III, Level 3, Marriott

AGING AND MOURNING IN THE GAY AND LESBIAN COMMUNITY  
APA New York County District Branch's Committee on Gay and Lesbian Issues
Co-Chps.: Benjamin H. McCommon, Jr., M.D., Jordan F. Karp, M.D.  
Participants: Alan Schwartz, M.D., Duane D. Shubert, M.D.,  
Jennifer I. Downey, M.D.

COMPONENT WORKSHOP 10  9:00 a.m.-10:30 a.m.  
Rooms 401-403, Level 4, Marriott

PSYCHIATRY IN THE NEUROSCIENCE CURRICULUM: PROMISE AND PERIL  
APA Committee on Medical Student Education
Chp.: Carl B. Greiner, M.D.  
Participants: Jonathan Polan, M.D., Linda F. Pessar, M.D.,  
Surender P. Punia, M.D., Michael J. Vergare, M.D.

COMPONENT WORKSHOP 11  9:00 a.m.-10:30 a.m.  
Rooms 407-409, Level 4, Marriott

THE ROLE OF THE GERIATRIC PSYCHIATRIST IN PALLIATIVE CARE  
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly
Chp.: Judith H. W. Grossett, M.D.  
Participants: Julian Offsay, M.D., Colleen J. Northcott, M.D.,  
Jaime M. Benitez, M.D.

ISSUES 1-18

ISSUE WORKSHOP 1  9:00 a.m.-10:30 a.m.  
Room 113 A, Street Level, Convention Center

HOW TO GET THE MOST OUT OF SUPERVISION: WHAT RESIDENTS NEED TO KNOW
Chp.: Sarah M. Whitman, M.D.

ISSUE WORKSHOP 2  9:00 a.m.-10:30 a.m.  
Room 113 C, Street Level, Convention Center

NURSING HOME PSYCHIATRY: PROBLEMS AND SOLUTIONS
Chp.: Marc I. Rothman, M.D.  
Participants: Istvan J.E. Boksay, M.D., David L. Snyder, M.D.,  
Nancy O'Dowd

ISSUE WORKSHOP 3  9:00 a.m.-10:30 a.m.  
Room 202 A, Level 200, Convention Center

COGNITIVE-BEHAVIORAL THERAPY TRAINING FOR RESIDENTS: HOW TO TEACH, MEASURE, AND ATTAIN RESIDENT
Chp.: Donna M. Sudak, M.D.  
Participants: Judith S. Beck, Ph.D., Jesse H. Wright, M.D.,  
Hinda F. Dubin, M.D.

ISSUE WORKSHOP 4  9:00 a.m.-10:30 a.m.  
Room 202 B, Level 200, Convention Center

SUPERVISION 101: SEX, LIES, AND VIDEOTAPE?
Chp.: Chelsea L. Chesen, M.D.  
Participants: Francisco A. Moreno, M.D., Gayle Masterson, M.D.,  
John C. Racy, M.D.
MONDAY

ISSUE WORKSHOP 5  9:00 a.m.-10:30 a.m.
Room 203 A, Level 200, Convention Center

CHILDREN OF PSYCHIATRISTS: 21ST-CENTURY INSIGHTS

Co-Chps.: Leah J. Dickstein, M.D., Michelle B. Riba, M.D.
Participants: Gail M. Barton, M.D., Zachary Myers, Elizabeth Bakalar

ISSUE WORKSHOP 6  9:00 a.m.-10:30 a.m.
Room 203 B, Level 200, Convention Center

THE POLICING OF PHYSICIAN-PATIENT BOUNDARIES: SOME INTERNATIONAL PERSPECTIVES

Chp.: Gail E. Robinson, M.D.
Participants: Werner Tschan, M.D., Carolyn Quadrio, M.D., Linda M. Jorgenson, J.D.

ISSUE WORKSHOP 7  9:00 a.m.-10:30 a.m.
Room 204 A, Level 200, Convention Center

PERSONALITY DISORDERS IN THE MENTAL RETARDATION AND DEVELOPMENT DISORDERS POPULATION

Co-Chps.: Harvey Stabinsky, M.D., Susan Stabinsky, M.D.
Participant: Michael M. Scimeca, M.D.

ISSUE WORKSHOP 8  9:00 a.m.-10:30 a.m.
Rooms 304-306, Level 3, Marriott

THE IMPACT ON CLINICIANS OF SUICIDE

Co-Chps.: Eric M. Plakun, M.D., Jane G. Tillman, Ph.D.
Participants: Edward R. Shapiro, M.D., Edward K. Rynearson, M.D.

ISSUE WORKSHOP 9  9:00 a.m.-10:30 a.m.
Liberty Ballroom B, Level 3, Marriott

CAREER DEVELOPMENT FOR INTERNATIONAL MEDICAL GRADUATES

Chp.: Renato D. Alarcon, M.D.
Participants: Nyapati R. Rao, M.D., Norma C. Panahon, M.D., Gabrielle F. Beaubrun, M.D.

ISSUE WORKSHOP 10  9:00 a.m.-10:30 a.m.
Rooms 411/412, Level 4, Marriott

EVALUATION OF TELEPSYCHIATRY SERVICES IN AN INTEGRATED HOSPITAL SYSTEM IN THE VETERANS ADMINISTRATION AND DEPARTMENT OF DEFENSE

Co-Chps.: Paul E. Ruskin, M.D., Stephen J. Cozza, M.D.
Participants: Brian J. Grady, M.D., Stephen I. Deutsch, M.D., James J. Nocks, M.D.

ISSUE WORKSHOP 11  9:00 a.m.-10:30 a.m.
Rooms 414/415, Level 4, Marriott

ACCESS TO PSYCHOTHERAPY TRAINING IN RESIDENCY: A CURRENT PERSPECTIVE

Chp.: Robert W. Guynn, M.D.
Participants: Sandra Sexson, M.D., Anu A. Matorin, M.D., Vinay Kapoor, M.D.

ISSUE WORKSHOP 12  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon A, Level 5, Marriott

USE OF THE PERSONAL DIGITAL ASSISTANT IN PSYCHIATRY

Psychiatric Society of Informatics

Chp.: John Luo, M.D.
Participants: Daniel A. Deutschman, M.D., Sol Herman, M.D.

ISSUE WORKSHOP 13  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon B, Level 5, Marriott

SCHIZOPHRENIA WITH COMORBID CONDITIONS: CLINICAL AND RESEARCH ISSUES

Co-Chps.: Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.
Participants: Lewis A. Opler, M.D., Naveed Iqbal, M.D.

ISSUE WORKSHOP 14  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon C, Level 5, Marriott

PSYCHOTHERAPY TRAINING FOR THE 21ST-CENTURY PSYCHIATRIST

Co-Chps.: Diane M. Roston, M.D., Rebecca R. Neal, M.D.

ISSUE WORKSHOP 15  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon D, Level 5, Marriott

TRAINING A CULTURALLY COMPETENT PSYCHIATRIC WORKFORCE

Co-Chps.: Janet E. Osterman, M.D., Albert C. Gaw, M.D.
Participant: Joop De Jong, M.D.

ISSUE WORKSHOP 16  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon I, Level 5, Marriott

TRANSGENDER CARE: NEW PERSPECTIVES

Chp.: Dan H. Karasic, M.D.
Participants: Daniel Garza, M.D., Vernon A. Rosario, M.D., Melanie E. Spritz, D.O.
ISSUE WORKSHOP 17  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon J, Level 5, Marriott

HOW TO EFFECTIVELY INTEGRATE MENTAL HEALTH SERVICES IN GENERAL CARE SYSTEMS

Chp.: Ann Marie T. Sullivan, M.D.
Participants: Neal L. Cohen, M.D., Martin H. Maurer, M.D., Juan E. Mezzich, M.D., Amy S. Hoffman, M.D., Richard A. Young, M.D.

ISSUE WORKSHOP 18  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon K, Level 5, Marriott

BREAKING THE CYCLE OF MATERNAL ADDICTION: AN INTEGRATED TREATMENT PROGRAM MAKING A DIFFERENCE

Chp.: Cynthia C. Crone, A.P.N.
Participants: Linda L.M. Worley, M.D., Leanne Whiteside-Mansell, Ed.D., Veronica L. Williams, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Rooms 201 A-C, Level 200, Convention Center

UNDERSTANDING THE BRAIN AND BODY IN THE TREATMENT OF DEPRESSION AND SCHIZOPHRENIA

APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chp.: Philip R. Muskin, M.D.

Participants: Robert Carney, M.D., on Depression and Coronary Heart Disease: Epidemiology, Treatment, and Mechanisms
Alexander H. Glassman, M.D., on Depression, Coronary Artery Disease and Mortality
Carol A. Tamminga, M.D., on Schizophrenia: What Can Functional Brain Imaging Tell?
Herbert Y. Meltzer, M.D., on Advances in Psychopharmacologic Treatment of Schizophrenia and Related Psychosis

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 5-8
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Glen O. Gabbard, M.D., on Psychodynamic Psychiatry in Clinical Practice: Third Edition (Meet the Authors)
Room 308, Level 3, Marriott

6 William Breitbart, M.D., on Psychiatry and Palliative Medicine
Room 410, Level 4, Marriott

7 Charles E. Schwartz, M.D., on Working with HIV-Positive Patients and Their Physicians
Room 413, Level 4, Marriott

8 Brian A. Fallon, M.D., on Recognizing and Treating Neuropsychiatric Lyme Disease
Room 501, Level 5, Marriott

LECTURES 4-5
MASTER EDUCATOR CLINICAL CONSULTATIONS 3-4

11:00 a.m.-12:30 p.m.
Rooms 109 A/B, Street Level, Convention Center
Mary Jeanne Kreek, M.D.

Opioids and Single-Nucleotide Polymorphisms: Implications for Heroin and Cocaine Addictions

Chp.: Richard N. Rosenthal, M.D.
Co-Chp.: Joyce A. Tinsley, M.D.

Mary Jeanne Kreek, M.D., examines the contributions of the endogenous opioid system to the "rewarding" effects of drugs of abuse and to drug-induced changes in the brain and discusses gene polymorphisms of the endogenous opioid system that may play a role in addiction. Dr. Kreek is Professor and Head of the Laboratory of the Biology of Addictive Disease at Rockefeller University and Senior Physician at Rockefeller University Hospital in New York. In the 1960s, she was part of the Rockefeller Institute team that conducted the initial studies on methadone in the management of heroin addiction. More recently her research has focused on the molecular and neurobiological basis of addictive diseases and on human molecular genetics in the development of addictions. A Fellow of the American College of Neuropsychopharmacology and the New York Academy of Science, Dr. Kreek has received the R. Brinkley Smithers Distinguished Scientist Award from the American Society on Addiction Medicine and the Nathan B. Eddy Memorial Award for Lifetime Excellence in Drug Abuse Research from the College on Problems of Drug Dependence. Dr. Kreek received her medical degree from Columbia University College of Physicians and Surgeons and her postgraduate training in internal medicine, gastroenterology, and neuroendocrinology at Cornell University-New York Hospital Medical Center.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPELED.

MEDIA SESSIONS 5-6

MEDIA SESSION 5 11:00 a.m.-2:00 p.m.
Washington Rooms A-C, Third Floor, Loews

CULTURAL COLLISIONS

Chp.: Jacquelyn B. Chang, M.D.

5 Carved from the Heart: A Portrait of Grief, Healing, and Community
(30 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

Grieving father, Stan Marsden, loses his son to a cocaine overdose. A Tsimshian wood carver, Marsden decides to create a totem pole and invites the town of Craig, Alaska, to help. The project grows and brings people of diverse ages and backgrounds together. It acknowledges common problems of drug abuse and violence and promotes healing within the community. Carved from the Heart acknowledges the intergenerational grief that grows out of rapid changes in lifestyles and interruptions to the passage of tradition and knowledge within Alaska Native and American Indian communities.

Discussant: Yadollah M. Jabbarpour, M.D.

6 Homeland
(57 minutes)

Distributor: University of California Extension
For V6 Center for Media and Independent Learning
& V7 2000 Center Street, 4th Floor
Berkeley, CA 94704

Set against the stunning backdrop of the Northern Plains, Homeland is a rich and engaging documentary that weaves together the stories of four Lakota Indian families on the Pine Ridge Indian Reservation in South Dakota. Shot over several years, the film provides an inspiring and intimate portrait of contemporary Native American life, as well as a unique and compelling depiction of the strength and vitality of Native culture as it unfolds to the viewer over the course of the years. Ultimately, the film balances the many troubles that beset the reservation system with the resilience and fortitude of Lakota culture and spirituality. In doing so, it challenges viewers to recognize and appreciate the power of family, the immense spirit of the natural world, and the healing potential of humor and faith.

7 Between Worlds
(57 minutes)

Between Worlds explores over a period of six years the lives of several Vietnamese Amerasians and their families who left Vietnam in 1992. Each of the families was sent to a refugee camp in the Philippines for six months of cultural orientation, before resettling in the U.S. The film details their experiences in camp and follows their lives for five years as they struggle to learn English, find jobs, and pursue their education.
M & M Smith: For Prosperity's Sake eloquently explores the lives and work of Morgan and Marvin Smith, twin brothers and prolific African-American artists. The Smiths moved from Kentucky to New York in 1933 to pursue careers unavailable to them in the segregated South. In 1937, they opened a studio next to Harlem's Apollo Theatre and began 50 year-long careers as artists and still and motion film photographers. The Smiths and their cameras covered events in Harlem such as political rallies, street corner orators, the training ground of Joe Louis, and the exciting nightclub scene. They documented the celebrated and common citizens of their community and opened doors for models and actresses as they sought careers in the white dominated media. The film features Marvin and Morgan Smith, performer Eartha Kitt, and photo historian Deborah Willis.

MEDICAL UPDATE 1

11:00 a.m.-12:30 p.m.
Room 103 A, Street Level, Convention Center

MIGRAINE: DIAGNOSIS, TREATMENT, AND COMORBIDITY

Chp.: N. Kalaya Okereke, M.D.
Presenter: Stephen C. Silverstein, M.D.

11:00 a.m.
5 Perfectionism, Training, and Eating Behaviors in Runners
Jason M. Andrus, M.D., Deborah Goebert, Ph.D., Alayne Yates, M.D.

11:30 a.m.
7 Topiramate Treatment of Bulimia Nervosa
Scott P. Hoopes, M.D., Frederick W. Reimherr, M.D., Marc Kamin, M.D., Debra Karvois, M.S., Norman E. Rosenthal, M.D., Rezaul Karim, Ph.D.

CONSULTATION-LIAISON PSYCHIATRY

11:00 a.m.
8 Mixed Anxiety Depressive Disorder in a Sample of Primary Care Patients
Risa B. Weisberg, Ph.D., Larry Culpepper, M.D., Martin B. Keller, M.D.

11:30 a.m.
9 Psychopathological Aspects in 86 Chronic Fatigue Syndrome Patients
Massimo di Giannantonio, M.D., Anatolia Salone, M.D., Delia Racciatti, M.D., Daniela Mezzano, M.D., Eligio Pizzigallo, M.D., Maria F. Ferro
12 noon
10 Low Expression of Negative Affect and Denial Predict Breast Cancer Recurrence
   Karen L. Weihs, M.D., Timothy Enright, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 202 B, Level 200, Convention Center

ISSUES IN CROSS-CULTURAL PSYCHIATRY
Chp.: Giovanni Caracci, M.D.
Co-Chp.: Dinu P. Gangure, M.D.

11:00 a.m.
11 Is the Wechsler Intelligence Scale for Children, Third Edition (WISC-III UK) Applicable to Ghana?
   Ama K. Edwin, M.B.

11:30 a.m.
12 Dissociation, Childhood Trauma, and Ataque De Nervios
   Roberto Lewis-Fernandez, M.D., Pedro J. Garrido, Ph.D.,
   Amaro Lalia, Ph.D., Maricarmen Bennasar, Psy.D.,
   Guoguang Ma, M.S., Elsie Parrilla, L.C.S.W., Eva Petkova, Ph.D.

12 noon
13 Trauma, Creative Cognition, and Success Among Tribal South-African Students
   Albert Rothenberg, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 203 A, Level 200, Convention Center

ISSUES IN MID LIFE AND BEYOND
Chp.: Lesley M. Blake, M.D.
Co-Chp.: Dylan P. Wint, M.D.

11:00 a.m.
14 Long-Term Effects of Depression on Symptoms and Function in Mid-Life Women
   Joyce T. Bromberger, Ph.D., Charlotte Brown, Ph.D.,
   Adriana Cordal, M.D., Howard M. Kravitz, D.O., Karen Matthews, Ph.D.

11:30 a.m.
15 Socioeconomic Status and Depression Among Older Adults
   John Cairney, M.A., Terrance J. Wade, Ph.D.

12 noon
16 Psychotherapy with the Elderly
   Daniel A. Plotkin, M.D.
   THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Independence Ballroom I, Level 3, Marriott

SUICIDE

Chp.: Maria A. Oquendo, M.D.
Co-Chp.: Robert C. Marks, M.D.

11:00 a.m.
23 Suicides in Youths Involved with Juvenile Justice and Child Welfare Services
Johanne Renaud, M.D., Francois Chagnon, Ph.D., Lambert Farand, M.D.

11:30 a.m.
24 Predictors of Suicide Attempts in a Personality Disorder Sample
Shirley Yen, Ph.D., M. Tracie Shea, Ph.D., Carlos M. Grilo, Ph.D.,
Charles A. Sanislow, Ph.D., Mary C. Zanarini, Ed.D.,
Robert L. Stout, Ph.D., John G. Gunderson, M.D.

12 noon
25 Hostility and Impulsivity Among Suicidal Bipolar Patients
Benjamin H. Michaelis, M.A., Glen P. Davis, B.A., Joseph F. Goldberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Independence Ballrooms II/III, Level 3, Marriott

BPD

Chp.: Vivian B. Pender, M.D.
Co-Chp.: Jennifer K. Coffman, M.D.

11:00 a.m.
26 BPD, Medical Illness, Lifestyle Choices, and Health Care Utilization
Frances R. Frankenburg, M.D., Mary C. Zanarini, Ed.D.,
John Hennen, Ph.D., Kenneth R. Silk, M.D.

11:30 a.m.
27 Impulsivity, Gender, and 5HT in BPD
Paul H. Soloff, M.D., Thomas M. Kelly, Ph.D., Stephen J.
Stroutmeyer, M.P.H., Kevin M. Malone, M.D., J. John Mann, M.D.

12 noon
28 Diagnostic Efficiency of BPD and Antisocial Personality Disorder (APD) Criteria in Monolingual Hispanic Men
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., Luis M.
Anez, Psy.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Rooms 407-409, Level 4, Marriott

TOPICS IN SCHIZOPHRENIA

Chp.: Lawrence A. Real, M.D.
Co-Chp.: Brian Martis, M.D.

11:00 a.m.
29 The Relationship Between Negative and Positive Symptoms: A 15-Year Follow-Up
Martin Harrow, Ph.D., Ellen S. Herbener, Ph.D., Thomas H.
Jope, M.D., Joseph F. Goldberg, M.D., Eileen M. Martin, Ph.D.

11:30 a.m.
30 Neurological Soft Signs and Psychopathology in Schizophrenia
Giuseppe Bersani, Simona Gherardelli, M.D., Paolo Pancheri

12 noon
31 Heterogeneity in Schizophrenia: Cognitive Deficits and Brain Abnormalities
Bruce E. Wexler, M.D., Patricia S. Goldman-Rakic, Ph.D.,
Robert K. Fulbright, M.D., John C. Gore, Ph.D., Bradley S.
Petersen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Grand Ballroom Salon B, Level 5, Marriott

OLANZAPINE: BIPOLAR DISORDERS AND AGITATION

Chp.: Philip G. Janicak, M.D.
Co-Chp.: Paul P. Yeung, M.D.

11:00 a.m.
32 Effectiveness of Rapid Initial Dose Escalation of Oral Olanzapine for Acute Agitation
Robert W. Baker, M.D., Bruce J. Kinon, M.D., Hong Liu, Ph.D.,
Angela Richey, B.S., Angela L. Hill, Pharm.D., Richard F.
Bergstrom, Ph.D., Leslie M. Schuh, Ph.D.

11:30 a.m.
33 Olanzapine Combined with Lithium or Valproate for Relapse Prevention of Bipolar Disorder: An 18-Month Study
Mauricio F. Tohen, M.D., K.N. Roy Chengappa, M.D., Patricia
Suppes, M.D., Robert W. Baker, M.D., Richard C. Risser, M.S.C.,
Angela R. Evans, Ph.D., Joseph R. Calabrese, M.D.

12 noon
34 Olanzapine Versus Divalproex Sodium for Mania: A 47-Week Study
Robert W. Baker, M.D., Mauricio F. Tohen, M.D., Lori L.
Altshuler, M.D., Carlos M. Zarate, Jr., M.D., Patricia
Suppes, M.D., Terence A. Ketter, M.D., Richard C.
Risser, M.S.C.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Grand Ballroom Salon C, Level 5, Marriott

HEALTH SERVICES RESEARCH
Chp.: Arthur L. Lazarus, M.D.
Co-Chp.: Alisa B. Busch, M.D.

11:00 a.m.
35 Consensus Development on Core Quality Measures for Mental Health Care
Richard C. Herrmann, M.D., Scott E. Provost, M.S.W., Jeffrey Chan, B.S., Greta Lagodmos, B.A., Michael Schwartz, Ph.D., R. Heath Palmer, M.D.

11:40 a.m.
36 Improving the Competency of Clinicians Treating People with Mental Illness
Alexander S. Young, M.D., Sandra L. Forquer, Ph.D., Matthew J. Sherman, Ph.D., Melissa Rowe, Ph.D., Anita Miller, Ph.D., Edward Knight, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 12-18

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Rooms 102 A/B, Street Level, Convention Center

NAVIGATING GERIATRIC PSYCHIATRY RESEARCH: ISSUES FOR THE BEGINNING RESEARCHER
APA Committee on Ethnic Minority Elderly and APA Council on Aging
Chp.: Josepha A. Cheong, M.D.
Participants: Arturo G. Quaison, M.D., Warachal E. Faison, M.D., Michael J. Frants, M.D., Jacobo E. Mintzer, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 103 B, Street Level, Convention Center

EXPERTS OR PAWNS? PSYCHIATRIC CONSULTATION FOR GOVERNMENT AGENCIES
APA Committee on Misuse and Abuse of Psychiatry and Psychiatrists
Chp.: Robert P. Cabaj, M.D.
Participants: Jerry M. Wiener, M.D., Jose E. de La Gandara, M.D., Abraham L. Halpern, M.D., Juan E. Mezzich, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room 104 A, Street Level, Convention Center

LEGAL AND PSYCHIATRIC CONTROVERSIES IN INTERFERON TREATMENT OF HEPATITIS-C
APA New York County Branch AIDS Committee
Chp.: Kristina L. Jones, M.D., Scott Burris, J.D.
Participants: Silvia Halliger, M.D., John A.R. Grimaldi, Jr., M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Room 104 B, Street Level, Convention Center

THE GOOD-ENOUGH MENTOR: PERSPECTIVES ON MENTORING IN PSYCHIATRIC TRAINING
APA/GlaxoWellcome Fellows
Chp.: Paul E. Holtzheimer III, M.D.
Participants: Laurel L. Williams, D.O., Seema Malhotra, M.D., Lyle B. Forehand, Jr., M.D., John B. Levine, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Rooms 112 A/B, Street Level, Convention Center

TALKING ON YOUR FEET: SURVIVAL TIPS AND TECHNIQUES FOR MEDIA INTERVIEWS
APA Joint Commission on Public Affairs
Co-Chps.: Michael Blumenfield, M.D., Sandra C. Walker, M.D.
Participants: William E. Callahan, Jr., M.D., James M. Maier, M.D., John B. Blampinh

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Room 203 B, Level 200, Convention Center

PSYCHIATRY WITHOUT BORDERS: BREAKING THE BARRIERS
APA Committee on International Medical Graduates
Co-Chps.: Gopalakrishna K. Upadhya, M.D., Godehard Oopen, M.D.
Participants: Bruce Singh, M.D., Deborah Spitz, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Rooms 401-403, Level 4, Marriott

PSYCHIATRIC CASUALTIES IN THE MENTAL HEALTH OF HISPANIC IMMIGRANTS
APA Committee of Hispanic Psychiatrists
Co-Chps.: Ana E. Campo, M.D., Eugenio M. Rothe, M.D.
Participant: Rodrigo A. Munoz, M.D.

ISSUES 19-28

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.
Rooms 302/303, Level 3, Marriott

TREATING PSYCHOSIS ACROSS DIAGNOSIS
Chp.: Lewis A. Opler, M.D.
Participants: Ian E. Alger, M.D., Clarice J. Kestenbaum, M.D., Eric R. Marcus, M.D.
MONDAY

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.
Room 307, Level 3, Marriott

CHALLENGES OF THE CHIEF RESIDENT IN PSYCHIATRY
Chp.: Sadiq H. Al-Samarrai, M.D.
Participant: Thomas S. Newmark, M.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.
Rooms 309-310, Level 3, Marriott

NONSEXUAL BOUNDARY VIOLATIONS: SPECIAL PROBLEMS IN SMALL COMMUNITIES
Chp.: Malkah T. Notman, M.D.
Participants: Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Carol C. Nadelson, M.D.

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m.
Liberty Ballroom C, Level 3, Marriott

COGNITIVE THERAPY FOR PERSONALITY DISORDERS
Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.
Rooms 411/412, Level 4, Marriott

ASSESSING PSYCHOTHERAPY COMPETENCIES OF RESIDENTS
Chp.: Joel Yager, M.D.
Participants: David A. Goldberg, M.D., Lisa A. Mellman, M.D., Jerald Kay, M.D., Jessey H. Wright, M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.
Rooms 414/415, Level 4, Marriott

PROFESSIONALISM IN THE TEACHER/LEARNER RELATIONSHIP
Chp.: Alison M. Heru, M.D.
Participants: Marilyn Price, M.D., Patricia R. Recupero, M.D.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon D, Level 5, Marriott

PSYCHOTHERAPY TERMINATION: A CHALLENGE IN PSYCHIATRIC RESIDENCY TRAINING
Chp.: Anu A. Matorin, M.D.
Participants: Pedro Ruiz, M.D., Vinay Kapoor, M.D., David W. Preven, M.D., Madhuri V. Kamble, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon I, Level 5, Marriott

CONFIDENTIALITY ISSUES AND LEGAL ESSENTIALS IN SEXUAL HARASSMENT CASES
Co-Chps.: Rita R. Newman, M.D., Annette J. Hollander, M.D.
Participants: Diane K. Shrier, M.D., Margaret F. Jensvold, M.D., David W. Garland, Esq., Francine Weiss, Esq.

ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon J, Level 5, Marriott

PSEUDOEDEMENTIA IN THE 21ST CENTURY
Chp.: Maurice Preter, M.D.
Participants: Randolph B. Schiffer, M.D., Robin C. Hilsabeck, Ph.D.

ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon K, Level 5, Marriott

WHAT WORKS IN SUBSTANCE ABUSE TREATMENT?
Substance Abuse and Mental Health Services Administration
Chp.: A. Thomas McLellan, Ph.D.
Participants: D. Dwayne Simpson, Ph.D., Joseph C. J. Finney, M.D., Shelly F. Greenfield, M.D.

12 noon Sessions

FORUMS 1-4

FORUM 1 12 noon-1:30 p.m.
Rooms 107 A/B, Street Level, Convention Center

NEW YORK ACADEMIC CENTERS' RESPONSE TO THE WORLD TRADE CENTER ATTACK
Chp.: Randall D. Marshall, M.D.
Participants: Rachel Yehuda, M.D., Marylene Cloutier, Ph.D., Spencer Eth, M.D., Harold S. Koplewicz, M.D.

FORUM 2 12 noon-1:30 p.m.
Room 113 A, Street Level, Convention Center

LEADERSHIP CHALLENGES IN MENTAL HEALTH AND SUBSTANCE ABUSE: A MEETING OF THE MINDS
Substance Abuse and Mental Health Services Administration
Chp.: Charles Curie

FORUM 3 12 noon-1:30 p.m.
Room 113 C, Street Level, Convention Center

EVIL
Chp.: Samuel C. Klagsbrun, M.D.
Participants: Professor Robert Pollack, Carl Goldberg, Ph.D.
MONDAY

FORUM 4  12 noon-1:30 p.m.
Liberty Ballroom A, Level 3, Marriott

MUSIC AND MOOD DISORDERS: TCHAIKOVSKY
Chp.: Richard Kogan, M.D.

12:30 p.m. Session

MEDIA SESSION 7
12:30 p.m.-2:00 p.m.
Congress Rooms A-C, Fourth Floor, Loews

WHEN NOT TO KEEP A SECRET
APA Alliance
Chp.: Alicia A. Munoz, B.S.C.

9  In the Mix
(30 minutes)

Distributor: Sue Castle
Castle Entertainment
114 East 32nd Street, #903
New York, NY 10016

In the Mix is a weekly, half-hour PBS television series produced for, with, and by teens. From alcohol to activism, school violence to careers, fashion to finding money for college, music to relationships, the series tackles the topics teen care about in probing, thought-provoking investigative reports, and provides information teens need to make positive life choices and to be savvy consumers. In this segment, teens find a way to share their concerns about violence and mental illness affecting their peers and community.

Discussant: Alicia A. Munoz, B.S.C.

1:00 p.m. Sessions

COURSES 51-56
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 51  1:00 p.m.-5:00 p.m.
Ormandy East, Street Level, DoubleTree

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE
Director: Karl Doghramji, M.D.
Faculty: John W. Winkelman, M.D., Thomas D. Hurwitz, M.D.

COURSE 52  1:00 p.m.-5:00 p.m.
Concerto B, Third Floor, DoubleTree

TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 53  1:00 p.m.-5:00 p.m.
Overture, Third Floor, DoubleTree

COGNITIVE THERAPY: THE BASICS
Director: Dean Schuyler, M.D.

COURSE 54  1:00 p.m.-5:00 p.m.
Minuet, Fourth Floor, DoubleTree

ENGAGING RESISTANT AND HOSTILE PATIENTS INTO PARTICIPATORY TREATMENT
Director: David Mee-Lee, M.D.

COURSE 55  1:00 p.m.-5:00 p.m.
Rhapsody, Fourth Floor, DoubleTree

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD
Director: Howard E. Book, M.D.

COURSE 56  1:00 p.m.-5:00 p.m.
Sonata 5, Fifth Floor, DoubleTree

NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-4
1:00 p.m.-2:30 p.m.
2  SCHIZOPHRENIA
Room 202 A, Level 200, Convention Center

3  SUBSTANCE ABUSE AND MOOD DISORDERS
Room 202 B, Level 200, Convention Center

4  ANXIETY DISORDERS AND ETHICS
Room 203 A, Level 200, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
2:00 p.m. Sessions

ADVANCES IN PSYCHOPHARMACOLOGY
2:00 p.m.-5:30 p.m.
Rooms 201 A-C, Level 200, Convention Center

AN UPDATE ON THE ESSENTIALS OF CLINICAL PSYCHOPHARMACOLOGY
Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Charles B. Nemeroff

1 New Antidepressants in Development: Corticotrophin Releasing Hormone and Neurokinin Antagonists
Ranga K. Krishnan, M.D.

2 Nonbenzodiazepine Anxiolytics
Philip T. Ninan

3 Atypical Antipsychotics
Michael J. Owens, M.D.

4 Anticonvulsants as Mood Stabilizers
Susan L. McElroy, M.D.

5 Treatment of the Pregnant or Postpartum Woman
Zachary N. Stowe, M.D.

MEDIA SESSIONS 8-9

MEDIA SESSION 8 2:00 p.m.-5:00 p.m.
Washington Rooms A-C, Third Floor, Loews

TRANSGENDER TRIALS
Chp.: Dan H. Karasic, M.D.

10 Southern Comfort
(90 minutes)

Distributor: Kate Davis
412 West End Avenue, #3E
New York, NY 10024

Southern Comfort is the story of the last year of life for Robert Eades, a female-to-male transsexual in rural Georgia, and his found family of transgendered people. Mr. Eades is a pipe-smoking, self-proclaimed hillbilly, comfortable in his country environment. But the intolerant world in which he lives is evident in his difficulty obtaining medical care when he develops ovarian cancer. The film is able to demonstrate many truths about the lives of transgendered people in general, and is named after a highlight for Eades and his friends, an annual convention for transgendered people in Atlanta.

Discussant: Dan H. Karasic, M.D.

11 Just Call Me Kade
(26 minutes)

Distributor: Frameline Distribution
346 Ninth Street
San Francisco, CA 94103-3829

Kade Farlow Collins is a 16-year old female-to-male transgendered person residing in Tucson, Arizona. Kade’s parents maintain a supportive and nurturing relationship to help their teenage child face many challenges. As Kade’s body began to transform during puberty, he became nearly suicidal. Realizing that the issue was more complex than Kade being a tomboy or lesbian, the family searched for information. Through a local support group and the internet, Kade’s mother found books and other resources pertaining to transgenderism. The family agreed to have their lives documented in order to bring awareness to the subject.
HBO series, *The Sopranos* is a complex drama built around a mobster, Tony Soprano, who struggles with two families: his wife and kids, and his gun-toting gang. The first season was built around what Tony learns when, whipsawed between those two worlds, he finds himself plunged into depression and seeks psychotherapy. With analysis built into the very spine of the show's elaborate episodic structure, creator/writer David Chase, produces an unpredictable series of parallel plots that twist from tragedy, to farce, to social realism.

**PRESIDENTIAL SYMPOSIUM**

2:00 p.m.-5:00 p.m.
Room 103 B, Street Level, Convention Center

**WHAT WILL THE 21ST CENTURY BRING TO THE TRAINING OF PSYCHIATRISTS?**

Chp.: Lisa A. Mellman, M.D.
Co-Chp.: Ronald O. Rieder, M.D.

**Presenters:** Richard K. Harding, M.D., Carol A. Bernstein, M.D.,
David Leach, M.D., Charles F. Reynolds III, M.D., Juan E. Mezzich, M.D.

**Discussant:** Sheldon I. Miller, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 2-26**

**SYMPOSIUM 2** 2:00 p.m.-5:00 p.m.
Rooms 102 A/B, Street Level, Convention Center

**ADVANCES IN THE DIAGNOSIS AND TREATMENT OF DELIRIUM**

Chp.: John W. Barnhill, M.D.
Co-Chp.: Khakasa H. Wapenyi, M.D.

A **The Experience of Delirium in Cancer Patients**
William Breitbart, M.D.

B **The Clinical Diagnosis of Delirium**
John W. Barnhill, M.D.

C **Clinical Utility and Cost-Benefit Profile of Diagnostic Testing in Delirium**
Christopher I. Kauffman, M.D.

D **The Use of Atypical Antipsychotics in the Treatment of Delirium**
Stephen J. Ferrando, M.D.

E **An Open Trial of Olanzapine in the Treatment of Delirium**
William Breitbart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 3** 2:00 p.m.-5:00 p.m.
Room 103 A, Street Level, Convention Center

**PLAGUES, PRIONS, AND PARANOIA: THE NEUROPSYCHIATRY OF INFECTIOUS DISEASE**

Chp.: Stanley N. Caroff, M.D.
Co-Chp.: E. Cabrina Campbell, M.D.

A **Psychiatric and Cognitive Features of Lyme Disease**
Felice A. Tager, Ph.D., Brian A. Fallon, M.D.

B **Regional Specificity and the Neuropathophysiology of HIV-1 in Brain**
Karl Goodkin, M.D., Frances L. Wilkie, Ph.D., Diana Lee, Psy.D., Robert Lecusay, Teri T. Baldevicz, Ph.D.,
Deshratn Asthana, Ph.D., Paul Shapshak, Ph.D.

C **The Neuropsychiatry of the Transmissible Spongiform Encephalopathies**
David N. Irani, M.D.

D **Psychiatric Manifestations of Acute Viral Encephalitis**
Stanley N. Caroff, M.D., Stephan C. Mann, M.D., Michael F. Gliatto, M.D., Kenneth A. Sullivan, Ph.D., E. Cabrina Campbell, M.D.

E **Neurosphilis: A History and Clinical Review**
Michael F. Gliatto, M.D., Stanley N. Caroff, M.D.

**Discussant:** Jan A. Fawcett, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 4** 2:00 p.m.-5:00 p.m.
Room 103 C, Street Level, Convention Center

**FEAR AND LOATHING IN THE MEDICATION CLINIC**

**APA Commission on Psychotherapy by Psychiatrists**

Chp.: Bernard D. Beitman, M.D.

A **To Monitor or to Relate?**
Jerald Kay, M.D.

(Continued on next page)
**MONDAY**

**B** Split-Treatment Angst  
Michelle B. Riba, M.D.

**C** The Divided Hour: Psychotherapy in the Medication Check and Other Brief Sessions  
Jesse H. Wright, M.D.

Discussants: Rachel Z. Ritvo, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 5**  
2:00 p.m.-5:00 p.m.  
Rooms 106 A/B, Street Level, Convention Center

**HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT: CLINICAL APPLICATIONS AND IMPLICATIONS**  
Chp.: Norman E. Alessi, M.D.

A Basic Health Insurance Portability and Accountability Act Overviews  
Norman E. Alessi, M.D.

B Confidentiality and Security Concerns Under Health Insurance Portability and Accountability Act  
Charles J. Rainey, M.D.

C Data Protection in Practice: The Impact of the Data Protection Act and Other Legislation in the United Kingdom  
Brian Lunn, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 6**  
2:00 p.m.-5:00 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**EATING DISORDERS 2002: BIOLOGICAL, CLINICAL, AND SOCIAL PERSPECTIVES**  
Chp.: Joel Yager, M.D.  
Co-Chp.: David B. Herzog, M.D.

A Trait-Related 5HT 1A Disturbances in Anorexia Nervosa: Relationship to Susceptibility  
Walter H. Kaye, M.D., Guido Frank, M.D., Carolyn C. Meltzer, M.D., Julie Price, Ph.D.

B Who's Dying from an Eating Disorder?  
David B. Herzog, M.D., Pamela K. Keel, Ph.D., David J. Dorer, Ph.D., Debra Franko, Ph.D., Kamryn T. Eddy, B.A., Valerie E. Charat, B.A., Dana Charatan, B.A.

C The Role of the Dentist in the Care of Eating-Disorder Patients  
James E. Mitchell, M.D., James Roerig, Pharm.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., Melissa Burgard, B.S.

D Primary Prevention of Eating Disorders: A Tale of Two Countries  
Katherine A. Halmi, M.D., Claire V. Wiseman, Ph.D., Suzanne R. Sunday, Ph.D., Francesca Bortolotti, M.D.

E E-Technologies and Eating Disorders: Problems and Prospects  
Joel Yager, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 7**  
2:00 p.m.-5:00 p.m.  
Room 111 B, Street Level, Convention Center

**MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID DISORDERS**  
Chp.: Michael Y. Hwang, M.D.  
Co-Chp.: Leslie L. Citrome, M.D.

A Management of Schizophrenia with Depression  
Samuel G. Sins, M.D.

B Management of Schizophrenia with Comorbid Anxiety Disorders  
Michael Y. Hwang, M.D.

C Clinical Management of Persistent Aggressive Behavior in Schizophrenia  
Leslie L. Citrome, M.D., Jan Volavka, M.D.

D Long-Term Outcome and Comorbid Conditions: Why Do We Know so Little?  
Nina R. Schooler, Ph.D.

Discussants: Lewis A. Opler, M.D., Ming T. Tsuang, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 8**  
2:00 p.m.-5:00 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**DEPRESSIVE SPECTRUM DISORDER IN LATE LIFE: IMPLICATIONS FOR CLINICAL CARE**  
Chp.: Helen Lavretsky, M.D.

A Nonmajor Clinically Significant Depression: The Existing Evidence of a Continuum  
Anand Kumar, M.D.

B Clinical Features of a Depressive Continuum  
George S. Alexopoulos, M.D.

C Dysthymic Disorder in the Elderly  
Davangere P. Devanand, M.D.

D Depression and Symptomatic Anxiety  
Alastair J. Flint, M.B.  
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 9  2:00 p.m.-5:00 p.m.
Room 113 A, Street Level, Convention Center

INTERACTION OF STRESS AND PERSONALITY
Association for Research in Personality Disorders

Chp.: James H. Reich, M.D.

A  Stress and Personality: Biological Implications
Kenneth R. Silk, M.D.

B  Clinical Characteristics of Stress-Induced Personality Disorders
James H. Reich, M.D.

C  Relationship Between Adjustment, Anxiety, and Depressive Disorders
Peter Tyrer, M.D.

D  Job Stress Among Young Physicians: Working Conditions or Personality, A Prospective Study
Per Vaglum, M.D., Reidar Tyssen, M.D., Nina Gronvold, M.D., Oivind Ekeberg, M.D.

E  Schema-Focused Cognitive Therapy and Stress-Exacerbated Personality Disorders
David P. Bernstein, Ph.D.

Discussant: Cesare Maffei, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 10  2:00 p.m.-5:00 p.m.
Room 113 B, Street Level, Convention Center

EVIDENCE-BASED PSYCHODYNAMIC THERAPY
PART II: WHAT DO THE DATA SHOW?
American Academy of Psychoanalysis and American Psychoanalytic Association

Chp.: Sheila Hafter-Gray, M.D.
Co-Chp.: Ann-Louise S. Silver, M.D.

William H. Gottsdiner, Ph.D., Nick Haslam

B  Controlled Trials of Psychoanalytic Therapies for Young People
Peter Fonagy, Ph.D., Geoffrey Baruch, M.D., Anthony Bateman, M.D.

C  The Limited Effectiveness of Short-Term Therapy for Anorexia Nervosa
Anurag L. Robin, Ph.D., Patricia Siegel, Ph.D.

D  Randomized Clinical Trial of a Psychoanalytic Treatment of BPD
Anthony Bateman, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 11  2:00 p.m.-5:00 p.m.
Room 113 C, Street Level, Convention Center

SOCIAL PSYCHIATRIC ASPECTS OF VIOLENCE
AND TRAUMA
American Association for Social Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Lawrence Hartmann, M.D.

A  Trauma and Violence: A U.S. Perspective
Carl C. Bell, M.D.

B  Social Aspect of Trauma
S. Arshad Husain, M.D.

C  Nostalgia as a Defense Against Fully Experiencing the Trauma of Immigration
Salman Akhtar, M.D.

D  Consequences of Psychosocial Interventions: The Potential to Harm and Help
Daniel L. Creson, M.D., Pedro Ruiz, M.D., Patricia Blakeney, Ph.D.

E  PTSD and Cultural Competency
Edward F. Foulks, M.D.
Discussants: Steven S. Sharfstein, M.D., R. Rao Gogineni, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 12  2:00 p.m.-5:00 p.m.
Room 203 B, Level 200, Convention Center

SADISTIC PERSONALITY DISORDER: ITS WIDE RANGE AND IMPORTANCE AS A DIAGNOSIS

Chp.: Michael H. Stone, M.D.

A  Sadism and Forensic Psychiatry
Michael M. Welner, M.D.

B  Sadistic Personality Disorder: The Need to Reinstate in Future Editions of DSM
Michael H. Stone, M.D.

C  Sadistic Behaviors and Victim Response
Ann Burgess, D.N.

D  The Empirical Relationship Between Psychopathy and Sadism
J. Reid Meloy, Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 13  2:00 p.m.-5:00 p.m.
Rooms 302/303, Level 3, Marriott

FROM RESEARCH TO PRACTICE: PRIMARY CARE RESEARCH IN SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES FOR ELDERLY
Substance Abuse and Mental Health Services Administration

(Continued on next page)
MONDAY

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Independence Ballroom I, Level 3, Marriott

THE SOCIAL BRAIN AND PSYCHOTHERAPY
World Psychiatric Association

Chp.: Russell J. Gardner, Jr., M.D.
Co-Chp.: John O. Behars, M.D.

A Clinical Sociophysiology
Russell J. Gardner, Jr., M.D.

B Sociodynamics in Psychotherapy
John O. Behars, M.D.

C The Social Brain as Site of Truth and Deception
Godehard Oepen, M.D.

D Biology of Family Psychotherapy
Douglas A. Kramer, M.D.

E A Skeptic's View of Bridging Efforts
Alan A. Stone, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Independence Ballrooms II/III, Level 3, Marriott

SPECIAL TOPICS IN WOMEN'S MENTAL HEALTH

Chp.: Claudio N. Soares, M.D.
Co-Chp.: Adele C. Viguera, M.D.

A Mood Disturbance and Pregnancy: Pros and Cons of Pharmacological Treatment
Adele C. Viguera, M.D., Claudio N. Soares, M.D., Lee S. Cohen, M.D.

B Psychiatric Characteristics of Binge Eating Disorder in Obese Women
Jose C. Appolinario, M.D.

C Gender and Addiction: What Is New?
Monica L. Zilberman, Ph.D., Hermano Tavares, Ph.D., Nady El-Guebaly, M.D.

D Impact of Estrogen and Other Sexual Hormones on Mood Disturbances
Claudio N. Soares, M.D., Jennifer Poitras, B.A., Jennifer Prouty, R.N.C., Lee S. Cohen, M.D.

E Estrogens and Alzheimer's Disease in Elderly Women
Monica Z. Scalco, M.D., Robert Van Reekum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Rooms 401-403, Level 4, Marriott

PRACTICING PSYCHIATRY IN 2002

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: Harold I. Eist, M.D.
A The Minnesota Physician-Patient Alliance
   Lee H. Beecher, M.D.

B Solo Practice Psychiatry in the Community
   Thomas W. Dodson, M.D.

C Brain and Mind in Clinical Practice
   Ronald D. Abramson, M.D.

D Psychiatry in the 21st Century
   Garry M. Vickar, M.D.

E Practicing Public Psychiatry in the 21st Century
   Roger Peele, M.D.

F General Hospital Psychiatry for the Future
   John C. Urbaitis, M.D.

G Practicing Psychiatry Today with Enjoyment and
   Integrity Despite Managed Care
   Brian Crowley, M.D.

Discussants: Edward Gordon, M.D., Janis G. Chester, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Rooms 407-409, Level 4, Marriott

LOVE FROM PATHOLOGY TO NORMALITY

Chp.: Yves Thoret, M.D.
Co-Chp.: John A. Talbott, M.D.

A Change of Heart Between Attachment Network and
   Romantic Love in Arranged Marriages
   Danielle Groleau, Ph.D.

B Clinical Considerations About Pedophilia: Love, Sex,
   and Transgressions
   Roland M. Coutanceau, M.D., Arnaud Martorell, M.D., Anne
   Andronikof, Ph.D.

C The Love Life of Melancholics
   Peter D. Kramer, M.D.

D Skin Deep: Transsexuality, Gender Identity, and the
   Psychopathology of Love
   Nancy M. Blake, Ph.D.

E Love as a Mirror of Human Distress: A Transcultural
   Perspective
   Richard Rechtman, M.D., James K. Boehnlein, M.D.

Discussant: Glen O. Gabbard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Rooms 411/412, Level 4, Marriott

ADOLESCENCE: THE TUMULTUOUS YEARS

Chp.: Mark H. Rapaport, M.D.

A Meeting the Needs of Students Exposed to Violence
   Through School-Based Programs
   Bradley D. Stein, M.D., Sheryl H. Kataoka, M.D., Lisa
   Jaycox, Ph.D., Marleen Wong, M.S.W., Arlene Fink, Ph.D.

B Adolescent Alcohol and Drug Abuse: Challenges and
   Transitions
   Sandra A. Brown, Ph.D.

C Treatment Implications of Teen-Onset Mania
   Gabrielle Carlson, M.D.

D Diagnosis and Treatment of Dysthymia and Double
   Depression
   David L. Dunner, M.D.

Discussant: Mark H. Rapaport, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Rooms 414/415, Level 4, Marriott

IS THERE A BIPOLAR SPECTRUM?

Chp.: S. Nassir Ghaemi, M.D.
Co-Chp.: Frederick K. Goodwin, M.D.

A The Validity of the Bipolar Spectrum
   Hagop S. Akiskal, M.D.

B Predictors of Unipolar to Bipolar Conversion in
   Affective Disorders
   Joseph F. Goldberg, M.D.

C The Bipolar Spectrum: The Clinician’s View
   Jacob J. Katzow, M.D.

D Criticism of the Bipolar Spectrum as a Concept
   S. Nassir Ghaemi, M.D.

This session will be audiotaped.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon A, Level 5, Marriott

UPDATE ON TREATMENT OF STIMULANT ABUSE

Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial Treatments
   Douglas M. Ziedonis, M.D., Jonathan Krejci, Ph.D., Marc
   Steinberg, M.A., Jill Williams, M.D., Sylvia Atdjian, Jeffrey A.
   Berman, M.D.

B Therapy and Placement Approaches for Cocaine-Abuse
   Treatment
   David R. Gastfriend, M.D., Estee Sharon, Psy.D., Sandrine
   Pirard, M.D.

(Continued on next page)
C Pharmacological Treatment of Stimulant Abuse
David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers
Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: 2002 Update
Steven L. Batki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon B, Level 5, Marriott

NEW FRONTIERS IN THE NEUROENDOCRINOLOGY OF AFFECTIVE DISORDERS
Chp.: Natalie L. Rasgon, M.D.
Co-Chp.: Mark A. Frye, M.D.

A Assessing Vulnerability to Depression: Role of HPA Axis Dysfunction
D. Jeffrey Newport, M.D.

B Gender Differences in Thyroid Indices in Depression
Mark A. Frye, M.D., George Klee, M.D., Natasha S. Sane, M.D., Teresa Huggins, P.H.D., Lori L. Altshuler, M.D., Michael J. Gitlin, M.D., Robert M. Post, M.D.

C Testosterone and Depression in Men: A Clinical Review
Stuart N. Seidman, M.D., Steven P. Roose, M.D.

D Estrogen Use, Mood, and Cerebral Metabolism in Menopausal Women
Natalie L. Rasgon, M.D., Gary W. Small, M.D., Prahba Siddarth, Karen Miller, Linda M. Ercoli, Susan Y. Bookheimer, Micheal E. Phelps, M.D.

Discussants: Stuart N. Seidman, M.D., D. Jeffrey Newport, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon C, Level 5, Marriott

ADDITIONS: CUTTING EDGE TREATMENTS FOR GAMBLING AND SUBSTANCE ABUSE
Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Treatment of Cocaine Dependence
Adam M. Bisaga, M.D.

B Treatment of Heroin Dependence
Herbert D. Kleber, M.D.

C Marijuana and Club Drugs: Cutting-Edge Developments, New and Potential Treatments
David M. McDowell, M.D.

D Cutting-Edge Treatment of Gambling Addiction
Eric Hollander, M.D., Stefano Pallanti, M.D., Erica Sood, B.A., Nicolo Baldini-Rossi, M.D., Sallie J. Hadley, M.D.

E Treatment of Comorbid Conditions
Frances R. Levin, M.D.
Discussant: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon D, Level 5, Marriott

PSYCHOTHERAPY RESEARCH: CHALLENGES FOR THE 21ST CENTURY
Chp.: John C. Perry, M.D.

A Patient Response to the Brief Psychodynamic Investigation
Jean-Nicolas Despland, M.D., Yves De Roten

B Matching Patients to Therapy: A Review of Empirical Studies of Psychotherapy
Per A. Hoglund, M.D.

C Moving Cognitive Therapy from the Research Clinic to General Psychiatric Practice
Robert J. DeRubeis, Ph.D.

D Are Recovery and Healthy Functioning Achievable Treatment Goals for Axis II Disorders?
John C. Perry, M.D.

E Long-Term Psychotherapy: Current Status and Future Directions
Paul Crites-Christoph, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon I, Level 5, Marriott

A RESEARCH AGENDA FOR DSM-V
Chp.: David J. Kupfer, M.D.
Co-Chp.: Darrel A. Regier, M.D.

A Nomenclature Recommendations
Bruce J. Rounsaville, M.D., Renato D. Alarcon, M.D., Gavin Andrews, M.D., James S. Jackson, Ph.D., Robert E. Kendell, M.D., Kenneth S. Kendler, M.D., Laurence J. Kirmayer, M.D.

B Neuroscience Recommendations
Dennis S. Charney, M.D., David Barlow, Ph.D., Kelly N. Botteron, M.D., Jonathan D. Cohen, M.D., Raquel E. Gur, M.D., Keh-Ming Lin, M.D., Eric J. Nestler, M.D.
C Developmental Recommendations
Daniel Pine, M.D., Margarita Alegria, Ph.D., Edwin H. Cook, Jr., M.D., E. Jane Costello, Ph.D., Ronald E. Dahl, M.D., Mina K. Dulcan, M.D., Doreen S. Koretz, Ph.D.

D Disability and Impairment Recommendations
Anthony F. Lehman, M.D., George S. Alexopoulos, M.D., Howard H. Goldman, M.D., Dilip V. Jeste, M.D., Dan Offord, M.D., T. Bedirhan Ustun, M.D.

E Cross-Cultural Recommendations
Renato D. Alarcon, M.D., Margarita Alegria, Ph.D., Carl C. Bell, M.D., James S. Jackson, Ph.D., Laurence J. Kirmayer, M.D., Keh-Ming Lin, M.D., T. Bedirhan Ustun, M.D.

F Gaps in the Current System: Recommendations
Michael B. First, M.D., Carl C. Bell, M.D., John H. Krystal, M.D., David Reiss, M.D., M. Tracie Shea, Ph.D., Thomas A. Widiger, Ph.D., Katherine L. Wisner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26
2:00 p.m.-5:00 p.m.
Grand Ballroom Salon J, Level 5, Marriott

ACADEMIC AND COMMUNITY MENTAL HEALTH: CAN THIS MARRIAGE BE SAVED?
American Association of Community Psychiatrists
Chp.: Peter L. Forster, M.D.
Co-Chp.: Stephen M. Goldfinger, M.D.

A Public Academic Liaison: Can This Marriage Be Saved?
Anita Everett, M.D.

B How Do You Keep Them Down on the Farm? Training, Recruitment, and Retention
Barbara M. Rohland, M.D.

C UC Davis and Sacramento County: A Shotgun Wedding Turned Shared Vision for Public Mental Health
Thomas J. Sullivan, M.S.W., Jonathan Nevfeld, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Exhibit Hall D, Street Level, Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
MONDAY

Robert T. Morse Writers Awards
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
Rodger McFarlane

LECTURE 7
6:00 p.m.-7:30 p.m.
Ballrooms A/B, Ballroom Level
Convention Center

WILLIAM C. MENNINGER MEMORIAL LECTURE
AND APA'S PATIENT ADVOCACY AWARD WINNER

Rodger McFarlane

Psychiatry and the Medical Consumer Movement

Rodger McFarlane is one of America's most respected medical consumer activists. He is author of the bestseller, "The Complete Bedside Companion: No-Nonsense Advice on Caring for the Seriously Ill" (Simon & Schuster). He is a former director of clinical outcomes research for the American Association of Health Plans, and a former senior executive at Empire Blue Cross Blue Shield, charged with consumer medical-decision support. In 1982, Mr. McFarlane started America's first AIDS hotline on his personal answering service. He served as Executive Director of the first and largest AIDS service group, the Gay Men's Health Crisis, Inc. He is President-Emeritus of Bailey House, the nation's largest supportive housing program for terminally ill, dual-diagnosis patients. He is a founder and former executive director of Broadway Cares, and one of the instigators of the red ribbon AIDS awareness campaign on all the awards show telecasts. He has helped raise over $200 million for AIDS groups worldwide. During the 1980's, Mr. McFarlane was a senior consultant to the Commissioner of Mental Health of NYC, in charge of developing HIV screening, referral, and treatment capabilities in every hospital and psychiatric facility in all five boroughs. Mr. McFarlane is also a Tony-winning producer, an elite competitive athlete in several disciplines, and veteran of seven over-ice treks to the North Pole (including three solo). He represented the U.S. in the 1998 Eco-Challenge ("the world's toughest race"), and will again represent the U.S. there this fall. He is an honorably discharged and highly decorated former U.S. Navy "nuke," having run the nuclear engineering plant on the attack submarine that set the still-standing under-ice navigation record. In this year's William C. Menninger Memorial Convocation Lecture, Mr. McFarlane will address the effect of consumer empowerment on psychiatric practice, as well as the impact of information available on the Internet, in broadcast, and in print advertising. He will delineate the new power of consumers in influencing directly FDA approval of new drugs, Congressional appropriations for research at NIH (and NIMH), their influence with America's largest employers, and the handful of giant companies that compete to underwrite employee health. Mr. McFarlane will outline how new legislation could benefit both mental health practitioners, as well as the consumer/patient. He will discuss the creation of specific alliances between medical professional associations and organized consumer advocacy in order to pursue mutual goals in the new century.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY, MAY 21, 2002

155TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 25-30

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 25, PART 2
7:00 a.m.-8:30 a.m.
Millennium Hall, Second Floor, Loews

CLINICAL CHALLENGES IN DEPRESSION
Supported by GlaxoSmithKline

Chp.: Prakash S. Masand, M.D.

A Can Long-Term Outcome Be Improved in Depression?
The Role of Side Effects and Compliance
Prakash S. Masand, M.D.

B Helping Patients with Sexual Dysfunction During Antidepressant Treatment
Lori Calabrese, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 2
7:00 a.m.-8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews

NOVEL ANTIPSYCHOTIC DRUGS: ADVANCES IN THE TREATMENT OF PSYCHOTIC SPECTRUM DISORDERS
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A The Role of Antipsychotics in Acute Mania
John M. Zajecka, M.D.

B Clinical Challenges in Managing Psychosis in the Elderly
Dilip V. Jeste, M.D., Christian Dolder, Pharm.D., Hoang A. Nguyen, M.D., Laura B. Dunn, M.D., Jorge F. Porras, M.D., Enid Rockwell, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH: ABOVE ALL DO NO HARM
Supported by AstraZeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.

A Avoiding Neuroendocrine Disruptions with Atypical Antipsychotic Agents
David C. Henderson, M.D.

B Emerging Bioethical Issues in Antipsychotic Pharmacotherapy: Do Unto Others
Henry A. Nasrallah, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

UNDERSTANDING SLEEP MEDICINE: WHAT THE PSYCHIATRIST NEEDS TO KNOW
Supported by Wyeth Pharmaceuticals

Chp.: Milton K. Erman, M.D.

A Morbidity of Insomnia
Thomas Roth, Ph.D.

B Mechanism of Action of Hypnotics
Stephen Stahl, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2
7:00 a.m.-8:30 a.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

ONE SIZE DOESN'T FIT ALL: DEPRESSION THERAPIES FOR THE 21ST CENTURY
Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A Lost in Depression: The Treatment-Resistant Patient
Holly A. Swartz, M.D.

B Depression and Substance Use
Kathleen T. Brady, M.D.

C Putting the Pieces Together: Treatments for the Present and Future
David L. Dunner, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2
7:00 a.m.-8:30 a.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

BREAKING THE SILENCE OF CHILDREN'S MENTAL ILLNESS: NATIONAL INITIATIVES, EARLY DETECTION, AND NEW PHARMACOTHERAPIES
Supported by Janssen Pharmaceuticals

(Continued on next page)
TUESDAY

8:00 a.m. Sessions

COURSES 57-64
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 57 8:00 a.m.-12 noon
Ormandy East, Street Level, DoubleTree
DRUG TREATMENT OF SCHIZOPHRENIA
Director: Philip G. Janicak, M.D.
Faculty: Stephen R. Marder, M.D., Rajiv Tandon, M.D., Rajiv P. Sharma, M.D.

COURSE 58 8:00 a.m.-12 noon
Ormandy West, Street Level, DoubleTree
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 59 8:00 a.m.-12 noon
Aria A, Third Floor, DoubleTree
SEXUAL DISORDERS: DIAGNOSIS AND TREATMENT
Director: Waguih W. Ishak, M.D.
Faculty: Marina Bussel, M.D., Steve A. Eklund, M.D., Romana Markvitsa, M.D., Anatoly Postolov, M.D.

COURSE 60 8:00 a.m.-12 noon
Overture, Third Floor, DoubleTree
ECT PRACTICE UPDATE
Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Room 103 B, Street Level, Convention Center

DEPRESSION IN THE MEDICAL SETTING REVISITED: THE PROBLEM OF THE DEPRESSIVE SPECTRUM DISORDERS
Moderator: Robert J. Boland, M.D.
Presenter: Colin J. Harrington, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2
9:00 a.m.-12 noon
Rooms 106 A/B, Street Level, Convention Center

LIVES AND TREATMENTS: TWO PATIENTS, TWO THERAPISTS

Moderator: James W. Lomax II, M.D.
Presenters: Glen O. Gabbard, M.D., Irma J. Bland, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 65-69
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 65 9:00 a.m.-4:00 p.m.
Orchestra Room, Second Floor, DoubleTree

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehl, M.D.
Faculty: Alan R. Beeber, M.D., Tewfik Said, M.D.

COURSE 66 9:00 a.m.-4:00 p.m.
Concerto B, Third Floor, DoubleTree

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 67 9:00 a.m.-4:00 p.m.
Symphony Ballroom, Third Floor, DoubleTree

MED-PSYCH DRUG-DRUG INTERACTIONS: AN UPDATE

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: Jessica R. Oesterheld, M.D., David Benedek, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Sonata 3, Fifth Floor, DoubleTree

BEING AN EFFECTIVE SCHOOL CONSULTANT

Director: Lois T. Flaherty, M.D.
Faculty: Trina B. Allen, M.D., Richard L. Gross, M.D., Eugenio M. Rothe, M.D.

COURSE 69 9:00 a.m.-4:00 p.m.
Sonata 4, Fifth Floor, DoubleTree

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

DEBATE
9:00 a.m.-10:30 a.m.
Rooms 107 A/B, Street Level, Convention Center

RESOLVED: POLITICAL CORRECTNESS HAS NO PLACE IN MEDICINE?

Moderator: Patricia I. Ordorica, M.D.
Affirmative: Sally L. Satel, M.D.
Negative: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 9-13
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

9 Carol A. Bernstein, M.D., on Surviving Residency: Perspectives from the Training Office
Room 308, Level 3, Marriott

10 Silvia Hafliger, M.D., on Living Organ Donation: Psychiatric Aspects and Ethical Dilemmas for Donor and Recipient
Room 410, Level 4, Marriott

11 Paula T. Trzepacz, M.D., on Delirium: Phenomenology, Neuropathogenesis, and Treatment Interrelationships
Room 413, Level 4, Marriott

12 Stuart C. Yudofsky, M.D., on Neuropsychiatry and the Future of Psychiatry (Meet the Authors)
Room 501, Level 5, Marriott

13 Robert I. Simon, M.D. and Daniel W. Shuman, on Retrospective Assessment of Mental States in Litigation: Predicting the Past (Meet the Authors)
Room 502, Level 5, Marriott
LECTURE 8

9:00 a.m.-10:30 a.m.
Rooms 108 A/B, Street Level, Convention Center

Mary Jane Massie, M.D.

You Are Twenty-Four and You Have What?

Chp.: Donna E. Stewart, M.D.
Co-Chp.: Diana Chapa, M.D.

Researchers have described the psychological concerns of women with breast cancer, but little attention has been given to young women with this disease and the special problems they face in education, work and career, body image, relationships, sexuality, childbearing, and childrearing. Mary Jane Massie, M.D., discusses the risk factors for and treatment of breast cancer in young women and the issues that arise in the psychiatric treatment of young women with this disease. Dr. Massie is Director of the Barbara White Fishman Center for Psychological Counseling at Memorial Sloan-Kettering Cancer Center in New York and Professor of Clinical Psychiatry at Weill Medical College of Cornell University in New York. Her current research focuses on community outreach to improve opportunities for breast cancer education and screening of minority women. A Fellow of the APA, Dr. Massie has chaired the APA Committee on Consultation/Liaison Psychiatry and Primary Care Education and the Elections Committee. She is currently President-Elect of the Academy of Psychosomatic Medicine. Dr. Massie received her medical degree from the State University of New York at Buffalo School of Medicine and completed her residency in psychiatry at Montefiore Hospital/Albert Einstein College of Medicine in the Bronx and a fellowship in psychiatric oncology at Memorial Sloan-Kettering Cancer Center.

Distinguished Psychiatrist Lecture Series

LECTURE 9

9:00 a.m.-10:30 a.m.
Rooms 109 A/B, Street Level, Convention Center

APA'S BENJAMIN RUSH AWARD LECTURE

James P. Comer, M.D.

Problems Facing Inner-City School Educators and the Role of Psychiatry in Addressing Them

Chp.: Richard J. Thurrell, M.D.
Co-Chp.: Jack C. Westman, M.D.

Academic and personal development can be significantly improved for students from marginal and difficult environments through the application of child development and mental health principles in schools. James P. Comer, M.D., founder of the School Development Program, which has been disseminated to more than 700 schools across the country, discusses the program's approach for mobilizing school staff and parents to support students' learning and overall development. Dr. Comer is the Maurice Falk Professor of Child Psychiatry at Yale Child Study Center and Associate Dean of Yale University School of Medicine in New Haven, Connecticut. His research interests in schools as a preventive psychiatry focus, race relations, and child rearing are reflected in his books School Power, Beyond Black and White, and Raising Black Children and in numerous other publications in psychiatry and education. A Fellow of the American Academy of Arts and Sciences, Dr. Comer has received APA's Special Presidential Commendation and the Presidential Citation of the American Educational Research Association. Dr. Comer graduated from Howard University School of Medicine in Washington, D.C., completed a master's degree in public health at the University of Michigan, and received his training in psychiatry at Yale University School of Medicine, Yale Child Study Center, and Hillcrest Children's Center in Washington, D.C.

LEcTURE 10 - CANCELLED

MASTER EDUCATOR CLINICAL CONSULTATIONS 5-6

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Kenneth Z. Altshuler, M.D., on the Psychotherapies: Do Similarities Outweigh Differences?
Room 111 A, Street Level, Convention Center

6 Lisa A. Mellman, M.D., on Brief Dynamic Therapy: For the Patient or for Managed Care?
Room 351, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-11

MEDIA SESSION 10 9:00 a.m.-10:30 a.m.
Washington Rooms A-C, Third Floor, Loews

PLANETARY PRESSURES

Chp.: Elyse D. Dubo, M.D.
Half of the world's six billion people are under the age of 25. The decisions they make about how many children to have and when to have them will be critical in shaping life on earth in the next 50 years. This thought-provoking documentary is perhaps the most comprehensive introduction available on video to the interconnected issues of population growth, economic development, equal rights and opportunities for women, and environmental protection around the world.

MEDIA SESSION 11
Congress Rooms A-C, Fourth Floor, Loews
UP CLOSE AND PERSONAL
Chp.: Ian E. Alger, M.D.

14 Slippery Blisses
(42 minutes)

Kissing is one of our most complex and delicate forms of communication. It brings our senses of touch, smell, and taste together with a variety of powerful emotions and behavioral messages. Slippery Blisses interweaves the commentary of ordinary people who recall their best and worst kisses with a quirky cast of behavioral experts who discuss the “science” of kissing and raise numerous discussion-inducing questions. The film depicts a visit to Paris, the world’s most romantic city, and along the way explores the turbulent history of kissing in the movies, interviews a sex therapist, and features a socialite hairdresser who shows how cheek-kissing bonds high-society together. Slippery Blisses ultimately demonstrates that, as with all human behavior and communication, there is nothing simple about a simple kiss.

15 Personal Space: Exploring Human Proxemics
(28 minutes)

Space is a silent language, and we all speak it, whether consciously or not. Personal Space: Exploring Human Proxemics is a fascinating and frequently funny video that portrays the effects of space on everyday human behavior in an engaging and dramatic manner. Topics covered in the video include: 1) individual reactions to invasions of personal space; 2) the powerful effect of cultural differences and strong habitual patterns in how individuals use space; 3) family spatial arrangements; 4) how spatial factors affect our perceptions of relationships; and 5) hierarchical space in organizations. The video blends student testimony and often amusing field experiments to illuminate the use of space, territory, and touching in virtually every facet of life.
WORKSHOPS

COMPONENTS 19-22

COMPONENT WORKSHOP 19  9:00 a.m.-10:30 a.m.
Room 103 C, Street Level, Convention Center

HEALTH CARE LEGISLATION: THE ROLE FOR
THE 21ST-CENTURY BLACK PSYCHIATRIST
APA Committee of Black Psychiatrists

Co-Chps.: Michelle O. Clark, M.D., Lishan Workeneh, M.D.
Participants: Bethany J. Tucker, M.D., Honorable Louis Stokes

COMPONENT WORKSHOP 20  9:00 a.m.-10:30 a.m.
Liberty Ballroom C, Level 3, Marriott

HOW TO LAUNCH A SUCCESSFUL PRIVATE
PRACTICE: PART I
APA Committee of Early Career Psychiatrists

Co-Chps.: William F. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

COMPONENT WORKSHOP 21  9:00 a.m.-10:30 a.m.
Rooms 407-409, Level 4, Marriott

MEDICAL STUDENT EDUCATION IN ADDICTION:
COMPETENCIES AND RESOURCES
APA Committee on Training and Education in Addiction Psychiatry and
American Academy of Addiction Psychiatry

Co-Chps.: Jonathan I. Ritvo, M.D., Richard S. Schottenfeld, M.D.
Participants: William M. Greenberg, M.D., Timothy W. Fong, M.D.,
Christopher J. Welsh, M.D., Marjorie E. Waldbaum, M.D.

COMPONENT WORKSHOP 22  9:00 a.m.-10:30 a.m.
Rooms 411/412, Level 4, Marriott

DISCUSSION: SURGEON GENERAL’S REPORT ON
AMERICAN INDIANS AND ALASKA NATIVES
APA Committee of American Indian, Alaska Native, and Native
Hawaiian Psychiatrists

Co-Chps.: Frank W. Brown, M.D., Yvonne L. De Cory-
Woronoff, M.D.
Participants: Mary H. Roessel, M.D., Richard L. Livingston, M.D.,
R. Dale Walker, M.D.

ISSUES 29-57

ISSUE WORKSHOP 29  9:00 a.m.-10:30 a.m.
Rooms 102 A/B, Street Level, Convention Center

WORKING WITH PARENTS DURING THEIR BABY’S
FIRST YEAR OF LIFE

Chp.: James M. Murphy, M.D.

ISSUE WORKSHOP 30  9:00 a.m.-10:30 a.m.
Room 103 A, Street Level, Convention Center

THE NEUROBIOLOGY OF LEARNING:
IMPLICATIONS FOR TEACHING

Chp.: Janet E. Osterman, M.D.

ISSUE WORKSHOP 31  9:00 a.m.-10:30 a.m.
Room 104 A, Street Level, Convention Center

EXPLORING THE MEDIA’S ROLE IN IMITATION
VIOLENCE

Chp.: Paul A. Kettl, M.D.
Participant: Kathleen Jamison, Ph.D.

ISSUE WORKSHOP 32  9:00 a.m.-10:30 a.m.
Room 104 B, Street Level, Convention Center

WE CAN IMPROVE CARE FOR THOSE WITH
MENTAL HEALTH AND SUBSTANCE ABUSE
DISORDERS

Chp.: Katherine E. Watkins, M.D.
Participants: John Sheehe, M.S.W., Dina Daleo, Ph.D.

ISSUE WORKSHOP 33  9:00 a.m.-10:30 a.m.
Rooms 112 A/B, Street Level, Convention Center

COUPLES TREATMENT BY PARALLEL
COORDINATED INDIVIDUAL PSYCHOTHERAPY

Chp.: Michael C. Hughes, M.D.
Participant: Eva C. Ritvo, M.D.

ISSUE WORKSHOP 34  9:00 a.m.-10:30 a.m.
Room 113 A, Street Level, Convention Center

MOTION PICTURES: THE THERAPEUTIC
MODALITY OF THE 21ST CENTURY

Chp.: M. Fuat Ulus, M.D.
Participants: Conni Sharp, Ed.D., Eda Ulus, B.S.

ISSUE WORKSHOP 35  9:00 a.m.-10:30 a.m.
Room 113 B, Street Level, Convention Center

INNOVATIVE STRATEGIES IN THIRD-YEAR
MEDICAL STUDENT PSYCHIATRIC EDUCATION

Chp.: Molly J. Hall, M.D.
Participants: Timothy J. Lacy, M.D., Brenda J. Roman, M.D.,
Donald A. West, M.D., Stephen B. Shanfield, M.D.
<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Time</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
</table>
| 36            | 9:00 a.m.-10:30 a.m. | Room 113 C, Street Level, Convention Center | NATIONAL COMMISSION ON MARIJUANA AND DRUG ABUSE REPORT: 30 YEARS LATER  
Chp.: J. Thomas Ungerleider, M.D.  
Participant: Michael R. Sonnenreich, J.D. |
| 37            | 9:00 a.m.-10:30 a.m. | Room 202 A, Level 200, Convention Center | BRIDGING THE GAP: DEPRESSION, CHRONIC MEDICAL DISEASE, CULTURE, AND ETHNICITY  
Chp.: Annelle B. Primm, M.D.  
Participants: William T. Regenold, M.D., Evelyn L. Lewis, M.D. |
| 38            | 9:00 a.m.-10:30 a.m. | Room 202 B, Level 200, Convention Center | OLFACTORY DYSFUNCTION IN PSYCHIATRY AND NEUROLOGY  
Co-Chps.: Teodor T. Postolache, M.D., Richard L. Doty, Ph.D.  
Participants: Paul J. Moberg, Ph.D., Marilyn Jones Gotman, Ph.D. |
| 39            | 9:00 a.m.-10:30 a.m. | Room 203 A, Level 200, Convention Center | NEUROBEHAVIORAL SEQUELAE OF TRAUMA TO THE FRONTAL LOBES  
Chp.: Marilyn F. Kraus, M.D.  
Participants: Harvey Levin, Ph.D., Thomas Gualtieri, M.D. |
| 40            | 9:00 a.m.-10:30 a.m. | Room 203 B, Level 200, Convention Center | CULTURAL COMPETENCE IN PSYCHIATRIC RESIDENCY TRAINING PROGRAMS  
Substance Abuse and Mental Health Services Administration  
Chp.: Francis G. Lu, M.D.  
Participants: Renato D. Alarcon, M.D., Pedro Ruiz, M.D., James W. Thompson, M.D. |
| 41            | 9:00 a.m.-10:30 a.m. | Room 204 A, Level 200, Convention Center | A LEGAL PRIMER FOR PSYCHIATRISTS INVOLVED IN ISSUES OF SEXUAL ORIENTATION  
Co-Chps.: John E. Fryer, M.D., Mark-Allen Taylor, J.D.  
Participants: Nancy J. Knauer, J.D., David I. Scasta, M.D. |
| 42            | 9:00 a.m.-10:30 a.m. | Room 204 B, Level 200, Convention Center | TEN YEARS OF TEACHING ABOUT BOUNDARIES: WHAT HAVE WE LEARNED?  
Chp.: Gregg E. Gorton, M.D.  
Participants: Steven E. Samuel, Ph.D., Gail Zivin, Ph.D. |
| 43            | 9:00 a.m.-10:30 a.m. | Rooms 302/303, Level 3, Marriott | EVIDENCE-BASED TREATMENT FOR MARIJUANA DEPENDENCE  
Substance Abuse and Mental Health Services Administration  
Chp.: Karen Steinberg, Ph.D.  
Participants: Roger A. Roffman, D.S.W., Ronald Kadden, Ph.D., Jerome H. Jaffe, M.D. |
| 44            | 9:00 a.m.-10:30 a.m. | Rooms 304-306, Level 3, Marriott | ENHANCING AND FUNDING MENTAL HEALTH SERVICES: NEW FREEDOM INITIATIVE  
Substance Abuse and Mental Health Services Administration  
Co-Chps.: Mary Jane England, M.D., Eileen Elias, M.Ed.  
Participants: Shelley E. Bishop, Vincent J. Hughes, Eileen C. Wolkstein, Ph.D., Marilyn L. Eckley, M.P.A. |
| 45            | 9:00 a.m.-10:30 a.m. | Room 307, Level 3, Marriott | BUPRENORPHINE: A NEW OFFICE-BASED TREATMENT FOR OPIOID DEPENDENCE  
Substance Abuse and Mental Health Services Administration  
Co-Chps.: Herbert D. Kleber, M.D., H. Westley Clark, M.D. |
| 46            | 9:00 a.m.-10:30 a.m. | Independence Ballroom I, Level 3, Marriott | IMPROVING THE QUALITY OF SERVICE IN A MEDICAID HMO  
Chp.: James M. Schuster, M.D.  
Participants: Deborah Wastlchak, Frank Ghinassi, Kelly Kelleher, M.D. |
| 47            | 9:00 a.m.-10:30 a.m. | Independence Ballrooms II/III, Level 3, Marriott | IMPLEMENTATIONS OF DBT IN CORRECTIONAL ENVIRONMENTS  
Chp.: Robert L. Trestman, M.D.  
Participants: Daniel Bannish, Psy.D., M. Paul Chaplin, Ph.D. |
TUESDAY

ISSUE WORKSHOP 48  9:00 a.m.-10:30 a.m.
Rooms 401-403, Level 4, Marriott
HEPATITIS-C IN ADDICTION PSYCHIATRY
Chp.: Vasant P. Dhopesh, M.D.
Participants: Kyong-Mi Chang, M.D., Robert M. Weinsteib, M.D.

ISSUE WORKSHOP 49  9:00 a.m.-10:30 a.m.
Rooms 414/415, Level 4, Marriott
GROUP PSYCHOTHERAPY FOR SUBSTANCE ABUSERS
Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 50  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon A, Level 5, Marriott
WORLD FEDERATION OF PSYCHIATRIC TRAINEES: SATISFACTION AND INTERNATIONAL EXCHANGE IN PSYCHIATRIC
Co-Chps.: Victor J.A. Buwalda, M.D., Michelle B. Riba, M.D.

ISSUE WORKSHOP 51  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon B, Level 5, Marriott
SPIRITUAL DIMENSION AND RELIGIOUS ISSUES IN AN URBAN CMHC CLINICAL PRACTICE
Haitian-American Psychiatric Association
Chp.: Jean B. Tropnas, M.D.
Participants: Ophie Franklin, Yvette Sealy, Ph.D., Meeta Gandhi, M.S.W., Donna M. Serrant, M.S.W.

ISSUE WORKSHOP 52  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon C, Level 5, Marriott
ETHICS OF PHARMACEUTICAL INVOLVEMENT IN PSYCHIATRIC EDUCATION
Chp.: Nalini V. Juthani, M.D.
Participants: Jeffrey M. Levine, M.D., Uday K. Mukherjee, M.D., Huma K. Khan, M.D., Mikhail Y. Ziskin, M.D.

ISSUE WORKSHOP 53  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon D, Level 5, Marriott
THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILMS
Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 54  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon I, Level 5, Marriott
HIV, AIDS, HEPATITIS-C, MENTAL ILLNESS, AND SUBSTANCE ABUSE: CONVERGING ILLNESS
Substance Abuse and Mental Health Services Administration
Chp.: Marshall Forstein, M.D.
Participants: Marvin S. Swartz, M.D., Lawrence Brown, M.D., Jennifer F. Havens, M.D.

ISSUE WORKSHOP 55  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon J, Level 5, Marriott
ADDITION TREATMENT 2002: NEW DIRECTIONS
Chp.: Richard J. Frances, M.D.
Participants: Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Marc Galanter, M.D., Robert B. Millman, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

ISSUE WORKSHOP 56  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon K, Level 5, Marriott
TARASOFF REVISITED: CHANGING TRENDS IN DUTY TO WARN THIRD PARTIES
Chp.: Chowallur D. Chacko, M.D.
Participants: Robert L. Sadoff, M.D., Liz M. Chacko

ISSUE WORKSHOP 57  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon L, Level 5, Marriott
IMPLEMENTING AN EFFECTIVE TRUANCY-REDUCTION PROGRAM
Chp.: Stephen M. Sotlys, M.D.
Participants: Mary Jo Davoren, M.Ed., David Mahrer, Ph.D., Kenneth M. Rogers, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 14-18
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

14 Rachel Yehuda, Ph.D., on Treatment of Trauma Survivors: Theory Versus Practice (Meet the Authors)
Room 308, Level 3, Marriott

15 Frances R. Levin, M.D., on Treating Substance Abusers with Comorbid Psychiatric Disorders: Potential Pitfalls
Room 419, Level 4, Marriott

16 Thomas N. Wise, M.D., on Depression in the Medically Ill
Room 413, Level 4, Marriott

17 Elisabeth J.S. Kunkel, M.D., on Managing Depression and Anxiety in Patients with Cancer and Other Medical Illnesses
Room 501, Level 5, Marriott

18 Karen K. Milner, M.D., on Integrating Physical-Mental Health Care: The WCHO Experience
Room 502, Level 5, Marriott
LECTURE 11
11:00 a.m.-12:30 p.m.
Rooms 108 A/B, Street Level, Convention Center
APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE
Marc Galanter, M.D.
Healing Through Social and Spiritual Affiliation
Chp.: Richard Balon, M.D.
Co-Chp.: Patrick I. Ordorica, M.D.
Although largely overlooked by conventional biomedical practice, social and spiritual affiliation can be valuable in promoting recovery from psychiatric disorders, particularly substance abuse. Marc Galanter, M.D., draws on research on addicted patients’ experience in Alcoholics Anonymous to illustrate the potent impact of a spiritual message imparted in a cohesive social group. He also discusses the model of ideologically grounded affiliation as it relates to behavioral changes observed in cultic, terrorist, and mental health support groups. Dr. Galanter is Professor of Psychiatry and Director of the Division of Alcoholism and Drug Abuse at New York University School of Medicine. A Fellow of the APA, Dr. Galanter is Past President of the American Academy of Addiction Psychiatry and the American Society of Addiction Medicine and the Editor-in-Chief of Substance Abuse. He received the McGovern Award from the Association for Medical Education and Research in Substance Abuse, and his clinical program received the APA Gold Achievement Award for innovative care. His research is presented in more than 250 publications, including two books, Cults: Faith, Healing, and Coercion and Network Therapy for Alcohol and Drug Abuse. Dr. Galanter received his medical and psychiatric training at Albert Einstein College of Medicine in the Bronx.

MASTERS EDUCATOR CLINICAL CONSULTATIONS 7-8
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

7 Jerald Kay, M.D., on Integrating Psychotherapy and Pharmacotherapy
Room 111 A, Street Level, Convention Center

8 Lawrence Hartmann, M.D., on Child and Adolescent Clinical Work: Integrating Bio-, Psycho-, and Social
Room 301, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

LECTURE 12
11:00 a.m.-12:30 p.m.
Rooms 109 A/B, Street Level, Convention Center
Ira R. Byock, M.D.
Dying Well: Beyond Symptoms and Suffering, Human Development at the End-of-Life
Chp.: Mary E. Foti, M.D.
Co-Chp.: Maurice D. Steinberg, M.D.
Narratives of people confronting life’s end provide empirical evidence of the range of human experience that can occur during the time of life termed “dying.” Although suffering is common among dying patients, the ability to make meaning, review one’s life, complete relationships, express love, and explore spiritual realms all may continue to exist. Ira R. Byock, M.D., describes a developmental conceptual framework for understanding the nature of suffering and opportunity at the end of life and discusses ways in which psychiatric specialists can alleviate suffering and preserve the opportunity for people to grow, individually and together, through the very end of life. Dr. Byock is Director of Palliative Care Service in Missoula, Montana, and Research Professor in the Department of Philosophy at the University of Montana, where he is also a faculty member in the Practical Ethics Center. His numerous publications on end-of-life care include the book Dying Well: The Prospect for Growth at the End of Life. He has received the National Hospice Organization’s Person of the Year award and the National Coalition of Cancer Survivorship’s Natalie Davis Spingarn Writers Award. Dr. Byock graduated from the University of Colorado School of Medicine and completed his residency in family practice at Valley Medical Center in Fresno, California.

MEDIA SESSIONS 12-13

MEDIA SESSION 12
11:00 a.m.-1:00 p.m.
Washington Rooms A-C, Third Floor, Loews
AFTER APARTHEID
Chp.: J. Charles Ndlela, M.D.

(Continued next page)
This film captures some of the pain with an outpouring of emotions during the hearing before the Truth and Reconciliation Commission, which was a process chosen by South Africa to facilitate healing from Apartheid trauma. Nobel Prize Laureate Archbishop Desmond Tutu states, “This is an impressive, heart-rending film and deserves wide circulation.” The directors have attempted to explore the workings of the “restorative justice” in a dramatic presentation accompanied by rich, emotionally arousing South African music.

Discussant: J. Charles Ndlela, M.D.

MEDIA SESSION 13 11:00 a.m.-12:30 p.m.
Congress Rooms A-C, Fourth Floor, Loews

VICTIMS AT AN EARLY AGE

Chp.: Edward K. Rynearson, M.D.

17 Making Visible the Hidden: Serving Child Victims in the Healthcare Community
(15 minutes)

Distributor: Deborah Spungen, M.S.S.
AVP
633 West Rittenhouse Street, #C-14
Philadelphia, PA 19144

Healthcare providers are often the first to respond to child victims of violence, but their focus on treating the physical wounds sometimes causes them to overlook children’s emotional and mental (the hidden) needs. Without timely and appropriate intervention, the effects of trauma can last a lifetime. Making Visible the Hidden: Serving Child Victims in the Healthcare Community highlights three programs in which professionals in medical settings are incorporating victim-oriented practices into the service they provide. The stories of child victims vividly illustrate the importance of early intervention.

Discussant: Deborah Spungen, M.S.S.

18 Take This Heart
(58 minutes)

Distributor: University of California Extension
Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

For the nearly one million American children who are compelled to live in foster care, daily life is a forbidding venture. Cast adrift at an early age, dispossessed of everyone they have known or loved, they are left to grow up in a world that has proven deeply unreliable, with strangers who may or may not offer comfort and protection. Take This Heart is the story of three boys who struggle to make sense of their harsh fates, each in his own way. Their stories reveal the remarkable resiliency and the tough-minded will with which they go on with their lives, not utterly consoled, but not broken. The film explores the experiences of a few children in one foster home in Seattle, and in so doing gives voice to an invisible population of children otherwise consigned to silence at the margins of society.

MEDICAL UPDATE 2
11:00 a.m.-12:30 p.m.
Room 103 A, Street Level, Convention Center

CARDIAC EFFECTS OF OPIOID ADDICTION
PHARMACOTHERAPY
Substance Abuse and Mental Health Services Administration

Chp.: Richard S. Schottenfeld, M.D.
Presenters: Elinore F. McCance-Katz, M.D., Robert Maslansky, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.

1 Steven P. Roose, M.D., on Depressed Patients with Heart Disease and Late-Life Depression
Anthony Room, Third Floor, Loews

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 13-24

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Room 103 C, Street Level, Convention Center

GENDER ISSUES

Chp.: Antonia L. Baum, M.D.
Co-Chp.: Melva I. Green, M.D.

11:00 a.m.
37 Meat Consumption and Risk of Depression: A Prospective, Population-Based Study
Antti Tanskanen, M.D., Heimo Viinamaki, M.D., Kaisa Haatainen, M.H.Sc., Kristina Nyyssonen, Ph.D., Tiina H. Rissanen, R.N., Sari Voutilainen, Ph.D., Jukka T. Salonen, M.D.
11:30 a.m.
38 A Multinational Study of the Emergence of Gender Differences in Depression
Terrance J. Wade, Ph.D., John Cairney, M.A., David J. Pevalin, M.A.

12 noon
39 Efficacy and Safety of Sildenafil Citrate in Men with Depression and Erectile Dysfunction: Six-Month, Open-Label Treatment
Stuart N. Seidman, M.D., Steven P. Roose, M.D., Vera J. Stecher, Ph.D., Matthew A. Menza, M.D., Raymond C. Rosen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room 113 B, Street Level, Convention Center

BIPOLAR TREATMENT ISSUES
Chp.: David L. Dunner, M.D.
Co-Chp.: N. Kalaya Okereke, M.D.

11:00 a.m.
40 End-Stage Chronic Renal Failure from Prolonged Lithium Therapy
Gregory Braden, M.D., David L. Honeyman, M.D., Anthony Poindexter, M.D., Jane Garb, M.S., Michael Germain, M.D., Lewis M. Cohen, M.D.

11:30 a.m.
41 Topiramate in the Treatment of Refractory Bipolar Depression
Mohammad Z. Hussain, M.D., Zabaida A. Chaudhry, M.D., Seema Hussain, M.D.

12 noon
42 Prescribing Practices in Bipolar Disorder
Bonnie L. Szarek, R.N., John W. Goethe, M.D., Uzma S. Faheem, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room 113 C, Street Level, Convention Center

DRUG THERAPY OF ADHD
Chp.: Paul P. Yeung, M.D.
Co-Chp.: Albert Y. Ma, M.D.

11:00 a.m.
43 Once-Daily Administration of Atomoxetine: A New Treatment for ADHD
David Michelson, M.D.

11:30 a.m.
44 ADHD Treatment with a Once-Daily Formulation of Methylphenidate Hydrochloride: A Two-Year Study
Timothy E. Wilens, M.D., William E. Pelham, Jr., Ph.D., Mark Stein, Ph.D., C. Keith Conners, Ph.D., Howard Abikoff, Ph.D.

12 noon
45 Long-Term Safety and Efficacy of Adderall Extended Release in Children with ADHD
Mark C. Chandler, M.D., Frank A. Lopez, M.D., Joseph Biederman, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Room 204 A, Level 200, Convention Center

CULTURAL ISSUES IN VIOLENCE
Chp.: Jose M. Canive, M.D.
Co-Chp.: Martin A. Adeoye, M.D.

11:00 a.m.
46 Partner Violence and Risk of Major Depression in Chinese-American Women
Madelyn H. Hicks, M.D.

11:30 a.m.
47 Violence in Colombia: Mental Health Impact in Children
Ruby C. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Sandra-Rocio Castillo Puentes, M.D., Wilma-Ines Castilla Puentes, M.D., Miguel Habeych, M.D., Linda McWilliams, M.P.H., Boris Birmaher, M.D.

12 noon
48 Epidemiology, Trauma, and Transcultural Psychiatry
Joop De Jong, M.D., Ivan Kompare, Ph.D., Mark Van Ommeren, Daya Somasundaram, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Room 204 B, Level 200, Convention Center

BIPOLAR DISORDER
Chp.: Paul J. Goodnick, M.D.
Co-Chp.: Daniel Tsao, M.D.

11:00 a.m.
49 Increased Rates of Antipsychotic-Induced EPS in Mood Disorders: Myth or Reality?
Patrizia A. Cavazzoni, M.D., Paul H. Berg, M.S., Robert W. Baker, M.D., Angela R. Evans, Ph.D., Mauricio F. Tohen, M.D.

(Continued next page)
TUESDAY

11:30 a.m.
50 Cyclothymia in Atypical Depression: The Borderline-Bipolar II Connection
Giulio Perugi, M.D., Christina Toni, M.D., Chiara Travieso, M.D., Giuseppe Ruffolo, M.D., Hagop S. Akiskal, M.D.

12 noon
51 Substance Use and Perceived Symptom Improvement in Bipolar Disorder
Roger D. Weiss, M.D., Monika Kolodziej, Ph.D., Margaret L. Griffin, Ph.D., Lisa M. Najavits, Ph.D., Lara M. Jacobson, B.A., Shelly F. Greenfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Independence Ballrooms II/III, Level 3, Marriott

PREDICTORS OF OUTCOME

Chp.: Linmarie Sikich, M.D.
Co-Chp.: Michael A. Scharf, M.D.

11:00 a.m.
52 Outcome of Early-Phase Psychosis Concurrent with Substance Use
Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D., Michael B. First, M.D., Ellen M. Stevenson, M.D., Robert E. Drake, M.D., Francine Cournos, M.D., Patrick Shrout, Ph.D.

11:30 a.m.
53 Predictors of Syndromal and Functional Recovery in Patients with First-Episode Mania
Mauricio F. Tohen, M.D., John Hennen, Ph.D., Carlos M. Zarate, Jr., M.D., Stephan M. Strakowski, M.D., Ross J. Baldessarini, M.D.

12 noon
54 High Birth Weight as a Predictor of Schizophrenia: A 31-Year Follow-Up
Kristina Molinaen, M.D., Jari Jokelainen, M.S.C., Anna-Liisa Hartikainen, Ph.D., Marjo-Riitta Jarvelin, Ph.D., Peter B. Jones, Ph.D., Matti K. Isomalli, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Rooms 407-409, Level 4, Marriott

BEHAVIOR AND COGNITIVE THERAPY

Chp.: John C. Markowitz, M.D.
Co-Chp.: Anton C. Trinidad, M.D.

11:00 a.m.
55 Does Cognitive-Behavioral Group Treatment Improve Personality Measures in Panic Disorder Patients?
Frederico Cavaglia, M.S.C., Cristina Pablo, M.D., Ana Matos-Pires, M.S.C., Nuno Goncalves, M.D.

11:30 a.m.
56 Visually Enhanced Psychosexual Therapy
Frank G. Sommers, M.D.

12 noon
57 Dichotomous Thinking and Thought Suppression in Managing Anger
David M. Magder, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:50 a.m.-12:30 p.m.
Grand Ballroom Salon B, Level 5, Marriott

ETHICAL AND EXPLANATORY MODELS IN PSYCHIATRY

Chp.: Alan M. Gruenberg, M.D.
Co-Chp.: David M. McDowell, M.D.

11:50 a.m.
58 Principles of Clinical Explanation in 21st-Century Psychiatry
David H. Brendel, M.D.

11:30 a.m.
59 Experience of Research Participation by Patients with Severe Mental Illness
Russell S. Omens, Psy.D., Cherise Rosen, M.A., Sheila Donovan, Ph.D., Martin Harrow, Ph.D., Philip G. Janicak, M.D.

12 noon
60 Attitudes of Physicians Towards Gifts from the Pharmaceutical Industry: A Pilot Study
Amar Singh Ghorpade, M.D., Saurabh Kaushik, M.D., Parinda Patil, M.D., Vasundhara Kalasapudi, M.D., Sheldon S. Berman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:50 a.m.-12:30 p.m.
Grand Ballroom Salon C, Level 5, Marriott

RELIGION, SPIRITUALITY, AND PSYCHIATRY

Chp.: John P. Hendrick, M.D.

11:50 a.m.
61 Effects of Falun Gong Practice on Physical and Mental Health
Jing-Duan Yang, M.D., Ashwin A. Patkar, M.D., Li-Shan Huang, Ph.D., Daniel A. Monti, M.D., Sue Jiang, M.S., Cuirong Ren, Ph.D.

11:40 a.m.
62 Moral Conflict as a Component of Anxiety and Worry
Jerome L. Kroll, M.D., Kathleen S. Carey, M.S., Paul Erickson, M.D., Elizabeth Egan, Ph.D., Myles Johnson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Grand Ballroom Salon J, Level 5, Marriott

USES OF MODAFINIL
Chp.: Maria T. Caserta, M.D.
Co-Chp.: Kevan R. Wylie, M.D.

11:00 a.m.
63 Effect of Modafinil on Mood and Quality of Life in Patients with Narcolepsy
Philip M. Becker, M.D., Jonathan Schwartz, M.D., Neil Feldman, M.D., Rod J. Hughes, Ph.D.

11:30 a.m.
64 Long-Term Safety and Efficacy of Modafinil for Daytime Sleepiness
Mary B. O'Malley, M.D.

12 noon
65 Modafinil Enhances Motivation in the Absence of Overt Sleepiness
Matthew S. Miller, Ph.D., Elaine Fiocchi, B.S., Dorothy G. Flood, Ph.D., Amy DiCamillo, M.S.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Grand Ballroom Salon K, Level 5, Marriott

CROSS-CULTURAL PSYCHIATRY: ASIAN ISSUES
Chp.: Maria R. Yee, M.D.
Co-Chp.: Victor Hong

11:00 a.m.
66 Integrating Psychiatry and Primary Care Improves Treatment Acceptability Among Asian Americans
Albert Yeung, M.D., Grace E. F. Rabenstein, B.A., Henry Chung, M.D., Pamela A. Roffi, B.S., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D., David Mischoulon, M.D.

11:30 a.m.
67 Anger Discomfort in Japanese, Chinese, and Caucasian Females
Alayne Yates, M.D., Jeanne Edman, Ph.D., Maia Anguette, Ph.D.

12 noon
68 Anatomy of Jeong
Christopher K. Chung, M.D., Samson J. Cho, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Grand Ballroom Salon L, Level 5, Marriott

EPIDEMIOLOGY
Chp.: Steven A. Epstein, M.D.
Co-Chp.: Henry W.J. Weisman, M.D.

11:00 a.m.
69 The Burden of Hepatitis-C Among Mentally Ill Persons in Long-Term Care
Elsie J. Freeman, M.D., Kenneth S. Duckworth, M.D.

11:30 a.m.
70 Double Jeopardy: Mental Illness, Medical Conditions, and Early Death
Elsie J. Freeman, M.D., Kenneth S. Duckworth, M.D., Robert Goldstein, Ph.D., MaryLou Sudders

12 noon
71 Prevalence and Symptom Patterns of Depression Among College Students
Shamsah B. Sonawalla, M.D., Nicole B. Neault, B.A., Christina D. Dording, M.D., Megan E. Hughes, B.A., Albert Yeung, M.D., Timothy J. Petersen, Ph.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 23-31

COMPONENT WORKSHOP 23 11:00 a.m.-12:30 p.m.
Rooms 102 A/B, Street Level, Convention Center

MENTAL HEALTH CARE FOR ASIAN AMERICANS AND PACIFIC ISLANDERS
APA Committee of Asian-American Psychiatrists

Co-Chps.: Nang Du, M.D., Suninder S. Nand, M.D.
Participants: Francis G. Lu, M.D., Keh-Ming Lin, M.D., Kana Enomoto, M.A.

COMPONENT WORKSHOP 24 11:00 a.m.-12:30 p.m.
Room 104 A, Street Level, Convention Center

SURVIVOR MUR: WHO GETS VOTED IN?
APA Assembly Committee of Representatives of Minority/Underrepresented Groups

Co-Chps.: Jeffrey Akaka, M.D., Ana E. Campo, M.D.
Participants: Donna M. Norris, M.D., Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D., Nada L. Stotland, M.D., R. Dale Walker, M.D.

COMPONENT WORKSHOP 25 11:00 a.m.-12:30 p.m.
Room 104 B, Street Level, Convention Center

AMBULATORY DETOXIFICATION FROM ALCOHOL: HOW TO DO IT WELL AND GET PAID TOO
APA Committee on Treatment Services for Addicted Patients

Co-Chps.: George F. Kolodner, M.D., Samuel M. Silverman, M.D.
Participants: Brealy M. Sellars, M.D., Victor Sierra, M.D.
COMPONENT WORKSHOP 26  11:00 a.m.-12:30 p.m.
Rooms 112 A/B, Street Level, Convention Center

THE TERRORIST CRISIS OF 2001: USE AND IMPACT
OF ELECTRONIC COMMUNICATION
APA Committee on Information Technology, APA New York County
District Branch, and the Psychiatric Society for Informatics
Co-Chps.: Ronnie S. Stangler, M.D., Julie K. Schulman, M.D.

COMPONENT WORKSHOP 27  11:00 a.m.-12:30 p.m.
Room 202 A, Level 200, Convention Center

KIDS, SCHOOLS, AND PARENTS: FROM THE 20TH
CENTURY INTO THE 21ST CENTURY
APA Committee on History and Library
Chp.: Richard J. Thurrell, M.D.
Participants: David F. Musto, M.D., James P. Comer, M.D.,
Elissa P. Benedek, M.D., Jack C. Westman, M.D.

COMPONENT WORKSHOP 28  11:00 a.m.-12:30 p.m.
Rooms 302/303, Level 3, Marriott

THE MENTAL HEALTH CARVEOUT: STRATEGIES
TO ERASE THE STIGMA
APA Work Group on Carveouts
Co-Chps.: Lawrence B. Lurie, M.D., Jonathan E. Gudeman, M.D.
Participants: Janis G. Chester, M.D., Norman A. Clemens, M.D.,
Jerome H. Rogoff, M.D., Kenneth R. Silk, M.D.

COMPONENT WORKSHOP 29  11:00 a.m.-12:30 p.m.
Room 307, Level 3, Marriott

MISSION IMPOSSIBLE II: WHEN THE
DISORDERED CHILD BECOMES AN ADULT
APA Committee on Children with Mental or Developmental Disorders
Chp.: Roxanne C. Dryden-Edwards, M.D.
Participants: Paula J. Lockhart, M.D., Donald J. Mordecai, M.D.,
Lisa J. Nelson, M.D., Lee M. Price, L.S.W.

COMPONENT WORKSHOP 30  11:00 a.m.-12:30 p.m.
Liberty Ballroom A, Level 3, Marriott

CLINICIAN SAFETY
APA Task Force on Psychiatric Aspects of Violence
Chp.: Arthur Z. Berg, M.D.
Participants: Carl C. Bell, M.D., Bradley R. Johnson, M.D.

COMPONENT WORKSHOP 31  11:00 a.m.-12:30 p.m.
Liberty Ballroom C, Level 3, Marriott

HOW TO LAUNCH A SUCCESSFUL PRIVATE
PRACTICE: PART II
APA Committee of Early Career Psychiatrists
Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUES 58-68

ISSUE WORKSHOP 58  11:00 a.m.-12:30 p.m.
Room 202 B, Level 200, Convention Center

PSYCHODYNAMICS IN TREATMENT-REFRACTORY
DEPRESSION
Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.
Participant: David L. Mintz, M.D.

ISSUE WORKSHOP 59  11:00 a.m.-12:30 p.m.
Room 203 A, Level 200, Convention Center

THE ART OF THE UNCONSCIOUS: SHAKESPEARE,
POETRY, FILM, AND PSYCHIATRY
Co-Chps.: Steven E. Pflanz, M.D., Charles R. Joy, M.D.

ISSUE WORKSHOP 60  11:00 a.m.-12:30 p.m.
Room 203 B, Level 200, Convention Center

USE OF RESTRAINTS IN PSYCHIATRIC PRACTICE:
PROS, CONS, AND ALTERNATIVES
Chp.: Ann Marie T. Sullivan, M.D.
Participants: William F. Haning III, M.D., Walter Ling, M.D.

ISSUE WORKSHOP 61  11:00 a.m.-12:30 p.m.
Rooms 309-310, Level 3, Marriott

METHAMPHETAMINE TREATMENT: WHAT
PSYCHIATRISTS NEED TO KNOW
Chp.: Richard A. Rawson, M.D.
Participants: William F. Haning III, M.D., Walter Ling, M.D.

ISSUE WORKSHOP 62  11:00 a.m.-12:30 p.m.
Liberty Ballroom B, Level 3, Marriott

FROM PSYCHOANALYTIC PSYCHOTHERAPIST TO
PSYCHOANALYTIC ORGANIZATIONAL CORPORATE
CONSULTANT: AN INTRODUCTORY WORKSHOP
Chp.: Howard E. Book, M.D.
Participant: Jeffrey P. Kahn, M.D.

ISSUE WORKSHOP 63  11:00 a.m.-12:30 p.m.
Independence Ballroom I, Level 3, Marriott

ROLE OF AMYTAL IN CONVERSION DISORDER
Chp.: Sadiq H. Al-Samarrai, M.D.
Participant: Thomas S. Newmark, M.D.
TUESDAY

ISSUE WORKSHOP 64 11:00 a.m.-12:30 p.m.
Rooms 401-403, Level 4, Marriott
MINORITY PSYCHIATRISTS WHO HAVE SUFFERED MENTAL ILLNESS: OVERCOMING STIGMA
National Alliance for the Mentally Ill
Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Michelle O. Clark, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.

ISSUE WORKSHOP 65 11:00 a.m.-12:30 p.m.
Rooms 411/412, Level 4, Marriott
THE CHALLENGE OF PARENTAL MENTAL ILLNESS
Substance Abuse and Mental Health Services Administration
Chp.: Judith Katz-Leavy, M.Ed.
Participants: Beth Hinden, Ph.D., Lucinda Mallen, William R. Beardslee, M.D., Joanne Nicholson, Ph.D.

ISSUE WORKSHOP 66 11:00 a.m.-12:30 p.m.
Rooms 414/415, Level 4, Marriott
AFTERMATH OF PROFESSIONAL BOUNDARIES VIOLATIONS: TREATMENT OF VICTIMS
Chp.: Gail E. Robinson, M.D.
Participants: P. Susan Penfold, M.D., Werner Tschan, M.D., Gary R. Schoener, Psy.D.

ISSUE WORKSHOP 67 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon D, Level 5, Marriott
A RECIPE FOR ACADEMIC/PERSONAL SUCCESS: SOME KEY INGREDIENTS
Association for Academic Psychiatry
Chp.: Linda L.M. Worley, M.D.
Participants: Josepha A. Cheong, M.D., Robert J. Boland, M.D., Donald M. Hilty, M.D., Michelle B. Riba, M.D.

ISUES WORKSHOP 68 11:00 a.m.-12:30 p.m.
Grand Ballroom Salon I, Level 5, Marriott
THE BODY IN 21ST-CENTURY PSYCHIATRY: DIAGNOSTIC DIMENSIONS AND THERAPEUTIC CHALLENGES
Co-Chps.: Elena B. Bezzubova, M.D., Barton J. Blinder, M.D.
Participants: Jon E. Grant, M.D., Donca Vianu, M.D.

12 noon Sessions

FORUMS 5-8

FORUM 5 12 noon-1:30 p.m.
Room 103 B, Street Level, Convention Center
HOMOSEXUALITY AND RELIGION: HEALING THE WOUND
Association of Gay and Lesbian Psychiatrists and APA Committee on Gay, Lesbian, and Bisexual Issues
Chp.: Daniel W. Hicks, M.D.
Participants: David L. Scasta, M.D., Stuart M. Sotsky, M.D., Thomas P. Welch, M.D.

FORUM 6 12 noon-1:30 p.m.
Rooms 107 A/B, Street Level, Convention Center
THE DEATH PENALTY AND THE ROAD TO EXECUTION: PSYCHOLOGICAL ISSUES FOR CORRECTIONAL OFFICERS; APPROPRIATE AND INAPPROPRIATE ROLES FOR PSYCHIATRISTS
Chp.: Robert Michels, M.D.
Co-Chp.: Philip G. Zimbardo, Ph.D.
Participants: Michael J. Ososfky, Howard J. Ososfky, M.D., Warden B. Cain

FORUM 7 - CANCELLED

FORUM 8 12 noon-1:30 p.m.
Room 113 A, Street Level, Convention Center
THE CHALLENGES OF IDENTIFYING AND INTERVIEWING POTENTIAL SUBSTANCE ABUSERS
Substance Abuse and Mental Health Services Administration
Chp.: Joseph H. Autry III, M.D.
Co-Chp.: H. Westley Clark, M.D.

NEW RESEARCH POSTER SESSION 6
12 noon-2:00 p.m.
Exhibit Hall D, Street Level, Convention Center
BRAIN IMAGING; GENETICS; RESEARCH ISSUES; COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY; BEHAVIOR AND COGNITIVE THERAPIES; NEUROPSYCHIATRY; BIOLOGICAL, CONSULTATION-LIAISON, AND GERIATRIC PSYCHIATRY; OCD; AND COGNITIVE, SOMATOFORM, AND ANXIETY DISORDERS

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
**TUESDAY**

**1:00 p.m. Sessions**

**COURSES 70-78**
Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 70**  
1:00 p.m.-5:00 p.m.  
Ormandy East, Street Level, DoubleTree

**VAGAL NERVE STIMULATION**

Co-Directors: Ziad H. Nahas, M.D., Mustafa M. Husain, M.D.
Faculty: Linda L. Carpenter, M.D., Robert H. Howland, M.D., Mitchel A. Kling, M.D.

**COURSE 71**  
1:00 p.m.-5:00 p.m.  
Ormandy West, Street Level, DoubleTree

**I FOUND IT AT THE MOVIES: USING FILM CLIPS TO UNDERSTAND AND TEACH PSYCHIATRY**

Director: Frederick W. Engstrom, M.D.

**COURSE 72**  
1:00 p.m.-5:00 p.m.  
Aria A, Third Floor, DoubleTree

**THE ADVANCED PRACTICE OF PSYCHOTHERAPY**

Director: T. Byram Karasu, M.D.

**COURSE 73**  
1:00 p.m.-5:00 p.m.  
Concerto A, Third Floor, DoubleTree

**ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT**

Director: John W. Tsuang, M.D.
Faculty: Andrew P. Ho, M.D., Thomas Newton, M.D.

**COURSE 74**  
1:00 p.m.-5:00 p.m.  
Overture, Third Floor, DoubleTree

**INTEGRATED MODEL FOR TREATMENT OF CO-OCCURRING PSYCHIATRIC AND SUBSTANCE DISORDERS**

Director: Kenneth Minkoff, M.D.

**COURSE 75**  
1:00 p.m.-5:00 p.m.  
Maestro, Fourth Floor, DoubleTree

**COMPUTERS IN PSYCHIATRY: A PRIMER**

Director: Robert S. Kennedy, M.A.
Faculty: Carlyle H. Chan, M.D., John Luo, M.D.

**COURSE 76**  
1:00 p.m.-5:00 p.m.  
Minuet, Fourth Floor, DoubleTree

**MULTICULTURAL APPROACH TO THE TREATMENT OF WOMEN**

Director: Susan R. Downs, M.D.
Faculty: Ellen Haller, M.D., Sylvia W. Olarte, M.D., Gloria Pitts, D.O., Alice C. Tso, M.D.

**COURSE 77**  
1:00 p.m.-5:00 p.m.  
Rhapsody, Fourth Floor, DoubleTree

**ARTS AND HUMANITIES FOR SELF-RENEWAL**

Director: Paul R. Miller, M.D.
Faculty: Margaret Nazarey, M.S.N.

**COURSE 78**  
1:00 p.m.-5:00 p.m.  
Sonata 5, Fifth Floor, DoubleTree

**SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS**

Director: Gail E. Robinson, M.D.
Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D., Michael F. Myers, M.D.

**MEDIA SESSIONS 14-15**

**MEDIA SESSION 14**  
1:00 p.m.-2:00 p.m.  
Washington Rooms A-C, Third Floor, Loews

**WE ARE WHAT WE EAT**

Chp.: Sandra C. Walker, M.D.

19 A World of Food: Tastes and Taboos in Different Cultures  
(34 minutes)

Distributor: University of California Extension Center for Media and Independent Learning  
2000 Center Street, 4th Floor  
Berkeley, CA 94704

From vegans to cannibals, human beings consume an infinite variety of foods. They also form fiercely emotional views about people who follow food practices unlike their own. Many Americans, for example, are horrified by the consumption of dog meat in certain Asian countries. But staples of the American diet may be equally horrifying to others. *A World of Food* is the perfect antidote to ethnocentrism, the all too common assumption that one's own culture is superior to others. This video will teach the critical lesson that all cultures consume foods that people in other cultures see as highly debatable, inherently disgusting, or simply too bizarre to eat at all. It will help develop an enhanced understanding of food practices in other cultures.
and a deeper awareness of the need for cross-cultural understanding in an increasingly interconnected world.

MEDIA SESSION 15  1:00 p.m.-2:00 p.m.
Congress Rooms A-C, Fourth Floor, Loews

ATTACK ON AMERICA: LOOKING BACK, LOOKING INWARD AND VIRTUAL REALITY ENHANCED EXPOSURE THERAPY FOR PTSD AFTER SEPTEMBER 11

Co-Chps.: Richard E. D'Alli, M.D., Ian E. Alger, M.D., Edward K. Rynearson, M.D., JoAnn Difede, Ph.D.

20 World Trade Center and Pentagon Disasters (30 minutes)

Distributor: Richard E. D'Alli, M.D.
Department of Psychiatry
Johns Hopkins Medical Institute
600 N. Wolfe Street, CMSC 387
Baltimore, MD 21287

From the first horrifying images of lower Manhattan and the Pentagon on September 11, 2001, through the war that followed, the media refocused America, if not much of the world, on a common enemy. How did the media's choice of imagery affect the meaning of the course of events since that dark day? Dr. Difede will give a presentation, which will enable the audience to view the "virtual world" of the World Trade Center attack.

2:00 p.m. Sessions

LECTURES 13-14

LECTURE 13
2:00 p.m.-3:30 p.m.
Rooms 108 A/B, Street Level, Convention Center
George S. Alexopoulos, M.D.
What Can Late Life Teach Us About Depression?
Chp.: Gary J. Kennedy, M.D.
Co-Chp.: Joseph A. Cheong, M.D.

Late-life depression occurs in the context of ill health and disability. George S. Alexopoulos, M.D., discusses recent research on the pathophysiology of late-life depression and its potential impact on the development of pharmacological and nonpharmacological interventions. Dr. Alexopoulos is Professor of Psychiatry at Weill Medical College of Cornell University and Professor at the Graduate School of Medical Sciences at Cornell University. He is Director of the NIMH-funded Clinical Research Center for Geriatric Mood Disorders at the Cornell Institute of Geriatric Psychiatry, of which he is the founding Director. Dr. Alexopoulos has conducted studies on clinical, neuropsychological, electrophysiological, neurochemical, imaging, and treatment aspects of geriatric mood disorders. His research has focused on course and long-term outcomes as means of addressing the heterogeneity of geriatric mood disorders. Dr. Alexopoulos has received the Senior Investigator's Award from the American Association for Geriatric Psychiatry. He is the Editor for North America of the International Journal of Geriatric Psychiatry. He received his medical degree from the National University of Athens (Greece) and completed his residency in psychiatry at New Jersey Medical School, New Jersey College of Medicine and Dentistry.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 14
2:00 p.m.-3:30 p.m.
Rooms 109 A/B, Street Level, Convention Center
APA'S ALEXANDRA SYMONDS AWARD LECTURE
Carol C. Nadelson, M.D.
Women's Leadership in Medicine and Psychiatry
Chp.: Donna E. Stewart, M.D.
Co-Chp.: Cheryl F. McCartney, M.D.

Throughout history women have been caretakers and healers and, more rarely, leaders and policy makers in health and mental health. Carol C. Nadelson, M.D., reviews the history of women's health care roles and proposes strategies to advance women's leadership in contemporary medicine and psychiatry. Dr. Nadelson is Clinical Professor of Psychiatry at Harvard Medical School. She was the first woman to serve as APA President, in 1984-1986. A former President and Chief Executive Officer of the American Psychiatric Press, Inc., she has served on the Editorial Boards of many journals, including Hospital and Community Psychiatry, Journal of Mental Health and Family Therapy, and Journal of Psychoanalytic Obstetrics and Gynecology. She is the author of more than 200 papers and book chapters and is the co-editor of 20 books. Dr. Nadelson has received the Elizabeth Blackwell Award from the American Medical Women's Association, the Distinguished Service Award from the American College of Psychiatrists, and the Seymour Vesterman Award from APA. She graduated from the University of Rochester Medical School, was a resident in psychiatry at Massachusetts Mental Health Center and Beth Israel Hospital in Boston, and received her psychoanalytic training at the Boston Psychoanalytic Institute.

THIS SESSION WILL BE AUDIOTAPED.
MEDIA SESSIONS 16-17

MEDIA SESSION 16
2:00 p.m.-5:00 p.m.
Washington Rooms A-C, Third Floor, Loews

WOMANHOOD... SISTERHOOD

Chp.: Robert L. Sadoff, M.D.

21 Standing on My Sisters' Shoulders
(60 minutes)

Distributor: Laura J. Lipson
ABC
802 Sierra Drive
Beverly Hills, CA 90210

Standing on My Sister's Shoulders is a documentary that dramatically portrays the involvement of both black and white women working together during the Civil Rights period. Their efforts helped to change the rules of race relations in the South forever. Issues relating to voter registration; desegregation of schools; and individual, family, and community involvement will be experienced through the words and feelings of women who were there and who participated in the historical events. The film is certain to touch the lives of those who view it.

Discussants: Robert L. Sadoff, M.D., Joan Sadoff, M.S.W.

22 Women of the Wall
(31 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

In 1989, a group of Jewish women marched toward the Western Wall in Jerusalem carrying a Torah scroll, determined to pray openly as women without male leadership or approval. Violently attacked by right-wing opposition, the Women of the Wall filed a petition with the Supreme Court asserting their right to pray openly. This documentary is an insightful exploration of the women's struggle for free spiritual expression in a climate of increasing governmental control over religious practice.

Discussants: Robert L. Sadoff, M.D., Joan Sadoff, M.S.W.

23 Loyalties
(58 minutes)

Distributor: Filmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

Loyalties is the poignant story of two women who discover they share two halves of a common past in the painful lineage of slave and slave holder. Carmelita Robertson, a black graduate student who worked at a museum of national history and her co-worker, Dr. Ruth Holmes Whitehead, a white ethnologist, met for a professional lunch. They soon discover that they have a strange common thread. Almost certainly, one of Ruth's ancestors owned one of Carmelita's as a slave. As a result, the pair decide to travel to South Carolina to unravel their linked heritage. This video shows their journey through pain, resentment, embarrassment, and ultimately acceptance, as each woman, in her own way, comes to terms with their shared history.

MEDIA SESSION 17
2:00 p.m.-5:00 p.m.
Congress Rooms A-C, Fourth Floor, Loews

PSYCHIATRY GOES TO THE MOVIES

Chp.: Ronald L. Kamm, M.D.

24 Remember the Titans
(114 minutes)

Distributor: Buena Vista Home Entertainment
Department CS
Burbank, CA 91521

Next to a family, a team is one of the most influential groups to which an individual ever belongs. Remember the Titans tells the true story of the 1971 integration of a previously all-white Alexandria, Virginia, high school and its football team. Not only are black students bussed to the school over the objection of the white community, but also a black coach, played by Denzel Washington, is brought in to replace a beloved, white coach. Washington's character, Herman Boone, is faced with the daunting task of creating a cohesive, winning team when half his squad is racially at war with the other. The coach's strengths are his unwavering commitment to win, his caring relationship with players of both races, and the evolving willingness of his white counterpart, Bill Yoast, to take a subordinate role for the sake of the team. This is a class study of how to form a cohesive group to all those trying to bridge the racial divide that still exists.

Discussants: Ian R. Tofler, M.D., Herman Boone, Coach Bill Yoast, Terry "Rev." Harris (the Titans Quarterback)

REVIEW OF PSYCHIATRY: SECTION 2
2:00 p.m.-5:30 p.m.
Rooms 201 A-C, Level 200, Convention Center

THE MANY FACES OF DEPRESSION IN CHILDHOOD AND ADOLESCENCE

Co-Chps.: David Shaffer, M.D., Bruce D. Waslick, M.D.

6 Depression in Children and Adolescents: An Overview
Bruce D. Waslick, M.D., Rachel Kandel, Aphrodite Kakouros

7 Psychotherapy for Depression and Suicidal Behavior in Children and Adolescents
Laura Mufson, Ph.D., Drew M. Velting, Ph.D.

8 Pharmacological Treatment of Children and Adolescents with MDD
Boris Birmaher, M.D., David A. Brent, M.D.
9 Bipolar Disorder in Youth: A Critical Review
Gabrielle Carlson, M.D.

10 Child and Adolescent Suicide and Suicidal Behavior
David Shaffer, M.D., Ted Greenberg, M.P.H.

SYMPOSIA 27-56

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Rooms 102 A/B, Street Level, Convention Center
NEW TREATMENT TARGET IN SCHIZOPHRENIA:
UPDATE ON SOCIAL ANXIETY
Chp.: Stefano Pallanti, M.D.
Co-Chp.: Robert G. Stern, M.D.
A Shyness, Sociability, and Social Dysfunction in Schizophrenia
Joel Goldberg, Ph.D., La Schmick, M.D., M.K. Jetha
B Comparison and Assessment Procedures of Primary Versus Comorbid Social Anxiety
Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Adolfo Pazzagli, Ph.D.
C Determining and Treating Social Anxiety in Psychosis
David Castle, M.D.
D The Relationship of Social Anxiety to Level of Function Over Time in Patients with Schizophrenia
Robert G. Stern, M.D., Denise Frank, B.A., Suhala Farook, M.D., Michelle Beyer, B.A.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Room 103 A, Street Level, Convention Center
PSYCHOTIC SYMPTOMS IN CHRONIC PTSD:
PREVALENCE, COMORBIDITY, AND TREATMENT
Chp.: Daniella David, M.D.
A Psychotic Features, Illness Severity, and Atypical Antipsychotics in PTSD
Mark B. Hamner, M.D., Christopher B. Frueh, Ph.D., Helen G. Ulmer, M.S.W., George W. Arana, M.D.
B Adjunctive Risperidone Treatment in Combat Veterans with Chronic PTSD
Daniella David, M.D., Ludmila Defaria, M.D., Olga M. Lapeyra, M.D., Thomas A. Mellman, M.D.
C Racial Differences in Psychotic Symptoms Among Combat Veterans with PTSD
Christopher B. Frueh, Ph.D., Mark B. Hamner, M.D., Jason B. Belant, Ph.D., George W. Arana, M.D., Samuel M. Turner, Ph.D., Terence M. Keane, Ph.D.
D Familial and Biological Characteristics of Psychotic PTSD
Fredric J. Sautter, Ph.D., Janet J. Johnson, M.D., Arth Issette, Ph.D., Justin Wiley, Ph.D., John Cornwell, Ph.D., Madeline Uddo, Ph.D., Gina Mire, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Room 103 B, Street Level, Convention Center
NEW DEVELOPMENT IN MEDICATIONS FOR THE TREATMENT OF SUBSTANCE ABUSE
American Academy of Addiction Psychiatry
Chp.: Marc Galanter, M.D.
A Overview of Medications Development for Alcohol and Drug Dependence
Henry R. Kranzler, M.D.
B Buprenorphine for Opioid Dependence
Eric C. Strain, M.D.
C Stimulant Treatment of Cocaine Dependence
Frances R. Levin, M.D.
D Ondansetron Is Effective in Treating Biological Alcoholism
Bankole A. Johnson, M.D., Nassima Ait-Daoud, M.D.
E Anticonvulsants in Substance-Use Disorders
Kathleen T. Brady, M.D., Hugh Myrick, M.D., Robert J. Malcolm, Jr., M.D.
Discussants: Richard N. Rosenthal, M.D., Jonathan I. Ritvo, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 103 C, Street Level, Convention Center
HYPERAROUSAL AND BPD: NEW STUDIES ON ORIGINS, IMAGING, TAXONOMY, AND TREATMENT
Chp.: Thomas H. McGlashan, M.D.
A Construct Validity of BPD
Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., Thomas H. McGlashan, M.D.
B Borderline Symptoms in Maltreated Children
Joan Kaufman, Ph.D., Deborah S. Lipschitz, M.D., Seth R. Axelrod, Ph.D., Steven M. Southwick, M.D.
C Exploring the Phenomenological Interface of BPD and PTSD
Seth R. Axelrod, Ph.D., Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., Deborah S. Lipschitz, M.D., Thomas H. McGlashan, M.D., Steven M. Southwick, M.D.

(Continued next page)
D Neural Substrates of Affective Dysregulation in BPD
Nelson H. Donegan, Ph.D., Charles A. Sanislow, Ph.D.,
Robert K. Fulbright, M.D., John C. Gore, Ph.D., Pawel
Skudlarski, Ph.D., Thomas H. McGlashan, M.D., Bruce E.
Wexler, M.D.

E Repetitive Transcranial Magnetic Stimulation for BPD
Adrian Preda, M.D., Ralph E. Hoffman, M.D., Thomas H.
McGlashan, M.D.

F The BPD Status Change Scale: An Interview to Assess
Change and Functioning
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D.,
Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.
Rooms 106 A/B, Street Level, Convention Center

FALSE MEMORY SYNDROME: RECOVERY AND
FAMILY RECONCILIATION

Chp.: Paul R. McHugh, M.D.
Co-Chp.: Harold I. Lief, M.D.

A The False Memory Foundation and Its Survey of Family
Reconciliations
Pamela Freyd

B Recovered Memory Accusers of Incest: Interactions
With Their Families
Harold I. Lief, M.D., Janet M. Fetkewicz, B.A.

C Memory and Hypnosis: Facts and Fictions
Herbert Spiegel, M.D.

D Recovered Memory in the Courts
Alan A. Stone, M.D.

E The Recovered Memory Craze Onset and Offset from
1990-1998
Paul R. McHugh, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.
Rooms 107 A/B, Street Level, Convention Center

COURSE AND TREATMENT OF BPD

Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A Course of Diagnoses and Impairment in Patients with
BPD
Andrew E. Skodol II, M.D., Thomas H. McGlashan, M.D.,
M. Taciie Shea, Ph.D., John G. Gunderson, M.D., Leslie C.
Morey, Ph.D., Robert L. Stout, Ph.D., Ingrid R.
Dyck, M.P.H.

B BPD and MDD: Their Co-Occurrence and Implications
for Treatment
John G. Gunderson, M.D.

C Principles of Psychotherapy for BPD
Glen O. Gabbard, M.D.

D A Comparison of Cognitive-Behavioral and
Psychodynamic Therapy for BPD
John F. Clarkin, Ph.D., Ken Levy, Ph.D.

E Do Patients with BPD Receive Appropriate Medications
John M. Oldham, M.D., Andrew E. Skodol II, M.D.,
Donna S. Bender, Ph.D., Ingrid R. Dyck, M.P.H.

Discussant: Mary C. Zanarini, Ed.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.
Room 111 B, Street Level, Convention Center

DARWINIAN EVOLUTION: AFFECTIVE
TEMPERAMENT AND CLINICAL
CONSIDERATIONS

Chp.: Daniel R. Wilson, M.D.
Co-Chp.: Hagop S. Akiskal, M.D.

A Affective Temperaments: Evolutionary Significance
Hagop S. Akiskal, M.D.

B Evolutionary Epidemiology and the Neuropsychiatry of
Manic Depression
Daniel R. Wilson, M.D.

C Affective Disorders as Communicational State: Brain
Research Implications
Russell J. Gardner, Jr., M.D.

D Evolutionary Trait Variation: Implications for Clinical
Care and Research
Michael McGuire, M.D.

Discussant: Russell J. Gardner, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.
Rooms 112 A/B, Street Level, Convention Center

SUCCESSFUL CLINICAL APPLICATIONS OF
TELEPSYCHIATRY

Chp.: Steven E. Hyler, M.D.

A The Invisible Interface of Telepsychiatry: Is It Really?
Norman E. Alessi, M.D.

B Sustaining an Extensive Prison Telepsychiatry Network
William M. Tucker, M.D., Gerald Segal, M.S., Steven E.
Hyler, M.D.
C Telepsychiatry: A Canadian Perspective on Program Design and Implementation
Harry Karlinsky, M.D., James Coyle, M.A., Julian Somers, Ph.D., Elliot M. Goldner, M.D., Susan Quinn, R.N.

D Success of Telepsychiatry with Geriatric Patients
Beverly N. Jones, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 113 A, Street Level, Convention Center

DEPRESSION AND THE TRANSITION TO PERIMENOPAUSE: THE HARVARD STUDY OF MOODS AND CYCLES
Chp.: Lee S. Cohen, M.D.
Co-Chp.: Bernard L. Harlow, Ph.D.

A The Methods and Characteristics of Women Participants in the Harvard Study of Moods and Cycles
Bernard L. Harlow, Ph.D., Lee S. Cohen, M.D., Michael W. Otto, Ph.D., D. Speigelman, Daniel W. Cramer, M.D.

B The Impact of a Mood Disorder on Reproductive Function During the Menopausal Transition
Lee S. Cohen, M.D., Michael W. Otto, Ph.D., Claudio N. Soares, M.D., Bernard L. Harlow, Ph.D.

C Depression and Its Influence on Menopausal Transitions: Clinical and Public Health Implications
Claudio N. Soares, M.D., Lee S. Cohen, M.D., Michael W. Otto, Ph.D., Bernard L. Harlow, Ph.D.

D Psychosocial Predictors of Depression in the Harvard Study of Moods and Cycles
Michael W. Otto, Ph.D., Lee S. Cohen, M.D., Bernard L. Harlow, Ph.D.
Discusant: Stephen M. Stahl, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 113 B, Street Level, Convention Center

THE PSYCHOLOGICAL WOUNDS OF NATIONAL TRAUMA: CAUSES, CONSEQUENCES, AND TREATMENTS
Chp.: Jerrold M. Post, M.D.

A Hate-Mongering Leaders and Vulnerable Followers: The Psychopolitics of Hatred
Jerrold M. Post, M.D.

B Processing Collective Trauma: The Israeli Society and the Mental Health Community
Arie Nadler, Ph.D.

C The Enemy's Daughter: Psychological Effects of Stalinism on Female Children of Political Prisoners
Jana H. Svehlova, Ph.D.

D Telling Histories: Survivors' Testimonies of Political Violence
Stevan M. Weine, M.D.

E Countering Sequelae of Culturecide in Kosovo
James L. Griffith, M.D., Ferid Agani, M.D., Stevan M. Weine, M.D., Afrim Blita, M.D., John S. Rolland, M.D., Shqipe Ukimshi, Ph.D., Melita Kallaba, M.D.

F Recovery from the Cambodian Holocaust: The Role of Political, Religious, and Medical Leaders
David S. Liebling, M.D.
Discusant: David A. Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 113 C, Street Level, Convention Center

UNDERSTANDING PSYCHOLOGICAL TRAUMA: MULTIDISCIPLINARY PERSPECTIVE
Chp.: Randall D. Marshall, M.D.

A The Cognitive-Affective Science of Trauma and Development
Dan J. Stein, M.D.

B Variable for Aging Demand Rearing in Primates: Relevance to Trauma
Jeremy D. Coplan, M.D., Eric L. Smith, Ph.D., Bruce A. Scharf, Shinn Baptiste, Altamash I. Qureshi, M.D., Jack M. Gorman, M.D., Leonard A. Rosenblum, Ph.D.

C Ethnocultural Factors in PTSD
Roberto Lewis-Fernandez, M.D., J. Blake Turner, Ph.D., Randall D. Marshall, M.D., Bruce Dohrenwend, Ph.D.

D Contemporary Psychodynamic Perspective on Trauma
Arieh Y. Shalev, M.D.

E Integrating Therapeutic Models for Psychological Trauma
Randall D. Marshall, M.D.
Discusant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 202 A, Level 200, Convention Center

BEYOND THE SURGEON GENERAL’S REPORT: PSYCHIATRY FOR A DIVERSE POPULATION
Substance Abuse and Mental Health Services Administration

Chp.: William B. Lawson, M.D.

A Policy Implications of the Surgeon General’s Report for a Diverse Population
Kana Enomoto, M.A.

B Mental Health: Culture, Race, and Ethnicity
Jeanne Miranda, Ph.D.

C Interface Between Biology, Pharmacology, and Culture
William B. Lawson, M.D.

D Alcohol and Drug Use in College Samples: Racial Differences
Deborah Deas, M.D.

E Influence of Culture on Child Development and Early Psychopathology in the 21st Century
Harry H. Wright, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.
Room 202 B, Level 200, Convention Center

DEFINING EVIL: CLINICAL AND FORENSIC IMPLICATIONS

Chp.: Michael M. Welner, M.D.

A Dilemmas in Defining Depravity at the Criminal Law and Psychiatry Interface
Michael M. Welner, M.D.

B Sadistic Mothers and Fathers: Parents at the Edge of Evil
Michael H. Stone, M.D.

C Theology Challenges to Defining Depravity: Can Accountability Meet Therapy and Redemption?
Lawrence Gesy, M.D.

D Depravity at the Workplace: Clinical and Forensic Implications
Joseph P. Merlino, M.D.

E The Depravity Scale: Validating a Psychiatric and Forensic Measure of Evil Actions
Michael M. Welner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.
Room 203 A, Level 200, Convention Center

THE THERAPEUTIC MISCONCEPTION IN RESEARCH: BARRIER OR NECESSITY?

Chp.: Philip J. Candilis, M.D.

A An Empirical Study of Therapeutic Misconception
Charles Lidz, Ph.D., Paul S. Appelbaum, M.D., Thomas Grisso, M.D.

B Decisional Capacity and Therapeutic Misconception in Alzheimer’s Disease
Scott Y. Kim, M.D.

C Historical Perspectives on the Therapeutic Misconception
Gary S. Belkin, M.D.

D Therapeutic Misconception and Therapeutic Intent: Where Do the Problems Lie?
Donna T. Chen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.
Room 203 B, Level 200, Convention Center

COMBINED TREATMENT: DYNAMIC PSYCHOTHERAPY AND MEDICATION
American College of Psychoanalysts and APA Illinois Psychiatric Society

Chp.: Jerome A. Winer, M.D.

A Dilemmas for Psychiatrists Doing Split Psychotherapy and Pharmacotherapy
Malkah T. Notman, M.D.

B The Ethics of the Pharmaceutical Dynamic Complex
Brenda C. Solomon, M.D.

C The Teaching and Learning of Conjoint Psychotherapy and Pharmacotherapy
Sidney H. Weissman, M.D.

D When the Well-Meaning Psychiatrist Becomes the Patient’s Negative Other
Jerome A. Winer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.
Room 204 A, Level 200, Convention Center

AMERICA ATTACKED: THE AMERICAN PSYCHIATRIC ASSOCIATION AND ITS MEMBERS RESPOND
APA Committee on Psychiatric Dimensions of Disasters

Chp.: Ann E. Norwood, M.D.
Co-Chp.: Michael Blumenfield, M.D.
A The American Psychiatric Association Leadership Responds to the Terrorism: Lessons Learned
Richard K. Harding, M.D.

B The Saint Vincent's Psychiatric Response to the September 11th Terrorist Attack
Spencer Eth, M.D.

C New York City Responds to the Attack on the World Trade Center
Neal L. Cohen, M.D.

D Psychiatry at Ground Zero
Vivian B. Pender, M.D.

E Psychiatric Intervention at the Pentagon Following the September 11th Terrorist Attack
Stephen J. Cozza, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43
2:00 p.m.-5:00 p.m.
Room 204 B, Level 200, Convention Center

WHAT'S NEW IN EATING DISORDERS: A CLINICAL RESEARCH TREATMENT UPDATE
Chp.: Evelyn Attia, M.D.

A Treatment of Bulimia in a Primary Care Setting
B. Timothy Walsh, M.D., Christopher Fairburn, M.D., Diane Mickley, M.D., Robyn Sysko, B.A.

B Optimizing Treatment for Binge-Eating Disorders
Michael J. Devlin, M.D., Juli A. Goldfein, Ph.D., Pamela S. Raizman, Ph.D., B. Timothy Walsh, M.D.

C Partial Hospitalization for Anorexia Nervosa: Who Gains, How and at What Cost?
Angela S. Guarda, M.D., Leslie J. Heinberg, Ph.D.

D Family-Based Treatment for Adolescents with Anorexia Nervosa
Katherine L. Loeb, Ph.D., Ilene M. Reeman, M.D., B. Timothy Walsh, M.D., James D. Lock, M.D.

E Bulimia Nervosa in Adolescents: Do Adult Treatments Translate to Teens?
Lisa A. Kotler, M.D., Michael J. Devlin, M.D., B. Timothy Walsh, M.D.

Discussant: G. Terrence Wilson, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44
2:00 p.m.-5:00 p.m.
Rooms 302/303, Level 3, Marriott

EVIDENCE-BASED PSYCHIATRY: PRINCIPLES, EXAMPLES, AND CRITIQUES IN THE U.S. AND FRANCE

French Federation of Psychiatry

Chp.: John A. Talbott, M.D.
Co-Chp.: Herve Bokobza, M.D.

A Principles of Evidence-Based Practice: U.S. Style
Robert A. Rosenheck, M.D.

B Effective Implementation of Guidelines: An Example of Suicide Prevention in France
Jacques Glikman, M.D., Boland Bouet, M.D., Catherine Mayault, M.D., Jean-Louis Terra, M.D.

C Assertive Community Treatment as Evidence-Based Practice
Robert E. Drake, M.D., Kim T. Mueser, Ph.D., Gary R. Bond, Ph.D.

D The French Sectorization System: What Evidence?
Francois C. Petitjean, M.D., Valerie Siari, M.D., Jean-Claude Demant, M.D., Denis Leguay, M.D.

E The Efficacy-Effectiveness Gap Limits Confidence in Evidence-Based Practices
Lisa B. Dixon, M.D.

F Evidence-Based Medicine in the Treatment of Patients with Schizophrenia: A Critical Point of View
J. M. Vanelle, J. C. Loirat

Discussant: Alexandra MacLean, M.D.

SYMPOSIUM 45
2:00 p.m.-5:00 p.m.
Rooms 304-306, Level 3, Marriott

COLLABORATIVE PRACTICE IN PSYCHIATRY: DATA AND PRINCIPLES FOR PRACTICE
Chp.: Mark S. Bauer, M.D.
Co-Chp.: Gregory E. Simon, M.D.

A Collaborative Practice for Bipolar Disorder: A Multisite Controlled Trial
Mark S. Bauer, M.D.

B Using Collaborative Care Models to Improve the Treatment of Schizophrenia
Alexander S. Young, M.D., Donna L. Bean, M.B.A., Stephen R. Marder, M.D.

C Collaborative Management of Depression
Gregory E. Simon, M.D.

D Improving Depression Care for Older Adults
Jurgen Unutzer, M.D.

E Collaborative Management of Chronic Lower Back Pain
Benjamin H. K. Balderson, Ph.D.

Discussants: Lydia J. Lewis, B.A., Michael E. Thase, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Liberty Ballroom C, Level 3, Marriott

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART III
APA Committee of Early Career Psychiatrists

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
Ann S. Maloney, M.D.

B Office Location and Design for Efficiency and Success
Barry W. Wall, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

Discussants: Ann S. Maloney, M.D., Barry W. Wall, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Independence Ballroom I, Level 3, Marriott

MAJOR DEPRESSION: CURRENT GUIDELINES, PRACTICES, AND EFFECTIVENESS RESEARCH
Chp.: Darrel A. Regier, M.D.
Co-Chp.: John S. McIntyre, M.D.

A Evidence-Based Treatment Guidelines for MDD
Alan J. Gelenberg, M.D.

B Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
A. John Rush, M.D.

C Results from the Texas Medication Algorithm Project
MDD Treatment Module
Madhukar H. Trivedi, M.D.

D The Treatment of MDD in Routine Practice
Joyce C. West, Ph.D., Farifteh F. Duffy, Ph.D., Steve Marcus, William E. Narrow, M.D., Victoria E. Cosgrove, B.A., Darrel A. Regier, M.D.

Discussant: Martin B. Keller, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 50  2:00 p.m.-5:00 p.m.
Rooms 407-409, Level 4, Marriott

THE PSYCHIATRIC TREATMENT OF HIV DISEASE IN THE THIRD DECADE OF AIDS
APA Commission on AIDS

Chp.: Marshall Forstein, M.D.

A HIV Treatment Update
Marshall Forstein, M.D.

B CNS Manifestations
Karl Goodkin, M.D.

C Mood and Anxiety Disorders
Stephen J. Ferrando, M.D.

D The Multiply Diagnosed HIV Patient and Drug-Drug Interactions
Francine Cournos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51  2:00 p.m.-5:00 p.m.
Rooms 411/412, Level 4, Marriott

AMERICAN PSYCHIATRIC ASSOCIATION’S RESPONSES TO THE SURGEON GENERAL’S REPORTS ON MENTAL HEALTH

Chp.: Altha J. Stewart, M.D.

A Mental Health: A Report of the Surgeon General
Zebulon C. Taintor, M.D.

B Suicide: An American Psychiatric Association Plan of Action
Selby C. Jacobs, M.D.

C Child and Adolescent Disorders: Treatment and Prevention
G. Pirooz Sholevar, M.D.

D Youth Violence: A Report of the Surgeon General
Carl C. Bell, M.D.

E Mental Health: Cultural Issues
Altha J. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52  2:00 p.m.-5:00 p.m.
Rooms 414/415, Level 4, Marriott

SOCIAL ANXIETY DISORDER AND COMORBID MAJOR DEPRESSION

Chp.: Franklin R. Schneier, M.D.

A Perspectives on Social Phobia and Depressive Comorbidity
Murray B. Stein, M.D.

B Implications of Comorbid Social Phobia for Major Depressive Subtypes and Course
Jonathan E. Alpert, M.D., Megan E. Hughes, B.A., Joel A. Pava, Ph.D., Nicole B. Neault, B.A., Timothy J. Petersen, Ph.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

C Interpersonal Sensitivity in SAD
Gerlinde C. Harb, M.S., Richard G. Heimberg, Ph.D., Vito Agosti, M.S.W., Franklin R. Schneier, M.D., Michael R. Liebowitz, M.D.

D Social Phobia and Comorbidity with Depression: A Dichotic Listening Study
Gerard E. Bruder, Ph.D., Franklin R. Schneier, M.D., Jonathan W. Stewart, M.D., Patrick J. McGrath, M.D., Paul Leite, M.A., Frederick M. Quitkin, M.D.

E Citalopram Treatment of Comorbid Social Anxiety Disorder and Major Depression
Franklin R. Schneier, M.D., Michael R. Liebowitz, M.D., Raphael Campeas, M.D., Carlos Bianco, M.D., Roberto Lewis-Fernandez, M.D., Randall D. Marshall, M.D., J. Arturo Sanchez-Lacy, M.D.

Discussant: R. Bruce Lydiard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon A, Level 5, Marriott

ADAPTATIONS TO SEVERE STRESS: NORMAL RESPONSES AND THERAPEUTIC STRATEGIES

Chp.: Lenore C. Terr, M.D.

A Preschool Witnesses of Domestic Violence: Pathways to Recovery
Alicia F. Lieberman, Ph.D., Patricia Van Horn, Ph.D., Chandra Ghosh-Ippen, Ph.D.

B The Effect of Trauma on the Grieving Process in Children When One Parent Kills the Other
Guinevere Tufnell, M.R.C., Dora Black, Tony Kaplan, M.R.C., Jean Harris-Hendriks

C Gender Similarities and Differences in the Stress Reaction of Kurdish and Swedish Boys and Girls
Viveka Sundelin-Wahlsten, Ph.D., Abdulbaghi Ahmad, M.D.

D Coping with the Diagnosis and Progression of Cancer
David Spiegel, M.D., Lisa Butler, Ph.D., Cheryl Koopman, Ph.D., Matthew Cordova, Ph.D.

E Natural Healing Processes in the Essays of 111 Columbine Students at 2-3 Weeks
Lenore C. Terr, M.D., Daniel Bloch, Ph.D.

Discussant: Robert Michels, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 54  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon B, Level 5, Marriott

FAMILY TREATMENT OUTCOMES OF ADOLESCENTS WITH SUBSTANCE USE DISORDERS: CULTURAL ISSUES
Chp.: Jose M. Canive, M.D.
Co-Chp.: Joan D. Koss-Chioino, Ph.D.

A Engagement and Retention in Family Therapy for Mexican-American Adolescents
Luis Vargas, Ph.D., Joan D. Koss-Chioino, Ph.D., Jose M. Canive, M.D.

B Outcomes of Treating Southwestern Latino Youth: Salient Questions
Joan D. Koss-Chioino, Ph.D., Luis Vargas, Ph.D., Jose M. Canive, M.D.

C Involving Parents and Adolescents in Adolescent Drug-Abuse Treatment
Michael S. Robbins, Ph.D., James F. Alexander, Ph.D., Charles W. Turner, Ph.D.

D Clinical Trial Outcomes for Treatment of Adolescent Alcohol and Drug Abuse
Holly B. Waldron, Ph.D., Charles W. Turner, Ph.D., Janet Brody, Ph.D., Thomas R. Peterson, M.S., Sheryl Kern-Jones, Ph.D.

E Trauma Exposure and Consequences: The Case of Latino Adolescents
Jose M. Canive, M.D., Joan D. Koss-Chioino, Ph.D., Luis Vargas, Ph.D.

Discussant: Pedro Ruiz, M.D.

SYMPOSIUM 55  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon C, Level 5, Marriott

COMBINATION THERAPY FOR BIPOLAR DISORDER: RATIONALES AND CONTROVERSIES
Chp.: Joseph F. Goldberg, M.D.

A The Rationale for Combining Medications in the Management of Bipolar Disorder
Frederick K. Goodwin, M.D.

B Complex Combination Therapy in Refractory Bipolar Illness
Robert M. Post, M.D.

C The Use of Atypical Antipsychotics Plus Standard Mood Stabilizers in Bipolar Disorder
Joseph F. Goldberg, M.D.

D Bipolar Depression: Mood Stabilizers Alone, or Antidepressant Augmentation?
S. Nassir Ghaemi, M.D.

E Augmenting Treatment of Bipolar Disorder with Psychotherapy
David J. Miklowitz, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon D, Level 5, Marriott

PAIN IN THE ADDICTED PATIENT: BASIC SCIENCE, THE LAW, AND TREATMENT
Substance Abuse and Mental Health Services Administration
Chp.: Howard A. Heit, M.D.

A Neurobiology of Pain
David Borsook, M.D.

B Addiction Mechanisms: Receptors, Neurotransmitters, and Pathways
Eliot L. Gardner, Ph.D.

C Relieving Pain While Preventing Diversion
David E. Joranson, M.S.W.

D Addiction, Physical Dependence, and Tolerance with Opioid Pain Management
Howard A. Heit, M.D.

E Approach to the Pain Patient with the Disease of Addiction
Seddon R. Savage, M.D.

THIS SESSION WILL BE AUDIOTAPED.

TELECOMMUNICATIONS SESSION 2  2:00 p.m.-5:00 p.m.
Room 204 C, Level 200, Convention Center

EVIDENCE-BASED MEDICINE AND TELEPSYCHIATRY
Chp.: Gregory E. Gray, M.D.

2:15 p.m.
1 Introduction to Evidence-Based Mental Health
Gregory E. Gray, M.D.

3:30 p.m.
2 Individual and Group Psychotherapy Via Telepsychiatry
Brian J. Grady, M.D.
3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7
3:00 p.m.-5:00 p.m.
Exhibit Hall D, Street Level, Convention Center
MOOD DISORDERS; SEXUAL AND GENDER DISORDERS; WOMEN'S HEALTH; PMDD; GENDER ISSUES; AND PSYCHOIMMUNOLOGY

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 31-37

INDUSTRY-SUPPORTED SYMPOSIUM 31
7:00 p.m.-10:00 p.m.
Ballrooms A/B, Ballroom Level, Convention Center

BIPOLAR DEPRESSION AND RAPID CYCLING: CURRENT MANAGEMENT STRATEGIES
Supported by GlaxoSmithKline

Chp.: Joseph R. Calabrese, M.D.
A The Underestimated Need and Treatment Challenges of Bipolar Depression
Mark A. Frye, M.D.
B Stabilizing Mood in Bipolar Disorder from Below Baseline Over Long Periods
Joseph F. Goldberg, M.D.
C Rapid Cycling: Clinical Presentation and Treatment Approaches
Robert M. Post, M.D.
D Managing Common Benign and Uncommon Serious Adverse Effects
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 32
7:00 p.m.-10:00 p.m.
Millennium Hall, Second Floor, Loews

THE NEW NEUROBIOLOGY OF MOOD AND ANXIETY DISORDERS
Supported by GlaxoSmithKline

Chp.: Charles B. Nemeroff, M.D.
A Clinical Relevance of Norepinephrine in Mood Disorders
Kerry J. Ressler, M.D.
B Childhood Trauma and the Neurobiology of Mood Disorders
Charles B. Nemeroff, M.D.
C Advances in Functional Brain Imaging in Depression and Anxiety
Clinton D. Kilts, M.D.
D Neurobiology, Sleep, and Mood Disorders: A New Look
David J. Kupfer, M.D.
E Stress, Neurogenesis, and the Adult Brain
Elizabeth Gould, Ph.D.
Discussant: Michael J. Owens, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 33
7:00 p.m.-10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews

MANAGING AGGRESSION ACROSS THE LIFE SPAN: FROM THE PEDIATRIC TO THE GERIATRIC PATIENT
Supported by Janssen Pharmaceuticals

Chp.: Douglas H. Hughes, M.D.
A Managing the Aggressive Patient
Douglas H. Hughes, M.D.
B Evidence-Based Approach to Pharmacotherapy of the Aggressive Child
Jorge L. Armenteros, M.D.
C Aggression and Psychiatric Disorders: Confronting the War Within
Robert R. Conley, M.D.
D Strategies and Interventions for Late-Life Aggression
Soo Borson, M.D.
E Long-Term Adverse Effects of Antipsychotic Therapy
Prakash S. Masand, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 34
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

TREATING FEAR: PERSPECTIVES ON THE BIOLOGY AND THERAPY OF ANXIETY DISORDERS
Supported by Solvay Pharmaceuticals, Inc.

Chp.: Jack M. Gorman, M.D.
A Neurobiology of Fear and Social Anxiety
Justine M. Kent, M.D.
B Developmental Antecedents of Anxiety Disorders
Daniel Pine, M.D.

(Continued next page)
C New Developments in Pharmacotherapy of Anxiety Disorders
Jonathan R.T. Davidson, M.D.

D Accelerating Response and Treating Comorbidity in Anxiety
Eric Hollander, M.D., Sallie J. Hadley, M.D., Stefano Pallanti, M.D., Sherie L. Novotny, M.D., Erica Sood, B.A.,
Nicolò Baldini-Rossi, M.D., Jennifer Friedberg, B.S.

E Minimizing Side Effects and Enhancing Compliance of Antianxiety Treatments
Francisco A. Moreno, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

RAISING EXPECTATIONS IN SCHIZOPHRENIA:
ENHANCING LONG-TERM OUTCOMES
Supported by Pfizer Inc.

Chp.: Daniel E. Casey, M.D.
Co-Chp.: Nina R. Schooler, Ph.D.

A Acute Psychotic Agitation: Challenges and Treatment
Alan J. Mendelowitz, M.D.

B Long-Term Treatment Goals
Nina R. Schooler, Ph.D.

C Adverse Effects Profile of New Antipsychotic Agents
Daniel E. Casey, M.D.

D Mechanisms of Medication-Associated Glucose Metabolism Impairment
David C. Henderson, M.D.

E Schizophrenia and the Risk of Cardiovascular Disease
Charles H. Hennekens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

CLINICAL DIFFERENCES IN SEROTONIN AND NOREPINEPHRINE ANTIDEPRESSANT EFFECTS
Supported by Eli Lilly and Company

Chp.: J. Craig Nelson, M.D.

A Serotonin and Norepinephrine Mechanisms of Action
Gerard Sanacora, M.D.

B Clinical Outcome of Serotonin and Norepinephrine Agents in Depression
Pedro L. Delgado, M.D.

C The Spectrum of Serotonin-Responsive Disorders
John H. Greist, M.D.
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 38-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 38, PART 1
7:00 a.m.-8:30 a.m.
Ballrooms A/B, Ballroom Level, Convention Center

CHRONIC EPISODIC DISORDERS: COMORBIDITY AND COMPREHENSIVE INTEGRATED TREATMENT
Supported by GlaxoSmithKline
Chp.: Julia K. Warnock, M.D.

A Unraveling the Complexity: Comorbidity, Mechanistic Link, and Pharmacologic Response
Anita H. Clayton, M.D.

B New Development in Obesity
Donna H. Ryan, M.D.

C Comorbid Physical Symptoms Associated with Female-Specific Mood Disorders
Julia K. Warnock, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 1
7:00 a.m.-8:30 a.m.
Millennium Hall, Second Floor, Loews

AGE, GENDER, AND DIAGNOSIS: INFLUENCES ON DRUG RESPONSE
Supported by Pfizer Inc.
Chp.: Alexander H. Glassman, M.D.

A Can Treating Depression Alter Cardiovascular Disease?
Alexander H. Glassman, M.D.

B Comorbidity and Its Implications on Treatment: Change Over the Life Span
Tana A. Grady-Weliky, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1
7:00 a.m.-8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews

THERAPEUTIC CHALLENGES, NOVEL APPROACHES: ANTIPSYCHOTICS IN THE MANAGEMENT OF MOOD AND ANXIETY DISORDERS
Supported by Eli Lilly and Company
Chp.: Richard C. Shelton, M.D.

A Pharmacological Properties of Antipsychotics: Teasing Out Potential Mechanisms of Action
Michael J. Owens, Ph.D.

B Restoring the Balance in Manic or Depressive Bipolar Patients Through Thoughtful Pharmacotherapy
S. Nassir Ghaemi, M.D.

C Augmentation Strategies to Expand Pharmacotherapeutic Potential in Treatment-Refractory Major Depression
Richard C. Shelton, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

THE PATHOPHYSIOLOGY AND TREATMENT OF IMPULSIVITY AND AGGRESSION IN PSYCHIATRIC DISORDERS
Supported by Abbott Laboratories
Chp.: Alan C. Swann, M.D.

A Mechanisms of Impulsivity
Alan C. Swann, M.D.

B Mood Stablilizers as Adjunctive Treatment in Schizophrenia
Daniel E. Casey, M.D.

C Aggression, Violence, and Psychopathology: A Developmental Approach
Hans Steiner, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

NEW PERSPECTIVES ON SCHIZOPHRENIA SPECTRUM DISORDERS AND THEIR TREATMENT
Supported by Janssen Pharmaceuticals
Chp.: Larry J. Siever, M.D.
Co-Chp.: Barbara Cornblatt, Ph.D.

A Validating Schizotaxia Criteria for Future Prevention of Schizophrenia
Ming T. Tsuang, M.D.

B The Schizophrenia Prodrome: Early Treatment Findings
Barbara Cornblatt, M.D., Todd Lencz, Ph.D., Michael Obuchowski, Christopher Smith, M.S., Manoj R. Shah, M.D.
8:00 a.m. Sessions

COURSES 79-84
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 79 8:00 a.m.-12 noon
Ormandy East, Street Level, DoubleTree
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Director: Jesse H. Wright, M.D.
Faculty: Monica A. Basco, Ph.D., Michael E. Thase, M.D.

COURSE 80 8:00 a.m.-12 noon
Aria A, Third Floor, DoubleTree
INSANITY DEFENSE EVALUATIONS
Director: Phillip J. Resnick, M.D.

COURSE 81 8:00 a.m.-12 noon
Maestro, Fourth Floor, DoubleTree
INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowitz, M.D.

COURSE 82 8:00 a.m.-12 noon
Rhapsody, Fourth Floor, DoubleTree
EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS
Director: Gregory E. Gray, M.D.
Faculty: Gabrielle F. Beaubrun, M.D., Letitia A. Pinson, M.D.

COURSE 83 8:00 a.m.-12 noon
Sonata 5, Fifth Floor, DoubleTree
PERSONALITY DISORDERS: COMBINED INTERPERSONAL AND PHARMACOTHERAPY
Director: Roy O. Resnikoff, M.D.

COURSES 85-90
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 84 8:00 a.m.-5:00 p.m.
Ormandy West, Street Level, DoubleTree
OFFICE-BASED TREATMENT OF OPIATE DEPENDENT PATIENTS
American Academy of Addiction Psychiatry, APA Council on Addiction Psychiatry, and Substance Abuse and Mental Health Services Administration
Co-Directors: Eric C. Strain, M.D., Thomas R. Kosten, M.D.
Faculty: H. Westley Clark, M.D., David Fiellin, M.D., Herbert D. Kleber, M.D., Laura F. McNicholas, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Room 103 B, Street Level, Convention Center

MOTIVATIONAL ENHANCEMENT THERAPY FOR THE MEDICALLY ILL, SUBSTANCE ABUSE PATIENT WITH DEPRESSION
Moderator: Robert M. Weinrieb, M.D.
Presenter: Deborah H.A. Van Dorn, Ph.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1
9:00 a.m.-12 noon
Rooms 106 A/B, Street Level, Convention Center
MANAGING NEGATIVE OUTCOMES IN GENERAL PSYCHIATRY
Moderator: Richard G. Hersh, M.D.
Presenter: Mary S. Sciutto, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSE 85 9:00 a.m.-4:00 p.m.
Orchestra Room, Second Floor, DoubleTree
PSYCHOTHERAPY OF BORDERLINE PERSONALITY
Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 86 9:00 a.m.-4:00 p.m.
Concerto A, Third Floor, DoubleTree
HOW TO PRACTICE EVIDENCE-BASED PSYCHIATRY
Director: David R.S. Haslam, M.D.
Faculty: John Geddes, M.R.C., Elliot M. Goldner, M.D.,
David M. Gardner, Pharm.D.
COURSE 87 9:00 a.m.-4:00 p.m.
Concerto B, Third Floor, DoubleTree

CARING FOR REFUGEES AND SURVIVORS OF TORTURE

Director: Linda Pwowarczyk, M.D.
Faculty: Michael A. Grodin, M.D., Ricardo Restrepo, M.D., Terence M. Keane, Ph.D.

COURSE 88 9:00 a.m.-4:00 p.m.
Symphony Ballroom, Third Floor, DoubleTree

A PRACTICAL APPROACH TO HERBS AND NUTRIENTS IN PSYCHIATRY

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 89 9:00 a.m.-4:00 p.m.
Minuet, Fourth Floor, DoubleTree

THE ASSESSMENT AND TREATMENT OF CHILD MOLESTERS

Director: John M. Bradford, M.B.
Faculty: Gene G. Abel, M.D., Graham G. Glancey, M.B., J. Paul Fedoroff, M.D.

COURSE 90 9:00 a.m.-4:00 p.m.
Sonata 3, Fifth Floor, DoubleTree

THE BIOPSYCHOSOCIAL FORMULATION: AN APPROACH TO ORAL BOARD PRESENTATIONS

Co-Directors: Robert M. Rohrbaugh, M.D., William H. Campbell, M.D.
Faculty: Catherine Chiles, M.D., Paul D. Kirwin, M.D., Richard Belitsky, M.D.

DISCUSSION GROUPS 19-22
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

19 Alan F. Schatzberg, M.D., on Essentials of Clinical Psychopharmacology (Meet the Authors)
Room 308, Level 3, Marriott

20 Jesse S. Rosenthal, M.D., on Psychopharmacologic Treatment of Comorbid Attention Disorders in Adults
Room 410, Level 4, Marriott

21 Peter A. Shapiro, M.D., on Psychiatric Aspects of Cardiovascular Disease
Room 413, Level 4, Marriott

22 Norman A. Clemens, M.D., on the APA Business Initiative and the Future of Psychiatric Practice
Room 502, Level 5, Marriott

LECTURES 15-18

LECTURE 15
9:00 a.m.-10:30 a.m.
Rooms 108 A/B, Street Level, Convention Center
Philip G. Zimbardo, Ph.D.
Evil in the World and Terror in Our Nation: Transferring Vulnerabilities into Resilience
Chp.: Howard J. Ososky, M.D.
Co-Chp.: Seeth Vikek, M.D.

On September 11, the well-coordinated terrorist attacks on the World Trade Center and the Pentagon plunged the United States into grief and terror. Americans found it almost inconceivable that an organized group would be willing to kill thousands of innocent individuals and methodically plan their own suicides by piloting hijacked planes to destruction. Philip G. Zimbardo, Ph.D., examines how situational forces contribute to evil behaviors and how propaganda is utilized to shape the beliefs of a culture. He also discusses mental health professionals' contributions to increasing the resilience of citizens faced with an uncertain terrorist threat. Dr. Zimbardo, the current President of the American Psychological Association, is Professor of Psychology at Stanford University and Director of the Stanford University Social Psychology Graduate Research Training Program. He is the author of more than 250 professional articles and book chapters and several books, including the introductory psychology text Psychology and Life and the trade books Hypnosis and The Sky Child. Dr. Zimbardo has won numerous awards for his distinguished teaching at Stanford and from other institutions and has also received awards for his research in social psychology and hypnosis. He received his doctoral degree from Yale University.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 16
9:00 a.m.-10:30 a.m.
Rooms 109 A/B, Street Level, Convention Center
APA'S OSKAR PFISTER AWARD LECTURE
TBA

The Nearly Forgotten Factor in Psychiatry: What a Difference a Decade Makes
Chp.: Irving S. Wiener, M.D.
Co-Chp.: Reverend Clark S. Hard, Ph.D.

Spiritual and religious factors that might either help patients cope or add to patients' conflicts have historically drawn scant attention in psychiatry. During
the past decade, however, a quiet but constructive transformation has increased the recognition and clinical understanding of spiritual and religious issues in patients' lives. David B. Larson, M.D., highlights the changes in psychiatric research, education, and care that have characterized this transformation. Dr. Larson is the President of the International Center for the Integration of Health and Spirituality in Rockville, Maryland. He also serves as Adjunct Professor at Duke University Medical Center in Durham, North Carolina, Northwestern University Medical School in Chicago, and the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Formerly a Senior Researcher in the Office of the Director at the National Institutes of Health, Dr. Larson is the author of more than 250 scientific papers and book chapters examining the impact of spirituality on a variety of physical and mental health outcomes. A Fellow of the APA, he received his medical degree from Temple University Medical School in Philadelphia, completed his residency in psychiatry and a geriatric fellowship at Duke University Medical Center, and received his master's degree in public health at the University of North Carolina in Chapel Hill.

This session will be audiotaped.

LECTURE 17
9:00 a.m.-10:30 a.m.
Room 113 B, Street Level, Convention Center

APA'S MARMOR AWARD LECTURE
Lenore C. Terr, M.D.

Terror, Horror, and Fright: Past and Current Perspectives

Chp.: John F. Greden, M.D.
Co-Chp.: Marcia K. Goin, M.D.

To understand the psychological challenges to our nation from war waged by terrorists, psychiatrists may need to become increasingly knowledgeable about the effects of trauma-related conditions. Lenore Terr, M.D., discusses the psychological effects of traumatizing events and the possibilities for healing, drawing on her research on children's reactions to the 1976 Chowchilla, California, school bus kidnapping, the 1986 Challenger space shuttle disaster, the 1999 Columbine High School shootings, and the terrorist attacks of September 11, 2001. Dr. Terr is Clinical Professor of Psychiatry at the University of California, San Francisco, and Attending Physician at the Langley Porter Neuropsychiatric Institute, and is in the private practice of adult and child psychiatry. Her books include Too Scared to Cry: Psychic Trauma in Childhood and Beyond: Love and Work: Why Adults Need to Play. A Fellow of the APA and the American Academy of Child and Adolescent Psychiatry, she has received APA's Blanche F. Itelson Award and Samuel G. Hibbs Award. Dr. Terr graduated from the University of Michigan Medical School in Ann Arbor and completed a residency in psychiatry at the University of Michigan Neuropsychiatric Institute and a fellowship in child psychiatry at the University of Michigan Children's Psychiatric Hospital.

This session will be audiotaped.

LECTURE 18
9:00 a.m.-10:30 a.m.
Lecture Hall 114, Street Level, Convention Center

APA'S PATIENT ADVOCACY AWARD LECTURE
David Satcher, M.D.

Mental Health: A Perspective from the Surgeon General Who Listens

Chp.: Carl C. Bell, M.D.
Co-Chp.: Neal L. Cohen, M.D.

David Satcher, M.D., was the 16th Surgeon General of the United States, serving a four-year term that ended in February 2002. Currently a Fellow at the Henry J. Kaiser Family Foundation, Dr. Satcher will assume the post of Director of the National Center for Primary Care at Morehouse School of Medicine in Atlanta in the fall of 2002. Dr. Satcher was Director of the Centers for Disease Control and Prevention and Administrator of the Agency for Toxic Substances and Disease Registry from 1993 to 1998 and President of Meharry Medical College in Nashville from 1982 to 1993. A former Robert Wood Johnson Clinical Scholar, Dr. Satcher has received numerous honors, including top awards from the American Medical Association, the American College of Physicians, the American Academy of Family Physicians, and Ebony magazine. He is a Fellow of the American Academy of Family Physicians, the American College of Preventive Medicine, and the American College of Physicians. Dr. Satcher received his medical and doctorate degrees from Case Western Reserve University in Cleveland and received residency and fellowship training at Strong Memorial Hospital in Rochester, New York, the University of Rochester, UCLA, and King-Drew Medical Center in Los Angeles.

This session will be audiotaped.

MASTER EDUCATOR CLINICAL CONSULTATIONS 9-11
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

9 Carol C. Nadelson, M.D., on Changing and Evoking Roles for the Clinicians
Room 111 A, Street Level, Convention Center
10 Barbara A. Schindler, M.D., on the Addicted Woman: Diagnostic and Treatment Challenges
Room 301, Level 3, Marriott

11 Eric R. Marcus, M.D., on Adults with Learning Disabilities and Mood Disorders
Room 501, Level 5, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 18-19

MEDIA SESSION 18 9:00 a.m.-10:30 a.m.
Washington Rooms A-C, Third Floor, Loews

SOUL OF A SISTER
Chp.: Lesly T. Mega, M.D.

25 Leona's Sister Gerri
(57 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

Leona's Sister Gerri is the story of Gerri Santoro, the real person in the police photograph of an anonymous woman collapsed on a motel room floor, dead from an illegal abortion. Reprinted thousands of times in newspapers, magazines, and books, this image has become a symbol for reproductive freedom. Addressing issues of reproductive rights and domestic violence, this video is the dramatic and engrossing story of a woman's life and society's response to her death.

MEDIA SESSION 19 9:00 a.m.-10:30 a.m.
Congress Rooms A-C, Fourth Floor, Loews

DENYING THE DEMON
Chp.: Richard E. D'Alli, M.D.

26 Blink
(57 minutes)

Distributor: University of Calif. Extension
Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

This powerful and thought-provoking documentary examines the dramatic story of one-time white supremacist leader Gregory Withrow, and in so doing, explores the underlying strains of violence and domination in American life and culture. Withrow's flight from the militant white Aryan resistance captured the attention of the national media when Withrow was found beaten and his hands nailed to a board. Now, more than a decade later, Withrow is married to a Mexican-American woman and lives a low-key, semi-isolated rural existence. Blink explores the complex middle ground where Withrow still battles his demons and questions the possibility of fundamental personal change.

REVIEW OF PSYCHIATRY: SECTION 3
9:00 a.m.-12:30 p.m.
Rooms 201 A-C, Level 200, Convention Center

PSYCHIATRY IN MEDICINE
Chp.: Nada L. Stotland, M.D.

11 Psychiatric Disorders and the Menstrual Cycle
Laura J. Miller, M.D.

12 Psychiatric Factors in Solid Organ Transplantation
Catherine A. Crone, M.D.

13 Gastroenterology
Thomas N. Wise, M.D.

14 Mind and Heart: The Interplay Between Psychiatric and Cardiac Illness
Theodore A. Stern, M.D.

WORKSHOPS

COMPONENTS 32-41

COMPONENT WORKSHOP 32 9:00 a.m.-10:30 a.m.
Room 104 A, Street Level, Convention Center

COMPETENCE REQUIREMENTS IN RESIDENT EDUCATION: PROGRESS AND PROBLEMS
APA Task Force on Competency and Graduate Education
Chp.: Sherwyn M. Woods, M.D.
Participants: Lisa A. Mellman, M.D., Eugene V. Beresin, M.D., Stephen C. Scheiber, M.D., Francis G. Lu, M.D.

COMPONENT WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room 104 B, Street Level, Convention Center

QUALITY INDICATORS FOR CHILDREN AND ADOLESCENTS: WHO CARES?
APA Council on Quality Improvement
Chp.: James C. MacIntyre II, M.D.
Participants: John M. Oklham, M.D., Rhonda Joyce R. Beale, M.D., Richard C. Hermann, M.D.

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room 111 B, Street Level, Convention Center

PRACTICING REWARDING PSYCHIATRY IN JAILS AND PRISONS: A PRACTICUM
APA Council on Psychiatric Services
Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D., Cassandra F. Newkirk, M.D., Annette L. Hanson, M.D., John S. Zili, M.D.
COMPONENT WORKSHOP 35  9:00 a.m.-10:30 a.m.
Rooms 112 A/B, Street Level, Convention Center

WHOSE CHILDREN? PSYCHIATRY IN THE
CULTURAL MOSAIC OF AMERICA'S SCHOOLS
*APA Committee on Psychiatry and Mental Health in the Schools*

Chp.: Mary E. Schwab-Stone, M.D.
Participants: Trina B. Allen, M.D., Eugenio M. Rothe, M.D.,
Hong Shen, M.D., Nichole D. Grier, M.D.

COMPONENT WORKSHOP 36  9:00 a.m.-10:30 a.m.
Room 202 A, Level 200, Convention Center

IT'S NOT GAY ENOUGH: INTERPRETING ANTIGAY
BIAS IN THE 21ST CENTURY
*APA Committee on Gay, Lesbian, and Bisexual Issues*

Chp.: Jack Drescher, M.D.
Participants: Kenneth B. Ashley, M.D., Daniel W. Hicks, M.D.,
Howard C. Rubin, M.D., Julie K. Schulman, M.D., Susan A.
Turner, M.D., Serena Yuan Volpp, M.D.

COMPONENT WORKSHOP 37  9:00 a.m.-10:30 a.m.
Rooms 304-306, Level 3, Marriott

DYNAMIC DUEL: DILEMMAS OF SPLIT
TREATMENT
*APA Consortium on Treatment Issues*

Co-Chps.: Sally L. Godard, M.D., Richard J. Kessler, D.O.

COMPONENT WORKSHOP 38  9:00 a.m.-10:30 a.m.
Room 307, Level 3, Marriott

TALKING WITH THE TERMINALLY ILL ABOUT
DEATH AND DYING
*APA Committee on End-of-Life Issues*

Co-Chps.: Maurice D. Steinberg, M.D., Edwin H. Cassem, M.D.
Participants: Ira R. Byock, M.D., Samuel C. Klagsbrun, M.D.

COMPONENT WORKSHOP 39  9:00 a.m.-10:30 a.m.
Rooms 309-310, Level 3, Marriott

PSYCHOLOGIST PRESCRIPTION PRIVILEGES: IS IT
COMING? SHOULD IT?
*APA Committee on Public Policy, Litigation, and Advocacy*

Co-Chps.: Amin N. Azzam, Raymond J. Kotwicki, M.D.
Participant: Frederick Y. Huang, M.D.

COMPONENT WORKSHOP 40  9:00 a.m.-10:30 a.m.
Liberty Ballroom A, Level 3, Marriott

COMBINED RESIDENCY TRAINING: YOU WANT
TO DO WHAT?
*APA Committee on Consultation-Liaison Psychiatry and Primary Care
Education*

Co-Chps.: Shannon T. Sue-Chan, M.D., Susan L. Padrazo, M.D.
Participants: Quinton E. Moss, Jodi E. Star, Dylan P. Wint, M.D.

COMPONENT WORKSHOP 41  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon J, Level 5, Marriott

THE RULES OF THE CLUB: CAREER
ADVANCEMENT FOR WOMEN
*APA Committee on Women*

Co-Chps.: Donna E. Stewart, M.D., Ami A. Matorin, M.D.
Participants: Deborah Spitz, M.D., Leslie H. Gise, M.D.

ISSUES 69-88

ISSUE WORKSHOP 69  9:00 a.m.-10:30 a.m.
Rooms 102 A/B, Street Level, Convention Center

TREATING GAY AND LESBIAN YOUTH AT RISK

Co-Chps.: William Resnick, M.D., Steven Sokoll, M.D.

ISSUE WORKSHOP 70  9:00 a.m.-10:30 a.m.
Room 103 A, Street Level, Convention Center

GRIEVOUS BODILY HARM AND CLUB DRUGS:
TREATMENT AND OTHER CONSIDERATIONS

Chp.: Jeffrey N. Wilkins, M.D.
Participants: Waguih W. Ishak, M.D., Romana Markvitsa, M.D.,
Katherine Mellott, M.D., Lewis Nelson, M.D.

ISSUE WORKSHOP 71  9:00 a.m.-10:30 a.m.
Room 103 C, Street Level, Convention Center

RECENT STUDIES ON PARITY AND EMPLOYER-
SPONSORED INSURANCE
*Substance Abuse and Mental Health Services Administration*

Chp.: Darrel A. Regier, M.D.
Participants: Jeffrey Buck, Ph.D., Mady Chalk, Ph.D.

ISSUE WORKSHOP 72  9:00 a.m.-10:30 a.m.
Room 113 A, Street Level, Convention Center

PSYCHOPHARMACOCENETICS AND ETHNICITY:
CURRENT PERSPECTIVES

Co-Chps.: Pedro Ruiz, M.D., Keh-Ming Lin, M.D.
Participants: William B. Lawson, M.D., Edmond H.T. Pi, M.D.,
Ricardo P. Mendoza, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 73  9:00 a.m.-10:30 a.m.
Room 202 B, Level 200, Convention Center

PRACTICAL PHARMACOTHERAPY OF MOOD
DISORDERS

Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, M.D.
<table>
<thead>
<tr>
<th>Workshop</th>
<th>Time</th>
<th>Room/Location</th>
<th>Title</th>
<th>Chp.</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 203 A, Level 200, Convention Center</td>
<td>MINDFULNESS AND AWARENESS PRACTICE IN THE MEDICINE BUDDHA TRADITION OF TIBET</td>
<td>James T. Sacamano, M.D.</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 203 B, Level 200, Convention Center</td>
<td>DRUG THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES</td>
<td>Peter Manu, M.D.</td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 204 A, Level 200, Convention Center</td>
<td>IN SEARCH OF THE EMPATHIC HEALER</td>
<td>Michael J. Bennett, M.D.</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 204 B, Level 200, Convention Center</td>
<td>DISABILITY MYTHS: UNDERSTANDING THE SOCIAL SECURITY ADMINISTRATION DISABILITY PROGRAM</td>
<td>Bernard J. Arseneau, D.O.</td>
<td>Cathy Lively, Ph.D., Henry G. Conroe, M.D.</td>
</tr>
<tr>
<td>78</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Liberty Ballroom B, Level 3, Marriott</td>
<td>NEW DIRECTIONS IN MENTAL HEALTH RESPONSE TO DISASTERS AND LARGE-SCALE CRISSES</td>
<td>Mary E. Nelson, M.S.W.</td>
<td>Matthew J. Friedman, M.D., Farris Tuma, Sc.D., Chip J. Felton, M.S.W., Elissa P. Benedek, M.D.</td>
</tr>
<tr>
<td>79</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Independence Ballrooms II/III, Level 3, Marriott</td>
<td>CHILDHOOD TRAUMA INTERVENTION AND AFTERMATH: ACCESS TO QUALITY CARE</td>
<td>Malcolm A. Gordon, Ph.D.</td>
<td>Judith A. Cohen, M.D., Mary Beth Williams, Ph.D., Chris M. Kirchner, M.S.W.</td>
</tr>
<tr>
<td>80</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 406, Level 4, Marriott</td>
<td>TEACHING BEHAVIORAL SCIENCES TO FAMILY DOCTORS</td>
<td>Jonathan S. Davine, M.D.</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Rooms 407-409, Level 4, Marriott</td>
<td>MUSIC AS MIRROR: REFLECTIONS OF THE PSYCHE IN WORKS BY THE GREAT COMPOSERS</td>
<td>Chelsea L. Chesen, M.D.</td>
<td>Eli S. Chesen, M.D.</td>
</tr>
<tr>
<td>82</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Rooms 411/412, Level 4, Marriott</td>
<td>ASSISTING PHYSICIANS AND OTHER PROFESSIONALS WHO VIOLATE BOUNDARIES</td>
<td>Werner Tschan, M.D.</td>
<td>Michael F. Myers, M.D., Carolyn Quadrio, M.D., Gary R. Schoener, Psy.D.</td>
</tr>
<tr>
<td>83</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Rooms 414/415, Level 4, Marriott</td>
<td>WOMEN AND SMOKING</td>
<td>Sarah M. Whitman, M.D., David Rubenstein, Psy.D.</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Grand Ballroom Salon A, Level 5, Marriott</td>
<td>CLOZAPINE USE IN HIV</td>
<td>Richard H. McCarthy, M.D.</td>
<td>Mara J. Fiorentino, M.D.</td>
</tr>
<tr>
<td>85</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Grand Ballroom Salon B, Level 5, Marriott</td>
<td>INTERGENERATIONAL ASPECT OF TRAUMA AND TRAUMA-RELATED BEHAVIORAL PATTERNS</td>
<td>Andrei Novae, M.D.</td>
<td>Rita R. Newman, M.D., Rachel Yehuda, Ph.D.</td>
</tr>
<tr>
<td>86</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Grand Ballroom Salon C, Level 5, Marriott</td>
<td>DO RESTRICTED FORMULARIES SERVE AS BARRIERS TO CARE?</td>
<td>Mitchel J. Stein, M.D., Joseph R. Mawhinney, M.D.</td>
<td>Stephen M. Goldfinger, M.D., Kenneth S. Duckworth, M.D., Peter L. Forster, M.D.</td>
</tr>
</tbody>
</table>
WEDNESDAY

ISSUE WORKSHOP 87  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon D, Level 5, Marriott

ADVOCACY 101: INFLUENCING MENTAL HEALTH POLICY

Chp.: Jay B. Cutler, J.D.
Participants: Heather Whyte, Helen M. Foster, M.D., John E. Kraus, Jr., M.D., Jason Pray

ISSUE WORKSHOP 88  9:00 a.m.-10:30 a.m.
Grand Ballroom Salon I, Level 5, Marriott

CAREER DEVELOPMENT AND RISK MANAGEMENT

Chp.: Barry W. Wall, M.D.
Participants: Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D., Joseph M. Schwartz, M.D.

11:00 a.m. Sessions

LECTURES 19-21

LECTURE 19
11:00 a.m.-12:30 p.m.
Rooms 108 A/B, Street Level, Convention Center
Edwin H. Cassem, M.D.

Can the Third Millennium Psychiatrist Help Persons at the End-of-Life?

Chp.: Jonathan F. Borus, M.D.
Co-Chp.: Theodore A. Stern, M.D.

Data from the Netherlands suggest that terminally ill patients who request euthanasia frequently do so for reasons involving psychiatric, psychosocial, cultural, existential, and spiritual factors. Edwin H. Cassem, M.D., discusses the effects of terminal illness on patients' sense of dignity and meaning and describes ways psychiatrists can help terminally ill persons and their family members to find new goals, enhance self-respect, and improve quality of life in the dying person's remaining time. An ordained priest in the Jesuit Order, Dr. Cassem is Professor of Psychiatry at Harvard Medical School and a psychiatrist at Massachusetts General Hospital, where he also completed a clinical and research fellowship in psychiatry.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 20
11:00 a.m.-12:30 p.m.
Rooms 109 A/B, Street Level, Convention Center

APA'S KUN-PO SOO AWARD LECTURE
Keh-Ming Lin, M.D.

Journey to the West: Reflections on Culture and Psychiatry Entering the New Century

Chp.: Nang Du, M.D.
Co-Chp.: John Luo, M.D.

Rooted in Western traditions, psychiatry has transcended sociocultural divides to find its niche nearly everywhere in the world. At the same time, cross-cultural experiences have challenged the universality of prevailing psychiatric concepts and practices. Keh-Ming Lin, M.D., examines the influence of culture on vulnerability and resilience to psychiatric illness and response to interventions and discusses the importance of integrating cultural and biomedical perspectives in psychiatric assessment and care. Dr. Lin is Professor of Psychiatry at the University of California, Los Angeles, and Director of the National Institute of Mental Health/Harbor-UCLA Research Center on the Psychobiology of Ethnicity. The founder of two mental health centers serving Asian Americans in California, he has made major contributions in cross-ethnic psychopharmacology and psychiatric nosology, epidemiology, medical anthropology, and refugee mental health. Dr. Lin is a Fellow of the APA, the American Association for Social Psychiatry, and the Pacific Rim College of Psychiatrists and currently serves on APA's Council on Research. A member of the Editorial Board of American Psychiatric Press, Inc., he is the author of more than 150 articles and book chapters and the author, editor, or translator of eight books. Dr. Lin received his medical training at National Taiwan University and postgraduate training at the University of Washington in Seattle.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21
11:00 a.m.-12:30 p.m.
Lecture Hall 114, Street Level, Convention Center
Elio J. Frattaroli, M.D.
The root meaning of the word “psychiatry” is “healing the soul,” but psychiatry has increasingly become focused on the physical and the external (brain and behavior) and given less attention to the emotional and the spiritual. Elio J. Frattaroli, M.D., discusses the disparity between biological and psychotherapeutic approaches in psychiatry in terms of a larger cultural conflict between opposing philosophies of life and the nature of illness and health. Dr. Frattaroli is a psychiatrist and psychoanalyst in private practice in Bala Cynwyd, Pennsylvania. He is also Assistant Clinical Professor of Psychiatry at the University of Pennsylvania, a member of the faculty of the Psychoanalytic Center of Philadelphia, and Associate Director of the center’s Psychodynamic Psychotherapy Training Program. Dr. Frattaroli studied Shakespeare at Harvard University and trained with Bruno Bettelheim at the University of Chicago before turning to medicine. He has written and lectured on Shakespeare as well as on psychiatry and psychoanalysis. Dr. Frattaroli received his medical degree at the University of Chicago, completed his residency in psychiatry at the Institute of Pennsylvania Hospital, and received his psychoanalytic training at the Institute of the Philadelphia Association for Psychoanalysis.

**MASTER EDUCATOR CLINICAL CONSULTATION**

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

12 Michelle T. Pato, M.D., on Obsessive Compulsive and Related Disorders

Room 111 A, Street Level, Convention Center

**MEDIA SESSIONS 20-21**

**MEDIA SESSION 20**

11:00 a.m.-12:30 p.m.

Washington Rooms A-C, Third Floor, Loews

**GROWING UP GAY**

**MEDIA SESSION 21**

11:00 a.m.-2:00 p.m.

Congress Rooms A-C, Fourth Floor, Loews

**TEMPERING TROUBLED MINDS**

Chp.: Bill Lichtenstein

28 West 47th Street

(108 minutes)

Distributor: Bill Lichtenstein

Lichtenstein Creative Media

25 West 36th Street

New York, NY 10018

West 47th Street offers an unprecedented window in the lives of people who are often feared, ignored, and seldom understood. This warm and intimate film follows five people with mental illness, off the streets and out of homeless shelters, in and out of the hospital, and at home and at work, over a three year period. The film presents a story about people who approach tremendous obstacles with humor, optimism, and grace.

Discussants: Bill Lichtenstein, June Peoples, Michael M. Faenza, M.S.S.W., Wayne S. Fenton, M.D., John A. Talbott, M.D.

**MEDICAL UPDATE 3**

11:00 a.m.-12:30 p.m.

Room 103 A, Street Level, Convention Center

**STRATEGIC UPDATE OF ALZHEIMER’S DISEASE: LINKING DISEASE WITH THERAPEUTICS**

Chp.: Marion Z. Goldstein, M.D.

Presenter: Carol Lippa, M.D.

THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 Raquel E. Gur, M.D., on Brain Behavior Studies in Schizophrenia
   Anthony Room, Third Floor, Loews

SCIENTIFIC AND CLINICAL REPORT SESSIONS 25-33

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Room 111 B, Street Level, Convention Center

TREATMENT OF PERSONALITY DISORDERS

Chp.: Andrew J. Kolodny, M.D.
Co-Chp.: David A. Rothstein, M.D.

11:00 a.m.
72 Risperidone Treatment of Schizotypal Personality Disorder
   Harold W. Koenigsberg, M.D., Marianne Goodman, M.D.,
   Antonia S. New, M.D., Vivian Mitropoulou, M.A., Robert L.
   Trestman, M.D., Jeremy Silverman, Ph.D., Larry J. Siever, M.D.

11:30 a.m.
73 A Preliminary Trial of Omega-3 Fatty Acids in Women with BPD
   Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.,
   Anna Vujanovic, A.B., Elizabeth A. Parachini, B.A.

12 noon
74 Is Chemical Imbalance a Useful Concept in Treating Personality Disorders?
   Kenneth R. Silk, M.D., Joann Heap, M.S.W.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Room 113 B, Street Level, Convention Center

ISSUES IN CHILD PSYCHIATRY

Chp.: Tanya R. Anderson, M.D.
Co-Chp.: Duru Sakhrani M.D.

11:00 a.m.
75 ADHD Comorbidity: Age and Gender Differences
   Atilla Turgay, M.D., Levent Tonga, M.D., Rubaba Ansari, M.A.,
   Hashem Khosroshah, M.D., David Ng, M.D.

11:30 a.m.
76 Psychiatric Diagnosis for Children Under Age Five Referred to a Public Mental Health System
   Harry H. Wright, M.D., Michael L. Cuccaro, Ph.D.,
   Rosetta H. Penny, M.S.W., Tami V. Leonhardt, Ph.D.,
   Kristin M. Wiedewilt, Ruth K. Abramson, Ph.D.

12 noon
77 Modafinil in Children with ADHD: A Double-Blind, Placebo-Controlled Study
   Thomas A. Ruggino, M.D., Teresa C. Samsock, M.S., Laura Adkins, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Room 113 C, Street Level, Convention Center

PSYCHOTHERAPIES

Chp.: Jerald Kay, M.D.
Co-Chp.: Frederick E. Miller, M.D.

11:00 a.m.
78 Music Therapy and Medication Compliance in Psychotic Patients
   Ruby C. Castilla-Puentes, M.D., Nora Danies, M.D., Janet
   Valero, M.S.C., Janet Vargas, R.N., Orlando Gongora, M.S.C.,
   Carmenleonor Pava, M.S.C., James Perel, Ph.D.

11:30 a.m.
79 Controlled Study of NAMI Family-to-Family Education Program
   Lisa B. Dixon, M.D., Joyce Burland, Ph.D., Alicia Lucksted, Ph.D.,
   Bette Stewart, B.S., Leticia T. Postrado, Ph.D., Colleen
   McGuire, M.A., Marcia Hoffman, M.A.

12 noon
80 An Additional Guideline for Choosing Appropriate Supportive Psychotherapy Techniques
   Frederick S. Mendelsohn, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room 202 A, Level 200, Convention Center

ADDITION PSYCHIATRY

Chp.: David W. Brook, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
81 Ecstasy: Complications and Neurotoxicity
   Tina M. Vreys, M.D.
11:30 a.m.
82 Predicting Treatment Outcome of Cocaine-Dependent Patients
Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D.,
Charles C. Thornton, Ph.D., Stephen F. Weinstein, Ph.D.,
Edward Gottheil, M.D., Wade H. Berrettini, M.D.,
Kevin P. Hill, B.A.

12 noon
83 5HT Uptake, Impulsivity, Aggression, and Craving Among Cocaine Abusers
Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D.,
Edward Gottheil, M.D., Wade H. Berrettini, M.D., Sean
Parnell, Kevin P. Hill, B.A., Stephen P. Weinstein, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Room 202 B, Level 200, Convention Center

ISSUES IN PSYCHIATRIC TREATMENT
Chp.: Dinu P. Gangure, M.D.
Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
84 Civil Commitment in Turkey: Reflections on a Bill Drafted by Psychiatrists
Rasim Arkan, M.D., Paul S. Appelbaum, M.D., Mustafa
Sercan, M.D., Solmaz Turkcan, M.D., Nevzat Satmis, M.D.,
Aslihan Polat, M.D.

11:30 a.m.
85 Malpractice Liability in Shared Treatment
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

12 noon
86 Assertive Community Treatment Team Patient Employment Outcomes
Jessica Hebrank, B.A., Carolyn M. Young, M.D., Catherine
Laughlan, Richard Leong, C.S.W., Brian F. Meade, Sandy
Pastor, M.S., Ranganathan Ram, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Room 203 A, Level 200, Convention Center

SOCIAL AND COMMUNITY PSYCHIATRY
Chp.: Susan Stabinsky, M.D.
Co-Chp.: Nelda F. Scott, M.D.

11:00 a.m.
87 Defining Disability Down
Howard W. Telson, M.D.

11:30 a.m.
88 Marital Disruption and Mental Health: A Nine Wave Panel Study
Terrance J. Wade, Ph.D., David J. Pevalin, M.A.

12 noon
89 Divorce and Marital Instability in Different Subtypes of Major Affective Disorders
Zoltan Rihmer, M.D., Erika Szadoczky, M.D., Sandor Rozsa,
Kitty Kiss, Janos Furedi, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Room 204 A, Level 200, Convention Center

ISSUES IN MEDICATION MANAGEMENT
Chp.: Lon R. Hays, M.D.
Co-Chp.: Elisabeth J.S. Kunkel, M.D.

11:00 a.m.
90 Compliance and Treatment Discontinuation in Panic-Disorder Patients
Giulio Perugi, M.D., Christina Toni, M.D., Franco Frare, M.D.,
Carlo Torti, M.D.

11:30 a.m.
91 Meta-Analysis of Antidepressant Levels in Lactating Mothers' Breastmilk and Nursing Infants
Alicia M. Weissman, M.D., Arthur J. Hartz, Ph.D., Suzanne
Bender, M.S., Mica Donohue, Vicki L. Ellingrodringold, Ph.D.,
Katherine L. Wisner, M.D.

12 noon
92 Clinical Problems in the Treatment of Adults with Comorbid ADD
Marc D. Schwartz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Room 204 B, Level 200, Convention Center

MANAGING SIDE EFFECTS AND DEFICITS
Chp.: Robert W. Baker, M.D.
Co-Chp.: Khakasa H. Wapenyi, M.D.

11:00 a.m.
93 Branched-Chain Amino Acid Treatment of Tardive Dyskinesia
Mary Ann Richardson, Ph.D., Margaret L. Bevans, R.N.,
Helen M. Chao, Ph.D., Laura L. Read, Ph.D., Leslie L.
Citrome, M.D., James D. Clelland

11:30 a.m.
94 Nonadrenergic Noncholinergic Sildenafil Treatment of SRI-Associated Sexual Dysfunction
H. George Nurnberg, M.D., Paula L. Hensley, M.D., Alan J.
Gelenberg, M.D., Maurizio Fava, M.D., John Lauriello, M.D.,
Susan Paine, M.D.

(Continued next page)
12 noon
95 Rivastigmine Tartrate in Neurocognitive Deficits in Schizophrenia Patients Treated with Clozapine
Mohammad Z. Hussain, M.D., Zabaida A. Chaudhry, M.D., Seema Hussain, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m.-12:30 p.m.
Liberty Ballroom A, Level 3, Marriott

MANAGEMENT OF DEPRESSION

Chp.: Megan T. Marumoto, M.D.
Co-Chp.: Abel A. Gonzalez, M.D.

11:00 a.m.
96 Psychosocial Functioning as a Predictor of Response to Nortriptyline in Treatment-Resistant Depression
Timothy J. Petersen, Ph.D., Heidi D. Montoya, B.A., Robert L. Gresham, B.A., George Papakostas, M.D., Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.
97 Efficacy of Citalopram as an Augmenting Strategy for Menopausal Women with Estrogen-Resistant Depression
Claudio N. Soares, M.D., Jennifer Poitras, B.A., Jan L. Shifren, M.D., Allison B. Alexander, M.D., Lee S. Cohen, M.D.

12 noon
98 Polypharmacy with Antidepressants
John W. Goethe, M.D., Bonnie L. Szarek, R.N.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 42-49

COMPONENT WORKSHOP 42  11:00 a.m.-12:30 p.m.
Rooms 102 A/B, Street Level, Convention Center

EDUCATING THE COURTS: RECENT APA AMICUS CURiae BRIEFS
APA Commission on Judicial Action

Chp.: Renee L. Binder, M.D.
Participants: Howard V. Zonana, M.D., Richard G. Taranto, J.D.

COMPONENT WORKSHOP 43  11:00 a.m.-12:30 p.m.
Room 104 A, Street Level, Convention Center

MEDICARE UPDATE 2002
APA Medicare Advisory Committee

Chp.: Edward Gordon, M.D.
Participants: Irvin L. Muszynski, J.D., Ellen Jaffe, Seth P. Stein, J.D., Gerald Rogan, M.D., Lloyd I. Sederer, M.D.

COMPONENT WORKSHOP 44  11:00 a.m.-12:30 p.m.
Room 104 B, Street Level, Convention Center

CRITICAL ISSUES FOR TREATING DOMESTIC VIOLENCE SURVIVORS AND THEIR CHILDREN
APA Committee on Family Violence and Sexual Abuse

Co-Chps.: Carole L. Warshaw, M.D., Graeme Hanson, M.D.
Participants: Susan M. Ditter, M.D., Sandra L. Bloom, M.D.

COMPONENT WORKSHOP 45  11:00 a.m.-12:30 p.m.
Rooms 112 A/B, Street Level, Convention Center

PSYCHIATRY'S RESPONSE TO THE DATA: SPIRITUALLY AS A RELEVANT CLINICAL FACTOR
APA Committee on Religion, Spirituality, and Psychiatry

Chp.: Irving S. Wiesner, M.D.
Participants: Harold G. Koenig, M.D., Francis G. Lu, M.D., S. Attezaz Saeed, M.D.

COMPONENT WORKSHOP 46  11:00 a.m.-12:30 p.m.
Room 203 B, Level 200, Convention Center

LESBIAN, GAY, BISEXUAL, AND TRANSGENDERED RESIDENTS: CHALLENGES IN TRAINING
APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgendered Issues

Chp.: Dan H. Karasic, M.D.
Participants: Ellen Haller, M.D., Rodney J. Erwin, M.D., Kristin P. Riley-Lazo

COMPONENT WORKSHOP 47  11:00 a.m.-12:30 p.m.
Liberty Ballroom A, Level 3, Marriott

NEW TRENDS AND CHALLENGES IN RESIDENCY EDUCATION
APA Committee on Graduate Education

Co-Chps.: Joyce A. Tinsley, M.D., Paul E. Holtzheimer III, M.D.
Participants: Leighton Y. Huey, M.D., Laura B. Dunn, M.D.

COMPONENT WORKSHOP 48  11:00 a.m.-12:30 p.m.
Liberty Ballroom B, Level 3, Marriott

HIPAA PRIVACY RULE: WHAT EVERY PSYCHIATRIST NEEDS TO KNOW
APA Council on Psychiatry and Law and APA Committee on Confidentiality

Chp.: Jeffrey L. Metzner, M.D.
Participants: Margo P. Goldman, M.D., William M. Reinhart, M.D.
MEETING THE MENTAL HEALTH NEEDS OF MINORITIES IN THE 21ST CENTURY
APA/Center for Mental Health Services Minority Fellows and APA/AstraZeneca Minority Fellows
Chp.: Michael J. Pratts, M.D.
Participants: Alvaro Camacho, M.D., Cherry Chevy, M.D., Denise De Guzman, M.D., Nancy Sheng-Shih Wu, M.D., Bethany J. Tucker, M.D.

ASSESSING EDUCATIONAL EXPERIENCES IN PSYCHIATRY
Chp.: Joel Yager, M.D.
Participants: Paula L. Hensley, M.D., Deepa N. Nadiga, Michael A. Hollifield, M.D.

THE PSYCHIATRIC FITNESS-FOR-DUTY EXAM
Chp.: Robert C. Larsen, M.D.

YOUTH VIOLENCE: A REPORT OF THE SURGEON GENERAL
Substance Abuse and Mental Health Services Administration
Co-Chps.: Marilyn B. Benoit, M.D., Norma Hatot
Participants: Delbert Elliott, Ph.D., Carl C. Bell, M.D.

SELF-MUTILATION IN PRISON
Co-Chps.: Lee H. Rome, M.D., James E. Dillon, M.D.

PSYCHIATRIC ILLNESS AND THE WORKPLACE
Chp.: Steven E. Pflanz, M.D.

ELECTRONIC MEDICAL RECORDS ENHANCE QUALITY AND PRODUCTIVITY: THE TIME HAS COME
Chp.: Daniel A. Deutschman, M.D.
Participant: Joshua E. Freedman, M.D.

DILEMMAS OF MELANCHOLIA: LET PHILOSOPHY HELP
Association for the Advancement of Philosophy and Psychiatry
Chp.: Michael F. Myers, M.D.
Participants: Jennifer Radden, Ph.D., Deborah Spitz, M.D., Leah J. Dickstein, M.D., Zachary Myers

FORUM 9
12 noon-1:30 p.m.
Room 103 B, Street Level, Convention Center
KILLING IN THE NAME OF GOD: OSAMA BIN LADEN AND RADICAL ISLAM
Chp.: Jerrold M. Post, M.D.
Participants: Ambassador Nathaniel Howell, Ph.D., Jessica Stern, Ph.D., Vamik D. Volkan, M.D.

FORUM 10
12 noon-1:30 p.m.
Room 103 C, Street Level, Convention Center
ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION
Chp.: Stephen C. Scheiber, M.D.
Participants: Glenn C. Davis, M.D., Michael H. Ebert, M.D., Larry R. Paulkner, M.D., Burton V. Reifler, M.D., Pedro Ruiz, M.D., James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D., Daniel K. Winstead, M.D.

FORUM 11
12 noon-1:30 p.m.
Room 113 A, Street Level, Convention Center
LATIN AMERICA
Chp.: Rodrigo A. Munoz, M.D.
Participants: Harold I. Eist, M.D., Gerardo Heinz, M.D., Juan E. Mezzich, M.D., Miguel R. Jorge, M.D., Gonzalo F. Viale, M.D., Rodrigo J. Munoz T, M.D.
NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Exhibit Hall D, Street Level, Convention Center

SCHIZOPHRENIA; CHILD AND ADOLESCENT PSYCHIATRY; TREATMENT TECHNIQUES AND OUTCOME STUDIES; SOCIAL AND COMMUNITY PSYCHIATRY; CROSS-CULTURAL AND MINORITY ISSUES; HEALTH SERVICES RESEARCH; AND PSYCHIATRIC REHABILITATION

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 22
12:30 p.m.-2:00 p.m.
Washington Rooms A-C, Third Floor, Loews

ACROSS THE GENERATIONS
Chp.: David C. Martinez, M.F.A.

29 Bubbeh Lee and Me
(35 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

What can a grandchild discover through a grandparent? When the filmmaker of Bubbeh Lee and Me arrives in Florida to visit his feisty, 87-year old Jewish grandmother and speaks with her heart-to-heart about love, death, and sexuality, their two worlds collide and the strength of their bond emerges. A spirited reflection on aging, identity, diversity, and acceptance, this classic film examines the legacies passed through families and generations, and shows that the journey of self-discovery can begin at any age.

30 The Frog in the Well: The Life and Work of Hoh-Kun Yuen
(28 minutes)

Distributor: The Freedom Archives
522 Valencia
San Francisco, CA 94110

This video chronicles the life and work of Hoh-Kun Yeun, physicist, father, ice skater, and radical documentarian. Yeun, a Chinese-American immigrant, recorded decades of social movements in and around Berkeley and the Bay Area beginning in 1963 with the Free Speech movement, including the Black Panther movement, the Women’s Movement, the anti-Vietnam War Movement, and the Anti-Apartheid struggles of the 80’s. His work, inspired by a radical view of science and history, is described using photos, tape recordings, newsprint, and film from Yuen’s archives which he named The Frog in the Well after a Chinese fable. The relationship of personal development and creativity; the immigrant experience in America; the boundary between productivity and obsessional dysfunction are issues raised by this video.

Discussant: David C. Martinez, M.F.A.

1:00 p.m. Sessions

COURSES 91-96
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 91 1:00 p.m.-5:00 p.m.
Ormandy East, Street Level, DoubleTree

SLEEP MEDICINE UPDATE: ADVANCED TOPICS

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Lois Krahn, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
Aria A, Third Floor, DoubleTree

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Co-Directors: Jesse H. Wright, M.D., Aaron T. Beck, M.D.
Faculty: Jan L. Scott, M.D.

COURSE 93 1:00 p.m.-5:00 p.m.
Overture, Third Floor, DoubleTree

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 94 1:00 p.m.-5:00 p.m.
Maestro, Fourth Floor, DoubleTree

CPT CODING AND DOCUMENTATION 2002

Director: Chester W. Schmidt, Jr., M.D.

COURSE 95 1:00 p.m.-5:00 p.m.
Rhapody, Fourth Floor, DoubleTree

IMPROVING MEDIA COVERAGE OF SUICIDE: THE ROLE OF THE PSYCHIATRIST

American Foundation for Suicide Prevention

Co-Directors: Herbert Hendin, M.D., Kathleen Jamison, Ph.D.
Faculty: John T. Maltzberger, M.D., Madelyn Gould, Ph.D., Patrick Jamieson

78
TREATMENT OF CREATIVE PATIENTS
Director: Albert Rothenberg, M.D.

2:00 p.m. Sessions

LECTURES 22-23

LECTURE 22
2:00 p.m.-3:30 p.m.
Rooms 108 A/B, Street Level, Convention Center
Benedetto Saraceno, M.D.
Chp.: Darrel A. Regier, M.D.
Co-Chp.: Regina C. Casper, M.D.

The World Health Organization World Health Report for 2001, Mental Health: New Understanding, New Hope, analyzes the costs of mental disorders in human, social, and economic terms and describes core actions needed to improve mental health in a manner compatible with the realities of development in individual countries. Benedetto Saraceno, M.D., Director of the WHO Department of Mental Health and Substance Dependence in Geneva, highlights the key findings and recommendations discussed in the report. Dr. Saraceno previously served as Head of the Laboratory of Epidemiology and Social Psychiatry and Director of the WHO Collaborating Center for Research in Mental Health at Mario Negri Institute in Milan and as advisor to the Pan American Health Organization, where he assisted policy makers in mental health services reform in several South and Central American countries. He was President of the World Association for Psychosocial Rehabilitation and a Founding Member and Vice-President of the Società Italiana di Epidemiologia Psichiatrica. The author of more than 100 scientific articles and the co-author or editor of several books, Dr. Saraceno received his medical degree from the University of Milan, his postdoctoral degree in psychiatry from the University of Parma, and his training in public health and epidemiology at Mario Negri Institute.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MEDIA SESSIONS 23-24

MEDIA SESSION 23 2:00 p.m.-5:00 p.m.
Washington Rooms A-C, Third Floor, Loews

PSYCHIATRY GOES TO THE MOVIES
Chp.: Max Fink, M.D.

31 A Beautiful Mind
(122 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

A Beautiful Mind is the true story of John Forbes Nash, Jr., a man whose formulas established the mathematical principles

(Continued next page)
of the “Game Theory” of economics. The theory eventually won Mr. Nash the Nobel Prize. By the age of 30, John Nash, Jr., was diagnosed with paranoid schizophrenia. He had a varied sexual life, which included an arrest for indecent exposure in a men’s restroom, and fathering a child out of wedlock. The film focuses on his relationship with his wife and the path his life took from success to mental illness to recovery.

MEDIA SESSION 24 2:00 p.m.-5:00 p.m.
Congress Rooms A-C, Fourth Floor, Loews

PSYCHIATRY GOES TO THE MOVIES
Chp.: Alan A. Stone, M.D.

32 King of Masks: Gender and Tradition in China
(101 minutes)
Distributor: Samuel Goldwyn Studio
1133 Broadway
New York, NY 10010

The King of Masks is the story of a proud artist in a Sichuan Province. The province has been shaken by war and ravaged by floods. Starving parents are selling their sons and will give their daughters to anyone who promises the child a home. The artist, called The King of Masks, takes advantage of the opportunity to buy a child. He does not want the daughters who are thrust at him by their mothers, but he wants a son. He is just about to give up when a child’s voice cries out “Yeh Yeh,” (grandfather in Chinese). The King of Masks turns back to behold who he thought was the son he always wanted, but is really a girl, and agrees upon a price. The film shows how this indignant little girl conquers that age-old tradition to the benefit of everyone.

Discussants: Alan A. Stone, M.D., Francis G. Lu, M.D., Nada L. Stodland, M.D.

REVIEW OF PSYCHIATRY: SECTION 4
2:00 p.m.-5:30 p.m.
Rooms 201 A-C, Level 200, Convention Center

MENTAL HEALTH ISSUES IN THE LESBIAN/GAY/BISEXUAL/TRANSGENDER COMMUNITY
Co-Chps.: Billy E. Jones, M.D., Marjorie Hill, Ph.D.

15 Gay, Lesbian, Bisexual, and Transgender Youth
Jeffrey S. Akman, M.D., Garry Fisher, M.D.

16 Taboo Topics in Psychiatry: Aging and Sexual Orientation
Douglas C. Kimmel, Ph.D.

17 Psychiatric Evaluation of Gay or Lesbian Identified Persons for Legal Processing
Richard G. Dudley, Jr., M.D.

18 History and Update on Sexual Conversion (Reparative) Therapies
Jack Drescher, M.D.

19 The Intersection of Transgender Mental Health with Homosexuality and Race
Donald E. Tarver II, M.D.

SYMPOSIUM 57-75
SYMPOSIUM 57 2:00 p.m.-5:00 p.m.
Room 103 A, Street Level, Convention Center

SPORTS THROUGH THE LIFE CYCLE
International Society for Sport Psychiatry
Chp.: Ronald L. Kamm, M.D.
A The Pros and Cons of Coaching One’s Own Child
Ronald L. Kamm, M.D.

B The Mid-Career Athlete: Coping with Psychiatric Illness
Antonia L. Baum, M.D.

C When the Cheering Stops: Career Termination Issues in Athletes
Joshua W. Calhoun, M.D.

Discussants: Marvis Frazier, Wendy Wilson, Gary Cobb
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.
Rooms 106 A/B, Street Level, Convention Center

COMMUNITY CARE IN GERIATRIC PSYCHIATRY IN THE 21ST CENTURY
Chp.: Paul A. Kettl, M.D.

A Mental Health Disorders Among Rural Elders
Kathleen M. Fisher, Ph.D.

B Primary Care Management of Late-Life Depression
Ira R. Katz, M.D.

C Managing the Behavioral Complications of Dementia
Robert P. Roca, M.D.

D Caring for Elder Depression in the 21st Century
Paul A. Kettl, M.D.

E Depression in Patients with Recent-Onset-Bilateral-Age-Related Macular Degeneration
Barry W. Rovner, M.D., Robin Casten, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 59  2:00 p.m.-5:00 p.m.
Room 111 B, Street Level, Convention Center

BRAIN STIMULATION IN NEUROPSYCHIATRIC ILLNESS

Chp.: Mark S. George, M.D.
Co-Chp.: Michael R. Trimble, M.D.

A Brain Stimulation from Above and Below: Theoretical Issues
Mark S. George, M.D., Ziad H. Nahas, M.D., Andrew F. Kozel, M.D., Xingpao Li, M.D., Jeong-Ho Chae, M.D.

B Seizures, ECT, and Transcranial Magnetic Stimulation: Therapeutic Options and New Directions
Harold A. Sackeim, Ph.D., Sarah H. Lisanby, M.D.

C Brain Stimulation, Mood, and Epilepsy
Michael R. Trimble, M.D.

D Vagus Nerve Stimulation in Affective Disorders: New Findings
Lauren B. Marangell, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60  2:00 p.m.-5:00 p.m.
Rooms 112 A/B, Street Level, Convention Center

LIFE-THREATENING HYPERTHERMIC SYNDROMES IN PSYCHIATRY

Chp.: Stanley N. Caroff, M.D.
Co-Chp.: Stephen C. Mann, M.D.

A 5HT Syndrome
Paul E. Keck, Jr., M.D., Lesley M. Arnold, M.D.

B Stimulant-Induced Hyperthermia
Una D. McCann, M.D.

C NMS: Still a Syndrome After All These Years?
Ronald J. Gurrera, M.D.

D The Malignant Catatonia Syndrome
Stephan C. Mann, M.D., Stanley N. Caroff, M.D., E. Cabrini Campbell, M.D., Henry R. Bleier, M.D., Robert A. Greenstein, M.D.

E Heatstroke, Heatwaves, and Psychiatric Illness
Nigel M. Bark, M.D.

Discussant: Alan J. Gelberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61  2:00 p.m.-5:00 p.m.
Room 113 B, Street Level, Convention Center

COURSE OF PSYCHOPATHOLOGY AND FUNCTIONING IN PERSONALITY DISORDERS

Chp.: Andrew E. Skodol II, M.D.
Co-Chp.: Mary C. Zanarini, Ed.D.

A Six-Year Symptomatic and Functional Course of BPD
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., John Hennen, Ph.D., Kenneth R. Silk, M.D.

B Two-Year Diagnostic Stability of Four DSM-IV Personality Disorders: Schizotypal Personality Disorder, BPD, Avoidant Personality Disorder, and OCD
Thomas H. McGlashan, M.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D.

C Using Factor Analysis to Test Dimensional Stability of Personality Disorder Constructs
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D., Robert L. Stout, Ph.D., Donna S. Bender, Ph.D.

D Course of Functional Impairment in Personality Disorders Over Two Years
Andrew E. Skodol II, M.D., John G. Gunderson, M.D., Thomas H. McGlashan, M.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Shirley Yen, Ph.D., Leslie C. Morey, Ph.D.

E Personality Disorders and Axis I Disorders: Longitudinal Associations of Course
M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Thomas H. McGlashan, M.D., Andrew E. Skodol II, M.D., Shirley Yen, Ph.D., Leslie C. Morey, Ph.D.

Discussant: Paul S. Links, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62  2:00 p.m.-5:00 p.m.
Room 113 C, Street Level, Convention Center

CIRCUITRY OF FAILED COGNITIVE STRATEGIES IN ADDICTION

Chp.: Edythe London, Ph.D.
Co-Chp.: Igor I. Galynker, M.D.

A Brain Metabolism During Early Abstinence from Methamphetamine Abuse
Edythe London, Ph.D., Yun Dong, M.D., Sara Simon, Ph.D., Steven Berman, M.P.H., Ann Shin, Ph.D., Mark Mandelkern, Ph.D., John A. Motchik, Ph.D.

B Impaired Decision Making and Impulse Control Associated with Drug Misuse and Personality Disorders
Robert D. Rogers, M.D.

C Nicotine and Cerebral Blood Flow During a Working Memory Task
Monique Ernst, M.D., John A. Motchik, Ph.D., Stephen J. Heishman, Ph.D., John D. Van Horn, Ph.D., Jack E. Henningfield, Ph.D.

(Continued next page)
D Differences in Cerebral Glucose Metabolism in Patients On and Off Opiate Replacement Therapy

E Prefrontal Lobe Functioning in Cocaine Users
Karen I. Bolla, M.D., Monique Ernst, M.D., Maria Mouradis, M.A., John A. Matochik, Ph.D., Dana Eldreth, B.A., Kent Kiehl, Varughese Kurian, M.P.H.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63  2:00 p.m.-5:00 p.m.
Room 202 A, Level 200, Convention Center

PERSONALITY AND PERSONALITY DISORDERS IN THE COMMUNITY
Chp.: Gerald Nestadt, M.D.

A Prevalence and Correlates of Personality Disorders in a Community Sample
Jack F. Samuels, Ph.D., William W. Eaton, Ph.D., Oscar J. Bienvenu III, M.D., Clayton Brown, Ph.D., Paul T. Costa, Jr., Ph.D., Gerald Nestadt, M.D.

B The Five Factor Model of Personality and Personality Disorders in a Community Study
Paul T. Costa, Jr., Ph.D., Jeffrey H. Herbst, Ph.D., Jack F. Samuels, Ph.D., Gerald Nestadt, M.D., Oscar J. Bienvenu III, M.D., Irving M. Reti, M.D., William W. Eaton, Ph.D.

C Dimensions of DSM-IV Personality Disorders and Their Relationship to the NEO-PI-R
Gerald Nestadt, M.D., Fang-Chi Hsu, Ph.D., Jack F. Samuels, Ph.D., Oscar J. Bienvenu III, M.D., Paul T. Costa, Jr., Ph.D., Irving M. Reti, M.D., William W. Eaton, Ph.D.

D Comorbidity of Anxiety and Depressive Disorders and Normal Personality Traits
Oscar J. Bienvenu III, M.D., Jack F. Samuels, Ph.D., Kung-Ye Liang, Ph.D., Paul T. Costa, Jr., Ph.D., William W. Eaton, Ph.D., Gerald Nestadt, M.D.

E The Role of Parenting in the Development of Personality
Irving M. Reti, M.D., William W. Eaton, Ph.D., Jack F. Samuels, Ph.D., Gerald Nestadt, M.D., Paul T. Costa, Jr., Ph.D., Oscar J. Bienvenu III, M.D.

Discussants: Thomas A. Widiger, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64  2:00 p.m.-5:00 p.m.
Room 203 A, Level 200, Convention Center

TAKING CONTROL OF THE FUTURE: ACADEMIC PSYCHIATRY AND 21ST-CENTURY PRACTICE
Chp.: Lee McCabe, Ph.D.

A Psychiatry of the 21st Century: The Role of Academic Health Systems
Leighton Y. Huey, M.D.

B Shaping the Future Through Education
Michael A. Hoge, Ph.D.

C Successful Models of Depression Disease Management
David J. Katzelnick, M.D.

D The Use of Performance Indicators in Quality Improvement and Financial Reimbursement
Allen S. Daniels, Ed.D.

E Academic Psychiatry Managing Managed Care
Joseph M. Schwartz, M.D., Peter J. Fagan, Ph.D., Chester W. Schmidt, Jr., M.D.

Discussant: Steven S. Sharfstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

SYMPOSIUM 66  2:00 p.m.-5:00 p.m.
Room 203 B, Level 200, Convention Center

RECENT PERSPECTIVES ON BEHAVIORAL ADDICTIONS
Chp.: David A. Gorelick, M.D.
Co-Chp.: Michel Lejoyeux, M.D.

A Application of Dependence Criteria to Uncontrolled Behaviors
Jean Ades, M.D.

B Pathological Gambling: Relationship to Substance Abuse
David A. Gorelick, M.D.

C Neurobiology of Pathological Gambling
Marc N. Potenza, M.D.

D Compulsive Buying: Clinical Aspects and Comorbidity
Michel Lejoyeux, M.D.

E Are Deviant Sexual Behaviors a Form of Addiction?
Florence Thibaut, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67  2:00 p.m.-5:00 p.m.
Room 204 A, Level 200, Convention Center

DIAGNOSIS AND TREATMENT OF ADHD IN YOUNG CHILDREN
Chp.: Christopher J. Kratochvil, M.D.

A A Population Perspective on Psychopharmacologic Treatment of ADHD in Youths: Review and Update
Julio M. Zito, Ph.D.

B Diagnostic Challenges in Preschool Children
Helen L. Egger, M.D.

C Development and Initiation of the Preschool ADHD Treatment Study (PATS)
Laurence L. Greenhill, M.D.

D Pharmacotherapies in Young Children with ADHD
Christopher J. Kratochvil, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68  2:00 p.m.-5:00 p.m.
Room 204 B, Level 200, Convention Center

CLUB DRUGS: TRENDS, TOXICITIES, AND TREATMENTS
Substance Abuse and Mental Health Services Administration
Chp.: David M. McDowell, M.D.
Co-Chp.: Jane C. Maxwell, Ph.D.

A Trends and Patterns in Club-Drug Use
Jane C. Maxwell, Ph.D.

B Neurotoxic Effects of 4-Methylenedioxymethamphetamine (Ecstasy)
George A. Ricaurte, M.D.

C Club Drugs: Emergency Management Issues
Brett A. Roth, M.D.

D A Review of Psychiatric Symptoms and Treatment for Club-Drug Use
Karen A. Miotto, M.D.

E Club Drugs: Current and Potential Treatments
David M. McDowell, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69  2:00 p.m.-5:00 p.m.
Rooms 401-403, Level 4, Marriott

NALTREXONE TREATMENT OF ALCOHOLISM: A DECADE OF CLINICAL PROGRESS
Chp.: Joseph R. Volpicelli, M.D.
Co-Chp.: Charles P. O'Brien, M.D.

A Efficacy of Naltrexone in the Treatment of Alcoholism
Charles P. O'Brien, M.D., Helen Pettinati, Ph.D., David W. Oslin, M.D.

B Optimizing Naltrexone Treatment of Alcohol Dependence
Joseph R. Volpicelli, M.D., Ronald R. Ulm, Ph.D.

C Naltrexone: Alcoholism in Patients with Comorbid Mental Illness
Stephanie S. O'Malley, Ph.D., Rajita Sinha, Ph.D., Ismene L. Petrakis, M.D., John H. Krystal, M.D., Bruce Rousaville, M.D.

D International Studies with Naltrexone
Philip Morris, Ph.D.

Discussant: Raye Z. Litten, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon B, Level 5, Marriott

STATE-OF-THE-ART ADOLESCENT SUBSTANCE ABUSE PREVENTION AND TREATMENT
Substance Abuse and Mental Health Services Administration
Chp.: Deborah R. Simkin, M.D.
Co-Chp.: Michael L. Dennis, Ph.D.

A Effective Prevention: Center for Substance Abuse Prevention's National Study of High-Risk Youth Programs
J. Fred Springer, Ph.D., Soledad Sambrano, Ph.D.

(Continued next page)
B Psychiatric Comorbidity and Pharmacology Among Adolescents Presenting to Treatment
Deborah R. Simkin, M.D.

C Main Findings of the Cannabis Youth Treatment Randomized Experiment
Michael L. Dennis, Ph.D.

D Outcomes from the Adolescent Treatment Model Programs
Marc Fishman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon C, Level 5, Marriott
TREATMENT OF VIOLENCE AND CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS
Chp.: R. Rao Gogineni, M.D.

A Functional Family Therapy in the Treatment of Youth with Conduct Disorder
Ellen H. Sholevar, M.D.

B Community-Based Treatment of Conduct Disorder
G. Pirooz Sholevar, M.D.

C Medication Usage in Conduct Disorders
Jacquelyn M. Zavodnick, M.D.
Discussant: David A. Baron, D.O.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon D, Level 5, Marriott
AFFECTIVE INSTABILITY IN BPD
Chp.: Harold W. Koenigsberg, M.D.

A Affective Instability and Borderline Symptoms and Defenses
Harold W. Koenigsberg, M.D., Philip D. Harvey, Ph.D.,
Marianne Goodman, M.D., Antonia S. New, M.D., Vivian Mitropoulou, M.A., Larry J. Siever, M.D.

B The Relationship Between Childhood Trauma and Affective Instability in BPD
Marianne Goodman, M.D., Harold W. Koenigsberg, M.D.,
Antonia S. New, M.D., Vivian Mitropoulou, M.A., Tenko Raykov, Ph.D., Larry J. Siever, M.D.

C Treating the Affective Instability Domain in BPD
Eric Hollander, M.D., Daphne Simeon, M.D., Andrea Allen, Ph.D., Jennifer Greenberg, B.A.

D Early Maltreatment and the Neurobiology of Affective Instability
Martin H. Teicher, M.D., Susan Andersen, Ph.D., Ann M. Polcari, R.N., Carl M. Anderson, Ph.D., Caryl P. Navalta, Ph.D.
Discussant: Larry J. Siever, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon I, Level 5, Marriott
CLINICAL AND TREATMENT CHALLENGES WITH HISPANIC PATIENTS
Inter-American Council of Psychiatric Organizations
Chp.: Roberto E. Chaskel, M.D.
Co-Chp.: Ruben J. Hernandez-Serrano, M.D.

A The Hispanic Patient and the DSM-IV
Carlos Berganza, M.D., Miguel R. Jorge, M.D.

B Perception of Illness in the Hispanic Patient
Carlos Leon-Andrade, M.D., Nestor F. Marchant, M.D.

C Personality and Hispanic Patients
Andres Heerlein, M.D., Roberto E. Chaskel, M.D.

D Psychotherapeutic Intervention with the Hispanic Patient
Amelia Mvsacchio, M.D., Rodolfo D. Fahrer, M.D.

E Psychopharmacological Issues with Hispanic Patients
Antonio Pacheco, M.D., Ruben J. Hernandez-Serrano, M.D.
Discussant: Renato D. Alarcon, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.
Grand Ballroom Salon J, Level 5, Marriott
PATIENTS WITH CHRONIC PAIN: MULTIDISCIPLINARY TREATMENT APPROACHES
Chp.: Allen Lebovits, Ph.D.
Co-Chp.: Matthew B. Smith, M.D.

A Pain and Psychiatry: A General Overview
Matthew B. Smith, M.D.

B An Integrative Model of the Psychobiology of Pain
Jeffrey D. Rome, M.D.

C The Use of Analgesics in Chronic Pain
Michel Dubois, M.D.

D Chronic Pain: Nonanalgesic and Adjuvant Pharmacological Options
Michael R. Clark, M.D.

E Cognitive-Behavioral Approaches to Chronic Pain
Allen Lebovits, Ph.D.
Discussant: Paul Gusmorino, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 75  2:00 p.m.-5:00 p.m.
Grand Ballroom Salon K, Level 5, Marriott

PHYSICIAN DISABILITY: TREATMENT, INDEPENDENT EVALUATION, INSURANCE, AND CONFLICTS

Chp.: Michael H. Gendel, M.D.
Co-Chp.: Richard F. Limoges, M.D.

A Area of Conflict Between Disabled Physician Patients and Disability Insurers
Richard F. Limoges, M.D.

B Disability Insurance: Technical and Legal Aspects
Mark F. Seltzer, Esq.

C Treating the Disabled Physician
Michael F. Myers, M.D.

D Performing an Independent Psychiatric Disability Evaluation as a Physician
Michael H. Gendel, M.D.

Discussant: Linda Logsdon, M.D.
THIS SESSION WILL BE AUDIOTAPED

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9
3:00 p.m.-5:00 p.m.
Exhibit Hall D, Street Level, Convention Center

PSYCHOPHARMACOLOGY; ADDICTION
PSYCHIATRY: ALCOHOL AND DRUG RELATED DISORDERS; EATING, PERSONALITY, AND DISSOCIATIVE DISORDERS; STRESS, VIOLENCE, TRAUMA, AND VICTIMIZATION; SUICIDE; AND DIAGNOSTIC ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-49

INDUSTRY-SUPPORTED SYMPOSIUM 43
7:00 p.m.-10:00 p.m.
Ballrooms A/B, Ballroom Level, Convention Center

NONCHOLINERGIC TREATMENTS FOR ALZHEIMER'S DISEASE: PRESENT KNOWLEDGE, FUTURE HOPE
Supported by Forest Laboratories, Inc.

Chp.: Jacobo E. Mintzer, M.D.
D Comorbidities in Schizophrenia: Depression and Substance Abuse
Peter F. Buckley, M.D.

E Why Patients Stop Their Antipsychotics and What to Do About It
Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m.-10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

IDENTIFICATION AND MANAGEMENT OF DAYTIME FATIGUE AND SLEEPINESS IN PSYCHIATRY
Supported by Cephalon Inc.

Chp.: John W. Winkelman, M.D.

A Sleepiness and Fatigue: Neurobehavioral and Physiological Features
David F. Dinges, Ph.D.

B Primary Sleep Disorders Associated with Excessive Daytime Sleepiness
Mary B. O'Malley, M.D.

C Fatigue and Excessive Daytime Sleepiness in Psychiatric Disorders
Karl Doghramji, M.D.

D Clinical Manifestations of Fatigue in Chronic Fatigue Syndrome
Anthony L. Komaroff, M.D.

E Novel Molecular Targets in Deficit Syndromes
Daniel R. Weinberger, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

ADULT ADHD: FROM RESEARCH TO CLINICAL PRACTICE
Supported by Shire US, Inc.

Chp.: Joseph Biederman, M.D.
Co-Chp.: Thomas J. Spencer, M.D.

A Overview and Patterns of Comorbidity in Adults with ADHD
Joseph Biederman, M.D.

B The Neuropsychology of Adult ADHD
Larry J. Seidman, Ph.D., Joseph Biederman, M.D., E. Valera, Ph.D., Allysia Doyle, Ph.D., Michael Monoteaux, B.A., Stephen V. Faraoe, Ph.D.

C A Genetic Perspective of the Validity of Adult ADHD
Stephen V. Faraoe, Ph.D.

D Functional and Structural Neuroimaging in ADHD
George Bush, M.D.

E Pharmacotherapy of Adults with ADHD
Thomas J. Spencer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

ADVANCES IN THE UNDERSTANDING AND TREATMENT OF BINGE-EATING DISORDER
Supported by Ortho-McNeil Pharmaceutical

Chp.: James I. Hudson, M.D.

A Binge-Eating Disorder: Diagnosis and Behavior
B. Timothy Walsh, M.D.

B Epidemiology and Risk Factors
William P. Carter, M.D.

C Treatment with Antidepressants
James I. Hudson, M.D.

D Treatment with Appetite Suppressants and Antiepileptics
Susan L. McElroy, M.D.

E Psychological Treatment
Denise E. Wilfley, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 49
7:00 p.m.-10:00 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

EXPLORATIONS IN DEMENTIA: NEW AND CURRENT PERSPECTIVES
Supported by Eisai Inc., Pfizer Inc.

Chp.: Gary W. Small, M.D.
Co-Chp.: Donna Masterman, M.D.

A Early Detection and Genetic Risk Assessment in Alzheimer's Disease
Gary W. Small, M.D.

B Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective
J. Michael Ryan, M.D.

C Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?
Bradley F. Boeve, M.D.

D Charting the Course in Cerebrovascular Dementia
Gustavo C. Roman, M.D.

E Alzheimer's Disease Therapy in the 21st Century: Examining the Evidence
Pierre N. Tariot, M.D.

F Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment
Donna Masterman, M.D.
THURSDAY, MAY 23, 2002

155TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 38-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 38, PART 2
7:00 a.m.-8:30 a.m.
Ballrooms A/B, Ballroom Level, Convention Center

CHRONIC EPISODIC DISORDERS: COMORBIDITY AND COMPREHENSIVE INTEGRATED TREATMENT
Supported by GlaxoSmithKline
Chp.: Julia K. Warnock, M.D.
A The Relationship Between Psychiatric Illness and Irritable Bowel Syndrome
R. Bruce Lydiard, M.D.
B Management of Pain Syndromes: Fibromyalgia, Migraines, and Chronic Pain
Diane S. Thompson, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 2
7:00 a.m.-8:30 a.m.
Millennium Hall, Second Floor, Loews

AGE, GENDER, AND DIAGNOSIS: INFLUENCES ON DRUG RESPONSE
Supported by Pfizer Inc.
Chp.: Alexander H. Glassman, M.D.
A Epidemiology, Course, and Drug Response: How Are Mood and Anxiety Disorders Different in Children?
John S. March, M.D.
B Treatment of Mood Disorders in Women
Kimberly A. Yonkers, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2
7:00 a.m.-8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews

THERAPEUTIC CHALLENGES, NOVEL APPROACHES: ANTIPSYCHOTICS IN THE MANAGEMENT OF MOOD AND ANXIETY DISORDERS
Supported by Eli Lilly and Company
Chp.: Richard C. Shelton, M.D.
A Prognosis and Pharmacological Management of Men and Women with PTSD
Frederick Petty, M.D.
B Interplay Between Disease and Treatment Regimen: Special Safety Considerations
Olga Brawman-Mintzer, M.D.

8:00 a.m. Sessions

COURSES 97-99
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 97 8:00 a.m.-12 noon
Ormandy East, Street Level, DoubleTree
ETHICAL DECISION-MAKING IN CLINICAL PRACTICE
Director: Stephen A. Green, M.D.
Faculty: Sydney Bloch, M.D.
THURSDAY

COURSE 98 8:00 a.m.-12 noon
Aria A, Third Floor, DoubleTree

THE MISSING PIECE OF THE PUZZLE: TIC DISORDERS IN ADULTS WITH OCD OR ADD

Director: Maria A. Pugliese, M.D.
Faculty: J. Paul Hieble, Ph.D., Michael N. Rubenstein, M.D., Orrin Palmer, M.D., Sue Levi-Pearl, Mary Lou Reaver, R.N.

COURSE 99 8:00 a.m.-12 noon
Concerto A, Third Floor, DoubleTree

ASSESSING THE RISK FOR VIOLENCE

Director: Bradley R. Johnson, M.D.
Faculty: Judith Becker, Ph.D.

9:00 a.m. Sessions

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2
9:00 a.m.-12 noon
Rooms 106 A/B, Street Level, Convention Center

MANAGING NEGATIVE OUTCOMES IN GENERAL PSYCHIATRY

Moderator: Richard G. Hersh, M.D.
Presenter: Mary S. Sciutto, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ATTENDANCE.

COURSES 100-102
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 100 9:00 a.m.-4:00 p.m.
Maestro, Fourth Floor, DoubleTree

Director: John R. Evaldson, M.D.
Faculty: Mark Erickson, M.D., Annette J. Hollander, M.D., David Mullen, M.D., Daniel R. Wilson, M.D.

COURSE 101 9:00 a.m.-4:00 p.m.
Sonata 3, Fifth Floor, DoubleTree

PTSD: AN HISPANIC UPDATE OF A UNIVERSAL PROBLEM (IN SPANISH)

Director: Luis F. Ramirez, M.D.
Faculty: Jose M. Canive, M.D., Dora Cardona, M.D., Roxana Galeno, M.D., Daniel Toledo, M.D., Renato D. Alarcon, M.D.

COURSE 102 9:00 a.m.-4:00 p.m.
Sonata 5, Fifth Floor, DoubleTree

THE CONCEPTUAL BASIS OF PSYCHIATRY

Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

WORKSHOPS

COMPONENTS 50-55

COMPONENT WORKSHOP 50 9:00 a.m.-10:30 a.m.
Room 104 A, Street Level, Convention Center

CAREER CHOICES IN PSYCHIATRY
APA Assembly Committee of Area Member-in-Training Representatives

Co-Chps.: Shauna P. Reinblatt, M.D., Pamela J. Petersen-Crair, M.D.
Participants: Blaine S. Greenwald, M.D., Keith W. Young, M.D., Scott Masters, M.D.

THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

COMPONENT WORKSHOP 51  9:00 a.m.-10:30 a.m.
Room 104 B, Street Level, Convention Center
CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements
Co-Chps.: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Participants: Ronald A. Shellow, M.D., Gerald Rogan, M.D.,
Joseph M. Schwartz, M.D., Edward Gordon, M.D.

COMPONENT WORKSHOP 52  9:00 a.m.-10:30 a.m.
Rooms 107 A/B, Street Level, Convention Center
PSYCHOLOGICAL ISSUES OF PEOPLE LIVING LONGER WITH HIV
APA Commission on AIDS
Chp.: Warren M. Liang, M.D.
Participants: Karl Goodkin, M.D., Ellen M. Tedaldi, M.D.,
Robert S. Stasko, M.D.

COMPONENT WORKSHOP 53  9:00 a.m.-10:30 a.m.
Room 111 B, Street Level, Convention Center
INFORMATION TECHNOLOGY: CORE COMPETENCIES FOR PSYCHIATRISTS
APA Committee on Information Technology
Chp.: Ronnie S. Stangler, M.D.
Participants: Thomas A.M. Kramer, M.D., Zebulon C.
Taintor, M.D., David F. McMahon, M.D.

COMPONENT WORKSHOP 54  9:00 a.m.-10:30 a.m.
Washington C, Third Floor, Loews
SURGEON GENERAL'S REPORT ON CULTURE, RACE, AND ETHNICITY: CLINICAL IMPLICATIONS
APA Council on National Affairs
Co-Chps.: Sylvia W. Olarte, M.D., Theresa M. Miskimen, M.D.
Participants: Robert P. Cabaj, M.D., Nang Du, M.D., R. Dale
Walker, M.D.

COMPONENT WORKSHOP 55  9:00 a.m.-10:30 a.m.
Rooms 401-403, Level 4, Marriott
BAD BOYS, BAD GIRLS: THE DEMONIZATION OF ADOLESCENCE
APA Committee on Juvenile Justice Issues
Chp.: Louis J. Kraus, M.D.
Participants: Michael G. Kalogerakis, M.D., Daphne
Dorce, M.D., Lois T. Flaherty, M.D., William Arroyo, M.D.

ISSUES 96-112

ISSUE WORKSHOP 96  9:00 a.m.-10:30 a.m.
Rooms 102 A/B, Street Level, Convention Center
STIGMA STAYED: THE COST OF PREJUDICE IN HIGH PLACES
Chp.: Karl S. Burgoyne, M.D.
Participants: Milton H. Miller, M.D., Marvin Southard, D.S.W.,
James Allen, M.B.A.

ISSUE WORKSHOP 97  9:00 a.m.-10:30 a.m.
Room 103 A, Street Level, Convention Center
THE OTHER SIDE OF THE MOUNTAIN: FROM RESIDENCY TO REALITY
Chp.: Stephen M. Goldfinger, M.D.
Participants: Deborah J. Hales, M.D., Mary Kay Smith, M.D.,
Ronald C. Albucher, M.D.

ISSUE WORKSHOP 98  9:00 a.m.-10:30 a.m.
Room 103 C, Street Level, Convention Center
TOWARDS GLOBAL DECRIMINALIZATION OF DRUG ADDICTION
Co-Chps.: Rodrigo A. Munoz, M.D., Guido Belsasso, M.D.
Participants: Gretchen Bergman, Pedro Ruiz, M.D., Jorge A.
Zapatel, M.D., Harold I. Eist, M.D., Maria C. Bayon, M.D.

ISSUE WORKSHOP 99  9:00 a.m.-10:30 a.m.
Rooms 112 A/B, Street Level, Convention Center
POEMS ON PSYCHIATRY
Chp.: Charles R. Joy, M.D.

ISSUE WORKSHOP 100  9:00 a.m.-10:30 a.m.
Room 113 A, Street Level, Convention Center
HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH
Chp.: Phillip J. Resnick, M.D.

ISSUE WORKSHOP 101  9:00 a.m.-10:30 a.m.
Room 113 B, Street Level, Convention Center
TEACHING PRIMARY CARE RESIDENTS ABOUT DEPRESSION AND SUICIDE: CAN TECHNOLOGY ALTER OUTCOMES?
Chp.: Donna M. Sudak, M.D.
Participant: Rory P. Houghtalen, M.D.
<table>
<thead>
<tr>
<th>Workshop Number</th>
<th>Time</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSUE WORKSHOP 102</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 113 C, Street Level, Convention Center</td>
</tr>
<tr>
<td><strong>THURSDAY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Francis G. Lu, M.D.</td>
<td>Participant: Christina M. Puchalski, M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 103</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 201 A, Level 200, Convention Center</td>
</tr>
<tr>
<td>LITHIUM REVISITED: INTEGRATING RECENT FINDINGS INTO CLINICAL PRACTICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Robert T. Dunn, M.D., Eric G. Smith, M.D.</td>
<td>Participants: Frederick K. Goodwin, M.D., Michael J. Gitlin, M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 104</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 201 B, Level 200, Convention Center</td>
</tr>
<tr>
<td>THE DISRUPTIVE PHYSICIANS AND HOSPITAL CULTURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 105</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 201 C, Level 200, Convention Center</td>
</tr>
<tr>
<td>EVIDENCE-BASED TABLES OF SIDE EFFECTS OF PSYCHOTROPIC MEDICATIONS: USEFUL?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: David N. Osser, M.D., Andrew A. Sassani, M.D.</td>
<td>Participants: Alfredo Martiña, M.D., Alexandrina Darabas, M.D., Michael J. Kittay, M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 106</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 203 B, Level 200, Convention Center</td>
</tr>
<tr>
<td>USING YOUR PSYCHIATRIC SKILLS TO BUILD A PRODUCTIVE TEAM AT WORK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Saul M. Levin, M.D.</td>
<td>Participant: Judy L. Stange, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 107</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 204 A, Level 200, Convention Center</td>
</tr>
<tr>
<td><strong>11:00 a.m. Sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDICAL UPDATE 4</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 103 A, Street Level, Convention Center</td>
</tr>
<tr>
<td>COMPREHENSIVE HIV CARE: TREATMENT AND SERVICE UPDATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Velda Y. Rexach, M.D.</td>
<td>Presenter: Marla J. Gold, M.D.</td>
<td></td>
</tr>
<tr>
<td><strong>THIS SESSION WILL BE AUDIOTAPED.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
THURSDAY

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

3 Elizabeth B. Weller, M.D., on Bipolar Disorders in Children and Adolescents
Adams Room, Third Floor, Loews

SCIENTIFIC AND CLINICAL REPORT SESSIONS 34-42

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Room 103 B, Street Level, Convention Center

FORENSIC PSYCHIATRY

Chp.: Rahn K. Bailey, M.D.
Co-Chp.: Thomas G. Cobb, M.D.

11:00 a.m.
99 Medications, Strange Intoxications, and Violent Crime
Michael M. Welner, M.D.

11:30 a.m.
100 Treating Mentally Ill Offenders in a Residential Treatment Unit
Cristinel M. Coconcea, M.D., Nicoleta Coconcea, M.D.

12 noon
101 Presidential Assassination Syndrome Revisited: New Understanding
David A. Rothstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m.-12:30 p.m.
Room 103 C, Street Level, Convention Center

ISSUES IN TRAUMA AND VIOLENCE

Chp.: Sandra L. Bloom, M.D.
Co-Chp.: Richard P. Kluft, M.D.

11:00 a.m.
102 Predicting Chronicity in Vietnam Veterans with PTSD: New Findings from the National Vietnam Veterans Readjustment Study
Randall D. Marshall, M.D., J. Blake Turner, Ph.D., Roberto Lewis-Fernandez, M.D., Karestan Koenan, Ph.D., Yuval Yuria, M.D., Bruce Dohrenwend, Ph.D.

11:30 a.m.
103 Community and Inpatient Violence in Major Psychiatric Disorders
Menahem I. Krakowski, M.D.

12 noon
104 Parental Separation at Birth and Criminality in Adulthood
Pirjo H. Maki, M.D., Helina Hakko, Ph.D., Matti Joukamaa, Ph.D., Matti K. Isohanni, M.D., Juha M. Veijola, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 36
11:00 a.m.-12:30 p.m.
Room 113 B, Street Level, Convention Center

USES OF ANTIPSYCHOTICS

Chp.: Harvey Stabinsky, M.D.
Co-Chp.: Paul E. Holtzheimer III, M.D.

11:30 a.m.
105 Polypharmacy in Patients with Schizophrenia
Robert E. McCue, M.D., Rubina Waheed, M.D., Leonel Urcuyo, M.D.

11:45 a.m.
106 The Use of Atypical Antipsychotics in Adults with Developmental Disability
Karen J. Shedlack, M.D., Christine Magee, M.S., Robert Sisson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 37
11:00 a.m.-12:30 p.m.
Room 113 C, Street Level, Convention Center

MOOD DISORDERS IN CHILDREN

Chp.: Jodi E. Star
Co-Chp.: Daniel A. Nelson, M.D.

11:00 a.m.
107 Anxiety Disorders in Children and Adolescents with Bipolar Disorder
Giulio Perugi, M.D., Gabriele Masi, M.D., Christina Toni, M.D., Maria Mucci, M.D., Stefania Millepiedi, M.D., Hagop S. Akiskal, M.D.

11:30 a.m.
108 Comorbidity in Child and Adolescent Major Depression
Atilla Turagay, M.D., David Ng, M.D., Lillian Mok, M.D., Joanna Blanchard, M.A.

12 noon
109 Evaluation and Intervention of Prodromal Symptoms of Bipolar I Disorder
Mohammad Z. Hussen, M.D., Zabaida A. Chaudhry, M.D., Seema Hussen, M.D.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 38
11:00 a.m.-12:30 p.m.
Room 204 A, Level 200, Convention Center

ISSUES IN DEPRESSION

Chp.: Teodor T. Postolache, M.D.
Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.
110 Dysthymic Disorder: Integrating Research Findings into Clinical Treatment
David J. Hellerstein, M.D.

11:30 a.m.
111 Effect of Adjunct Modafinil on Energy and Concentration in Depressed Patients
Matthew A. Menza, M.D., Karl Doghranji, M.D., Ronald R. Fieve, M.D., Murray H. Rosenthal, D.O.

12 noon
112 Parental Separation at Birth and Depression in Adulthood
Juha M. Veijola, M.D., Pirjo H. Maki, M.D., Matti Joukamaa, Ph.D., Helina Hakko, Ph.D., Matti K. Isohanni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39
11:00 a.m.-12:30 p.m.
Room 204 B, Level 200, Convention Center

CLINICAL APPROACHES IN SCHIZOPHRENIA

Chp.: Abel A. Gonzalez, M.D.
Co-Chp.: Donald M. Hilty, M.D.

11:00 a.m.
113 Low-Frequency Transcranial Magnetic Stimulation Cauters Medication-Resistant Auditory Hallucinations
Ralph E. Hoffman, M.D., Keith A. Hawkins, Psy.D., Faddie H. Rachid, M.D., Ralitza Gueorguieva, Ph.D., Kathleen M. Carroll, Ph.D., Nashaat N. Boutros, M.D., John H. Krystal, M.D.

11:30 a.m.
114 Sibutramine Treatment of Obesity in Schizophrenia
Liljana Rudulovic, M.D., Peter J. Weiden, M.D., David B. Allison, Ph.D., Catherine Camille, M.A.

12 noon
115 The Stabilization Phase of Schizophrenia: A Review of the Literature
Peter J. Weiden, M.D., Judy Greene, B.A., Nina R. Schooler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40
11:00 a.m.-12:30 p.m.
Room 204 C, Level 200, Convention Center

MANAGED CARE AND HEALTH CARE FINDINGS

Chp.: David A. Casey, M.D.
Co-Chp.: Daniel P. Chapman, M.D.

11:00 a.m.
116 Alzheimer’s Disease Increases Costs of Comorbidities in Medicare-Managed Care
Howard Fillit, M.D., Jerrold W. Hill, Ph.D., Robert Futterman, Ph.D., John R. Lloyd, B.S., Vera Mastey, M.S.

11:30 a.m.
117 Donepezil Is Associated with Lower Health Care Costs in Medicare-Managed Care
Jerrold W. Hill, Ph.D., Howard Fillit, M.D., Robert Futterman, Ph.D., Vera Mastey, M.S.

12 noon
118 Managed Care and Malpractice Liability: Update 2002
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 41
11:00 a.m.-12:30 p.m.
Congress Rooms A-C, Fourth Floor, Loews

TREATMENT TECHNIQUES

Chp.: Gary S. Sachs, M.D.
Co-Chp.: David M. McDowell, M.D.

11:00 a.m.
119 Matching Treatment to Type of Poor-Prognostic, Substance-Dependent Patients
Edward Gottheil, M.D., Charles C. Thornton, Ph.D., Stephen P. Weinstein, Ph.D.

11:30 a.m.
120 Tiagabine, a Selective GABA Reuptake Inhibitor for the Treatment of Anxiety
Daniel L. Crane, M.D.

12 noon
121 Adjunctive Use of Tiagabine with Antidepressants in PTSD
Michael E. Lara, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 42
11:00 a.m.-12:30 p.m.
Rooms 401-403, Level 4, Marriott

TRENDS IN SUICIDE RATES

Chp.: David I. Greenspan, M.D.
Co-Chp.: Hagit Bat-Avi, M.D.

(Continued on next page)
THURSDAY

11:00 a.m.
122 Female Suicides in Texas Cities: 1994-1998
   Veena R. Doddakashi, M.D., Richard Wilcox, Ph.D.,
   Lawrence A. Hauser, M.D.

11:30 a.m.
123 Trends in Suicide Rates in New York City:
   Implications for a Prevention Initiative
   Neal L. Cohen, M.D., Susan Wilt, Ph.D.

12 noon
124 Changing Suicide Rates in Europe: Possible Causes
   Zoltan Rihmer, M.D., Annamaria Rihmer

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 56-57

COMPONENT WORKSHOP 56 11:00 a.m.-12:30 p.m.
   Room 104 A, Street Level, Convention Center

GUIDELINES FOR THE TREATMENT OF SUICIDAL
   BEHAVIORS
   APA Steering Committee on Practice Guidelines
   Chp.: John S. McIntyre, M.D.
   Participants: Douglas G. Jacobs, M.D., Yeates Conwell, M.D.

COMPONENT WORKSHOP 57 11:00 a.m.-12:30 p.m.
   Room 104 B, Street Level, Convention Center

ASIAN AMERICANS IN INTERMARRIAGES:
   PSYCHOSOCIAL ADJUSTMENT AND IDENTITY
   APA Caucus of Asian-American Psychiatrists
   Chp.: Jagannathan Srinivasaraghavan, M.D.
   Participants: Prakash N. Desai, M.D., Kathleen M. Kim, M.D.,
   Francis G. Lu, M.D., Cynthia M. Nguyen, M.D.

ISSUES 113-119

ISSUE WORKSHOP 113 11:00 a.m.-12:30 p.m.
   Rooms 112 A/B, Street Level, Convention Center

BRIDGES FOR HEALING: INTEGRATING FAMILY
   THERAPY AND PSYCHOPHARMACOLOGY
   Chp.: Roy O. Resnikoff, M.D.

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
   Room 201 B, Level 200, Convention Center

VIDEO CASE STUDIES OF COUPLES IN
   TREATMENT
   Chp.: Ian E. Alger, M.D.

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
   Room 201 C, Level 200, Convention Center

OUTPATIENT COMMITMENT: KENDRA'S LAW
   AND THE NEW YORK CITY EXPERIENCE
   Co-Chps.: David A. Trachtenberg, M.D., Michael S. Lesser, M.D.
   Participants: Scott D. Rogge, M.D., Daniel Garza, M.D.,
   Robert H. Berger, M.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
   Room 202 B, Level 200, Convention Center

CREATING EFFECTIVE ALLIANCES WITH
   PHARMACEUTICAL INDUSTRY PHYSICIANS
   Chp.: Arthur L. Lazarus, M.D.
   Participants: Paul E. Keck, Jr., M.D., David L. Garver, M.D.,
   Rajiv Tandon, M.D.

ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
   Room 203 A, Level 200, Convention Center

SUBSTANCE ABUSE PREVENTION AND
   TREATMENT: A PSYCHIATRIC PERSPECTIVE
   Substance Abuse and Mental Health Services Administration
   Chp.: Sheila Harmison, D.S.W.
   Participants: Ruth Sanchez-Way, Ph.D., H. Westley Clark, M.D.

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
   Room 203 B, Level 200, Convention Center

HOW TO DEVELOP A LECTURE
   Co-Chps.: Marianne T. Guschwan, M.D., Susan Tapert, Ph.D.
   Participants: Christopher J. Welsh, M.D., Donna L. Londino, M.D.

ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m.
   Washington A, Third Floor, Loews

A CLINICIAN'S GUIDE TO SUBSTANCE ABUSE
   TREATMENT FOR GAY, LESBIAN, BISEXUAL, AND
   TRANSGENDER PERSONS
   Substance Abuse and Mental Health Services Administration
   Chp.: Saul M. Levin, M.D.
   Participants: Frank Y. Wong, Ph.D., Michele J. Eliason, Ph.D.

12 noon Sessions

FORUMS 12-13

FORUM 12 12 noon-1:30 p.m.
   Rooms 102 A/B, Street Level, Convention Center

PSYOP: PSYCHOLOGICAL OPERATIONS IN THE
   WAR AGAINST TERRORISM
   Chp.: Ronnie S. Stangler, M.D.
THURSDAY

FORUM 13
12 noon-1:30 p.m.
Rooms 107 A/B, Street Level, Convention Center

THE PHARMACEUTICAL INDUSTRY AND THE APA:
CONTROVERSIES AND APPROACHES
APA Committee on Commercial Support

Chp.: Stephen M. Goldfinger, M.D.
Participants: Nyapati R. Rao, M.D., Troy L. Thompson II, M.D.,
William B. Lawson, M.D., Anand Pandya, M.D., Philip R.
Muskin, M.D., Paula G. Panzer, M.D., David S. Wahl, M.D.,
Charles R. Goldman, M.D., James W. Thompson, M.D.

2:00 p.m. Sessions

SYMPOSIA 76-93

SYMPOSIUM 76
2:00 p.m.-5:00 p.m.
Rooms 102 A/B, Street Level, Convention Center

CULTURALLY COMPETENT MENTAL HEALTH
CARE: IDENTIFYING AND REDUCING
DISPARITIES

Chp.: Carl C. Bell, M.D.
Co-Chp.: Renato D. Alarcon, M.D.

A Bipolar Disorder in African Americans
William B. Lawson, M.D.

B Mental Health Care in Hispanic Populations: Clinical and
Therapeutic Issues
Renato D. Alarcon, M.D.

C Cultural Competence Standards for Mental Health Services
Francis G. Lu, M.D.

D Race, Ethnicity, and Variations in Psychiatric Diagnosis
and Treatment
Diane M. Herbeck, M.A., Carl C. Bell, M.D., Diana J. Fitek, B.A.,
Joyce C. West, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77
2:00 p.m.-5:00 p.m.
Room 103 A, Street Level, Convention Center

HIV TREATMENT DIMENSIONS AMONG DIVERSE
ETHNIC AND CULTURAL POPULATIONS
APA Commission on AIDS

Chp.: Altha J. Stewart, M.D.

A HIV-Positive Patient Panel
Altha J. Stewart, M.D.

B Cultural Considerations for Treating HIV-Infected
African-American Patients
Eric G. Bing, M.D.

C Cultural Considerations for Treating HIV-Infected
Latino Patients
Milton L. Wainberg, M.D.

SYMPOSIUM 78
2:00 p.m.-5:00 p.m.
Room 103 B, Street Level, Convention Center

BRAIN SUBSTRATES OF ADDICTION:
NEUROIMAGING AS A TOOL OF CHOICE IN THE
21ST CENTURY

Chp.: Anna R. Childress, Ph.D.
Co-Chp.: Charles P. O’Brien, M.D.

A Using PET to Image the Neuroanatomical and
Neurochemical Substances of Cocaine Craving
Anna R. Childress, Ph.D., Paul Acton, Ph.D., Kyle M.
Kampman, M.D., Teresa R. Franklin, Ph.D., Anna Fornash,
Charles P. O’Brien, M.D.

B Bold fMRI Versus Spin-Tagging in Cue-Induced
Cocaine Craving (4T)
John M. Listerud, M.D., Jionjiong Wang, Ph.D., J. Detre, M.D.,
Jason Gray, B.A., Charles P. O’Brien, M.D., Anna R. Childress, Ph.D.

C Functional MRI During Heroin Craving in Methadone-
Maintained Subjects
Daniel D. Langleben, M.D., Jionjiong Wang, Ph.D., Jason
Gray, B.A., John M. Listerud, M.D., Charles P. O’Brien, M.D.,
Anna R. Childress, Ph.D.

D fMRI of Cue-Induced Nicotine Craving
Teresa R. Franklin, Ph.D., Jason Gray, B.A., Charles P.
O’Brien, M.D., Anna R. Childress, Ph.D.

E Brain Substrates for Self-Control May Be Defective in
Addiction
John R. Monterosso, Ph.D., Ronald Ehram, Ph.D., Kimberly
Napier, B.A., Anna R. Childress, Ph.D., Charles P. O’Brien, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79
2:00 p.m.-5:00 p.m.
Room 103 C, Street Level, Convention Center

OPTIMAL STRATEGIES FOR IDENTIFYING AND
TREATING TRAUMATIZED CHILDREN

Chp.: Judith A. Cohen, M.D.

A Screening for Traumatic Exposure and PTSD
Symptoms in Pediatric Settings
Anthony P. Mannarino, Ph.D., Judith A. Cohen, M.D.,
Daphne Ruben, L.C.S.W.

B Cognitive-Behavioral Therapy for Traumatized Children
and Their Parents
Esther Deblinger, Ph.D.

C Developmental Traumatology: Neurobiological
Development in Childhood PTSD
Michael D. DeBellis, M.D., Matcheri S. Keshavan, M.D.,
Sue R. Beers, Ph.D., Neal D. Ryan, M.D.
D Pharmacological Treatments for Traumatized Children
Judith A. Cohen, M.D.

E Treating Child and Adolescent Victims of Crime: The New California Guidelines
Graeme Hanson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Room 104 A, Street Level, Convention Center

OPIATE-SUBSTITUTION TREATMENT: INTERNATIONAL TRENDS AND PERSPECTIVES
Chp.: Richard N. Rosenthal, M.D.
Co-Chp.: Michael Krausz, Ph.D.

A Buprenorphine: Experiences with Office-Based Substitution Treatment in Europe
Marc Auriacombe, M.D., Pascale Franques, M.D., Jean-Pierre Daulouede, M.D., Jean L. Tignol, M.D.

B Morphine Maintenance in the Treatment of Heroin Addiction
Gabriele Fischer, M.D., Romana Ortner, M.D., Shiro Schindler, M.D., Harald Eder, M.D.

C Is There a Gold Standard Medication in Opiate-Substitution Treatment?
Robert G. Newman, M.D.

D Heroin-Assisted Treatment Approaches in Europe
Wim Van Den Brink, M.D., Vincent Hendriks, Ph.D., Peter Blaken, M.A., Jan Van Ree

E Outcome Criteria and Guidelines from an International Point of View
Richard N. Rosenthal, M.D.

Discussant: Thomas R. Kosten, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Room 104 B, Street Level, Convention Center

ALCOHOL INTERVENTIONS ACROSS THE SPECTRUM FOR COMMUNITY PRACTITIONERS
Substance Abuse and Mental Health Services Administration
Chp.: Sheila B. Blume, M.D.

A Underage Drinking: Changing Community Norms
Robert Voas, Ph.D.

B Identification of Fetal Alcohol Syndrome: Differentiating Developmental Disorders from Fetal Alcohol Syndrome
Larry J. Burd, Ph.D., Jacob Kerbeshian, M.D.

C Implementing Naltrexone in Alcohol Treatment in Community Settings
Sherrie Gillette, M.A.

D Multisystemic Treatment of Alcohol-Abusing Adolescents: Outcomes
Scott W. Henggeler, Ph.D., Colleen A. Halliday-Boykins, Ph.D., Philippe B. Cunningham, Ph.D., Jeff Randell, Ph.D.

E Implementing Motivational Enhancement Therapy
Allen Zweiban, D.S.W.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Rooms 106 A/B, Street Level, Convention Center

THE SCHIZOPHRENIA PRODROME: UPDATE OF RESEARCH 2002
Chp.: Scott W. Woods, M.D.

A Intervention in the Schizophrenic Prodrome: Rationale, Studies, and Ethics
Thomas H. McGlashan, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Mauricio F. Tohen, M.D., Alan Freier, M.D., Scott W. Woods, M.D.

B Diagnosis and Symptom Assessment in the Schizophrenia Prodrome
Tandy J. Miller, Ph.D., Thomas H. McGlashan, M.D., Joanna L. Rosen, Ph.D., Jaak Rakfeldt, M.D., Shelly Nyman-Rose, M.S.W., Phillip Markovich, B.A., Scott W. Woods, M.D.

C A Trial of Olanzapine Versus PBO in the Prodrome: Protocol and Baseline Sample
Alan F. Breier, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Mauricio F. Tohen, M.D., Stacy R. David, Ph.D., Thomas H. McGlashan, M.D.

D Neuropsychological Status of the First-Episode Prodrome

E MRI and MRS Findings in Subjects with Prodromal Symptoms
Diana O. Perkins, M.D., Robert B. Zipursky, M.D., Guido Geric, Ph.D., Cecil Charles, Ph.D., Hongbin Gu, Ph.D., Jeffrey A. Lieberman, M.D.

F Olanzapine Versus Placebo for Prodromal Symptoms
Scott W. Woods, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Tandy J. Miller, Ph.D., Alan F. Breier, M.D., Thomas H. McGlashan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Rooms 107 A/B, Street Level, Convention Center

THE DUTY TO WARN AND PROTECT FOR THE 21ST-CENTURY PSYCHIATRIST
Chp.: Alan R. Felthous, M.D.
Co-Chp.: Claudia A. Kachigian, M.D.

(Continued next page)
A The Fin de Millenaire: Duty to Warn or Protect?
   Alan R. Felthous, M.D., Claudia A. Kachigian, M.D.

B Judicial Responses to Tarasoff Statutes
   Claudia A. Kachigian, M.D., Alan R. Felthous, M.D.

C Novel Approaches to Tarasoff
   Ralph Slovenko, L.L.B.

D Encroachments on Psychotherapist-Patient Privilege
   Robert Weinstock, M.D.

E Risk Assessment in Tarasoff Situations
   Randy Borum, Psy.D.

Discussant: Paul S. Appelbaum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84  2:00 p.m.-5:00 p.m.
Room 111 B, Street Level, Convention Center

CLINICAL CHALLENGES IN TREATING SCHIZOPHRENIA
Chp.: Prakash S. Masand, M.D.

A From First Psychotic Episode to Long-Term Outcome in Schizophrenia
   John L. Waddington, D.Sc., Paul J. Scully, M.D., David J.
   Meagher, M.D., John F. Quinn, M.D., Patizia A. Baldwin, M.D.,
   Maria G. Morgan, M.D., Anthony Kinsella, M.S.C.

B PET Imaging Studies of Atypical Antipsychotics: Implications of Dosing and Mechanism of Action
   Shitij Kapur, M.D.

C Managing Violent Behavior in Patients with Schizophrenia: Emerging Standards of Care
   Peter F. Buckley, M.D.

D Augmentation Strategies in Treatment-Refractory Schizophrenia
   Robert R. Conley, M.D., Deanna L. Kelly, Pharm.D.

E Management of Long-Term Side Effects of Novel Antipsychotics
   Prakash S. Masand, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85  2:00 p.m.-5:00 p.m.
Rooms 112 A/B, Street Level, Convention Center

COGNITIVE THERAPY VERSUS MEDICATIONS FOR SEVERE DEPRESSION
Chp.: Jan A. Fawcett, M.D.

A Background and Design of a Placebo-Controlled Comparison
   Robert J. DeRubeis, Ph.D., Jay D. Amsterdam, M.D., John P.
   O'Reardon, M.D., Paula R. Young, Ph.D.

B Response to Acute Treatment
   Jay D. Amsterdam, M.D., Robert J. DeRubeis, Ph.D., John P.
   O'Reardon, M.D., Paula R. Young, Ph.D.
D Individual Interpersonal Psychotherapy for PTSD  
Kathryn L. Bleiberg, Ph.D., John C. Markowitz, M.D.

E Interpersonal Therapy Versus Supportive Therapy for Social Phobia  
Joshua D. Lipsitz, Ph.D.

Discussant: Myrna M. Weissman, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.  
Room 113 C, Street Level, Convention Center

TREATING MENTAL ILLNESS AND SUBSTANCE ABUSE IN THE CRIMINAL JUSTICE SYSTEM  
Substance Abuse and Mental Health Services Administration

Chp.: Jeffrey L. Metzner, M.D.  
Co-Chp.: Michael English, Ph.D.

A Family Drug Courts: Early Evaluation Findings  
Nancy Young

B Pelican Bay Super Max: Treatment in Correctional Settings  
Shama Chaiken, Ph.D.

C Jail Diversion: Mechanisms and Services  
Henry Steadman

D Successful Community Reintegration of Offenders with Mental Illness  
Fred C. Osher, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.  
Room 201 B, Level 200, Convention Center

TRAUMATIC RESPONSE TO DISASTER: NEUROBIOLOGY AND TREATMENT

Chp.: Carol S. North, M.D.  
Co-Chp.: Elissa P. Benedek, M.D.

A Neurobiological Mechanisms of PTSD  
Dennis S. Charney, M.D.

B The Range of Human Response to Catastrophic Trauma  
Carol S. North, M.D.

C Disaster Overview: Clinical Presentation National and International Perspectives  
David Benedek, M.D.

D Psychopharmacotherapy of PTSD in Children and Adolescents  
Elizabeth B. Weller, M.D., Arman K. Danielyan, M.D., Ronald A. Weller, M.D.

E Psychopharmacology of Traumatic Response in Adults  
Richard Balon, M.D.

Discussant: Elissa P. Benedek, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.  
Room 201 C, Level 200, Convention Center

PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY: WHERE IS THE BOUNDARY?

Chp.: Amy C. Brodkey, M.D.

A Pharmaceutical Promotion: There Is no Free Lunch  
Amy C. Brodkey, M.D.

B Academia, Medical Education, and the Pharmaceutical Industry  
Frederick S. Sierles, M.D.

C The Pharmaceutical Industry and Public Psychiatry  
Robert M. Factor, M.D.

D Industry-Supported Medical Education: When Educators Serve Two Masters  
Diana M. Koziupa, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.  
Room 203 B, Level 200, Convention Center

THE EMPLOYMENT INTERVENTION DEMONSTRATION PROJECT: OUTCOME OF BEST PRACTICE  

Chp.: William R. McFarlane, M.D.

A Best Practice in Employment Research: Views from the Employment Intervention Demonstration Program Coordinating Center  
Judith A. Cook, Ph.D.

B The Hartford Study of Supported Employment for Severe Mental Illness: Employment and Nonvocational Outcomes  
Kim T. Mueser, Ph.D., Robin E. Clark, Ph.D., Michael Haines, M.A., Robert E. Drake, M.D., Gary R. Bond, Ph.D., Deborah R. Becker, M.Ed., Gregory McHugh, Ph.D., Susan M. Essock, Ph.D., Rosemarie Wolfe, MA, Anjana Sengupta, Ph.D.

C Effects of Fact and an Employers Consortium on Employment in Severe Mental Illness  
William R. McFarlane, M.D., William Cook, Ph.D., Richard Balser, Cindy Boyak, M.D., Renee Leavitt, O.T.

D Improving Employment Outcomes for Persons with Severe Mental Illness  
Anthony F. Lehman, M.D.

E Effectiveness of Long-Term Employment Support for Individuals with Severe Mental Illness  
Laura E. Bianhertz, Ph.D.
THURSDAY

F Rural-Based Supported Employment Approaches: Results from the South Carolina Site of the Employment Intervention Demonstration Project
Neil Meisler, M.S.W.

G The Texas EARNS Supported Employment Demonstration Project
Marcia Toprac, Ph.D., Sue K. Hoppe, Ph.D., Pamela Daggett, M.A., Kate Wambach, Ph.D., Steven Onken, Ph.D., Susan Burek, Shelley Blozis, Ph.D.

Discussant: Crystal Byler, Ph.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room 204 A, Level 200, Convention Center

TREATMENT OF ADHD: FROM CLINICAL TRIALS TO ROUTINE CLINICAL PRACTICE

Chp.: Benedetto Vitiello, M.D.
Co-Chp.: Farifteh F. Duffy, Ph.D.

A The AACAP Stimulant Medication Practice Parameter for Treatment of ADHD
Laurence L. Greenhill, M.D.

B Treatment of ADHD: From Multimodal Treatment ADHD Trials to Routine Psychiatric Practice
Peter S. Jensen, M.D.

C Stimulant and Psychosocial Treatment of ADHD in Latino Children
Glorisa Canino, Ph.D., Jose J. Bauermeister, Ph.D., Maritza Rubio-Stipec, Sc.D.

D The Role of Comorbidity in the Treatment of ADHD in Routine Psychiatric Practice
Farifteh F. Duffy, Ph.D., William E. Narrow, M.D., Donald Rae, M.A.

E Insurance Factors and ADHD Treatment in Psychiatric Practice
William E. Narrow, M.D., Donald Rae, M.A., Farifteh F. Duffy, Ph.D.

Discussant: Mark A. Riddle, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room 204 B, Level 200, Convention Center

VIRTUAL REALITY AND MENTAL HEALTH: STATE OF THE ART AND FUTURE DIRECTIONS

Chp.: Henry J. Moller, M.D.
Co-Chp.: Albert A. Rizzo, Ph.D.

A Virtual Environments: Using a Driving Simulator to Understand Consciousness
Henry J. Moller, M.D.
2002 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Eating Disorders
7. Mental Retardation (Child/Adolescent/Adult)
8. Mood Disorders
9. Personality Disorders
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders

PRACTICE AREAS/SETTINGS
14. Psychiatric Administration and Services: Public, Private, and University
15. Other

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Brain Imaging
19. Child and Adolescent Psychiatry and Disorders
20. Consultation-Liaison and Emergency Psychiatry
21. Cross-Cultural and Minority Issues
22. Diagnostic Issues
23. Epidemiology
24. Ethics and Human Rights
25. Forensic Psychiatry
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Psychiatric Education
29. Psychiatric Rehabilitation
30. Psychoanalysis
31. Research Issues
32. Social and Community Psychiatry
33. Stress
34. Suicide
35. Violence, Trauma, and Victimization

TREATMENTS
36. Behavior and Cognitive Therapies
37. Combined Pharmacotherapy and Psychotherapy
38. Couple and Family Therapies
39. Group Therapy
40. Individual Psychotherapies
41. Psychopharmacology
42. Other Somatic Therapies
43. Treatment Techniques and Outcome Studies

OTHER ISSUES
44. Computers
45. Creativity and the Arts
46. Electronic Medical Records
47. Gender Issues
48. Health Services Research
49. Historical Questions
50. Information Technology
51. Lesbian/Gay/Bisexual/Transgender Issues
52. Managed Care and Health Care Funding
53. Men’s Health Issues
54. Political Questions
55. Professional and Personal Issues
56. Religion, Spirituality, and Psychiatry
57. Resident and Medical Student Concerns
58. Presidential Theme: The 21st Century Psychiatrist
59. Stigma/Advocacy
60. Telepsychiatry
61. Virtual Reality
62. Women’s Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
<table>
<thead>
<tr>
<th>DISORDERS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Managing Depression and Anxiety in Patients with Cancer and Other Medical Illnesses</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Switching from Imipramine to Sertraline in Panic Disorder with Agoraphobia</td>
</tr>
<tr>
<td>3</td>
<td>Atypical Depression in Primary Anxiety Disorders</td>
</tr>
<tr>
<td>4</td>
<td>Risk Factors for PTSD in North Korean Defectors</td>
</tr>
<tr>
<td>8</td>
<td>Mixed Anxiety Depressive Disorder in a Sample of Primary Care Patients</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Obsessive Compulsive and Related Disorders</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>PTSD Versus Panic Disorder: Differences in HPA Axis/Noradrenergic Functioning</td>
</tr>
<tr>
<td>18</td>
<td>Beyond One-Year Imipramine Maintenance in Panic Disorder with Agoraphobia</td>
</tr>
<tr>
<td>19</td>
<td>Social Phobia Treatment Survey</td>
</tr>
<tr>
<td>25</td>
<td>Cigarette Smoking and Risk for Anxiety Disorders</td>
</tr>
<tr>
<td>121</td>
<td>Adjunctive Use of Tiagabine with Antidepressants in PTSD</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Psychotic Symptoms in Chronic PTSD: Prevalence, Comorbidity, and Treatment</td>
</tr>
<tr>
<td>52</td>
<td>Social Anxiety Disorder and Comorbid Major Depression</td>
</tr>
<tr>
<td><strong>TOPIC 4: ATTENTION SPECTRUM DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>Advanced Assessment and Treatment of ADD</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Psychopharmacologic Treatment of Comorbid Attention Disorders in Adults</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>New Approaches for Treating ADHD: The Whole-Life Perspective</td>
</tr>
<tr>
<td>47</td>
<td>Adult ADHD: From Research to Clinical Practice</td>
</tr>
<tr>
<td><strong>MEDIA PROGRAM</strong></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Memento</td>
</tr>
</tbody>
</table>
# TOPIC 6: EATING DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Multimodal Treatment of Eating Disorders</td>
<td>2</td>
</tr>
<tr>
<td>25 Therapeutic Interventions in Eating Disorders: Basic Principles</td>
<td>7</td>
</tr>
</tbody>
</table>

## INDUSTRY-SUPPORTED SYMPOSIUM

| Advances in the Understanding and Treatment of Binge-Eating Disorder   | 86   |

## SCIENTIFIC AND CLINICAL REPORTS

| 5 Perfectionism, Training, and Eating Behaviors in Runners            | 22   |
| 6 Self-Reported Hunger and Parasympathetic Tone                       | 22   |
| 7 Topiramate Treatment of Bulimia Nervosa                              | 22   |
| 114 Sibutramine Treatment of Obesity in Schizophrenia                 | 92   |

## SYMPOSSIA

| Eating Disorders 2002: Biological, Clinical, and Social Perspectives  | 30   |
| What's New in Eating Disorders: A Clinical Research Treatment Update | 59   |

## TOPIC 7: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)

| The Use of Atypical Antipsychotics in Adults with Developmental Disability | 91   |

## TOPIC 8: MOOD DISORDERS

### ADVANCES IN PSYCHOPHARMACOLOGY

| Anticonvulsants as Mood Stabilizers                                  | 28   |

### ADVANCES IN RESEARCH

| Depression and Coronary Heart Disease: Epidemiology, Treatment, And Mechanisms | 20   |
| Depression, Coronary Artery Disease, and Mortality                    | 20   |

### CLINICAL CASE CONFERENCE

| Depression in the Medical Setting Revisited: The Problem of the Depressive Spectrum Disorders | 38   |

## COURSES

| Evidence-Based Management of SAD: Focus on Light Therapy             | 2    |
| Neuroendocrinology in Mood Disorder: Dysregulation and Treatment    | 2    |
| Anticonvulsants in Bipolar Disorder                                 | 5    |
| Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders | 8    |
| Using Humanities to Understand Mood Disorders                       | 14   |
| The Conceptual Basis of Psychiatry                                 | 88   |

## DISCUSSION GROUP

| Depression in the Medically Ill                                    | 44   |

## INDUSTRY-SUPPORTED SYMPOSSIA

| Bipolar Disorder: New Nationwide Data on Misdiagnosis and Community Costs | 3    |
| Improving Patient Outcomes Across the Spectrum of Bipolar Disorder    | 3    |
| Depressive Subtypes: The Multiple Faces of Depression                  | 6    |
| Recovery from Depression: New Perspectives to Improve Outcomes        | 6    |
| Customizing Care for Patients with Bipolar Disorder                   | 8    |
| The Aging Brain and Vulnerability to Depression                       | 9    |
| Long-Term Management of Mood Disorders                                | 9    |
| Atypical Depression: Overview and New Developments                    | 11   |
| New Developments in the Treatment of Bipolar Disorder                 | 11   |

## LECTURE

| What Can Late Life Teach Us About Depression?                        | 53   |

## RESEARCH CONSULTATION

| Depressed Patients with Heart Disease and Late-Life Depression       | 46   |

## REVIEW OF PSYCHIATRY: SECTION 1

### Treatment of Recurrent Depression: A Call to Arms

| Fluoxetine-Induced Weight Change in Depressive Subtypes              | 23   |
| Adjunct Modafinil for Fatigue and Wakefulness in MDD                | 23   |
| Short-Term Use of Estradiol as an Antidepressant Strategy in Perimenopausal and Postmenopausal Women | 23   |
| A Comparison of the Prevalence and Correlates of Anger Attacks in Bipolar Disorder | 23   |
| Topiramate Treatment of Rapid-Cycling Mood Disorder                  | 23   |
| Cognitive and Psychosocial Deficits in Bipolar Disorder and Schizophrenia | 23   |
| Increased Rates of Antipsychotic-Induced EPS in Mood Disorders: Myth or Reality? | 47   |
| Cyclothymia in Atypical Depression: The Borderline-Bipolar II Connection | 48   |
| Substance Use and Perceived Symptom Improvement in Bipolar Disorder  | 48   |
| Psychosocial Functioning as a Predictor of Response to Nortriptyline in Treatment-Resistant Depression | 76   |
| Efficacy of Citalopram as an Augmenting Strategy for Menopausal Women with Estrogen-Resistant Depression | 76   |
| Polypharmacy with Antidepressants                                    | 76   |
| Evaluation and Intervention of Prodromal Symptoms of Bipolar I Disorder | 91   |
| Dysthymic Disorder: Integrating Research Findings into Clinical Treatment | 92   |
| Effect of Adjunct Modafinil on Energy and Concentration in Depressed Patients | 92   |
| Parental Separation at Birth and Depression in Adulthood             | 92   |

## SYMPOSSIA

| Is There a Bipolar Spectrum?                                       | 33   |
| New Frontiers in the Neuroendocrinology of Affective Disorders      | 34   |
| Depression and the Transition to Perimenopause: The Harvard Study of Moods and Cycles | 57   |
| Major Depression: Current Guidelines, Practices, and Effectiveness Research | 60   |
| Depression Care in Medical Settings: Approaches for the Future       | 60   |

## WORKSHOP - ISSUE

| Bridging the Gap: Depression, Chronic Medical Disease, Culture, and Ethnicity | 43   |

## TOPIC 9: PERSONALITY DISORDERS

### COURSES

| Disorders of the Self: Differential Diagnosis and Treatment         | 15   |
| Partial Hospitalization for Patients with BPD                       | 38   |
| Personality Disorders: Combined Interpersonal and Pharmacotherapy   | 66   |
| Psychotherapy of Borderline Personality                             | 66   |

(Continued on next page)
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>LECTURE</td>
<td>Page #</td>
</tr>
<tr>
<td>2 Personality Disorders: New Findings and Current Controversies</td>
<td>15</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>26 BPD, Medical Illness, Lifestyle Choices, and Health Care Utilization</td>
<td>24</td>
</tr>
<tr>
<td>27 Impulsivity, Gender, and SHT in BPD</td>
<td>24</td>
</tr>
<tr>
<td>28 Diagnostic Efficiency of BPD and Antisocial Personality Disorder (APD) Criteria in Monolingual Hispanic Men</td>
<td>24</td>
</tr>
<tr>
<td>72 Risperidone Treatment of Schizotypal Personality Disorder</td>
<td>74</td>
</tr>
<tr>
<td>73 A Preliminary Trial of Omega-3 Fatty Acids in Women with BPD</td>
<td>74</td>
</tr>
<tr>
<td>74 Is Chemical Imbalance a Useful Concept in Treating Personality Disorders?</td>
<td>74</td>
</tr>
<tr>
<td>SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>9 Interaction of Stress and Personality</td>
<td>31</td>
</tr>
<tr>
<td>12 Sadistic Personality Disorder: Its Wide Range and Importance as a Diagnosis</td>
<td>31</td>
</tr>
<tr>
<td>30 Hypersurial and BPD: New Studies on Origins, Imaging, Taxonomy, and Treatment</td>
<td>55</td>
</tr>
<tr>
<td>32 Course and Treatment of BPD</td>
<td>56</td>
</tr>
<tr>
<td>61 Course of Psychopathology and Functioning in Personality Disorders</td>
<td>81</td>
</tr>
<tr>
<td>63 Personality and Personality Disorders in the Community</td>
<td>82</td>
</tr>
<tr>
<td>72 Affective Instability in BPD</td>
<td>84</td>
</tr>
<tr>
<td>82 The Schizophrenia Preadona: Update of Research 2002</td>
<td>95</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>3 Cognitive-Behavioral Therapy Training for Residents: How to Teach, Measure, and Attain Resident Competency</td>
<td>18</td>
</tr>
<tr>
<td>7 Personality Disorders in the Mental Retardation and Developmental Disorders Population</td>
<td>19</td>
</tr>
<tr>
<td>22 Cognitive Therapy for Personality Disorders</td>
<td>26</td>
</tr>
<tr>
<td>101 Teaching Primary Care Residents About Depression and Suicide: Can Technology Alter Outcomes?</td>
<td>89</td>
</tr>
<tr>
<td>TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS</td>
<td></td>
</tr>
<tr>
<td>ADVANCES IN RESEARCH</td>
<td></td>
</tr>
<tr>
<td>Advances in Psychopharmacologic Treatment of Schizophrenia and Related Psychoses</td>
<td>20</td>
</tr>
<tr>
<td>COURSE</td>
<td>19 Training in the Use of the Positive and Negative Syndrome Scale</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>6 Antipsychotic Therapy and Cardiovascular Disease: The Unfolding Story</td>
<td>3</td>
</tr>
<tr>
<td>12 Advances in the Treatment of Psychosis: Minimizing the Burden of Disease</td>
<td>6</td>
</tr>
<tr>
<td>17 The Adherence Challenge: Chronic Issues and Emerging Solutions with Antipsychotic Therapy</td>
<td>9</td>
</tr>
<tr>
<td>18 Challenges and Opportunities in the Management of Psychotic Disorders</td>
<td>9</td>
</tr>
<tr>
<td>26 Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders, Part 1</td>
<td>13</td>
</tr>
<tr>
<td>26 Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders, Part 2</td>
<td>13</td>
</tr>
<tr>
<td>33 Managing Aggression Across the Life Span: From the Pediatric to the Geriatric Patient</td>
<td>63</td>
</tr>
<tr>
<td>35 Raising Expectations in Schizophrenia: Enhancing Long-Term Outcomes</td>
<td>64</td>
</tr>
<tr>
<td>42 New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment, Part 1</td>
<td>65</td>
</tr>
<tr>
<td>42 New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment, Part 2</td>
<td>87</td>
</tr>
<tr>
<td>MEDIA PROGRAM</td>
<td>Page #</td>
</tr>
<tr>
<td>31 A Beautiful Mind</td>
<td>79</td>
</tr>
<tr>
<td>RESEARCH CONSULTATION</td>
<td></td>
</tr>
<tr>
<td>2 Brain Behavior Studies in Schizophrenia</td>
<td>74</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>29 The Relationship Between Negative and Positive Symptoms: A 15-Year Follow-Up</td>
<td>24</td>
</tr>
<tr>
<td>30 Neurological Soft Signs and Psychopathology in Schizophrenia</td>
<td>24</td>
</tr>
<tr>
<td>31 Heterogeneity in Schizophrenia: Cognitive Deficits and Brain Abnormalities</td>
<td>24</td>
</tr>
<tr>
<td>52 Outcome of Early-Phase Psychosis Concurrent with Substance Use</td>
<td>48</td>
</tr>
<tr>
<td>53 Predictors of Syndromal and Functional Recovery in Patients with First-Episode Mania</td>
<td>48</td>
</tr>
<tr>
<td>54 High Birth Weight as a Predictor of Schizophrenia: A 31-Year Follow-Up</td>
<td>48</td>
</tr>
<tr>
<td>113 Low-Frequency Transcranial Magnetic Stimulation Currals Medication-Resistant Auditory Hallucinations</td>
<td>92</td>
</tr>
<tr>
<td>SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>7 Management of Schizophrenia with Comorbid Disorders</td>
<td>30</td>
</tr>
<tr>
<td>27 New Treatment Target in Schizophrenia: Update on Social Anxiety</td>
<td>55</td>
</tr>
<tr>
<td>84 Clinical Challenges in Treating Schizophrenia</td>
<td>96</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>13 Schizophrenia with Comorbid Conditions: Clinical and Research Issues</td>
<td>19</td>
</tr>
<tr>
<td>84 Clozapine Use in HIV</td>
<td>71</td>
</tr>
<tr>
<td>TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>59 Sexual Disorders: Diagnosis and Treatment</td>
<td>38</td>
</tr>
<tr>
<td>89 The Assessment and Treatment of Child Molestors</td>
<td>67</td>
</tr>
<tr>
<td>MEDIA PROGRAM</td>
<td>11 Just Call Me Kade</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>18 Love from Pathology to Normality</td>
<td>33</td>
</tr>
<tr>
<td>TOPIC 12: SLEEP DISORDERS</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>35 Irresistible Sleep: Narcolepsy Update</td>
<td>8</td>
</tr>
<tr>
<td>51 Overview and Update of Sleep Disorders Medicine</td>
<td>27</td>
</tr>
<tr>
<td>91 Sleep Medicine Update: Advanced Topics</td>
<td>78</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>28 Understanding Sleep Medicine: What the Psychiatrist Needs to Know, Part 1</td>
<td>13</td>
</tr>
<tr>
<td>28 Understanding Sleep Medicine: What the Psychiatrist Needs to Know, Part 2</td>
<td>13</td>
</tr>
<tr>
<td>44 Sleep Disorders and Psychiatric Illnesses: Scientific Foundations</td>
<td>85</td>
</tr>
<tr>
<td>46 Identification and Management of Daytime Fatigue and Sleepiness in Psychiatry</td>
<td>86</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>63 Effect of Modafinil on Mood and Quality of Life in Patients with Narcolepsy</td>
<td>49</td>
</tr>
<tr>
<td>64 Long-Term Safety and Efficacy of Modafinil for Daytime Sleepiness</td>
<td>49</td>
</tr>
</tbody>
</table>
TOPIC 19: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

COURSES
3 ADD in Children and Adolescents 1
68 Being an Effective School Consultant 39

INDUSTRY-SUPPORTED SYMPOSIA
7 Diagnosis and Treatment Issues in Child and Adolescent Bipolar Disorders 5
30 Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies, Part 1 14
30 Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies, Part 2 14

LECTURE
23 Mania in Youth: A Transition from Ignorance to Enlightenment to Confusion 79

MASTER EDUCATOR CLINICAL CONSULTATIONS
1 Child Forensic Psychiatry Contemporary Issues 16
2 the Aftermath of Childhood Parental Loss 16
8 Child and Adolescent Clinical Work: Integrating Bio-, Psycho-, and Social 45

MEDIA PROGRAMS
9 In the Mix 27
17 Making Visible the Hidden: Serving Child Victims in the Healthcare Community 46
18 Take This Heart 46

RESEARCH CONSULTATION
3 Bipolar Disorders in Children and Adolescents 91

REVIEW OF PSYCHIATRY: SECTION 2
The Many Faces of Depression in Childhood and Adolescence 54

SCIENTIFIC AND CLINICAL REPORTS
38 A Multinational Study of the Emergence of Gender Differences in Depression 47
43 Once-Daily Administration of Atomoxetine: A New Treatment for ADHD 47
44 ADHD Treatment with a Once-Daily Formulation of Methylphenidate Hydrochloride: A Two-Year Study 47
45 Long-Term Safety and Efficacy of Adderall Extended Release in Children with ADHD 47
75 ADHD Comorbidity: Age and Gender Differences 74
77 Modafinil in Children with ADHD: A Double-Blind, Placebo-Controlled Study 74
107 Anxiety Disorders in Children and Adolescents with Bipolar Disorder 91
108 Comorbidity in Child and Adolescent Major Depression 91

SYMPOSIA
19 Adolescence: The Turbulent Years 33
54 Family Treatment Outcomes of Adolescents with Substance Use Disorders: Cultural Issues 62
57 Sports Through the Life Cycle 80
67 Diagnosis and Treatment of ADHD in Young Children 83
70 State-of-the-Art Adolescent Substance Abuse Prevention and Treatment 83
71 Treatment of Violence and Conduct Disorders in Children and Adolescents 84
86 Reducing Aggressive Behavior: Changing the Trajectory for Drug Use 96
92 Treatment of ADHD: From Clinical Trials to Routine Clinical Practice 98

WORKSHOPS - COMPONENTS
3 The American Psychiatric Association and Its Alliance Go to America's Schools 17
29 Mission Impossible II: When the Disordered Child Becomes an Adult 50

WORKSHOP - ISSUE
57 Implementing an Effective Truancy-Reduction Program 44

TOPIC 20: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

COURSE
40 Psychiatric Consultations in Medical Settings: The Basics 14

MEDICAL UPDATE
1 Migraine: Diagnosis, Treatment, and Comorbidity 22

RESEARCH ADVANCES IN MEDICINE
Long-Term Mechanical Circulatory Support 41

REVIEW OF PSYCHIATRY SECTIONS
Emergency Psychiatry 41
3 Psychiatry in Medicine 69

SCIENTIFIC AND CLINICAL REPORTS
9 Psychopathological Aspects in 86 Chronic Fatigue Syndrome Patients 22
10 Low Expression of Negative Affect and Denial Predict Breast Cancer Recurrence 23

SYMPOSIUM
2 Advances in the Diagnosis and Treatment of Delirium 29

WORKSHOP - COMPONENT
14 Legal and Psychiatric Controversies in Interferon Treatment of Hepatitis-C 25

WORKSHOP - ISSUE
17 How to Effectively Integrate Mental Health Services in General Care Systems 20

TOPIC 21: CROSS-CULTURAL AND MINORITY PSYCHIATRY

COURSES
17 DSM-IV-TR Cultural Formulations: Diagnosis and Therapy 5
76 Multicultural Approach to the Treatment of Women 52

DISCUSSION GROUP
6 Psychiatry and Palliative Medicine 20

FORUM
11 Latin America 77

LECTURES
9 Problems Facing Inner-City School Educators and the Role of Psychiatry in Addressing Them 40
20 Journey to the West: Reflections on Culture and Psychiatry Entering the New Century 72

MEDIA PROGRAMS
5 Carved from the Heart: A Portrait of Grief, Healing, and Community 21
6 Homeland 21
7 Between Worlds 21
19 A World of Food: Tastes and Taboos in Different Cultures 52
21 Standing on My Sisters' Shoulders 54
SCIENTIFIC AND CLINICAL REPORTS

12 Trauma, Creative Cognition, and Success Among Tribal South-African Students 23
66 Integrating Psychiatry and Primary Care Improves Treatment Acceptability Among Asian-Americans 49
67 Anxiety Discomfort in Japanese, Chinese, and Caucasian Females 49
68 Anatomy of Jeong 49
71 Prevalence and Symptom Patterns of Depression Among College Students 49

SYMPOSIA

38 Beyond the Surgeon General's Report: Psychiatry for a Diverse Population 58
51 American Psychiatric Association's Responses to the Surgeon General's Reports on Mental Health 61
73 Clinical and Treatment Challenges with Hispanic Patients 84
76 Culturally Competent Mental Health Care: Identifying and Reducing Disparities 94

WORKSHOPS - COMPONENTS

4 When Your Physician Patient Is from an Ethnic Minority: A Cross-Cultural Approach to Treatment 17
17 Psychiatry Without Borders: Breaking the Barriers 25
18 Psychiatric Casualties in the Mental Health of Hispanic Immigrants 25
19 Health Care Legislation: The Role for the 21st-Century Black Psychiatrist 42
22 Discussion: Surgeon General's Report on American Indians and Alaska Natives 42
23 Mental Health Care for Asian Americans and Pacific Islanders 49
35 Whose Children? Psychiatry in the Cultural Mosaic of America's Schools 70
49 Meeting the Mental Health Needs of Minorities in the 21st Century 77
54 Surgeon General's Report on Culture, Race, and Ethnicity: Clinical Implications 89
57 Asian Americans in Intermarriages: Psychosocial Adjustment and Identity 93

WORKSHOPS - ISSUES

9 Career Development for International Medical Graduates 19
15 Training a Culturally Competent Psychiatric Workforce 19
72 Psychopharmacogenetics and Ethnicity: Current Perspectives 70

TOPIC 22: DIAGNOSTIC ISSUES

COURSE
46 Advanced Interviewing Techniques 15

TOPIC 23: EPIDEMIOLOGY

SCIENTIFIC AND CLINICAL REPORTS

69 The Burden of Hepatitis-C Among Mentally Ill Persons in Long-Term Care 49
70 Double Jeopardy: Mental Illness, Medical Conditions, and Early Death 49

INDUSTRY-SUPPORTED SYMPOSIA

8 Late-Life Depression: Old Myths and New Data 5
37 Behavioral Disturbances in Dementia: Diagnostic and Treatment Guidelines 64
49 Explorations in Dementia: New and Current Perspectives 86

LEcTURe
6 Alzheimer's Disease: The Challenges of Big Risks and Small Gains 28
### TOPIC INDEX

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>87 Defining Disability Down</td>
<td>75</td>
</tr>
<tr>
<td>88 Mental Disruption and Mental Health: A Nine Wave Panel Study</td>
<td>75</td>
</tr>
<tr>
<td>89 Divorce and Mental Instability in Different Subtypes of Major Affective Disorders</td>
<td>75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposiums</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 Academic and Community Mental Health: Can This Marriage Be Saved?</td>
<td>35</td>
</tr>
<tr>
<td>42 America Attacked: The American Psychiatric Association and Its Memers Respond</td>
<td>58</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 We Can Improve Care for Those with Mental Health and Substance Abuse Disorders</td>
<td>42</td>
</tr>
<tr>
<td>65 The Challenge of Parental Mental Illness</td>
<td>51</td>
</tr>
<tr>
<td>77 Disability Myths: Understanding the Social Security Administration Disability Program</td>
<td>71</td>
</tr>
<tr>
<td>111 Joining Forces: Working with Law Enforcement to Serve the Mentally Ill</td>
<td>90</td>
</tr>
<tr>
<td>115 Outpatient Commitment: Kendra's Law and the New York City Experience</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 33: Stress</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Media Program</td>
<td></td>
</tr>
<tr>
<td>3 Time Frenzy</td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>55 Adaptations to Severe Stress: Normal Responses and Therapeutic Strategies</td>
<td>61</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop - Issue</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>93 Psychiatric Illness and the Workplace</td>
<td>77</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 34: Suicide</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course</td>
<td></td>
</tr>
<tr>
<td>95 Improving Media Coverage of Suicide: The Role of the Psychiatrist</td>
<td>78</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 Suicides in Youths Involved with Juvenile Justice and Child Welfare Services</td>
<td>24</td>
</tr>
<tr>
<td>24 Predictors of Suicide Attempts in a Personality Disorder Sample</td>
<td>24</td>
</tr>
<tr>
<td>25 Hostility and Impulsivity Among Suicidal Bipolar Patients</td>
<td>24</td>
</tr>
<tr>
<td>122 Female Suicides in Texas Cities: 1994-1998</td>
<td>93</td>
</tr>
<tr>
<td>123 Trends in Suicide Rates in New York City: Implications for Prevention Initiatives</td>
<td>93</td>
</tr>
<tr>
<td>124 Changing Suicide Rates in Europe: Possible Causes</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop - Component</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 Guidelines for the Treatment of Suicidal Behaviors</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 The Impact on Clinicians of Suicide</td>
<td>19</td>
</tr>
<tr>
<td>107 The Frontier of Public Health Psychiatry: Preventing Suicide</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic 35: Violence, Trauma, and Victimization</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Courses</td>
<td></td>
</tr>
<tr>
<td>41 Risk Assessment for Violence</td>
<td>14</td>
</tr>
<tr>
<td>43 Families and Medical Illness: An Integrative Treatment Approach</td>
<td>14</td>
</tr>
<tr>
<td>78 Sexual Harassment: Psychological and Legal Aspects</td>
<td>52</td>
</tr>
<tr>
<td>87 Caring for Refugees and Survivors of Torture</td>
<td>67</td>
</tr>
<tr>
<td>99 Assessing the Risk for Violence</td>
<td>88</td>
</tr>
<tr>
<td>Discussion Group</td>
<td></td>
</tr>
<tr>
<td>14 Treatment of Trauma Survivors: Theory Versus Practice (Meet the Authors)</td>
<td>44</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Forums</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 New York Academic Centers' Response to the World Trade Center Attack</td>
<td>26</td>
</tr>
<tr>
<td>3 Evil</td>
<td>26</td>
</tr>
<tr>
<td>9 Killing in the Name of God: Osama bin Laden and Radical Islam</td>
<td>77</td>
</tr>
<tr>
<td>12 PSYOP: Psychological Operations in the War Against Terrorism</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence</td>
<td>10</td>
</tr>
<tr>
<td>17 Terror, Horror, and Fright: Past and Current Perspectives</td>
<td>68</td>
</tr>
<tr>
<td>21 Healing the Soul in the Age of the Brain: Reflections on the Meaning of Psychiatry After September 11</td>
<td>73</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Media Programs</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Our Children</td>
<td>12</td>
</tr>
<tr>
<td>20 World Trade Center and Pentagon Disasters</td>
<td>53</td>
</tr>
<tr>
<td>26 Blink</td>
<td>69</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>46 Partner Violence and Risk of Major Depression in Chinese-American Women</td>
<td>47</td>
</tr>
<tr>
<td>47 Violence in Colombia: Mental Health Impact in Children</td>
<td>47</td>
</tr>
<tr>
<td>48 Epidemiology, Trauma, and Transcultural Psychiatry</td>
<td>47</td>
</tr>
<tr>
<td>102 Predicting Chronicity in Vietnam Veterans with PTSD: New Findings from the National Vietnam Veterans Readjustment Study</td>
<td>91</td>
</tr>
<tr>
<td>103 Community and Inpatient Violence in Major Psychiatric Disorders</td>
<td>91</td>
</tr>
<tr>
<td>104 Parental Separation at Birth and Criminality in Adulthood</td>
<td>91</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposiums</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Social Psychiatric Aspects of Violence and Trauma</td>
<td>31</td>
</tr>
<tr>
<td>36 The Psychological Wounds of National Trauma: Causes, Consequences, and Treatments</td>
<td>57</td>
</tr>
<tr>
<td>37 Understanding Psychological Trauma: Multidisciplinary Perspective</td>
<td>57</td>
</tr>
<tr>
<td>79 Optimal Strategies for Identifying and Treating Traumatized Children</td>
<td>94</td>
</tr>
<tr>
<td>89 Traumatic Response to Disaster: Neurobiology and Treatment</td>
<td>97</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Components</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Clinician Safety</td>
<td>50</td>
</tr>
<tr>
<td>44 Critical Issues for Treating Domestic Violence Survivors and Their Children</td>
<td>76</td>
</tr>
<tr>
<td>55 Bad Boys, Bad Girls: The Demonization of Adolescence</td>
<td>89</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 Exploring the Media's Role in Imitation Violence</td>
<td>42</td>
</tr>
<tr>
<td>78 New Directions in Mental Health Response to Disasters and Large-Scale Disasters</td>
<td>71</td>
</tr>
<tr>
<td>79 Childhood Trauma Intervention and Aftermath: Access to Quality Care</td>
<td>71</td>
</tr>
<tr>
<td>85 Intergenerational Aspect of Trauma and Trauma-Related Behavioral Patterns</td>
<td>71</td>
</tr>
<tr>
<td>91 Youth Violence: A Report of the Surgeon General</td>
<td>77</td>
</tr>
</tbody>
</table>

| Treatments                                  |        |

<table>
<thead>
<tr>
<th>Topic 36: Behavior and Cognitive Therapies</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Courses</td>
<td></td>
</tr>
<tr>
<td>53 Cognitive Therapy: The Basics</td>
<td>27</td>
</tr>
<tr>
<td>55 Engaging Resistant and Hostile Patients into Participatory Treatment</td>
<td>27</td>
</tr>
<tr>
<td>66 Introduction to Cognitive-Behavioral Therapy</td>
<td>39</td>
</tr>
<tr>
<td>79 Cognitive Therapy for Severe Mental Disorders</td>
<td>66</td>
</tr>
<tr>
<td>92 Cognitive Therapy for Schizophrenia</td>
<td>78</td>
</tr>
</tbody>
</table>

(Continued on next page)
### TOPIC INDEX

**SCIENTIFIC AND CLINICAL REPORTS**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Does Cognitive-Behavioral Group Treatment Improve Personality Measures in Panic Disorder Patients?</td>
</tr>
<tr>
<td>48</td>
<td>Dichotomous Thinking and Thought Suppression in Managing Anger</td>
</tr>
</tbody>
</table>

**WORKSHOP - ISSUE**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>Implementations of DBT in Correctional Environments</td>
</tr>
</tbody>
</table>

**TOPIC 37: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY**

**COURSES**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Money Matters: Using Theory in Clinical Practice</td>
</tr>
<tr>
<td>8</td>
<td>Integrating Pharmacotherapy and Psychotherapy</td>
</tr>
</tbody>
</table>

**INDUSTRY-SUPPORTED SYMPOSIA**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>One Size Doesn’t Fit All: Depression Therapies for the 21st Century, Part 1</td>
</tr>
<tr>
<td>37</td>
<td>One Size Doesn’t Fit All: Depression Therapies for the 21st Century, Part 2</td>
</tr>
</tbody>
</table>

**MASTER EDUCATOR CLINICAL CONSULTATIONS**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>The Doctor-Patient Relationship in Pharmacotherapy</td>
</tr>
<tr>
<td>45</td>
<td>Integrating Psychotherapy and Pharmacotherapy</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Music Therapy and Medication Compliance in Psychotic Patients</td>
</tr>
</tbody>
</table>

**SYMPOSIA**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Fear and Loathing in the Medication Clinic</td>
</tr>
<tr>
<td>59</td>
<td>Collaborative Practice in Psychiatry: Data and Principles for Practice</td>
</tr>
</tbody>
</table>

**WORKSHOPS - ISSUES**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Treating Psychosis Across Diagnosis</td>
</tr>
<tr>
<td>50</td>
<td>Psychodynamics in Treatment Refractory Depression</td>
</tr>
<tr>
<td>93</td>
<td>Bridges for Healing: Integrating Family Therapy and Psychopharmacology</td>
</tr>
</tbody>
</table>

**TOPIC 38: COUPLE AND FAMILY THERAPIES**

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Controlled Study of NAMI Family-to-Family Education Program</td>
</tr>
</tbody>
</table>

**WORKSHOPS - ISSUES**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Children of Psychiatrists: 21st Century Insights</td>
</tr>
<tr>
<td>42</td>
<td>Working with Parents During Their Baby's First Year of Life</td>
</tr>
<tr>
<td>93</td>
<td>Video Case Studies of Couples in Treatment</td>
</tr>
</tbody>
</table>

**TOPIC 39: GROUP THERAPY**

**DISCUSSION GROUP**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Save Time, Make Money, Have Fun! Outpatient Group Therapy for the Seriously Mentally Ill</td>
</tr>
</tbody>
</table>

**MEDIA PROGRAM**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>The Puppets of Di Con: New Psychodrama Approach</td>
</tr>
</tbody>
</table>

**TOPIC 40: INDIVIDUAL PSYCHOTHERAPIES**

**COURSES**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Interpersonal Psychotherapy</td>
</tr>
<tr>
<td>2</td>
<td>Dream Translation: One Empirically-Based Approach</td>
</tr>
</tbody>
</table>
### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 Effectiveness of Rapid Initial Dose Escalation of Oral Olanzapine for Acute Agitation</td>
<td>24</td>
</tr>
<tr>
<td>33 Olanzapine Combined with Lithium or Valproate for Relapse Prevention of Bipolar Disorder: An 18-Month Study</td>
<td>24</td>
</tr>
<tr>
<td>34 Olanzapine Versus Divalproex Sodium for Mania: A 47-Week Study</td>
<td>24</td>
</tr>
<tr>
<td>40 Early-Stage Chronic Renal Failure from Prolonged Lithium Therapy</td>
<td>47</td>
</tr>
<tr>
<td>41 Topiramate in the Treatment of Refractory Bipolar Depression</td>
<td>47</td>
</tr>
<tr>
<td>42 Prescribing Practices in Bipolar Disorder</td>
<td>47</td>
</tr>
<tr>
<td>43 Modafinil Enhances Motivation in the Absence of Overt Sleepiness</td>
<td>49</td>
</tr>
<tr>
<td>44 Compliance and Treatment Discontinuation in Panic-Disorder Patients</td>
<td>75</td>
</tr>
<tr>
<td>45 Meta-Analysis of Antidepressant Levels in Lactating Mothers' Breastmilk and Nursing Infants</td>
<td>75</td>
</tr>
<tr>
<td>46 Branched-Chain Amino Acid Treatment of Tardive Dyskinesia</td>
<td>75</td>
</tr>
<tr>
<td>47 Nonadrenergic Noncholinergic Sildenafil Treatment of SRI-Associated Sexual Dysfunction</td>
<td>75</td>
</tr>
<tr>
<td>48 Rivastigmine Tartrate in Neurocognitive Deficits in Schizophrenia Patients Treated with Clozapine</td>
<td>76</td>
</tr>
<tr>
<td>49 Polypharmacy in Patients with Schizophrenia</td>
<td>91</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 Life-Threatening Hyperthermic Syndromes in Psychiatry</td>
<td>81</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>73 Practical Pharmacotherapy of Mood Disorders</td>
<td>70</td>
</tr>
<tr>
<td>103 Lithium Revisited: Integrating Recent Findings into Clinical Practice</td>
<td>90</td>
</tr>
<tr>
<td>105 Evidence-Based Tables of Side Effects of Psychotropic Medications: Useful?</td>
<td>90</td>
</tr>
<tr>
<td>108 Medication Use for Children in Systems of Care</td>
<td>90</td>
</tr>
</tbody>
</table>

### TOPIC 42: OTHER SOMATIC THERAPIES

<table>
<thead>
<tr>
<th>Courses</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 ECT Practice Update</td>
<td>38</td>
</tr>
<tr>
<td>70 Vagal Nerve Stimulation</td>
<td>52</td>
</tr>
<tr>
<td>88 A Practical Approach to Herbs and Nutrients in Psychiatry</td>
<td>67</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>63 Role of Amytal in Conversion Disorder</td>
<td>50</td>
</tr>
<tr>
<td>75 Drug Therapy for Functional Somatic Syndromes</td>
<td>71</td>
</tr>
<tr>
<td>110 Alpha-Down EEG Biofeedback: A Novel Treatment for Anxiety</td>
<td>90</td>
</tr>
</tbody>
</table>

### TOPIC 43: TREATMENT TECHNIQUES AND OUTCOME STUDIES

<table>
<thead>
<tr>
<th>Advances in Psychopharmacology</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Antidepressants in Development: Corticotrophin Releasing Hormone and Neurokinin Antagonists</td>
<td>28</td>
</tr>
</tbody>
</table>

### CLINICAL CASE CONFERENCE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Motivational Enhancement Therapy for the Medically Ill, Substance Abuse Patient with Depression</td>
<td>66</td>
</tr>
</tbody>
</table>

### CONTINUOUS CLINICAL CASE CONFERENCES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Lives and Treatments: Two Patients, Two Therapists: Part 1</td>
<td>15</td>
</tr>
<tr>
<td>2 Lives and Treatments: Two Patients, Two Therapists: Part 2</td>
<td>39</td>
</tr>
<tr>
<td>1 Managing Negative Outcomes in General Psychiatry: Part 1</td>
<td>66</td>
</tr>
<tr>
<td>2 Managing Negative Outcomes in General Psychiatry: Part 2</td>
<td>88</td>
</tr>
</tbody>
</table>

### COURSE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 Core Competencies in Workplace Psychiatry</td>
<td>7</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUPS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 What Makes People Change?</td>
<td>15</td>
</tr>
<tr>
<td>22 The APA Business Initiative and the Future of Psychiatric Practice</td>
<td>67</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>119 Matching Treatment to Type of Poor-Prognostic, Substance-Dependent Patients</td>
<td>92</td>
</tr>
<tr>
<td>120 Trazodone, a Selective GABA Reuptake Inhibitor for the Treatment of Anxiety</td>
<td>92</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>29 New Development in Medications for the Treatment of Substance Abuse</td>
<td>55</td>
</tr>
<tr>
<td>85 Cognitive Therapy Versus Medications for Severe Depression</td>
<td>96</td>
</tr>
<tr>
<td>88 Treating Mental Illness and Substance Abuse in the Criminal Justice System</td>
<td>97</td>
</tr>
<tr>
<td>91 The Employment Intervention Demonstration Project: Outcome of Best Practice</td>
<td>97</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>34 Motion Pictures: The Therapeutic Modality of the 21st Century</td>
<td>42</td>
</tr>
<tr>
<td>60 Use of Restraints in Psychiatric Practice: Pros, Cons, and Alternatives</td>
<td>50</td>
</tr>
<tr>
<td>66 Aftermath of Professional Boundaries Violations: Treatment of Victims</td>
<td>51</td>
</tr>
</tbody>
</table>

### OTHER ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 Computers in Psychiatry: A Primer</td>
<td>52</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Use of the Personal Digital Assistant in Psychiatry</td>
<td>19</td>
</tr>
</tbody>
</table>

### TOPIC 45: CREATIVITY AND THE ARTS

<table>
<thead>
<tr>
<th>Courses</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Writing About Clinical Experiences</td>
<td>1</td>
</tr>
<tr>
<td>96 Treatment of Creative Patients</td>
<td>79</td>
</tr>
</tbody>
</table>

### FORUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Music and Mood Disorders: Tchaikovsky</td>
<td>27</td>
</tr>
</tbody>
</table>

### MEDIA PROGRAM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 M &amp; M Smith: For Prosperity's Sake</td>
<td>22</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>53 The Portrayal of Psychiatry in Recent American Films</td>
<td>44</td>
</tr>
<tr>
<td>59 The Art of the Unconscious: Shakespeare, Poetry, Film, and Psychiatry</td>
<td>50</td>
</tr>
<tr>
<td>81 Music as Mirror: Reflections of the Psyche in Works by the Great Composers</td>
<td>71</td>
</tr>
<tr>
<td>99 Poems on Psychiatry</td>
<td>89</td>
</tr>
<tr>
<td>112 Erik Erikson Epigenesis as Depicted in Andrew Lloyd Webber's Musicals</td>
<td>90</td>
</tr>
</tbody>
</table>

### TOPIC 46: ELECTRONIC MEDICAL RECORDS

<table>
<thead>
<tr>
<th>Courses</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Computer-Assisted Diagnostic Interview</td>
<td>1</td>
</tr>
<tr>
<td>29 Build Your Own Relational Database Electronic Medical Record</td>
<td>7</td>
</tr>
</tbody>
</table>

### TELECOMMUNICATIONS PRESENTATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Open Infrastructure for Outcomes: From Plug and Play Web Forms to Evidence-Guided Treatment</td>
<td>41</td>
</tr>
</tbody>
</table>

### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>94 Electronic Medical Records Enhance Quality and Productivity: The Time Has Come</td>
<td>77</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### TOPIC 47: GENDER ISSUES

<table>
<thead>
<tr>
<th>MEDIA PROGRAM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 King of Masks: Gender and Tradition in China</td>
<td>80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>44 Evidence-Based Psychiatry: Principles, Examples, and Critiques in the U.S. and France</td>
<td>59</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - COMPONENT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>41 The Rules of the Club: Career Advancement for Women</td>
<td>70</td>
</tr>
</tbody>
</table>

#### TOPIC 48: HEALTH SERVICES RESEARCH

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Outcomes: Use of Rating Scales</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DISCUSSION GROUP</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 Psychiatric Aspects of Cardiovascular Disease</td>
<td>67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>35 Consensus Development on Core Quality Measures for Mental Health Care</td>
<td>25</td>
</tr>
<tr>
<td>36 Improving the Competency of Clinicians Treating People with Mental Illness</td>
<td>25</td>
</tr>
<tr>
<td>76 Psychiatric Diagnosis for Children Under Age Five Referred to a Public Mental Health System</td>
<td>74</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIAS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 From Research to Practice: Primary Care Research in Substance Abuse and Mental Health Services for Elderly (PRISMe)</td>
<td>32</td>
</tr>
<tr>
<td>49 Global Psychiatry and Patients' Rights: Informed Consent</td>
<td>60</td>
</tr>
</tbody>
</table>

#### TOPIC 49: HISTORICAL QUESTIONS

<table>
<thead>
<tr>
<th>MEDIA PROGRAM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 The Frog in the Well: The Life and Work of Hoh-Kun Yuen</td>
<td>78</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - COMPONENT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Kids, Schools, and Parents: From the 20th Century into the 21st Century</td>
<td>50</td>
</tr>
</tbody>
</table>

#### TOPIC 50: INFORMATION TECHNOLOGY

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>61 How to Use Your Palm Personal Digital Assistant in Psychiatric Practice</td>
<td>38</td>
</tr>
<tr>
<td>82 Evidence-Based Medicine: An Introduction for Psychiatrists</td>
<td>66</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TELECOMMUNICATIONS PRESENTATIONS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 The Use of Digital Streaming Video for Distance Education in Telepsychiatry</td>
<td>41</td>
</tr>
<tr>
<td>4 Introduction to Evidence-Based Mental Health</td>
<td>62</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - COMPONENT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>53 Information Technology: Core Competencies for Psychiatrists</td>
<td>89</td>
</tr>
</tbody>
</table>

#### TOPIC 51: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

<table>
<thead>
<tr>
<th>FORUM</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Homosexuality and Religion: Healing the Wound</td>
<td>51</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIA PROGRAMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Southern Comfort</td>
<td>28</td>
</tr>
<tr>
<td>27 &quot;In the Life&quot; Television News Magazine</td>
<td>73</td>
</tr>
</tbody>
</table>

#### TOPIC 52: MANAGED CARE AND HEALTH CARE FUNDING

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATION</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Brief Dynamic Therapy: For the Patient or for Managed Care?</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>116 Alzheimer's Disease Increases Costs of Comorbidities in Medicare-Managed Care</td>
<td>92</td>
</tr>
<tr>
<td>117 Donepezil Is Associated with Lower Health Care Costs in Medicare-Managed Care</td>
<td>92</td>
</tr>
<tr>
<td>118 Managed Care and Malpractice Liability: Update 2002</td>
<td>92</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - COMPONENTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 How to Convince Corporate CEOs that Mental Health Is a Good Investment</td>
<td>17</td>
</tr>
<tr>
<td>28 The Mental Health Carveout: Strategies to Erase the Stigma</td>
<td>50</td>
</tr>
<tr>
<td>43 Medicare Update 2002</td>
<td>76</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - ISSUES</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>44 Enhancing and Funding Mental Health Services: New Freedom Initiative</td>
<td>43</td>
</tr>
<tr>
<td>46 Improving the Quality of Service in a Medicaid HMO</td>
<td>43</td>
</tr>
<tr>
<td>71 Recent Studies on Parity and Employer-Sponsored Insurance</td>
<td>70</td>
</tr>
<tr>
<td>86 Do Restricted Formularies Serve as Barriers to Care?</td>
<td>71</td>
</tr>
</tbody>
</table>

#### TOPIC 53: MEN'S HEALTH ISSUES

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>37 Meat Consumption and Risk of Depression: A Prospective, Population-Based Study</td>
<td>46</td>
</tr>
<tr>
<td>39 Efficacy and Safety of Sildenafil Citrate in Men with Depression and Erectile Dysfunction: Six-Month, Open-Label Treatment</td>
<td>47</td>
</tr>
</tbody>
</table>

#### TOPIC 54: POLITICAL QUESTIONS

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Personality and Political Behavior</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FORUMS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 The Death Penalty and the Road to Execution: Psychological Issues for Correctional Officers; Appropriate and Inappropriate Roles for Psychiatrists</td>
<td>51</td>
</tr>
<tr>
<td>13 The Pharmaceutical Industry and the APA: Controversies and Approaches</td>
<td>94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - COMPONENT</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>39 Psychiatrist Prescription Privileges: Is It Coming? Should It?</td>
<td>70</td>
</tr>
</tbody>
</table>
**TOPIC 55: PROFESSIONAL AND PERSONAL ISSUES**

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Treating Medical Students and Physicians</td>
</tr>
<tr>
<td>77</td>
<td>Arts and Humanities for Self-Renewal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>You Are Twenty-Four and You Have What?</td>
</tr>
<tr>
<td>22</td>
<td>Global Implications on the World Health Organization’s World Health Report 2001 on Mental Health</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Practicing Psychiatry in 2002</td>
</tr>
<tr>
<td>64</td>
<td>Lessons Learned: Looking Back to Move Forward</td>
</tr>
<tr>
<td>90</td>
<td>Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - COMPONENTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Risk Management Issues in Psychiatric Practice</td>
</tr>
<tr>
<td>24</td>
<td>Professionalism in the Teacher/Learner Relationship</td>
</tr>
<tr>
<td>52</td>
<td>Ethics of Pharmaceutical Involvement in Psychiatric Education</td>
</tr>
<tr>
<td>64</td>
<td>Minority Psychiatrists Who Have Suffered Mental Illness: Overcoming Stigma</td>
</tr>
<tr>
<td>67</td>
<td>A Recipe for Academic/Personal Success: Some Key Ingredients</td>
</tr>
<tr>
<td>82</td>
<td>Assisting Physicians and Other Professionals Who Violate Boundaries</td>
</tr>
<tr>
<td>88</td>
<td>Career Development and Risk Management</td>
</tr>
<tr>
<td>104</td>
<td>The Disruptive Physicians and Hospital Culture</td>
</tr>
<tr>
<td>106</td>
<td>Using Your Psychiatric Skills to Build a Productive Team at Work</td>
</tr>
</tbody>
</table>

**TOPIC 56: RELIGION, SPIRITUALITY, AND PSYCHIATRY**

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>Issues in Transpersonal Psychiatry</td>
</tr>
<tr>
<td>69</td>
<td>Transpersonal Psychiatry: Clinical Applications</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Healing Through Social and Spiritual Affiliation</td>
</tr>
<tr>
<td>16</td>
<td>The Nearly Forgotten Factor in Psychiatry: What a Difference a Decade Makes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIA PROGRAM</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Long Night’s Journey into Day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>Effects of Falun Gong Practice on Physical and Mental Health</td>
</tr>
<tr>
<td>62</td>
<td>Moral Conflict as a Component of Anxiety and Worry</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP - COMPONENT</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Psychiatry’s Response to the Data: Spirituality as a Relevant Clinical Factor</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOPS - ISSUES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>Spiritual Dimension and Religious Issues in an Urban CMHC Clinical Practice</td>
</tr>
<tr>
<td>74</td>
<td>Mindfulness and Awareness Practice in the Medicine Buddha Tradition of Tibet</td>
</tr>
<tr>
<td>102</td>
<td>Religious and Spiritual Assessment in Clinical Practice</td>
</tr>
</tbody>
</table>

**TOPIC 57: RESIDENT AND MEDICAL STUDENT CONCERNS**

<table>
<thead>
<tr>
<th>DISCUSSION GROUP</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Surviving Residency: Perspectives from the Training Office</td>
</tr>
</tbody>
</table>

**RESIDENTS' SESSION**

Meet the Experts Sunny-Side Up | 14

**SYMPOSIUM**

46 How to Launch a Successful Private Practice: Part III | 60

**WORKSHOPS - COMPONENTS**

10 Psychiatry in the Neuroscience Curriculum: Promise and Peril | 18
20 How to Launch a Successful Private Practice: Part I | 42
31 How to Launch a Successful Private Practice: Part II | 50
40 Combined Residency Training: You Want to Do What? | 70
50 Career Choices in Psychiatry | 88

**WORKSHOPS - ISSUES**

1 How to Get the Most Out of Supervision: What Residents Need to Know | 18
4 Supervision 101: Sex, Lies, and Videotape? | 18
11 Access to Psychotherapy Training in Residency: A Current Perspective | 19
20 Challenges of the Chief Resident in Psychiatry | 26
35 Innovative Strategies in Third-Year Medical Student Psychiatric Education | 42
50 World Federation of Psychiatric Trainees: Satisfaction and International Exchange in Psychiatric Education | 44
89 Assessing Educational Experiences in Psychiatry | 77
97 The Other Side of the Mountain: From Residency to Reality | 89

**TOPIC 58: PRESIDENTIAL THEME: "THE 21ST CENTURY PSYCHIATRIST"**

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page</th>
</tr>
</thead>
</table>
| 100    | Back to the Future: The Evolutionary Framework for Psychiatry | 88

**MASTER EDUCATOR CLINICAL CONSULTATION**

9 Changing and Evolving Roles for the Clinicians | 68

**PRESIDENTIAL SYMPOSIUM**

What Will the 21st Century Bring to the Training of Psychiatrists? | 29

**SCIENTIFIC AND CLINICAL REPORT**

58 Principles of Clinical Explanation in 21st-Century Psychiatry | 48

**SYMPOSIUM**

5 Health Insurance Portability and Accountability Act: Clinical Applications and Implications | 30
24 Psychotherapy Research: Challenges for the 21st Century | 34
78 Brain Substrates of Addiction: Neuroimaging as a Tool of Choice in the 21st Century | 94

**WORKSHOPS - COMPONENTS**

5 The Psychiatrist and Migration in the 21st Century | 18
26 The Terrorist Crisis of 2001: Use and Impact of Electronic Communication | 50
33 Quality Indicators for Children and Adolescents: Who Cares? | 69

**WORKSHOPS - ISSUES**

14 Psychotherapy Training for the 21st-Century Psychiatrist | 19
68 The Body in 21st-Century Psychiatry: Diagnostic Dimensions and Therapeutic Challenges | 51
76 In Search of the Empathic Healer | 71

**TOPIC 59: STIGMA/ADVOCACY**

<table>
<thead>
<tr>
<th>LECTURES</th>
<th>Page</th>
</tr>
</thead>
</table>
| 7        | Psychiatry and the Medical Consumer Movement | 36
| 18       | Mental Health: A Perspective from the Surgeon General Who Listens | 68

(Continued on next page)
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>31 False Memory Syndrome: Recovery and Family Reconciliation</td>
<td>56</td>
</tr>
<tr>
<td>WORKSHOP - COMPONENT</td>
<td></td>
</tr>
<tr>
<td>16 Talking on Your Feet: Survival Tips and Techniques for Media Interviews</td>
<td>25</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>87 Advocacy 101: Influencing Mental Health Policy</td>
<td>72</td>
</tr>
<tr>
<td>96 Stigma Stayed: The Cost of Prejudice in High Places</td>
<td>89</td>
</tr>
<tr>
<td>TOPIC 60: TELEPSYCHIATRY</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>34 Successful Clinical Applications of Telepsychiatry</td>
<td>56</td>
</tr>
<tr>
<td>TELECOMMUNICATIONS PRESENTATION</td>
<td></td>
</tr>
<tr>
<td>5 Individual and Group Psychotherapy Via Telepsychiatry</td>
<td>62</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
<td></td>
</tr>
<tr>
<td>10 Evaluation of Telepsychiatry Services in an Integrated Hospital System</td>
<td>19</td>
</tr>
<tr>
<td>in the Veterans Administration and Department of Defense</td>
<td></td>
</tr>
<tr>
<td>TOPIC 61: VIRTUAL REALITY</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>93 Virtual Reality and Mental Health: State of the Art and Future Directions</td>
<td>98</td>
</tr>
<tr>
<td>TELECOMMUNICATIONS PRESENTATION</td>
<td></td>
</tr>
<tr>
<td>2 DAVID: Depression Animation Video Image Database</td>
<td>41</td>
</tr>
<tr>
<td>TOPIC 62: WOMEN'S HEALTH ISSUES</td>
<td></td>
</tr>
<tr>
<td>ADVANCES IN RESEARCH</td>
<td></td>
</tr>
<tr>
<td>Treatment of the Pregnant or Postpartum Woman</td>
<td>28</td>
</tr>
<tr>
<td>COURSE</td>
<td></td>
</tr>
<tr>
<td>33 Psychiatric Disorders in Pregnancy and Postpartum</td>
<td>8</td>
</tr>
<tr>
<td>DISCUSSION GROUP</td>
<td></td>
</tr>
<tr>
<td>4 Postpartum Depression: Prevention and Intervention</td>
<td>15</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>22 Treatment of Mood and Anxiety Disorders in Women: What Is Evidence and</td>
<td>11</td>
</tr>
<tr>
<td>What Is Art?</td>
<td></td>
</tr>
<tr>
<td>38 Chronic Episodic Disorders: Comorbidity and Comprehensive</td>
<td></td>
</tr>
<tr>
<td>Integrated Treatment, Part 1</td>
<td>65</td>
</tr>
<tr>
<td>38 Chronic Episodic Disorders: Comorbidity and Comprehensive</td>
<td></td>
</tr>
<tr>
<td>Integrated Treatment, Part 2</td>
<td>87</td>
</tr>
<tr>
<td>MASTER EDUCATOR CLINICAL CONSULTATION</td>
<td></td>
</tr>
<tr>
<td>10 The Addicted Woman: Diagnostic and Treatment Challenges</td>
<td>69</td>
</tr>
<tr>
<td>MEDIA PROGRAMS</td>
<td></td>
</tr>
<tr>
<td>22 Women of the Wall</td>
<td>54</td>
</tr>
<tr>
<td>23 Loyalties</td>
<td>54</td>
</tr>
<tr>
<td>25 Leona's Sister Gerri</td>
<td>69</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
</tr>
<tr>
<td>14 Long-Term Effects of Depression on Symptoms and Function in Mid-Life</td>
<td>23</td>
</tr>
<tr>
<td>Women</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>16 Special Topics in Women's Mental Health</td>
<td>32</td>
</tr>
</tbody>
</table>
APA 155TH ANNUAL MEETING

PARTICIPANT INDEX

A

Adam, Dorothy 38
Abramson, Ruth K 74
Abramson, Ronald D 33
Adekoye, Martins A 23, 47
Agnihotri, Bernard J 71
Aguiar, Mary 49
Ashley, Kenneth B 70

B

Asthana, Deshram 29
Awad, Evelyn 59
August, Gerald 96
Auriacombe, Marc 95
Autry III, Joseph H 51
Axelrod, Seth R 55
Ayontide, Deji 18
Azarni, Amir N 70

Bender, Donna S 56, 81
Benedek, David 39, 97
Benedek, Elisa P 16, 26, 50, 71, 97
Benitez, Jaime M 18
Bennett, Maricarmen 2
Bennett, Michael J 71
Benoit, Marilyn B 77
Benincasa, Suzanne 75
Beresin, Evgeni V 30
Berg, Arthur Z 50
Berg, Paul H 47
Berganza, Carlos 84
Berger, Robert H 93
Bergman, Greta 89
Bergstrom, Richard F 24
Berman, Jeffrey A 33
Berman, Sheldon S 48
Berman, Steven 81
Bernstein, Carol A 7, 14, 29, 39
Bernstein, David P 31
Berti, Clark D 87
Bertolino, Janet 50
Besse, Elena 87
Bincu, Carlos 51
Bianhertz, Laura E 97
Biederman, Joseph 38, 47, 86
Bienvenu, Oscar J 82
Bender, Renée L 52, 76
Bennett, Lynne 44, 99
Bisagha, Adam M 34
Bishop, Shelley 43
Black, Doris 61
Blake, Lesley M 23
Blake, Nancy M 33
Blakeney, Patricia 31
Blakney, Barton J 25
Bland, Ian J 90
Bland, Terrence 81
Blasgen, Burton J 8, 51
Blata, Ferna 57
Bloch, Daniel 61
Bloom, Sydney 69
Blum, Sandra L 76
Blum, Sheryl 98
Bohman, Michael 25, 58
Boehnlein, James K 33
Boeke, Bradley F 86
Boekel, Hans 59
Bokon, John B 25
Bollas, Joanna 91
Blume, Peter 99
Blasko, John G 99
Blum, Frederic C 32
Borzoo, Shervin 98
Bosch, Howard F 72, 82
Bookheimer, Susan Y 34
Bowden, Raymond 54
Borstein, J. David 63
Borszoci, Francesca 30
Borutzky, Walter 96
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davine, Jonathan S</td>
<td>71</td>
</tr>
<tr>
<td>Davis, Glen P</td>
<td>24</td>
</tr>
<tr>
<td>Davis, Glenn G</td>
<td>77</td>
</tr>
<tr>
<td>Davi, Kenneth L</td>
<td>12</td>
</tr>
<tr>
<td>Davoren, Mary Jo</td>
<td>44</td>
</tr>
<tr>
<td>Deas, Deborah</td>
<td>58</td>
</tr>
<tr>
<td>DeBellis, Michael D</td>
<td>94</td>
</tr>
<tr>
<td>Debling, Esther</td>
<td>94</td>
</tr>
<tr>
<td>De Corry-Woronoff, Yvonne L</td>
<td>1L</td>
</tr>
<tr>
<td>Defaria, Ludmila</td>
<td>55</td>
</tr>
<tr>
<td>De Guzman, Denisette</td>
<td>77</td>
</tr>
<tr>
<td>De Jong, Joop</td>
<td>19,47</td>
</tr>
<tr>
<td>De La Gandara, Jose E</td>
<td>25</td>
</tr>
<tr>
<td>Delgado, Pedro L</td>
<td>64</td>
</tr>
<tr>
<td>Demant, Jean-Claude</td>
<td>13</td>
</tr>
<tr>
<td>Dennis, Michael L</td>
<td>48</td>
</tr>
<tr>
<td>De Rozet, Yves</td>
<td>34</td>
</tr>
<tr>
<td>DeRubeis, Robert J</td>
<td>34, 96</td>
</tr>
<tr>
<td>Des, Prakash N</td>
<td>93</td>
</tr>
<tr>
<td>Des Jafaai, Donald C</td>
<td>82</td>
</tr>
<tr>
<td>Desland, Jean-Nicolas</td>
<td>34</td>
</tr>
<tr>
<td>Deutsch, Stephen I</td>
<td>19</td>
</tr>
<tr>
<td>Deutschman, Daniel A</td>
<td>19, 77</td>
</tr>
<tr>
<td>Devanand, Devangere P</td>
<td>50</td>
</tr>
<tr>
<td>DeVore, G, Linksy</td>
<td>2</td>
</tr>
<tr>
<td>Devarajan, S</td>
<td>13</td>
</tr>
<tr>
<td>Devlin, Michael J</td>
<td>7, 59</td>
</tr>
<tr>
<td>Dewan, Manish J</td>
<td>38</td>
</tr>
<tr>
<td>Dhorapeh, Vasant P</td>
<td>44</td>
</tr>
<tr>
<td>DiCamillo, Amy</td>
<td>34</td>
</tr>
<tr>
<td>Dickstein, Leah L</td>
<td>19, 27, 51, 77, 89</td>
</tr>
<tr>
<td>Di Cori, Ferruccio A</td>
<td>16</td>
</tr>
<tr>
<td>Dietrich, Allen</td>
<td>60</td>
</tr>
<tr>
<td>Diede, IoAnn</td>
<td>57</td>
</tr>
<tr>
<td>di Giannantonio, Massimo</td>
<td>22</td>
</tr>
<tr>
<td>Dillon, James E</td>
<td>7, 77</td>
</tr>
<tr>
<td>Dinges, David F</td>
<td>86</td>
</tr>
<tr>
<td>Dinwiddie, Stephen H</td>
<td>6</td>
</tr>
<tr>
<td>Ditter, Susan M</td>
<td>76</td>
</tr>
<tr>
<td>Dixon, Lisa B</td>
<td>74</td>
</tr>
<tr>
<td>Dixo, Randi</td>
<td>57</td>
</tr>
<tr>
<td>Dodakashi, Veena R</td>
<td>93</td>
</tr>
<tr>
<td>Dodsan, Thomas W</td>
<td>33</td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>13, 23, 27, 86, 92</td>
</tr>
<tr>
<td>Dohrenwend, Bruce</td>
<td>57, 91</td>
</tr>
<tr>
<td>Dolan-Sewell, Regina</td>
<td>17</td>
</tr>
<tr>
<td>Dolder, Christian</td>
<td>37</td>
</tr>
<tr>
<td>Donegan, Nelson H</td>
<td>56</td>
</tr>
<tr>
<td>Dong, Yun</td>
<td>81</td>
</tr>
<tr>
<td>Donohue, Micca</td>
<td>75</td>
</tr>
<tr>
<td>Donovan, Sheila</td>
<td>48</td>
</tr>
<tr>
<td>Doody, Rachel V.</td>
<td>85</td>
</tr>
<tr>
<td>Dooraumwir, P.</td>
<td>64</td>
</tr>
<tr>
<td>Dorce, Daphne</td>
<td>89</td>
</tr>
<tr>
<td>Dording, Christina M</td>
<td>23, 49</td>
</tr>
<tr>
<td>Dorer, David J</td>
<td>20</td>
</tr>
<tr>
<td>Doxy, Charles</td>
<td>23</td>
</tr>
<tr>
<td>Downey, Jennifer I</td>
<td>18</td>
</tr>
<tr>
<td>Downs, Susan R</td>
<td>52</td>
</tr>
<tr>
<td>Doyle, Alyssa</td>
<td>86</td>
</tr>
<tr>
<td>Draeger, John H</td>
<td>22</td>
</tr>
<tr>
<td>Drake, Robert E</td>
<td>48, 59, 97</td>
</tr>
<tr>
<td>Drescher, Jack</td>
<td>70, 80</td>
</tr>
<tr>
<td>Dreiner, Nehama</td>
<td>15</td>
</tr>
<tr>
<td>Dryden-Edwards, Roxanne C</td>
<td>49, 72, 89</td>
</tr>
<tr>
<td>Dua, Ning, Jeannine</td>
<td>49, 71</td>
</tr>
<tr>
<td>Dubin, Linda F</td>
<td>18</td>
</tr>
<tr>
<td>Dubo, Elise D</td>
<td>22, 40</td>
</tr>
<tr>
<td>Dubois, Michel G</td>
<td>37</td>
</tr>
<tr>
<td>Dudaworth, Kenneth S</td>
<td>49</td>
</tr>
<tr>
<td>Dudley, Jr. Richard G</td>
<td>80</td>
</tr>
<tr>
<td>Duffy, Farith F</td>
<td>60, 98</td>
</tr>
<tr>
<td>Dulcan, Nina K</td>
<td>35</td>
</tr>
<tr>
<td>Dumniewich, Edward R</td>
<td>51</td>
</tr>
<tr>
<td>Dunn, Laura B</td>
<td>37, 76</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

Krausz, Michael ..................................... 95
Kravitz, Howard M .................................. 23
Kreek, Mary Jean ...................... 21
Krejci, Jonathan .................................. 33
Krishnan, Ranga R ......................... 6, 11, 28
Kronke, Kurt ..................................... 60
Kroll, Jerome L ................................. 48
Krupnick, Janice L ......................... 96
Krytal, John H .................................. 35, 83, 92
Kumar, Anand .................................. 5, 30
Kunkel, Elisabeth J.S .................. 44, 75
Kuper, David J .................................. 3, 34, 63, 96
Kuran, Vahan ............................. 82

L

Lacy, Timothy J .................................. 42
Lagodinos, Greta .................................. 25
Lakia, Amaro ..................................... 23
Lam, Raymond W ............................. 2
Langeleben, Daniel D .................. 94
Lapoeza, Olga M .............................. 55
Lappin, Debra .................................. 60
Larson, Robert C ................................ 77
Laub, Dori ..................................... 12
Laughlin, Catherine ..................... 75
Lauriello, John .................................. 75
Lavretskey, Helen ............................. 30
Lawrence, Earl C ................................ 41
Lawson, William B ......................... 17, 58, 70, 94
Lazarus, Arthur L ......................... 25, 93
Leach, David .................................. 29
Leavitt, Renee .................................. 97
Lebovitz, Allen .................................. 64
Levey, Robert .................................. 29
Lee, Diana ..................................... 39
Legey, Denis .................................... 59
Lehman, Anthony F ......................... 35, 97
Lehman, Lauren S ......................... 18
Leiberlun, Ellen .................................. 3
Leite, Paul ...................................... 61
Lejoyeux, Michel ............................... 83
Lence, Todd ...................................... 65
Leibovitz, Marcie ......................... 21
Leon-Andrade, Carlos ................ 84
Leong, Richard .................................. 75
Leontzeh, Tami V ............................ 74
Lesser, Michael S ............................. 93
Leverduskey, Philip G ................... 39
Levenson, Alan L ............................. 18
Levenson, James L ......................... 41
Levi-Pearl, Sue ............................... 88
Levin, Frances R ............................... 34, 44, 55
Levin, Harvey .................................. 43
Levin, Saul M .................................. 90, 93
Levy, Jeffrey M ............................... 44
Levine, John B .................................. 25
Levitt, Anthony J .................................. 2
Levkoff, Sue E .................................. 32
Levy, Ken ...................................... 56
Lewis, David A ................................. 12
Lewis, Evelyn L .................................. 43
Lewis, Lydia J .................................. 59
Lewis-Fernandez, Roberto ............... 23, 57, 61, 91
Lew, Alfred J .................................... 8
Li, Xinghao ..................................... 81
Liang, Kung-Ye .................................. 82
Liang, Warren M .............................. 89
Lichtenstein, Bill ............................... 73
Lidz, Charles .................................. 58
Liebman, Alice F .............................. 58
Liebman, Jeffrey ................................ 10, 12
Liebling, David S ............................ 57
Liebowitz, Barry D ......................... 85

Liebowitz, Michael R ...................... 61
Lief, Harold I .................................. 56
Lim, Russell .................................... 31
Limoges, Richard F ...................... 85
Lint, Keh-Ming .................................. 34, 35, 49, 70, 72
Lindenmayer, Jean-Pierre ................ 41
Link, Gary ...................................... 50
Lisak, Paul S .................................. 81
Lippa, Carol ..................................... 73
Lipschitz, Deborah S ................... 55
Lipsitz, Joshua D ........................... 97
Lipsitz, Steven H .............................. 90
Lisby, Sarah H .................................. 14, 81
Listerud, John M .............................. 90
Litten, Raye Z ................................. 83
Litts, David A ................................. 24
Liu, Hong ....................................... 24
Lively, Cathy ..................................... 71
Livingston, Richard L .................. 42
Llorente, Maria D ............................ 32
Lloyd, John R .................................. 92
Loboyrakhia, Sheila M .................. 5
Lochman, John E ............................. 96
Lock, James D .................................. 59
Lockhart, Paula J ............................. 50
Loch, Katherine ................................ 59
Logsdon, Linda ............................... 85
Lourie, J. C. .................................. 59
Lomax II, James W ......................... 5, 15, 39
Londono, Donna L ............................ 93
London, Edythe ............................... 18, 82
London, Richard G ........................... 35
Lopes, Frank A ................................. 47
Losonczi, Miklos F ........................... 84
Lorant, Sandra Y ............................. 79
Loveless, Joe ..................................... 9
Lovett, Margaret .............................. 96
Lowenkopf, Eugene L ..................... 75, 92
Lu, Francis G .................................. 90, 93, 94
Luchins, Daniel J .............................. 32
Lusted, Alice .................................... 74
Lunn, Brian ..................................... 50
Luo, John ....................................... 50
Lune, Lawrence B ............................. 82
Lydiard, R. Bruce ......................... 10, 61, 87
Lyons, Constance G .................... 7

M

Ma, Albert Y .................................. 47
Ma, Guoguang ............................... 23
MacIntyre, John C ........................... 69
Maclean, Alejandro ....................... 59
Maffei, Cesare ................................. 31
Magerle, David M ............................ 48
Magee, Christine ............................. 91
Maguire, Gerald A ........................... 6
Maher, David .................................... 44
Maiers, James M ............................... 25
Maki, Pinho H .................................. 91, 92
Malcolm, Jr., Robert J ..................... 55
Mandari, Lisa ................................ 87
Malhotra, Noena ......................... 25
Mallen, Lucinda ............................... 51
Malmquist, Carl P ........................... 26
Malone, Kevin M .............................. 24
Maloney, Ann S ............................. 60
Maltese, Richard T ........................... 78
Maluh, Chiara ................................. 3
Manco, Catherine L ........................ 22
Mandern, Mark ............................... 81
Manji, Huseni K .............................. 12
Mann, J. John ................................. 24
Mann, Matthew C ......................... 29, 81
Manzoni, Anthony P ...................... 94
Mannes, Peter .................................. 71
Mannell, Laurie E ........................... 8, 11
Marazziti, Donata ......................... 7
March, John S .................................. 87
Marchant, Nestor F ........................... 84
Marcos, Eric R .................................. 69
Marie, Steve C ............................... 25
Marder, Stephen R ........................... 9, 38, 59
Margo, Katherine L ........................ 27
Margo, Mary Jane ......................... 40
Markowitz, John C .......................... 95
Marks, Robert .................................. 24
Markvista, Romana ...................... 38, 70
Marner, Charles R ......................... 57
Marshall, Randall D .......................... 17, 26, 57, 61
Marti, Alfredo .................................. 90
Martin, Eileen M .............................. 24
Martinez, David C ............................ 78
Martin, Brian ................................. 24
Mastroi, Arnaud .............................. 33
Marumoto, Megan T ...................... 76
Mason, Prakash S ............................ 13, 37, 63, 96
Mass, Gabriel .................................. 91
Matlandy, Robert ......................... 12
Matsie, Mary Jane ............................ 40
Masenmer, Donna ............................ 86
Mansor, Scott .................................. 88
Manso, Joyce ................................. 18
Mansi, James F .................................. 35
Masey, Vera .................................... 92
Marech, John A ................................ 81, 82
Marottin, Ana .................................. 19, 26, 70
Maurer, Martin H ............................. 23
Maurer, Martin H ............................. 20
Mavissalakian, Muriel R .................. 22
Mawhinney, Joseph R ...................... 71
Maxwell, Jane C ............................... 83
May, Catherine S .............................. 7
Mayault, Catherine ........................... 59
Mayeux, Richard ............................... 28
McCabe, Lee .................................... 82
McCull, W. Vaughan ....................... 38
McCune-Katz, Elmore F .................. 46
McCann, Una D ............................... 81
McCartney, Cheryl F ....................... 71
Markowitz, John C .......................... 95
McCue, Robert .................................. 91
McDonel-Herr, Betsy ...................... 32
McDougall, Christopher J ................ 14
McDowell, David M .......................... 34, 48, 73, 83, 92
McEloy, Susan L ............................. 28, 86
McEvoy, Joseph P ............................ 9, 10
McFarlane, Rodger ......................... 36
McFarlane, William R ...................... 97
McGlashan, Thomas H ..................... 24, 55, 56, 81, 95
McGrory, Patrick D .......................... 9
McGrath, Patrick J ............................ 61
McGuire, Colleen ............................. 74
McGuire, Michael ............................. 56
McHugh, Paul R ............................... 56
McIlvogue, Gregory ........................ 97
McIntyre, John S ............................ 32, 60, 93
McIlellan, A. Thomas ..................... 18, 26
McMahon, David F .......................... 77
McNicholas, Laura F ........................ 18, 66
McWilliams, Linda ......................... 47
Meade, Brian F ............................... 75
Meagher, David J ............................. 76
Mee, Lee ....................................... 27
Mega, Lesly T ................................. 69
Mei, Neil ....................................... 98
PARTICIPANT INDEX

Sadoff, Joan……... 54
Sadoff, Robert L…… 44, 54
Sadeq, S. Atef…………. 1, 76, 88
Saguns, Merleth L……. 90
Said, Tewfik………… 39
Sajjovic, Martha…… 2
Sakhrani, Dum………… 74
Salah, Kasir M……… 93
Salomon, Richard…… 96
Salome, Anatolia……… 22
Salonen, Jukka T……… 64
Sambro, Soledad…… 83
Samson, Teresa C…….. 74
Samson, Steven E…… 43
Samuels, Jack F……… 82
Sanacora, Gerard…… 64
Sanchez, Herman…… 32
Sanchez-Lucay, J. Amato…… 61
Sanchez-Way, Rush…… 93
Sane, Natasha S……… 34
Sanguineti, Vincenzo R…… 7
Sane, Natasha S……… 34
Sanghvi, Vincenzo R…… 7
Sarlow, Charles A……… 24, 55, 56, 81
Saro, Mary……… 85
Santilli, Silvio……… 90
Saraceno, Benedetto…… 17, 79
Sartoris, Norman……… 6, 60
Sassani, Andrew C……… 62
Satter, David……… 68
Sato, S. L……… 94
Saltzberg, Alan F……… 9, 28, 67
Scheiber, Stephen C……… 69, 77
Scheffer, Randolph B…… 5, 26
Schindler, Barbara A……… 35, 69
Schindler, Clary……… 95
Schmidt, La……… 55
Schmidt, Chestes W……… 50, 78, 82, 89
Schneider, Franklin R……… 61
Schoen, Gary R……… 13, 87
Schoen, Nira R……… 30, 64, 92
Schottenfield, Richard S……… 42, 46
Schouten, Ronald……… 7
Schubmehl, James Q……… 39
Schulman, Leslie M……… 24
Schulman, Julie K……… 50, 70
Schuler, Charles S……… 18
Schuster, James M……… 43
Schulte, Dean……… 66
Schwartz, Alan……… 49
Schwartz, Charles E……… 20
Schwartz, Jonathan……… 49
Schwartz, Joseph M……… 72, 82, 89
Schwartz, Marc M……… 75
Schweins, Michael M……… 19
Scirotto, Mary S……… 66, 88
Scott, C. E……… 27
Scott, Jan I……… 78
Scott, Marcia……… 7
Scott, Neld F……… 75
Scott, William M……… 90
Scotton, Bruce W……… 15
Scull, Paul J……… 96
Scull, J. H……… 77
Scull, Yvette……… 44
Sedra, Lloyd I……… 17, 76
Segal, Gerald……… 56
Seidman, Larry J……… 86
Seidman, Stuart N……… 2, 34, 47
Sellers, Beryl M……… 49
Seltzer, Mark F……… 85
Sengupta, Arvind……… 97
Serhan, Musa……… 75
Seryak, Michael J……… 3
Serrant, Donna M……… 44
Sesso, Sandra H……… 19
Shaffer, David……… 54, 55
Shah, Manoj R……… 65
Shalev, Anach Y……… 17, 57
Shanfield, Stephen B……… 42
Shapiro, Edward R……… 19, 50
Shapiro, Peter A……… 41, 67
Shapshak, Paul……… 29
Shartstein, Steven S……… 31, 82, 88
Sharma, Raj P……… 38
Sharon, Estee……… 33
Sharp, Conna……… 42
Shea, M. Tracie……… 24, 35, 56, 81
Shea, Shawn C……… 15
Shear, M. Katherine……… 11
Sheehan, David V……… 8, 13
Sheehe, John……… 42
Shellow, Ronald A……… 89
Shelton, Richard C……… 65, 87, 96
Shen, Hong……… 70
Shifrin, Jan L……… 23, 76
Shinn, Ann……… 81
Sholevar, Ellen H……… 23, 84
Sholevar, Gary K……… 63, 84
Shore, Diane K……… 26
Shrout, Patrick……… 48
Shubert, Duane ……… 18
Shuman, Daniel W……… 39
Shwartz, Michael S……… 25
San, Valerie……… 59
Siddharth, Prabha……… 34
Siegel, Glenn N……… 90
Siegled, Patricia……… 31
Siegel, Frederick S……… 97
Sierra, Victor……… 49
Sierra, Larry J……… 65, 74, 84, 87
Silk, Lammane……… 48
Silverman, Edward K……… 38
Silverbergen, Stephen C……… 22
Silk, Kenneth R……… 24, 31, 50, 74, 81
Silver, Alan……… 60
Silver, Ann-Louise S……… 17, 31
Silver, Stuart B……… 1
Silverman, Jeremy……… 74
Silverman, Samuel M……… 49
Silverman, Daphne……… 84
Sinden, Deborah R……… 83, 84
Simon, Gregory E……… 59
Simon, Naomi M……… 10
Simon, Robert I……… 39
Simon, Sara……… 81
Simpson, Thomas A……… 1, 32
Simpson, D. Dwayne……… 26
Singh, Bruce……… 25
Singh, Rajita……… 83
Sirs, Samuel G……… 30
Siss, Robert……… 91
Sivertz, Kristin S……… 8
Skiljan, Carol……… 17
Skodol, II, Andrew E……… 15, 56, 81
Skudlarski, Paul……… 56
Smolenko, Ralph……… 96
Small, Gary W……… 34, 86
Smith, Christopher……… 65
Smith, Erin C……… 90
Smith, Eric T……… 57
Smith, James……… 8
Smith, Mary Kay……… 89
Smith, Matthew B……… 84
Smoller, Jordan W……… 25
Snyder, David……… 18
Soares, Claudio N……… 23, 32, 57, 76
Sokol, Mae S……… 2
Sokoll, Steven……… 70, 73
Sollkham, Ramon……… 41
Soloroff, Paul H……… 24
Solomon, Brenda C……… 58
Soltys, Stephen M……… 44
Solum, Lionel P……… 44
Somaundaram, Daya……… 47
Somers, Julian……… 57
Sommer, Frank G……… 48
Sonawalla, Shamash B……… 49
Sorenenscheul, Michael R……… 43
Sood, Erica……… 34, 64
Sotsky, Stuart M……… 51
Southard, Marvin……… 89
Southwick, Steven M……… 55
Sowers, Wesley……… 6
Spigelman, D……… 57
Spencer, Thomas J……… 3, 86
Spero, Leonard T……… 17
Speigle, David……… 61
Speigle, Herbert……… 76
Spirt, Deborah……… 25, 70, 77
Spirt, Henry I……… 44
Springer, J. Fred……… 83
Sprinz, Melane E……… 15
Sparung, Deborah……… 46
Srivastava, Jaganathan……… 93
Stabinsky, Harvey……… 19, 91
Stabinsky, Susan……… 19, 75
Stahl, Stephen M……… 37, 57
Stange, Judy L……… 90
Stanger, Ronnie S……… 50, 89, 93
Stanley, Richard M……… 90
Star, Jodi E……… 70, 91
Starko, Robert S……… 89
Steinman, Henry……… 97
Stecher, Vera……… 47
Stein, Bradley D……… 33
Stein, Dan J……… 57
Stein, Mark A……… 47
Stein, Michel J……… 71
Stein, Mark A……… 47
Stein, Murray B……… 61
Stein, Seth P……… 18
Steinberg, Karen……… 43
Steinberg, Marc……… 33
Steinberg, Maurice D……… 45, 70
Stein, Hans……… 77
Stem, Jessica……… 77
Stem, Robert G……… 55
Stem, Theodore A……… 69, 72
Stevenson, Ellen M……… 46
Stewart, Alba V……… 61, 82, 94
Stewart, Bette……… 74
Stewart, Donna E……… 40, 53, 70
Stewart, Jonathan W……… 6, 61
Stokes, Honorable Lou……… 42
Stone, Alan A……… 10, 32, 56, 80
Stone, H. Michael……… 31, 58
Stothart, Nadia L……… 7, 49, 69, 80
Stout, Robert L……… 20, 66, 83
Stowe, Zachary N……… 28
Strain, Eric C……… 55, 66
Starkowski, Stephen M……… 48
Strauss, John S……… 1
Stromeyer, Stephen J……… 24
Stuart, Scott P……… 1
Suchinsky, Richard T……… 18
Sudak, Donna M……… 18, 89
Suddath, Mary L……… 56
Sulforo, Michelle……… 60
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Williams, John</td>
<td>60</td>
</tr>
<tr>
<td>Williams, Laurel L</td>
<td>25</td>
</tr>
<tr>
<td>Williams, Mary Beth</td>
<td>71</td>
</tr>
<tr>
<td>Williams, Richard</td>
<td>1</td>
</tr>
<tr>
<td>Williams, Veronica L</td>
<td>20</td>
</tr>
<tr>
<td>Williams-Woodson, Diane</td>
<td>13</td>
</tr>
<tr>
<td>Williams-Johnson, Denise M</td>
<td>38</td>
</tr>
<tr>
<td>Willick, Martin S</td>
<td>6</td>
</tr>
<tr>
<td>Wilson, Daniel R</td>
<td>56, 88</td>
</tr>
<tr>
<td>Wilson, G. Terrence</td>
<td>59</td>
</tr>
<tr>
<td>Wilh, Susan</td>
<td>93</td>
</tr>
<tr>
<td>Wim, Rosa</td>
<td>32</td>
</tr>
<tr>
<td>Winer, Jerome A</td>
<td>58</td>
</tr>
<tr>
<td>Winkleman, John W</td>
<td>10, 27, 86</td>
</tr>
<tr>
<td>Winstead, Darla</td>
<td>66</td>
</tr>
<tr>
<td>Wise, Thomas N</td>
<td>44, 69</td>
</tr>
<tr>
<td>Wiseman, Claire V</td>
<td>30</td>
</tr>
<tr>
<td>Winer, Katherine L</td>
<td>35, 75</td>
</tr>
<tr>
<td>Wohlford, Paul</td>
<td>32</td>
</tr>
<tr>
<td>Wolfe, Rosemarie</td>
<td>97</td>
</tr>
<tr>
<td>Wolfe, Eileen C</td>
<td>96</td>
</tr>
<tr>
<td>Wolkstein, Eileen C</td>
<td>43</td>
</tr>
<tr>
<td>Wonderlich, Stephen A</td>
<td>30</td>
</tr>
<tr>
<td>Wong, Frank Y</td>
<td>93</td>
</tr>
<tr>
<td>Wong, Marlene</td>
<td>33</td>
</tr>
<tr>
<td>Wood, William G</td>
<td>6</td>
</tr>
<tr>
<td>Woodley, Hazel</td>
<td>13</td>
</tr>
<tr>
<td>Woods, Scott W</td>
<td>95</td>
</tr>
<tr>
<td>Woods, Sherryn M</td>
<td>69</td>
</tr>
<tr>
<td>Woody, George E</td>
<td>18</td>
</tr>
<tr>
<td>Workman, Brian</td>
<td>42</td>
</tr>
<tr>
<td>Worley, Linda L</td>
<td>20, 51</td>
</tr>
<tr>
<td>Worthen, Mary R</td>
<td>11</td>
</tr>
<tr>
<td>Worthington III, John J</td>
<td>17, 23</td>
</tr>
<tr>
<td>Wozniak, Janet</td>
<td>3, 38</td>
</tr>
<tr>
<td>Wright, Harry H</td>
<td>58, 74</td>
</tr>
<tr>
<td>Wright, Jesse H</td>
<td>18, 26, 30, 66, 78</td>
</tr>
<tr>
<td>Wu, Nancy Sheng-Shah</td>
<td>77</td>
</tr>
<tr>
<td>Wyse, Kevan R</td>
<td>49</td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>7, 26, 30, 77</td>
</tr>
<tr>
<td>Yang, Jing-Duan</td>
<td>48</td>
</tr>
<tr>
<td>Yate, Aline</td>
<td>22, 49</td>
</tr>
<tr>
<td>Yee, Mani R</td>
<td>49</td>
</tr>
<tr>
<td>Yehuda, Rachel</td>
<td>8, 26, 44, 71</td>
</tr>
<tr>
<td>Yen, Shirley</td>
<td>24, 81</td>
</tr>
<tr>
<td>Yeomans, Frank E</td>
<td>66</td>
</tr>
<tr>
<td>Yent, Albert</td>
<td>49</td>
</tr>
<tr>
<td>Yung, Paul P</td>
<td>24, 47</td>
</tr>
<tr>
<td>Yoar, Bill</td>
<td>54</td>
</tr>
<tr>
<td>Yongers, Kimberly A</td>
<td>11, 87</td>
</tr>
<tr>
<td>Young, Alexander S</td>
<td>25, 59</td>
</tr>
<tr>
<td>Young, Carolyn M</td>
<td>75</td>
</tr>
<tr>
<td>Young, Keith W</td>
<td>42, 50, 60, 88</td>
</tr>
<tr>
<td>Young, Nancy</td>
<td>97</td>
</tr>
<tr>
<td>Young, Paula R</td>
<td>96</td>
</tr>
<tr>
<td>Young, Richard A</td>
<td>20</td>
</tr>
<tr>
<td>Yuan, Volpp, Serena</td>
<td>70</td>
</tr>
<tr>
<td>Yudofsky, Stuart C</td>
<td>13, 20, 37, 39</td>
</tr>
<tr>
<td>Yung, Alison R</td>
<td>9</td>
</tr>
<tr>
<td>Yurie, Yuval</td>
<td>91</td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Zajecka, John M</td>
<td>37</td>
</tr>
<tr>
<td>Zakaria, Konstantine K</td>
<td>98</td>
</tr>
<tr>
<td>Zanarini, Mary C</td>
<td>24, 56, 74, 81</td>
</tr>
<tr>
<td>Zapata, Jorge A</td>
<td>17, 89</td>
</tr>
<tr>
<td>Zarate, Jr., Carlos M</td>
<td>24, 48</td>
</tr>
<tr>
<td>Zavodnick, Jacquelyn M</td>
<td>84</td>
</tr>
<tr>
<td>Zerbe, Kathryn J</td>
<td>2</td>
</tr>
<tr>
<td>Zedonis, Douglas M</td>
<td>33</td>
</tr>
<tr>
<td>Zil, John S</td>
<td>69</td>
</tr>
<tr>
<td>Zilberman, Monica L</td>
<td>32</td>
</tr>
<tr>
<td>Zimbardo, Philip G</td>
<td>51, 67</td>
</tr>
<tr>
<td>Zimbardo, Philip B</td>
<td>95</td>
</tr>
<tr>
<td>Ziskin, Mikhail Y</td>
<td>44</td>
</tr>
<tr>
<td>Zito, Julio M</td>
<td>83</td>
</tr>
<tr>
<td>Zivin, Gail</td>
<td>43</td>
</tr>
<tr>
<td>Zolanski, Howard V</td>
<td>76</td>
</tr>
<tr>
<td>Zoubek, Cynthia</td>
<td>32</td>
</tr>
<tr>
<td>Zweigen, Allen</td>
<td>95</td>
</tr>
</tbody>
</table>
THE WIDEST ARRAY OF

At Your Annual Meeting Bookstore

APPI BOOKSTORE AT THE 2002 APA ANNUAL MEETING

Grow professionally and increase your knowledge of psychiatric practices through the extensive selection at the APPI bookstore. Our wide variety of topics allows you to pick up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!

Make sure to visit the APPI bookstore when you're in Philadelphia—you won't be disappointed!

APPI Bookstore Hours during the 2002 APA Annual Meeting

Saturday, May 18
11 am-5 pm
Sunday, May 19
11 am-4:30 pm
Monday, May 20
10 am-6 pm
Tuesday, May 21
10 am-6 pm
Wednesday, May 22
10 am-3 pm

Special Hours for Members-in-Training ONLY.

On Sunday, May 19th from 8:00am to 11:00am the bookstore will be open for members-in-training only. Members-in-Training will receive a 25% discount off the retail price during these hours.

Textbook of Anxiety Disorders
Edited by Dan J. Stein, M.B., and Eric Hollander, M.D.

This "one-stop" resource for both clinicians and researchers details not only the rigorous diagnostic schemas, sophisticated psychobiological models, and effective pharmacotherapy and psychotherapy interventions developed during the past few decades but also the latest advances in research, theory, and clinical knowledge in this diverse field. In this remarkable collection, 77 U.S. and international experts cover the phenomenology, etiology, psychotherapy, and pharmacotherapy of every major anxiety disorder.

2002 • 544 pages • ISBN 0-88048-829-8 • hardcover
$77.00 • Item #8829

1400 K Street, NW
Washington, DC 20005-2403
Phone: 202-682-6262 or 1-800-368-5777
Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 1-202-789-2648 • Email: appi@psych.org • Web: www.appi.org
Please reference priority code AH203 when ordering

The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry
Psychiatry in the Medically Ill, Second Edition
Edited by Michael G. Wise, M.D. and James R. Rundell, M.D.

Today, nearly 3,000 psychiatrists in the United States work at the forefront of psychiatry's interaction with other medical specialties, devoting at least 25% of their professional time to consultation-liaison psychiatry. This second edition, meticulously researched, clearly written, and designed for ease of use, brings together the body of knowledge and skills that defines the subspecialty of consultation-liaison psychiatry. More than 100 clinical and academic leaders share their knowledge, expertise, and research within these pages, offering practical guidance based on their firsthand clinical experience in evaluating and treating psychiatric disorders in patients with concomitant medical or surgical illness.

2002 • 1130 pages • ISBN 0-88048-393-8 • hardcover
$175.00 • Item #8393

Edited by Stuart C. Yudofsky, M.D., and Robert E. Hales, M.D.

PRAISE FOR THE PREVIOUS EDITION

First published 15 years ago as the only multiauthored, comprehensive textbook in the field, the fourth edition of this tremendously successful volume expands its focus on the neurosciences to encompass the great strides we've made. To convey this intensified focus, the editors have added "...and Clinical Neurosciences" to the title, with new and expanded chapters that cover topics such as the epidemiology and genetics of neuropsychiatric disorders, the neuropsychiatric aspects of delirium, the growth in clinical knowledge about and clinical relevance of drug-induced delirium and encephalopathies other than delirium, and educational and certification issues in neuropsychiatry.

2002 • 1420 pages • ISBN 1-58562-004-1 • hardcover
$219.00 • Item #62004

American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders
Compendium 2002

American Psychiatric Association

2002 • 896 pages • ISBN 0-89042-320-2 • hardcover
$74.95 • Item #2320

2002 • 896 pages • ISBN 0-89042-323-7 • paperback
$57.95 • Item #2323
CALL FOR PAPERS

PRESIDENT'S THEME:
The Promise of Science – The Power of Healing

Paul S. Appelbaum, M.D.
President

Geetha Jayaram, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 3, 2002</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 4, 2002</td>
</tr>
<tr>
<td>Reports</td>
<td>September 4, 2002</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 4, 2002</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 4, 2002</td>
</tr>
<tr>
<td></td>
<td>Component: September 17, 2002</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Jayaram at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Millennium Hall, Second Floor, Loews

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews

Molecules and Mood Disorders:
Drug Discovery and the Treatment of Depression

Educational Objectives:
- Review and understand the process of antidepressant drug discovery and development, the refinement of existing therapeutic options, and the state of the art of antidepressant treatment
- Understand the process behind the development of antidepressants to enhance clinical advantage
- Relate the identification and screening process, use, and significance of different animal models for the development of antidepressants
- Relate the history, significance, and trend of single isomers in drug development
- Identify the clinical implications and significance of single isomers in the treatment of depression
- Review the latest treatment options for depression and discuss future trends in depression management

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credit toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 888-357-7924 (within the US or Canada) or 202-682-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

SATURDAY DINNER, MAY 18
BIPOLAR DISORDER:
NEW NATIONWIDE DATA
ON MISDIAGNOSIS & COMMUNITY COSTS
6:30 - 7:00 p.m. Dinner 7:00 - 10:00 p.m. Clinical Program
Philadelphia Marriott • Salons E & F, 5th Floor

SYMPOSIUM CHAIR
MARK A. FEY, MD
University of Texas Medical Branch

Human Suffering and Economic Burden in a Large Community Sample
JOSEPH R. CARABRENS, MD
Case Western Reserve University

Preservation and Burden of Depression in the Community and Primary Care
MYRA M. WEISSMAN, PhD
Columbia University

The True Prevalence of Bipolar Spectrum Disorder
ROBERT M.A. HIRSCHFIELD, MD
University of Texas Medical Branch

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

159th APA Annual Meeting

Improving Patient Outcomes Across the Spectrum of Bipolar Disorder

Agenda
8:30-9:00 AM Dinner
9:00-9:30 AM Welcome and Introduction
9:30-9:45 AM Gender Variation in Bipolar Disorder
9:45-10:00 AM The Longitudinal Course of Bipolar Disorder
10:00-10:15 AM Acute Manic: Pharmacologic Treatment Strategies
10:15-10:30 AM Phase-Specific Psychotherapy for Bipolar Disorder
10:30-10:45 AM Question and Answer Session
10:45 AM Adjourn
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 18, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham
INDUSTRY-SUPPORTED SYMPOSIUM 7
Sunday, May 19, 8:00 a.m. - 11:00 a.m.
Millennium Hall, Second Floor, Loews

SUNDAY, MAY 19, 2002
7:30 am - 8:00 am Breakfast
8:00 am - 11:00 am Scientific Program
Philadelphia Loews Hotel Millennium Hall — Second Floor
8:00 - 8:05 am Welcome and Introduction
Karen D. Wagner, MD, PhD, Program Chairman
University of Texas Medical Branch
8:05 - 8:30 am Diagnosis and Course of Bipolar Disorder in Children and Adolescents
Karen D. Wagner, MD, PhD
8:30 - 8:55 am Genetic and Environmental Effects of Bipolar Disorder on Families
Ko D. Chang, MD, Stanford University
8:55 - 9:20 am Pharmacological Treatment of Children and Adolescents with Bipolar Disorders
Robert A. Kowatch, MD, University of Cincinnati Medical School
9:20 - 9:45 am Novel and Maintenance Treatment Approaches in Pediatric Bipolarity
Robert L. Findling, MD, University Hospitals of Cleveland
9:45 - 10:10 am Diagnostic and Treatment Implications of Psychiatric Co-morbidity in Juvenile Bipolar Disorder
Timothy E. Willens, MD, Harvard University
10:10 - 11:00 am Panel Discussion / Q & A

PROGRAM OBJECTIVE
- Diagnose bipolar disorder in children and distinguish it from other common childhood psychiatric disorders.
- Implement current treatment strategies for bipolar disorder in youth, including mood stabilizers, antidepressants, newer anticonvulsants and electroconvulsive therapy.

CREDIT DESIGNATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each participating physician should claim only those hours of credit that he/she actually spends in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7824 (within the U.S. or Canada) or 202-682-6000.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2003 Annual Meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 8
Sunday, May 19, 8:00 a.m. - 11:00 a.m.
Regency Ballrooms A-C, Second Floor, Loews

Late-Life Depression: Old Myths and New Data
APA 2002 Annual Meeting, Sunday, May 19, 2002, 8:00 - 11:00 a.m.
Breakfast 7:30 - 8:00 a.m., Regency Ballrooms A-C, Loews Philadelphia Hotel

8:00 - 8:05 a.m. Introduction
8:05 - 8:35 a.m. Late-Life Depression: Neuroanatomy and Medical Comorbidity
Araan Kamar, MD, Department of Psychiatry, UCLA Neuropsychiatric Institute
8:35 - 8:55 a.m. Depression, Pseudodemementia, and Executive Dysfunction
George S. Albertopolous, MD, Cornell University Medical College, New York Hospital
9:05 - 9:35 a.m. How Long Should Antidepressant Trials be in Geriatric Depression?
Harold A. Sackeim, PhD, Columbia University, New York State Psychiatric Institute
9:35 - 10:05 a.m. Treatment of Depression in the Old and Old-Old
Steven F. Roose, MD, Columbia Presbyterian Medical Center, New York State Psychiatric Institute
10:05 - 10:30 a.m. Interpersonal Psychotherapy in Late-Life Depression: Who Benefits?
Charles D. Reynolds, III, MD, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine
10:30 - 11:00 a.m. Questions (five minutes of questions will follow each presentation)

At the conclusion of the symposium the participants should be able to:
- Appreciate that the neurobiolgy of late-life depression differs from depression in younger patients, and that involvement of vascular illness and other medical co-morbidities can complicate treatment.
- Evaluate the effectiveness of pharmacotherapy and psychotherapy in the treatment of late-life depression, including parameters such as speed of onset and time to response.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7824 (within the U.S. or Canada) or 202-682-6000.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.
DEPRESSIVE SUBTYPES: The Multiple Faces of Depression

APA 155th Annual Meeting • Sunday, May 19, 2002
7:30 – 8:00 AM Breakfast • 8:00 – 11:00 AM Symposium
Philadelphia Marriott Hotel • Grand Ballroom Salons E/F, Level 5

Program Chair: Maurizio Fava, MD - Massachusetts General Hospital

8:00 AM Introduction
Maurizio Fava, MD
Massachusetts General Hospital

8:10 AM Atypical Depression: An Often Under-Recognized Condition
Jonathan W. Stewart, MD
New York State Psychiatric Institute

8:35 AM Treatment Challenges in Anxious Depression
Maurizio Fava, MD
Massachusetts General Hospital

9:00 AM Melancholic Depression: Are Dual-Action Antidepressants Superior to Selective Agents?
J. Craig Nelson, MD
Yale University School of Medicine

9:25 AM Vascular Depression
Rajesh Krishnan, MD
Duke University Medical Center

9:50 AM Practical Approaches to Psychotic Depression
Linda L. Carpenter, MD
Brown University

10:15 AM Questions and Answers

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and by the CME program of the ABS. Each participating learner will be issued credit that he/she actually spent in the educational activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at psych.org or contact the APA toll-free at 1-800-545-7788 (within the U.S. or Canada), or 202-522-3000.

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 10
Sunday, May 19, 8:00 a.m. - 11:00 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

BREAKFAST SYMPOSIUM
APA 155TH ANNUAL MEETING • SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION
8:00 to 11:00 am • Breakfast 7:30 – 8:00 am

RECOVERY FROM DEPRESSION: New Perspectives to Improve Outcomes

AGENDA AND FACULTY:
Opening Remarks: (8:00 – 8:15)
Chair, Michael E. Thase, M.D.
Recovery from Depression: Conceptual Underpinnings (8:15 – 8:45)
Michael E. Thase, M.D.
Professor of Psychiatry
University of Pittsburgh
Augmentation and Combination Strategies for the Newer Antidepressants (8:45 – 9:15)
Andrew A. Nierenberg, M.D.
Associate Professor of Psychiatry
Harvard University

Combining Psychotherapy and Medication for Depression (8:45 – 9:45)
John C. Markowitz, M.D.
Associate Professor of Psychiatry
Cornell Medical College
Maximizing Efficacy in the Treatment of Chronic Depression (9:45 – 10:15)
Susan G. Komstein, M.D.
Associate Professor of Psychiatry
Virginia Commonwealth University

EDUCATIONAL OBJECTIVE:
Learn about the process of recovery from depression, both in terms of risk factors and therapeutic strategies.

45 minutes have been allocated for questions and answers.
Supported by an unrestricted educational grant from Wyeth.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CMS requirement of the ABS. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at psych.org or contact the APA toll-free at 1-888-353-7788 (within the U.S. or Canada) or 202-463-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 19, 1:30 p.m. - 4:30 p.m.
Millennium Hall, Second Floor, Loews

Recent Developments in the Science and Treatment of PTSD

PROGRAM OBJECTIVES
After attending this continuing education program, the psychiatrist should be able to:

- Examine the latest evidence on the pathogenesis of PTSD, including risk and resilience factors
- Appreciate the contribution to our knowledge of PTSD that neuroimaging is making possible
- Review the medical strategies for management of PTSD

- Identify new tools for diagnostic, assessment, and treatment that have potential to improve outcomes in PTSD.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6400.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 19, 1:30 p.m. - 4:30 p.m.
Regency Ballrooms A-C, Second Floor, Loews

CUSTOMIZING CARE FOR PATIENTS WITH BIPOLAR DISORDER

AGENDA

1:00 PM - 1:30 PM
Lunch

1:30 PM
Opening Remarks
- GARY S. SACHS, MD
  (Princeton Champion)
  Nimble Medical School

1:40 PM
Significance of Psychosis
- CHARLES L. BOWDEN, MD
  University of Texas Southwestern Medical School

2:05 PM
Choosing Initial Mood Stabilizer
- GUY M. GOODWIN, MD
  Cleveland University

2:30 PM
Dealing With Comorbid Problems During Ongoing Treatment of Bipolar Disorder
- W. GORDON FRANKLE, MD
  Cleveland University

2:55 PM
Selection of an Anticonvulsant Treatment Strategy
- RICHARD Appel
  St. Vincent's Medical Center

3:20 PM
Mood Stabilization for Treatment-Resistant Patient
- PATRICIA SNAPPES, MD, PhD
  University of Texas Southwestern Medical School

4:00 PM
Questions and Answers

4:30 PM
Adjourn

LEARNING OBJECTIVES

After attending this symposium, participants will be able to:

- Identify factors that may be used in the creation of a treatment strategy, including
drug selection, polypharmacy, and other variables that affect outcomes of therapy.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.

- Apply principles that guide the use of specific mood stabilizers to achieve optimal outcomes and
dependent upon individual patient needs.
INDUSTRY-SUPPORTED SYMPOSIUM 15
Sunday, May 19, 1:30 p.m. - 4:30 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

The Aging Brain and Vulnerability to Depression

APA 155th Annual Meeting
Sunday, May 19, 2002
1:00-1:30 pm Luncheon
1:30-4:30 pm Symposium
Philadelphia Marriott Hotel • Level 5 • Grand Ballroom Salons E/F

Program Chair: Charles R. Reynolds III, MD • University of Pittsburgh School of Medicine

1:30 Introduction
Charles R. Reynolds III, MD
University of Pittsburgh School of Medicine

1:45 Age, Neurobiology, and Treatment Response
Madhukar Trivedi, MD
University of Texas Southwestern Medical Center

2:15 The Impact on Cognition of Pharmacological Treatment for Late-Life Depression
Ruth O'Hara, PhD
Stanford University School of Medicine

2:45 Pharmacogenetics in Geriatric Depression
Normin Murphy, Jr., MD, PhD
Stanford University School of Medicine

3:15 Treatment of the Depressed "Old-Ole" in Outpatient and Long-term Care
Facility Settings
Steven R. Kocsis, MD
Columbia University

3:45 Questions and Answers

The American Psychiatric Association 155th Annual Meeting Symposium is supported by an unrestricted educational grant from Ortho-McNeil, Inc.

American Psychiatric Association 2002 Annual Meeting
Long-Term Management of Mood Disorders

Sunday, May 19, 2002
Agenda
1:00 – 1:30 pm Luncheon
1:30 – 1:45 pm Welcome and Introduction
A. John Rush, MD • The University of Texas Southwestern Medical Center

1:45 – 2:10 pm Does Medication Change the Long-Term Course of Mood Disorders?
Susan O. Kornstein, MD • Medical College of Virginia

2:10 – 2:35 pm Does Psychotherapy Change the Long-Term Course of Mood Disorders?
Robin S. Jarrett, PhD • The University of Texas Southwestern Medical Center

2:35 – 3:00 pm Does ECT Alter the Long-Term Course of Mood Disorders?
Harold A. Sadock, MD • College of Physicians & Surgeons of Columbia University

3:00 – 3:25 pm Vagus Nerve Stimulation (VNS) for Depression: Methods and Mechanisms?
Mark S. George, MD • Medical University of South Carolina

3:25 – 3:50 pm Does Vagus Nerve Stimulation (VNS) Change the Long-Term Course of Mood Disorders?
Laurin B. Mannigel, MD • Baylor College of Medicine

3:50 – 4:30 pm Panel Discussion
*Each presentation will be followed by a 2-minute Question and Answer Session

Objectives
At the conclusion of this symposium, the participant should be able to:
• Individually the controversies, strategies, and tactics of maintenance pharmacotherapy
• Review the evidence for the long-term efficacy of the depression-specific psychotherapies
• Better understand the effects of electroconvulsive therapy (ECT) on switches to mania, potential for relapse, long-term prevention of suicide and overall mortality, and changes in the natural course of depression after illness
• Discuss the mechanisms of vagus nerve stimulation (VNS) and why it may be a promising new therapy for chronic or recurrent depressions
• Discuss the long-term efficacy of vagus nerve stimulation (VNS) in the treatment of depression

Supported by an unrestricted educational grant from Cyberonics, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 19, 1:30 p.m. - 4:30 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

The Adherence Challenge:
Chronic Issues and Emerging Solutions With Antipsychotic Therapy
A symposium to be held during the APA 2002 Annual Meeting

Agenda
1:00 - 1:10 PM Lunch
1:10 - 1:30 PM Welcome and Introduction
1:30 - 2:00 PM Approaching the Adherence Challenge
Steven A. Beiser, MD (Co-chair)
Geoffrey Los Angeles VA Medical Center
2:00 - 2:25 PM Pharmacologic Options for Schizophrenia: Implications for Compliance
John M. Kane, MD (Co-chair)
Norton Hospital
2:25 - 2:55 PM Research Experience With a Long-Acting Atypical Antipsychotic Medication
Samuel J. Kirschen, MD
University of New Mexico
2:55 - 3:25 PM Views From the Nursing Perspective: Problems and Solutions
Kathleen C. Walter, RN
Emory University
3:25 - 3:45 PM Session Recap
Janke Parise, MD (Discussant)
AMA: Room
3:45 - 4:00 PM Questions and Answers

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 19, 1:30 p.m. - 4:30 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

Challenges and Opportunities in the Management of Psychotic Disorders
Sunday, May 19, 2002 — Wyndham Franklin Plaza, Ballrooms C/D

Agenda:
1:30 PM Welcoming Remarks
1:35 PM Introducing Early in the Evolution of Schizophrenia: Novel Approaches During the Prodromal Phase
Patrick D. McCarry, MD, PhD
University of Melbourne
2:00 PM New Developments in Schizophrenia Pharmacotherapy: Management of Acute Episodes
Diana G. Perkins, MD, MPH
University of North Carolina at Chapel Hill
2:25 PM Improving Long-Term Outcomes in Patients With Schizophrenia
Peter A. Weiden, MD
State University of New York Health Science Center
2:50 PM The Impact of Safety and Tolerability on Patients’ Satisfaction With Therapy
Joseph P. McKay, MD
Duke University School of Medicine
3:15 PM Mechanism of Action as Predictor of Clinical Utility: Lessons From Schizophrenia Research
Jeffrey A. Lieberman, MD
University of North Carolina
3:40 PM Summary Remarks
Diana G. Perkins, MD, MPH
University of North Carolina at Chapel Hill
3:45 PM Panel Discussion / Questions and Answers

Learning Objectives:
After completion of this activity, participants should be better able to:
- Describe prodromal signs and symptoms of schizophrenia and the importance of and challenges associated with initiating therapy during this early phase
- Review results of recent clinical trials with current and emerging antipsychotic therapies and their implications for optimizing therapy for patients with schizophrenia
- Discuss the impact of tolerability profiles of antipsychotic drugs on the effectiveness of therapy and the patient’s overall ability to function
- Understand the relationship between mechanisms of action of antipsychotic agents and their clinical profiles

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and the CME requirement of the APA. Each physician should only claim those hours of credit that he/she actually spent in the activity. Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-800-548-7904 (within the U.S. or Canada) or 513/381-4600.

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.
INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 19, 7:00 p.m. - 10:00 p.m.
Millennium Hall, Second Floor, Loews

INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 19, 7:00 p.m. - 10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 19, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

New Developments in the Treatment of Bipolar Disorder

SUNDAY, MAY 19, 2002
6:30 – 7:00 pm Dinner
7:00 – 10:00 pm Scientific Program
Philadelphia Marriott Hotel — Grand Ballroom Salons E/F — Level 5

Robert M. A. Hirschfeld, MD
Program Chairman

Program Objective
Implement treatment strategies for bipolar illness based on recent guidelines, focusing on acute mania, bipolar depression, maintenance treatment, rapid cycling and mixed mania, and psychosocial issues.

CREDIT DESIGNATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-866-357-7124 (within the U.S. or Canada) or 202-682-6600.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2002 Annual Meeting.

TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN: What Is Evidence and What Is Art?

APA – 155th Annual Meeting
DINNER SYMPOSIUM Sunday, May 19, 2002
7:00 – 10:00 p.m. • Dinner 6:30 – 7:00 p.m.
The Philadelphia Marriott
Grand Ballroom Salons G/H, Level 5

Educational Objective:
At the conclusion of this symposium, participants should have:
an increased understanding of the components of treatment for women with mood and anxiety disorders that are evidence-based.

45 minutes have been set aside for questions and answers.

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-866-357-7124 (within the U.S. or Canada) or 202-682-6600.

Supported by an unrestricted educational grant from AVAN
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 19, 7:00 p.m. -10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder

Sunday, May 19, 2002
6:30pm-7:00pm Dinner
7:00pm-10:30pm Educational Program
Wyndham Ballrooms A/B
Philadelphia, Pennsylvania

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly and Company

Program Description
Mood-stabilizing medications are the cornerstone of treatment of bipolar disorder, and lithium has been the prototypic mood stabilizer for more than 50 years. The past decade has seen new medications emerge that have similar properties, and more is known about optimizing treatment adherence in comparison with psychosocial therapies. Physicians' recognition of the presence of depressive symptoms and mood swings in the course of bipolar illness, together with an understanding of the need to extend treatment for extended periods to maximize the maintenance of remission, can reduce the treatment challenges of these complicated diseases.

Learning Objectives
A. Clarify the need for mood stabilizers in the treatment of bipolar disorder.
B. Discuss the role of mood stabilizers in the treatment of mood disorders.
C. Compare and contrast the use of lithium and other mood stabilizers.

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 19, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

Molecules of the Mind
The Science of Schizophrenia

AGENDA
6:30 - 7:00 pm: Welcome Address
7:00 - 7:30 pm: The Neuroscience of Schizophrenia
7:30 - 8:00 pm: The Neurochemistry of Schizophrenia
7:00 - 7:30 pm: The Genetics of Schizophrenia
7:30 - 8:00 pm: The Pathophysiology of Schizophrenia
8:00 - 8:30 pm: The Treatment of Schizophrenia
8:30 - 9:00 pm: The Prevention of Schizophrenia

LEARNING OBJECTIVES
After attending this symposium, participants will be able to:
1. Discuss the various factors that contribute to the development of schizophrenia.
2. Describe the role of genetic and environmental factors in the development of schizophrenia.
3. Identify the current treatments for schizophrenia and their effectiveness.
4. Understand the importance of early intervention in the treatment of schizophrenia.
5. Explain the role of medication in the management of schizophrenia.

138
INDUSTRY-SUPPORTED SYMPOSIUM 25
Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.
Millennium Hall, Second Floor, Loews

Clinical Challenges in depression

PROGRAM OBJECTIVES
After attending this continuing education program, the psychiatrist should be able to:

- Gain an appreciation of the types of conditions and situations that clinicians encounter that will alert them to the challenge that treatment of these depressed patients may pose.
- Understand the special challenges that the treatment of bipolar depression and psychotic depression offer and learn how to better manage these patients.
- Identify the lack of diagnostic and treatment knowledge and experience that the adolescent patient poses and how to deal with this population.
- Identify the relationship between depression and cardiovascular disease death and the approach to management.
- Review the problem of long-term compliance with treatment of depressions and what can be done to improve long-term outcome.

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each morning of this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendance: A certificate of completion will be given to each attendee. Those wishing to claim CME credits must complete the registration form and the evaluation form at the symposium.

To register, contact the APA at 685 Third Avenue, New York, NY 10017-1597, or call 1-888-357-7924 (within the US or Canada) or 202-682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 26
Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews

Novel Antipsychotic Drugs: Advances in the Treatment of a Spectrum of Psychotic Disorders

Agenda:

Monday, May 20, 2002 (Day One)
7:00 AM Welcome and Introduction
Robert E. Hales, MD — University of California, Davis
Stuart C. Yudofsky, MD — Baylor College of Medicine
7:05 AM From Bench to Bedside: Rational Selection of Medications for the Management of Schizophrenia
Rana J. El, MD — Stanford University
7:30 AM Evolution of Antipsychotic Therapies: Impact on Long-term Outcomes
Jonathan M. Kane, MD — New York University
7:55 AM Summary Remarks
Stuart C. Yudofsky, MD — Baylor College of Medicine
8:05 AM Panel Discussion / Questions and Answers

Tuesday, May 21, 2002 (Day Two)
7:00 AM Welcome and Introduction — Brief Overview of Day One
Robert E. Hales, MD — University of California, Davis
7:10 AM The Emerging Role of Antipsychotic Agents for the Management of Acute Mania
John Zapata, MD — Rush Presbyterian-St. Luke's Medical Center
7:35 AM New Approaches to the Treatment of Psychosis in the Elderly
Dilip V. Jeste, MD — University of California, San Diego
8:00 AM Summary Remarks
Stuart C. Yudofsky, MD — Baylor College of Medicine
8:05 AM Panel Discussion / Questions and Answers

Learning Objectives:
- After completion of this 2-day symposium, the participants should be better able to:
  - Discuss current theories of the pathophysiologic basis for schizophrenia and their implications for disease management.
  - Review advances in long-term management of schizophrenia and the impact of antipsychotic therapies on cognitive function.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 1 hour in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the activity.

Attendance: A certificate of completion will be given to each attendee. Those wishing to claim CME credits must complete the registration form and the evaluation form at the symposium.

To register, contact the APA at 685 Third Avenue, New York, NY 10017-1597, or call 1-888-357-7924 (within the US or Canada) or 202-682-6000.

Sponsored by the American Psychiatric Association.

Supported to an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.
INDUSTRY-SUPPORTED SYMPOSIUM 27
Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 28
Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH

AGENDA

Monday, May 20, 2002
6:30-7:00 a.m. Breakfast
7:00 a.m. Convening Remarks
HENRY A. NASRALLAH, M.D.
(President, American Psychiatric Association)
7:15 a.m. Medical Complexity and Morbidity in Patients With Schizophrenia
S. CHARLES SCHULTZ, M.D.
(Clinical Director, AstraZeneca)
7:30 a.m. Antipsychotic Medications
DANIEL A. ASCALL, M.D., PH.D.
(Director of Psychiatry, AstraZeneca)
7:45 a.m. Antipsychotic Medications
DARWIN WHITMAN, M.D.
(Pharmacologist, AstraZeneca)
8:00 a.m. Session Break
8:30 a.m. Session

LEARNING OBJECTIVES

By attending this symposium participants will be able to:

- Recognize the role of antipsychotic medications in the management of psychiatric morbidities and improvement in neurocognitive function.
- Understand the role of antipsychotic medications in the management of psychiatric morbidities and improvement in neurocognitive function.
- Discuss the role of antipsychotic medications in the management of psychiatric morbidities and improvement in neurocognitive function.
- Understand the role of antipsychotic medications in the management of psychiatric morbidities and improvement in neurocognitive function.
- Discuss the role of antipsychotic medications in the management of psychiatric morbidities and improvement in neurocognitive function.

Astrazeneca

APA 155TH ANNUAL MEETING - BREAKFAST SYMPOSIUM
Sponsored by the American Psychiatric Association

7:00 a.m. to 8:30 a.m. / Breakfast 6:30 a.m. to 7:00 a.m.

Understanding Sleep Medicine: What the Psychiatrist Needs to Know

MONDAY, MAY 20
Agenda and Faculty:
- Introductory Remarks:
  - 7:00-7:05
  - Milton K. Erman, M.D.
- Sleep, Safety and Public Policy
  - 7:05-7:26
  - Mark R. Rappaport, Ph.D.
- Sleep Disorders: What the Psychiatrist Needs to Know
  - 7:26-7:45
  - Lois Krann, M.D.
  - Mayo Clinic
- Innovative Strategies in the Management of Insomnia
  - 7:45-8:05
  - Karl Doghrarmi, M.D.
  - Thomas Jefferson University

TUESDAY, MAY 21
Agenda and Faculty:
- Introductory Remarks:
  - 7:00-7:05
  - Milton K. Erman, M.D.
- Morbidity of Insomnia
  - 7:05-7:05
  - Thomas Roth, Ph.D.
- Mechanism of Action of Hypnotics
  - 7:35-8:05
  - Stephen M. Stahl, M.D., Ph.D.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been designated as a Category 1 credit toward the RMA Physician's Recognition Award. Each credit hour should count for only three hours of credit that may be applied for the renewal of the APA. The CME department of the APA. Each credit hour should count for only three hours of credit that may be applied for the renewal of the APA.
INDUSTRY-SUPPORTED SYMPOSIUM 31
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Ballrooms A/B, Ballroom Level, Convention Center

INDUSTRY-SUPPORTED SYMPOSIUM 32
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Millennium Hall, Second Floor, Loews
INDUSTRY-SUPPORTED SYMPOSIUM 33
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews

Managing Aggression Across the Lifespan:
From the Pediatric to the Geriatric Patient
A symposium to be held during the APA 2002 Annual Meeting

Agenda

6:30 - 7:00 PM Dinner
7:00 - 7:05 PM Welcome and Introduction
        Douglas R. Hughes, MD (Chair)
        Boston University Medical School
7:05 - 7:25 PM Managing the Aggressive Patient
        Douglas R. Hughes, MD
7:25 - 7:55 PM Evidence-Based Approach to
              Pharmacotherapy of the Aggressive Child
              Jorge L. Areano, MD
              University of Miami
7:55 - 8:25 PM Aggression and Psychiatric Disorders:
              Confronting the War Within
              Robert A. Looney, MD
              Maryland Psychiatric Research Center
8:25 - 8:55 PM Strategies and Interventions for
              Late-Life Aggression
              Sara Bronston, MD
              University of Washington
8:55 - 9:15 PM Long-Term Adverse Effects of
              Antipsychotic Therapy
              Prakash S. Misra, MD
              Duke University Medical Center
9:15 - 10:00 PM Questions and Answers

INDUSTRY-SUPPORTED SYMPOSIUM 34
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

Managing Aggression Across the Lifespan:
From the Pediatric to the Geriatric Patient
A symposium to be held during the APA 2002 Annual Meeting

Perspectives on the Biology and Therapy of Anxiety Disorders
INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham
INDUSTRY-SUPPORTED SYMPOSIUM 37
Tuesday, May 21, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms C/D, First Floor, Wyndham

 behavioural disturbances in dementia:
diagnostic and treatment
guidelines for the practicing clinician

Tuesday, 21 May 2002
19.00-22.00
Wyndham Ballrooms C/D
Refreshments served:
18.30-19.00 and
22.00-22.30

19.00 Chairs’ Welcome
Steven G. Potkin MD, Robert R Sprague Director of UCI Brain Imaging Center and Mustafa M Husain MD, University of Texas Southwestern Medical Center at Dallas

19.10 The Pathophysiology of Abnormal Behavior and Mood in Dementia
Mustafa M Husain, MD, as above*

19.40 Impact of Cholinesterase Inhibitors on Sleep Disturbance in Alzheimer’s Disease
P Murali Doraiswamy, MD, Duke University Medical Center

20.10 Dementia with Lewy Bodies: The Frontiers of Effective Treatment and Diagnosis
Martin R Farlow, MD, Indiana University School of Medicine

20.40 Treating the Behavioral Disturbances Observed in Alzheimer’s Disease: Pharmacologic and Non-pharmacologic Interventions
Steven G Potkin, MD, as above*

21.10 Questions and Answers

INDUSTRY-SUPPORTED SYMPOSIUM 38
Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.
Ballrooms A/B, Ballroom Level, Convention Center

Symposium Chair
JULIA K. WARNOCK, MD, PHD
Two-Part Breakfast Symposium

Chronic Episodic Disorders: Comorbidity & Comprehensive Integrated Treatment

Symposium Chair
JULIA K. WARNOCK, MD, PHD

Uraturing the Complexity: Comorbidity, Mechanistic Link and Pharmacologic Response

ANITA H. CLAYTON, MD
Symposium Co-Chair
University of Virginia Health System

New Developments in Obesity
DONNA H. RYAN, MD
Louisiana State University

Reproductive Life Events:
Depression and Sexual Dysfunction
JULIA K. WARNOCK, MD, PHD
University of Oklahoma

The Relationship of Psychiatric Illness and Irritable Bowel Syndrome
R. BRUCE LYDIARD, PHD, MD
Southeast Health Consultants

Management of Pain Syndromes:
Fibromyalgia, Migraines, and Chronic Pain
DIANE S. THOMPSON, MD
University of Hawaii

Part I – Wednesday, May 22

6:30 – 7:00 AM Breakfast
7:00 – 7:30 AM Clinical Program
Philadelphia Convention Center
Ballrooms A & B, Ballroom Level

Part II – Thursday, May 23

6:30 – 7:00 AM Breakfast
7:00 – 7:30 AM Clinical Program
Philadelphia Convention Center
Ballrooms A & B, Ballroom Level
INDUSTRY-SUPPORTED SYMPOSIUM 39
Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.
Millennium Hall, Second Floor, Loews

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.
Regency Ballrooms A-C, Second Floor, Loews
INDUSTRY-SUPPORTED SYMPOSIUM 41
Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salons E/F, Level 5, Marriott

The Pathophysiology and Treatment of Impulsivity and Aggression in
Psychiatric Disorders

MAY 22-23, 2002
6:30 - 7:00 am Breakfast
7:00 - 8:30 am Scientific Program
Philadelphia Marriott Hotel — Grand Ballroom Salons E/F — Level 5
7:00 - 7:05 am Welcome and Introductions
Alan C. Swann, MD, Program Chairman
University of Texas Medical School at Houston
7:05 - 7:30 am Mechanisms of Impulsivity
Alan C. Swann, MD
7:30 - 8:00 am Mood Stabilizers as Adjunctive Treatment in Schizophrenia
Daniel E. Casey, MD, Portland Veterans Administration Medical Center
8:00 - 8:30 am Aggression, Violence and Psychopathology: A Developmental Approach
Karin Steinher, MD, Stanford University School of Medicine

Program Objectives
- Understand mechanisms of impulsive behavior, their adaptations over time, and their role in major psychiatric disorders including bipolar, cluster B personality, substance use, stress-related disorders, and disruptive behavior disorders of childhood and adolescence.
- Learn the role of pharmacologic and other strategies in the psychologically based treatment of disorders where impulsivity is prominent.

Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 5.5 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-2924 (within the U.S. or Canada) or 301-652-8600.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2002 Annual Meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 42
Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.
Grand Ballroom Salons G/H, Level 5, Marriott

New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment
A symposium to be held during the APA 2002 Annual Meeting

AGENDA PAPER I: MAY 22
6:30 – 7:00 AM Breakfast
7:00 – 7:10 AM Welcome & Introduction
7:10 – 7:50 AM Schizoaffective Implications for Treatment and Prevention
Ming Li, Toronto, Canada
Norad University
7:50 – 8:00 AM The Schizophrenia Prognosis: Early Prediction Findings
Barbara Compton, PhD
Kisote Hospital
8:00 – 8:30 AM Questions & Answers

AGENDA PAPER II: MAY 23
6:30 – 7:00 AM Breakfast
7:00 – 7:20 AM Neuropsychology of Schizotypal Personality: Implications for Pharmacology
Lorre L. Owen, MD
Mt. Srct School of Medicine
7:20 – 7:40 AM Cognitive Enhancers in the Schizophrenia Spectrum
Morrie Goodman, MD
Mt. Srct School of Medicine
7:40 – 8:00 AM The Promise of Antipsychotics for Borderline Disorders
J. Charles Schatz, MD
University of Minnesota
8:00 – 9:00 AM Questions & Answers
Non-Cholinergic Treatment for Alzheimer's Disease: Present Knowledge, Future Hope

INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Ballrooms A/B, Ballroom Level, Convention Center

APA 2002 Annual Meeting, Wednesday, May 22, 2002, 7:00 - 10:00 p.m., Dinner 6:30 - 7:00 p.m.
Ballrooms A/B, Pennsylvania Convention Center

7:00 - 7:05 p.m. Introduction
7:05 - 7:35 p.m. The Diagnosis and Treatment of Alzheimer's Disease: An Overview
Barry D. Lebowitz, PhD, National Institute of Mental Health

7:35 - 8:05 p.m. Current Treatments for Alzheimer's Disease: Cholinesterase Inhibitors
Rachelle Doody, MD, PhD, Baylor College of Medicine

8:05 - 8:35 p.m. The Neuroanatomy of Alzheimer's Disease
Gary L. Wenk, PhD, Graduate Program in Cognition and Neural Systems, University of Arizona

8:35 - 9:05 p.m. Beyond Acetylcholine: The Search for Better Treatment Options (Part I)
Jacobo Mintzer, MD, Department of Psychiatry, Medical University of South Carolina

9:05 - 9:30 p.m. Beyond Acetylcholine: The Search for Better Treatment Options (Part II)
Mary Sano, PhD, Department of Neurology, Columbia Presbyterian Medical Center

9:30 - 10:00 p.m. Questions (five minutes of questions will follow each presentation)

At the conclusion of this symposium the participants should be able to:
- Understand existing cholinergic treatments of Alzheimer's disease;
- Better comprehend the neuroanatomy of Alzheimer's disease;
- Recognize alternative options that may be used alone or in combination with existing treatments; and
- Consider the future of Alzheimer's disease treatments.

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Millennium Hall, Second Floor, Loews

SLEEP DISORDERS AND PSYCHIATRIC ILLNESSES: Scientific Foundations

Wednesday, May 22, 2002, 7:00 - 10:00 p.m.
Millennium Hall, Second Floor, Loews Hotel, Philadelphia, PA
American Psychiatric Association 155th Annual Meeting

At the conclusion of this symposium, participants should be able to:
- recognize that insomnia is a correlate of both disease and psychosocial dysfunction, and that it has a very significant impact on healthcare costs;
- recognize the relationship between sleep disturbance and a number of psychiatric diseases, as well as understand the benefits of treating sleep disturbance in this patient population;
- have a better understanding of the commonly used treatments for insomnia and sleep disorders related to psychiatric illnesses and their neurological mechanisms.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 1.5 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7024 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 1.5 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.

Sponsored by the American Psychiatric Association

AAGC Sponsored by an unrestricted educational grant from Searle Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 45
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Regency Ballrooms A-C, Second Floor, Loews

**THE BURDEN OF SCHIZOPHRENIA**

*When Patients Don't Get Better*

**LEARNING OBJECTIVES**

- Explain the impact of comorbid depression and substance abuse on schizophrenia and the management thereof.
- Incorporate current data on new medications and interventions that are currently available.

**AGENDA**

6:30-7:00 pm Dinner

7:00 pm Opening Remarks/Introduction

7:15 pm Defining No-Response in Schizophrenia: Impact of Pretreatment and Treatment Don't Optimally Work

8:25 pm Consensus on Treatment for Resistant Schizophrenia

8:50 pm Why Patients Stop Their Antipsychotics and What to Do About It

2:15 pm Session #2: Stigma/Exclusion

9:15 pm Closing Remarks and Answers

10:00 pm Adjourn

---

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons E/F, Level 5, Marriott

**IDENTIFICATION AND MANAGEMENT OF DAYTIME FATIGUE AND SLEEPINESS IN PSYCHIATRY**

*Educational Council:*

- Chairperson: John W. Winkelmann, MD, PhD
- Harvard Medical School
- Boston, MA
- David F. Dinges, PhD
- University of Pennsylvania School of Medicine
- Philadelphia, PA
- Mary O'Malley, MD, PhD
- Northeast Hospital
- Norwalk, CT
- Karl Doghramji, MD
- Thessalon Healthcare, Inc.
- Philadelphia, PA
- Anthony L. Komaroff, MD
- Harvard Medical School
- Boston, MA
- Daniel R. Weinberger, MD
- National Institute of Mental Health
- Bethesda, MD

**AGENDA**

- Dinner will be provided from 6:30 pm to 7:00 pm.
- **Introduction**
  - John W. Winkelmann, MD, PhD
  - Harvard Medical School
  - Boston, MA
- **Sleepiness and Fatigue: Neurobehavioral and Physiological Features**
  - David F. Dinges, PhD
- **Primary Sleep Disorders Associated with Excessive Daytime Sleepiness**
  - Mary O'Malley, MD, PhD
  - Northeast Hospital
  - Norwalk, CT
- **Fatigue and Excessive Daytime Sleepiness in Psychiatric Disorders**
  - Karl Doghramji, MD
- **Clinical Manifestations of Fatigue in Chronic Fatigue Syndrome**
  - Anthony L. Komaroff, MD
- **Novel Molecular Targets in Debetis Syndrome**
  - Daniel R. Weinberger, MD
- **Discussion**
  - John W. Winkelmann, MD, PhD
  - Harvard Medical School
  - Boston, MA

**Participation:**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be assigned on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-577-7524 (within the U.S. or Canada) or 202-682-6000.
INDUSTRY-SUPPORTED SYMPOSIUM 47
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Grand Ballroom Salons G/H, Level 5, Marriott

APA 2002 Annual Meeting
Adult Attention Deficit Hyperactivity Disorder: From Research to Clinical Practice

PROGRAM
7:00 PM
Welcome/Introduction
Joseph Biederman, MD, Chair
Thomas J. Spencer, MD, Co-Chair
7:15 PM
Overview of Patterns of Comorbidity in Adults with ADHD
Joseph Biederman, MD
Massachusetts General Hospital
7:40 PM
The Neuropsychology of Adult ADHD
Larry J. Selden, PhD
Massachusetts Mental Health

8:00 PM
A Genetic Perspective of the Validity of Adult ADHD
Stephen V. Faraone, PhD
Massachusetts General Hospital

9:28 PM
Functional and Structural Neuroimaging in ADHD
George Bush, MD
Massachusetts General Hospital

6:00 PM
Pharmacotherapy of Adults with ADHD
Thomas J. Spencer, MD
Massachusetts General Hospital

9:15 PM
Q&A Session

Learning objectives
1. Be familiar with neuropsychology, genetics and imaging studies in adults with ADHD.
2. Be able to recognize the essential features of comorbidity, and apply the principles of treatment of ADHD in adulthood.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 2 hours of Category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the DOG requirement of the APA. Each physician should only claim those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 48
Wednesday, May 22, 7:00 p.m. - 10:00 p.m.
Wyndham Ballrooms A/B, First Floor, Wyndham

Advances in the Understanding and Treatment of Binge Eating Disorder
An educational symposium to be presented at the APA 2002 Annual Meeting of the American Psychiatric Association

Wednesday, May 22, 2002

6:30 pm - 7:00 pm
Reception

7:00 pm - 7:05 pm
Welcome and Introduction
Cochairpersons:
James I. Biederman, MD, SM - McLean Hospital, Harvard Medical School
Janice S. White, PhD - University of California, San Diego

7:05 pm - 7:30 pm
Diagnosis and Behavior
S. Timothy Walsh, MD - College of Physicians and Surgeons, Columbia University

7:30 pm - 7:55 pm
Epidemiology and Risk Factors
Elizabeth A. Cramer, MD - McLean Hospital, Harvard Medical School

7:55 pm - 8:15 pm
Questions and Answers

8:15 pm - 8:40 pm
Treatment with Antidepressants
James I. Biederman, MD, SM

8:40 pm - 9:05 pm
Treatment with Appetite Suppressants and Anticonvulsants
Susan J. McElroy, MD - University of Connecticut College of Medicine

9:05 pm - 9:30 pm
Psychological Treatment
Darcie L. Wiffey, PhD

9:30 pm - 9:50 pm
Summary and Conclusions
James I. Biederman, MD, SM

10:00 pm - 10:30 pm
Questions and Answers

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 2 hours of Category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the DOG requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Audience must be registered for the APA 2002 Annual Meeting to attend the symposium. Seating is limited and based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA at 1-888-557-7041 (within the US or Canada) or (202) 363-6000.

Sponsored by
The American Psychiatric Association
Supported by unrestricted educational grant from Shire US, Inc.
Explorations in DEMENTIA
May 22, 2002

AGENDA

6:30 - 7:00 PM  Dinner

1:00  Welcome and Introductions
Gary W. Small, MD, Chairperson
Director, UCLA Center on Aging
Fairbanks-Scholer Professor on Aging
University of California at Los Angeles
School of Medicine
Los Angeles, California

7:15  Early Detection and Genetic Risk Assessment in Alzheimer’s Disease
Gary W. Small, MD

7:35  Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective
J. Michael Ryan, MD
University of Rochester Medical Center
Program in Neurobehavioral Therapeutics
Monroe Community Hospital
Rochester, New York

7:55  Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?
Bradley F. Boeve, MD
Assistant Professor of Neurology
Department of Neurology
Mayo Clinic
Rochester, Minnesota

8:15  Charting the Course of Cerebrovascular Dementia
Gustavo C. Roman, MD
Professor of Medicine, Neurology
University of Texas Health Science Center
San Antonio, Texas

Alzheimer’s Disease Therapy in the 21st Century: Examining the Evidence
Ferrie N. Tariot, MD
Professor of Psychiatry, Medicine, and Neurology
University of Rochester Medical Center
Rochester, New York

Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment
Donna L. Masterson, MD, Cochairperson
Director, Alzheimer’s Disease Treatment Program
Assistant Professor of Neurology
University of California at Los Angeles
School of Medicine
Los Angeles, California

8:45  Questions and Answer Session
Faculty Panel

9:00  Adjourn
Distinguished Lecturers

CME Courses

Leadership and Career Development Seminars
(for Residents and Early Career Psychiatrists)

Industry-Supported Symposia

Medical Updates

Symposia

Workshops

Debates

Forums

Full-Day Sessions

Poster Sessions

Discussion Groups

Innovative Programs

Clinical Consultations

INSTITUTE OBJECTIVES:

At the conclusion of the 2002 Institute on Psychiatric Services, participants will:

1. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;

2. Better understand how the current health care system affects patient care;

3. Gain new knowledge and skills useful in public psychiatric settings; and

4. Understand the importance of all disciplines working together to ensure high quality patient care.

Did you know that...

- You can earn up to 48 hours of category 1 credit for attending the Institute?

- APA members receive a 40% discount on their cost for registration?

- Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?

- All scientific sessions will be held in the Palmer House Hilton Hotel in Chicago?

- There are prize drawings, beverages and receptions held daily in the exhibit hall?

- The 2001 Institute received the highest attendee-rated evaluations?

For further information, please call or write to:

Annual Meetings Department
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20025

Telephone: 1 (888) 357-7924 (Toll Free)
Fax: (202) 682-6345
E-Mail: apa@psych.org
Web: http://www.psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
As Questions Arise at the APA Annual Meeting, Keep One Place in Mind

Answers to all these questions and more can be found at the APA Resource Center.

Along with new research abstracts on CD-ROM, complimentary copies of the latest APA publications, and opportunities to advertise or apply for position openings, you'll find the latest HIV/AIDS treatment information; fellowship opportunities; how to report, track, and attain additional CME credits; and other resources of benefit to the 21st century psychiatrist. Even a place to reconnect to your 21st century life at the Internet Village.

So make the APA Resource Center part of your Annual Meeting experience and find out how the programs and resources of APA equip the 21st century psychiatrist and specifically how APA membership can work for you.